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Abstract 
Globally, it is estimated that 240 million people are infected with chronic viral hepatitis B and 
in excess of 185 million people with chronic hepatitis C.  The burden of disease from hepatitis 
is concentrated in developing countries where transmission of HBV occurs predominantly 
from mother to child (vertical transmission) and transmission of HCV through unsafe medical 
procedures and the transfusion of unscreened blood products.   
 
Global patterns of migration favour the movement of individuals from countries with medium 
or high risk prevalence of chronic viral hepatitis to countries with traditionally low prevalence 
among their indigenous populations, including the United Kingdom (UK).  In excess of 3.2% of 
the global population are international migrants, posing important implications for healthcare 
systems in host nations.  It is predicted that up to 7 million first and second generation 
immigrants, originating from high prevalence countries for viral hepatitis now reside 
permanently in the UK.  However, as a result of deficiencies in screening initiatives, the 
prevalence and associated burden of these diseases in these high-risk populations residing in 
the UK is yet to be determined. 
 
In order to establish the feasibility of inviting first and second generation immigrant 
populations to participate in viral hepatitis testing in primary care, as well to determine the 
prevalence and demography of viral hepatitis in four areas of the UK, a randomised controlled 
cross sectional cluster trial was conducted.  In HepFree clinical computer systems in general 
practice surgeries were interrogated to identify the target population that was then 
approached using a variety of different invitations to determine the most appropriate method 
for engaging this population.   
 
The outcomes of viral hepatitis testing from practices in one area of the UK are described in 
this thesis.  Despite multiple challenges encountered both in engaging practices and 
individuals in trial participation, results of this investigation suggest that if it is found to be 
cost effective, then viral hepatitis screening is feasible and the burden of disease in the UK is 
concentrated in first generation immigrants. 
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1.1 Overview 
Globally, it is predicted that in excess of 400 million people are infected with chronic viral 
hepatitis B and C (HBV, HCV) (1,2).  The burden of disease associated with viral hepatitis is 
concentrated in developing countries where transmission of HBV is most often vertical, from 
mother to child, and transmission of HCV is from unsafe medical procedures and the 
transfusion of unscreened blood products.  In developed countries including the United 
Kingdom (UK), the majority of cases of viral hepatitis arise as a result of injecting drug use.  
Multiple initiatives have been developed and implemented in this group of high-risk 
individuals to improve testing, diagnosis, and treatment of viral hepatitis. 
 
In England, HBV and HCV prevalence is estimated to be 0.5 and 1% respectively (3,4).  There is 
uncertainty surrounding the validity of these data for the following reasons; the unknown 
prevalence of disease in developing countries, the patterns of migration from high-risk to low-
risk countries and the absence of formal screening programmes for viral hepatitis in non-
indigenous populations residing in England. 
 
Global patterns of migration favour the movement of individuals from countries with medium 
or high-risk prevalence of chronic viral hepatitis to countries with traditionally low prevalence 
among their indigenous populations, one of which includes the UK.  In 2015, the United 
Nations (UN) estimated that 3.3% of the global population were international migrants, 
posing important implications for healthcare systems in host nations (5).  It is predicted that 
up to 7 million first and second generation immigrants originating from high prevalence 
countries now reside permanently in the UK and this figure is likely to be a conservative 
estimate of the true volume of migration (6).  Previous studies conducted in migrant 
populations in developed countries have suggested that the prevalence of disease in these 
groups reflects the disease prevalence in their country of origin (7,8). 
 
Chronic infection with viral hepatitis, in particular HCV, causes progressive damage to the liver 
resulting in cirrhosis, with or without the development of hepatocellular carcinoma (HCC).  
Highly effective antiviral therapies are available for the treatment of both HCV and HBV.  
Sustained virological response (SVR) otherwise known as ‘cure’ rates exceed ninety percent in 
individuals with genotype 1 HCV infection treated with new regimens (9,10) and up to eighty 
percent in individuals with genotypes 2 and 3 infection (11).   Despite the availability of these 
highly effective treatments, research has highlighted that identification of high-risk groups, 
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detection and subsequent treatment of viral hepatitis in the UK has previously been and 
continues to be suboptimal (12).   
 
The development of these highly effective antiviral therapies has, for the first time, made 
elimination of HCV a possibility.  The term elimination refers to a reduction to zero in the 
incidence of new infections caused by HCV in a defined geographical area.  This reduction in 
incidence occurs as a result of deliberate efforts made and requires continued action to 
prevent re-establishment of transmission of the virus.  In HCV, the deliberate efforts include 
the development and implementation of highly rigorous and effective case-finding 
programmes that target ‘at risk’ populations as well as promoting engagement with 
treatment and probably, most importantly, prevention education.  Whilst future elimination 
of HCV is a possibility, eradication may not be. The term eradication refers to the complete 
and permanent world-wide reduction of a disease to zero cases without the need for further 
intervention or disease control measures.   Although HCV has a limited host range and there 
are highly effective DAAs available for the treatment, the absence of a pan-genotypic vaccine, 
poor linkage to care for individuals diagnosed with the disease, the high current high cost of 
HCV treatment, and the potential risk of re-infection due to an un-diagnosed reservoir of 
infection in ‘difficult to reach’ populations are all factors that will prevent HCV eradication.    
 
HepFree, a randomised controlled cross-sectional cluster trial aimed to assess the feasibility 
and cost-effectiveness of case identification and subsequent treatment of viral hepatitis in 
immigrants originating from countries with a known prevalence of viral hepatitis of more than 
two percent.  The trial was developed by Professor Graham Foster, and following successful 
application,  was funded by the National Institute for Health and Research (NIHR) through the 
Programme Grants for Applied Research.   
 
The trial performed targeted testing for viral hepatitis in immigrants in General Practices (GP) 
in four geographically distinct areas of England.  Potential study participants were identified 
from lists of registered patients stored on clinical computer systems within practices.  
Participants were identified from pre-existing demographic data that was documented within 
their individual electronic medical record.  Once identified, potential study participants were 
sent an invitation through the post to attend for a viral hepatitis screening test.  HepFree 
commenced screening in Bradford, East London and South London in March 2014 and later in 
Oxfordshire in August 2015.   
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Through performing targeted testing in high-risk immigrant populations, we aimed to 
establish the demography of viral hepatitis in these groups of individuals in certain geographic 
locations in England.  Specific outcomes included disease prevalence, the characteristics of 
individuals affected and the associated burden of disease.  In addition to determining the 
prevalence of disease, through its methodology, HepFree aimed to establish the most 
effective way of engaging this population; letter invitation versus opportunistic testing.  
Finally by offering treatment to trial participants with a diagnosis of viral hepatitis in a variety 
of locations; satellite viral hepatitis clinics in the community outside of secondary care in 
addition to in secondary care (standard of care) the trial examined the impact of different 
locations on engagement, compliance and adherence to treatment. 
 
As the clinical fellow employed to work on the HepFree trial in Bradford, once full sponsorship 
for the trial had been granted in London, my first role was to set up Bradford as a 
coordinating trial site.  In order to do this, I facilitated the development and implementation 
of a contract between Barts Health NHS Trust and Bradford Teaching Hospitals NHS 
Foundation Trust.  Once the contract had been finalised, site feasibility was completed and an 
agreement produced between the Research Development team at Bradford Teaching 
Hospitals and the Research Management Group at the Bradford District Care NHS Foundation 
Trust to enable the trial to be performed in GP surgeries in the community.  Prior to recruiting 
practices to act as trial sites, I designed and created the searches that would be used on the 
clinical computer systems in primary care to identify potential study participants.  These 
searches were designed to identify individuals registered at each practice that originated from 
countries with a prevalence of viral hepatitis of more than two percent.  The searches 
identified potential study participants based on Read codes relating to ethnicity, country of 
birth and main spoken language that were recorded within each electronic medical record.  
The searches are described fully in Materials and Methods.  Once the searches had been 
developed and tested, recruiting practices that would perform the hepatitis testing 
commenced.   
 
In Bradford, I was solely responsible for recruiting, initiating, opening and assisting in the 
running of the trial in twenty-one practices.  Once sites had opened and targeted testing had 
commenced, all participants with a positive hepatitis test were offered an appointment to 
attend a diagnostic assessment appointment in secondary care.  I was responsible for the 
assessment, management and follow-up of all participants with a positive test.  Depending on 
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the outcome of randomisation, following the diagnostic assessment, subsequent 
appointments for treatment either took place in secondary care or in a satellite viral hepatitis 
clinic based at a GP surgery in the community.  In addition to these roles, I also collected, 
collated and entered all trial related data into trial electronic case report forms (eCRF).  In 
conjunction with the clinical fellow and data manager in London I had assisted in the 
development of, and testing of the aforementioned eCRF.  In Bradford, all clinical duties were 
overseen locally by the principal investigator (PI) and centrally by the trial chief investigator 
(CI).   
 
In addition to my roles in the national HepFree study, I designed, developed and implemented 
a unique sub-study exploring symptoms and healthcare utilisation in individuals with 
undiagnosed chronic HCV that had been identified through the HepFree trial.  The full 
methodology of the HepFree trial and the retrospective case-control sub-study are discussed 
in Materials and methods. 
 
1.2 The Hepatropic viruses 
Worldwide, the vast majority of cases of viral hepatitis are caused by hepatitis viruses A, B, C, 
D and E.  The natural history, routes of transmission, clinical manifestations, long-term 
consequences, and options for immunisation vary significantly between the viruses.  This 
thesis concentrates on hepatitis B and C viruses, however hepatitis A, D and E will be 
discussed initially. 
 
1.2.1 Hepatitis A 
Hepatitis A (HAV) is a single stranded, non-enveloped RNA virus belonging to the picornavirus 
family.  Transmission is predominantly faecal-oral, and presents clinically as an acute hepatitis 
with deranged liver function tests (LFTs) and jaundice.  Advancements in public health 
sanitation and an improvement in overall standards of living as well as the development of a 
vaccine have resulted in a decrease in the worldwide incidence of acute HAV infection (13).  
Mortality secondary to HAV, as a result of fulminant hepatic failure is rare, the estimated 
annual mortality rate is 1.2 deaths per 1 million persons (14).  Infection with HAV does not 
progress to chronic liver disease (15). 
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1.2.2 Hepatitis D 
Hepatitis D virus (HDV) is a defective RNA virus, dependent on HBV for its lifecycle (16).  The 
delta virus shares envelope proteins from HBV to enable attachment and entry into host cells 
(17–19).  Infection with HDV can occur simultaneously with HBV, known as co-infection, or 
subsequently, termed as super-infection (20).  Infection with HDV causes severe liver disease 
with rapid progression to cirrhosis (21–25).  Areas of endemicity include central and the horn 
of Africa, the Amazon basin, Eastern and Mediterranean Europe as well as the Middle East 
and parts of Asia (26).  It is estimated that in excess of 15 million people with chronic HBV 
infection have been exposed to and infected with HDV, corresponding to a global prevalence 
of approximately five percent (20).  In prevalence studies conducted in European countries 
including Italy, a decline in infection rates with HDV have been observed.  Investigators 
summarised that this change in prevalence has occurred in response to a decline in the 
prevalence of new HBV infections as a result of increased awareness, education and the 
development of a vaccine (27,28).  This decrease in prevalence however was not observed 
when the authors examined a further cohort of Italian subjects with chronic HBV in 2006, 
where a slight increase in prevalence was seen, nor has it  been observed in other European 
countries including the UK, where a rise in new cases of infection have been attributed to 
immigration (29–31).   
 
The current treatment option available for HDV infection is pegylated interferon alpha (32).  
Studies investigating the efficacy of interferon have demonstrated HDV negative rates of 
approximately 15-40% in individuals followed up twenty-four weeks after stopping therapy 
(33–35). 
1.2.3 Hepatitis E 
Hepatitis E virus (HEV) is a positive-sense, single stranded RNA virus, transmitted 
predominantly via the faecal-oral route (36).  Similarly to HAV, the highest rates of infection 
are observed in areas of the world with poor standards of sanitation. Acute infection results 
in a mild, self-limiting illness except in the context of pregnancy when infection can result in 
fulminant hepatitis with an associated mortality of up to thirty percent (37,38).  In addition to 
the increased risks associated with infection during pregnancy, a small case series performed 
in France identified that acute infection with HEV in organ transplant recipients can result in 
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chronic infection with progressive development of fibrosis (39).  Annually there are 
approximately 20 million episodes of infection with 3.3 million symptomatic cases of HEV and 
approximately 56,600 deaths (40). 
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1.3 Hepatitis B 
Hepatitis B is a partially double-stranded, enveloped DNA virus belonging to the 
hepadnaviridae family (41). Infection can either be acute or chronic, and clinical outcomes for 
both are discussed within this section.  Acute infection with HBV is either sub-clinical, or can 
be associated with constitutional symptoms including loss of appetite, muscle aches, malaise, 
fatigue and occasionally a fever.  Diagnosis is made with serum; the first marker detected in 
the blood of acutely infected individuals is HBV DNA, followed by hepatitis B surface antigen 
(HBsAg) and hepatitis B e antigen (HBeAg), the presence of which indicates high viral 
replication (41).   Acute infection is accompanied by elevated liver enzymes and complicated 
by jaundice in approximately ten percent of young children and in up to thirty to fifty percent 
of adults infected (41). In contrast to cases of acute infection, chronic infection with HBV is 
predominantly asymptomatic with symptoms arising only as a result of progression to chronic 
liver disease. 
 
The modes and patterns of transmission of HBV vary depending on the country and 
population sub-group studied (42).  Infection with HBV can occur through the following 
routes: vertical transmission in the perinatal period, horizontal transmission between 
household contacts, unprotected sexual intercourse, intravenous drug use (IVDU) and either 
percutaneous or parenteral contact with infected blood (43).  In countries with high 
endemicity including Africa and Asia, infection predominantly occurs in the perinatal period 
(43,44).  Conversely, in low endemic countries, sexual intercourse is the predominant mode of 
transmission with the risk of infection increased in the following groups; men who have sex 
with men, individuals with multiple sexual partners and individuals with co-existing sexually 
transmitted infections (43). 
 
Chronic HBV is defined as persistence of the virus for more than six months after initial 
infection and is diagnosed by the presence of HBsAg in blood.  Chronic infection represents a 
global health problem.  Worldwide there are estimated to be in excess of 240 million cases of 
chronic HBV infection and annually 1.2 million deaths are attributed to complications of 
chronic hepatitis including cirrhosis and HCC (43).  Long-term infection can lead to cirrhosis of 
the liver and the development of HCC which can occur in the absence of hepatic cirrhosis (45).  
The rate of spontaneous viral elimination in individuals with chronic infection is 
approximately one to two percent per annum (46).  Viral and host factors associated with 
HBsAg clearance include advancing age (47,48), the presence of moderate to severe hepatic 
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steatosis (49), genotype A infection (50) and anti-HBe positive status in combination with low 
serum surface antigen and low HBV DNA levels (51–53). 
 
Host age at the time of infection has a significant impact on the clinical course of the HBV.  
Viral infection in adulthood is associated with a ninety-five percent chance of clearance, 
whereas infection occurring during infancy results in chronic infection in approximately ninety 
percent of cases (54).  Vaccination is the single most effective method of preventing 
individuals from contracting HBV infection.  Historically, targeted vaccination in high risk 
populations was recommended however due to difficulties in identifying and engaging these 
populations, this method is seldom superior to universal vaccination.  The World Health 
Organisation therefore recommended that HBV vaccination be incorporated into the 
Expanded Program on Immunisation and following this, a significant decrease in chronic HBV 
infections was observed.  A minority of European countries including the UK are yet to adopt 
universal screening policies and therefore transmission here still poses as a much greater 
threat. 
 
1.3.1 The natural history of HBV 
Historically, chronic HBV acquired during childhood consisted of four phases of infection; 
immune tolerance, immune clearance, the inactive carrier state and HBV reactivation 
otherwise known as HBeAg negative chronic hepatitis (55,56).  Individuals infected with HBV 
can move back and forth between these four phases of infection.   
 
Within this section I will discuss the well-documented phases in the natural history of HBV in 
addition to more contemporary research that has challenged some of the more traditional 
definitions. 
1.3.1.1 Immune tolerance 
The immune tolerant phase of HBV is defined by a high circulating viral load (VL) in 
combination with positive HBeAg serology, normal serum alanine transaminase (ALT) levels 
and little or no evidence of hepatic inflammation on histological assessment of the liver (56–
58). Historically, it was hypothesised that high rates of chronic infection and the immune 
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tolerant phase of infection observed in infants was the result of trans-placental transfer of 
viral proteins coupled with HBV-specific T-cell hyporesponsiveness and an inefficient T-cell 
response.   
 
The concept of immune tolerance has been challenged by authors who suggest that chronic 
infection in children is neither associated with an insufficient nor a tolerant T-cell profile (59).  
In a study by Kennedy et al, T-cell cytokine profiles obtained from young adults with chronic 
HBV were compared to age-matched non-infected ‘healthy’ subjects.  In this study T-cells 
from infected individuals demonstrated superior ability to produce antiviral cytokines 
compared to healthy controls.  In addition to this, an increased expression of exhaustion 
markers on the T-cells of young individuals with chronic HBV was observed compared to the 
healthy control cohort (59).   
 
T-cell exhaustion occurs as a consequence of repetitive activation of reactive T-cells.  This 
finding therefore contradicts the theory that infants and young adults with chronic HBV 
display tolerance to the virus (59).  One other finding presented in this study further 
questioned the definition of the immune tolerant phase of infection.  In both the infected and 
non-infected cohorts, the frequency of chemokine ligand 3 (CCL-3) producing T-cells were 
measured.  These were lower in the ‘immune tolerant’ infected cohort compared to both age-
matched healthy controls and individuals with chronic active disease.  Elevated CCL-3 levels 
are found in the serum of individuals with T-cell mediated liver disease, therefore the 
investigators speculated that defective production of CCL-3 is responsible for the normal ALT 
levels that are observed and form part of the accepted definition of immune tolerance (59).  
 
The observation of minimal or no hepatic fibrosis at the time of histological assessment also 
forms part of the definition of immune tolerance.  This finding was supported by results from 
a liver biopsy trial performed in individuals with chronic HBV in China (60).  In this trial, 
participants underwent histological assessment using liver biopsy prior to recruitment and 
were then followed with a period of observation and serial ALT monitoring once every six 
months for five years. Exclusion criteria for the trial included the presence of fibrosis, Ishak 
score of greater than one on liver biopsy.  Participants were later withdrawn from follow-up 
in the event of an elevated ALT result (60).  During the trial, sixteen percent of subjects were 
prematurely withdrawn, and repeat biopsies in all cases demonstrated progression of fibrosis.  
The remaining participants that completed follow-up fulfilled the definition of ‘immune 
tolerance’, with evidence of either little or no fibrosis progression during the five year period 
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of observation (60).  The slow progression of fibrosis demonstrated in participants that 
remained in this study was supported by a paired transient elastography study performed in 
HBeAg positive individuals (61).   
 
Contradictory results were obtained in a study conducted in individuals with HBeAg positive 
disease by Lai et al.  Here eighteen percent of individuals with ALT values of less of less than 
40 IU/L on at least two occasions in the preceding six months had evidence of histologically 
active disease; Ishak fibrosis stage of two or greater on liver biopsy.  This study questioned 
the reliability of a ‘normal’ ALT in predicting fibrosis.  Trial limitations identified by the authors 
were that both the age and VL of the subjects studied were not typical of those in the 
immune tolerant phase of infection. A liver biopsy study performed in 452 participants with 
chronic HBV in different phases of infection further questioned the reliability of a normal ALT 
in predicting fibrosis.  Here,  irrespective of the value of ALT, histological evidence of 
inflammation was present within the liver of all individuals included in the trial (62). More 
advanced fibrosis was observed in HBeAg negative individuals compared to HBeAg positive 
subjects, however, approximately five percent of individuals with HBeAg positive disease did 
have evidence of advanced fibrosis (62). 
 
1.3.1.2 Immune clearance 
Individuals with chronic HBV typically enter the immune clearance phase of infection between 
the third and fifth decades of life.  This phase is defined as a period of immune-mediated liver 
damage manifesting as either intermittent or persistent elevations in serum ALT, combined 
with high HBV DNA levels and histological features of necro-inflammation with varying 
degrees of fibrosis on liver biopsy (58).  In this phase of infection, individuals either 
seroconvert from HBeAg positive to HBeAg negative, anti-HBe positive disease, often 
associated with VL suppression, or they fail to seroconvert, resulting in persistent hepatic 
inflammation and the development of fibrosis (58).  A well-documented relationship exists 
between the severity of ALT rise observed in individuals during the immune active phase of 
infection and the subsequent rate of seroconversion to anti-HBe positive disease (63).  In a 
large longitudinal study of individuals of  Chinese origin with chronic HBV, more than half of 
all participants with an ALT rise to greater than five-times the upper limit of normal (ULN) 
spontaneously seroconverted to anti-HBe compared with twenty-six percent of individuals 
with an ALT rise to less than five- times the ULN (64).  
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1.3.1.3 Anti-HBe positive HBV 
Following seroconversion, individuals with chronic infection either progress to an inactive 
phase of infection characterised by minimal, if any necroinflammatory activity within the liver, 
or alternatively they have on-going evidence of hepatic inflammation.  The following criteria 
are used to diagnose the inactive carrier state: HBeAg negative, anti-HBe positive serology in 
conjunction with normal ALT levels and a HBV DNA of equal or less than 2.0 x10
3
IU/mL (32).  
Individuals may not remain in this inactive phase of infection permanently, instead 
progressing to a second immune active phase referred to as HBeAg negative chronic hepatitis.  
This is  diagnosed by the presence of either transient or persistent elevations in serum ALT 
levels with serum HBV DNA levels exceeding 2.0 x10
3
IU/mL (65). 
 
1.3.2 Virology and immunology 
HBV is a partially double-stranded, enveloped DNA virus originating from the hepadnaviridae 
family (41).  The infectious portion of the virus, referred to as the Dane particle, consists of an 
outer envelope composed of lipids and glycoproteins including HBsAg and an inner 
nucleocapsid, containing a copy of double-stranded HBV DNA and the HBV DNA polymerase 
enzyme enclosed by hepatitis B core antigen (66).  Interactions between cell surface receptors 
and viral envelope proteins enable HBV entry into host hepatocytes.  Following binding of the 
virus, cell entry occurs as a result of endocytosis and the nucleocapsid is released into the cell 
cytoplasm.   
 
Once inside the cell, the virus nucleocapsid is uncoated and relaxed circular HBV DNA (rcDNA) 
is released into hepatocyte nucleus where it is repaired and converted into a covalently 
closed circular DNA molecule (cccDNA).  This DNA molecule serves as the template for 
subsequent viral RNA transcription.   
 
The double stranded HBV DNA genome encodes four major RNA templates, the largest of 
which has dual function acting both as messenger RNA and as pre-genomic RNA.  The 
translation of viral RNA into HBV proteins involves four overlapping open reading frames: 
surface envelope (S), core (C), polymerase (P) and X protein.  The S and C open reading frames 
possess in-frame initiation codons that facilitate the translation of different HBV proteins.  
Core antigen and pre-core proteins are encoded for by C and the S open reading frame 
encode three surface envelope proteins; small, middle and large surface antigen. 
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In the host cell endoplasmic reticulum (ER), pre-core proteins undergo proteolysis to become 
HBeAg.  This is responsible for both promoting chronic infection in the host and acts as an 
important marker for viral replication (67).  The P open reading frame encodes HBV 
polymerase, this has multiple roles including the synthesis of HBV DNA, reverse transcriptase 
which catalyses genome synthesis and the degradation of pregenomic RNA (41).  The 
functions of HBV X antigen protein encoded by the X open reading frame include signal 
transduction, transcriptional activation, DNA repair and protein degradation, necessary for 
productive HBV infection in vivo (41).  The HBV nucleocapsid is then assembled within the 
cytoplasm of the hepatocyte.  Pre-genomic RNA is encapsidated by cytoplasmic viral proteins 
where it acts as a template for reverse transcriptase leading to synthesis of new HBV DNA 
molecules.  The infective virions are then transported to the ER of the cell for further 
assembly and excreted from the infected cell through a process of budding and vesicular 
transport.  Within the nucleus of the infected hepatocyte, cccDNA continues to exist and is 
resistant to eradication.   
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Figure 1: Hepatitis B virus replication   
 
A diagram demonstrating a replication cycle of HBV as described in the text above. 
 Image taken from Hepatitis B: The Virus and Disease, Liang 2009.   
 
As previously stated, acute HBV infection in adulthood is associated with high rates of viral 
clearance.  The predominantly self-limiting nature of infection is the result of cluster of 
differentiation 4 positive (CD4+) and cluster of differentiation 8 positive(CD8+) T-cell 
responses.  CD4+ T-cells target HBV-core antigen epitopes producing the Type 1 T-helper (Th-
1) cytokines interferon-gamma (IFN-ɣ) and tumour necrosis factor-alpha (TNF-α).  
Simultaneously, CD8+ T-cells are also activated, these are the major immune cells that 
contribute to viral clearance (68,69).  Impaired HBV-specific T-cell responses and progressive 
loss of T-cell function, known as T-cell exhaustion,  have been identified as the reasons for 
viral persistence and development of chronic HBV (70).   
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In an exhausted state the proliferative capacity of T-cells is disrupted, cytokine production is 
impaired and there is up-regulation of the following inhibitory molecules; programmed cell 
death 1 (PD-1), cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), CD244, and T-cell 
immunoglobulin and mucin-domain containing-3 (Tim-3)(71,72).  Increased expression of the 
aforementioned co-inhibitory receptors in addition to the apoptosis gene BCL2-interacting 
mediator BIM occur in response to high levels of HBV antigen and DNA.   
Increased expression of these inhibitory molecules results in a reduction of T-cell 
responsiveness hindering viral elimination (71).  The role of each of the HBV exhaustion 
markers is discussed below. 
 
1.3.2.1 Programmed cell death-1 
PD-1 is the dominant inhibitory receptor on HBV specific CD8+ T-cells.  Up-regulation of PD-1 
expression occurs in response to a high HBV viral load (73).  A study investigating the effect of 
programmed death-ligand 1(PD-L1) blockade in peripheral mononuclear cells demonstrated 
partial improvements in both the expansion of, and cytokine secreting ability of CD8+ T-cells 
(73). 
 
1.3.2.2 Cytotoxic T-lymphocyte associated antigen 4 
Cluster of differentiation 28 (CD-28) dependent T-cell activation and production of 
interleukin-2 (IL-2) are both prevented by CTLA-4 (74).  A positive correlation has been 
identified between HBV-specific CD8+ T-cell expression of CTLA-4 and HBV viral load (75).  
Blockade of CTLA-4 results in decreased expression of BIM as well as increased proliferation 
of IFN ɣ producing T-cells in both peripheral mononuclear cells and in hepatocytes (75,76). 
 
1.3.2.3 T-cell immunoglobulin and mucin-domain containing-3 
Expression of Tim-3 by HBV specific T-cells results in decreased production of both IFN-ɣ and 
TNF-α (76).  In chronic HBV, Tim-3 expression occurs more frequently on HBV specific CD8 T-
cells compared with other CD8 T-cells within the same individual (77).   
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As the ability to clear HBV has been associated with a strong virus specific T-cell response, 
blockade of the co-inhibitory pathways described above may restore HBV-specific T-cell 
function and enable virus elimination.   
 
1.3.3 Hepatitis B genotypes 
The lack of a proof-reading function by HBV reverse transcriptase leads to high rates of viral 
variation.  These viral variants are categorised into different genotypes.  Historically there 
were eight well known genotypes A-H with specific geographic distributions and a further two 
genotypes, I&J have subsequently been identified (78).  Of the frequently encountered 
genotypes, A is predominantly identified in sub-Saharan Africa, Northern Europe and West 
Africa, B and C in south Asia and genotype D in Africa, Europe, Mediterranean countries and 
India (78).   
 
Studies conducted to evaluate the clinical significance of HBV genotypes have predominantly 
concentrated on individuals of Asian origin with genotypes B and C infection.  These studies 
identified that the prevalence of HBeAg positive chronic HBV was higher in individuals with 
genotype C disease, with spontaneous seroconversion to anti-HBe occurring more frequently 
in individuals with genotype B infection (79–81).  The authors of these studies concluded that 
individuals infected with genotype C disease remained in the HBeAg positive phase of disease 
for longer, associated with high levels of HBV replication and active liver disease, 
subsequently resulting in higher rates of cirrhosis (79–81).   
 
Studies investigating the relationship between HBV genotype and development of HCC in 
cohorts of individuals of Asian origin produced slightly more conflicting results.  Observational 
studies including a meta-analysis conducted in Japan, China and Hong Kong concluded that 
infection with genotype C disease was associated with an increased risk of HCC, with 
development of HCC occurring at an earlier age (82–84).  These findings were supported by 
an American study conducted in patients awaiting liver transplant (OLTx) (85).  However, in 
studies conducted by Kao and Chen et al in Taiwan, although a higher incidence of HCC was 
observed in individuals infected with genotype C disease, genotype B was associated with 
HCC at a younger age with the lesions often occurring in the absence of cirrhosis (86,87).  It 
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has been suggested that the discrepancy in the results of these studies may be due to sub-
types of the genotype B virus (88), or, given the multifactorial nature of HCC development,  a 
result of exposure to hepatoxins and/or a family history of hepatoma. 
 
There is a paucity of longitudinal data focussing on disease progression and clinical outcomes 
in individuals infected with HBV genotypes A and D.  Results from studies that have been 
conducted have produced contradictory results. In two studies conducted in sub-Saharan 
Africa and India, genotype A disease was associated with a greater risk of developing HCC, 
compared with non-A genotypes (89,90).  Due to the geographical variation in these studies, 
the findings supported the carcinogenic potential of genotype A virus infection irrespective of 
host ethnicity.  In a retrospective study conducted in Indian subjects infected with HBV by 
Kumar et al, genotype A was associated with progression to more significant liver disease (91) 
but this was contradicted in studies by Thakur and Toan where genotype D was associated 
with more severe liver disease and the development of HCC (92,93).  
 
The quality and quantity of data available for interpretation may account for the differences 
that have been reported in the consequences of long-term infection with these two 
genotypes.  Pre-existing evidence of reported outcomes for long-term infection with 
genotypes A and D consist of a limited number of small studies with a retrospective trial 
design.  In these trials, individuals were often recruited after presenting to secondary care for 
assessment for antiviral therapy; therefore the studies have potentially included biased 
sample populations.  
 
The larger longitudinal observational studies performed in Asian cohorts with genotypes B 
and C HBV have provided strong evidence relating to the clinical impact of different 
genotypes in HBV.  Performing studies with similar designs in genotype A and D cohorts 
would help to determine whether the same differences exist with regards to disease 
progression and clinical outcomes.  
 
The HepFree trial will provide the opportunity to conduct a longitudinal observational study 
on an unbiased sample of individuals diagnosed with chronic HBV through targeted testing in 
a pre-defined ‘at-risk’ population. Individuals of different genders, ages, countries of origin, 
ethnic backgrounds and HBV genotypes diagnosed through HepFree will be included and 
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studied to establish disease stage at the time of screening, disease progression, response to 
antiviral therapy if treatment is recommended, and long-term clinical outcomes. 
 
1.3.4 Treatment options for hepatitis B 
The treatment of acute and chronic HBV varies significantly.  Treatment options for acute HBV 
are predominantly supportive, treating symptoms that arise as a result of infection.  The use 
of antiviral agents in acute infection is reserved for individuals who clinically progress to 
fulminant hepatitis.   
 
In chronic HBV, the aims of treatment are to prevent progression of the disease and the 
development of HCC, thereby improving the quality of life of the infected individual.  The 
optimum end point of HBV therapy is serological response, classified either as HBeAg 
seroconversion or HBsAg conversion, the latter of which signifies virus eradication. HBsAg 
clearance does not occur frequently, therefore HBeAg clearance to anti-HBe with subsequent 
HBV DNA suppression and resultant improvement in biochemical and histological parameters 
are more realistic and achievable end points of therapy.   
 
Parameters taken into account when considering HBV therapy initiation include VL, ALT level 
and histological fibrosis stage.  Expert opinion regarding the degree of ALT elevation that 
should prompt consideration of treatment varies. Table 1 summarises treatment 
recommendations published by three expert groups.  Currently the two main treatment 
options available for individuals with chronic HBV are forty-eight weeks of response guided 
therapy with pegylated interferon or long-term therapy with a nucleoside anologue (NA). 
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Table 1: International guidelines for treatment of HBV 
A summary table containing recommendations for treatment in chronic HBV from EASL, 
AASLD and APASL. 
International guideline  HBeAg positive HBV Anti-HBe positive HBV HBV associated cirrhosis 
EASL  
(32) 
HBV DNA >2.0 
x10
3
IU/mL and/or ALT 
>ULN with histological 
evidence of moderate 
to severe disease on 
liver biopsy 
HBV DNA>2.0 
x10
3
IU/mL and/or 
ALT>ULN with 
histological evidence of 
moderate to severe 
disease on liver biopsy 
Compensated  
Any detectable level of 
HBV DNA. 
Decompensated 
Any detectable level of 
HBV DNA. 
AASLD  
(94) 
HBV DNA>2.0 x 
10
4
U/mL and ALT > 2 x 
ULN. 
 
Consider liver biopsy in 
cases of: 
HBV DNA >2.0 x 
10
4
U/mL with ALT < 2 x 
ULN in patients aged > 
40 or individuals with a 
family history of HCC 
and  commence 
treatment in cases of 
histological evidence of 
significant disease 
HBV DNA >2.0 
x10
3
IU/mL and ALT >2 x 
ULN. 
 
Consider liver biopsy in 
cases of: 
HBV DNA >2.0 
x10
3
IU/mL and ALT > 
ULN and commence 
treatment in cases of 
histological evidence of 
significant disease 
Compensated  
HBV DNA>2.0 
x10
3
IU/mL 
 
Consider treatment in 
cases of: 
 ALT > ULN and HBV 
DNA <2.0 x10
3
IU/mL 
 
Decompensated  
Any detectable level of 
HBV DNA. 
APASL  
(95) 
HBV VL >2.0 x 10
4
U/mL 
and ALT > 5 x ULN  
or  HBV DNA > 2.0 x 
10
4
U/mL and ALT 2-5 x 
ULN  
or HBV DNA >2.0 x 
10
4
U/mL and ALT < 2 x 
ULN but with evidence 
of moderate to severe 
inflammation or 
fibrosis on liver biopsy 
in individuals aged > 
40. 
HBV VL > 2.0 x 10
3
IU/mL 
and ALT > 2 x ULN for 3-
6 months or with 
concerns about hepatic 
decompensation or 
HBV >2.0 x 10
3
IU/mL 
and ALT < 2 x ULN with 
evidence of moderate 
to severe inflammation 
or fibrosis on liver 
biopsy. 
Compensated  
HBV DNA > 2000IU/mL 
 
Decompensated 
Any detectable level of 
HBV DNA. 
EASL: European Association for the Study of the Liver; AASLD: American Association for the Study of 
Liver Diseases; APASL: The Asian Pacific Association for the Study of the Liver; >: more than; <: less than. 
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1.3.4.1 Pegylated interferon 
Interferons, because of their potent antiviral, antiproliferative and immunomodulatory effects 
are a viable therapeutic option in the treatment of both HBeAg positive and anti-HBe chronic 
HBV.  The two major advantages of treatment with interferon therapy are that it is associated 
with a greater chance of HBsAg clearance when compared to treatment with a NA, and 
secondly that therapy is for a finite amount of time.  Interferon is administered in accordance 
with strict protocols that advise the monitoring of on-treatment surface antigen levels and 
include stopping-rules in cases of non-response.   
 
Pegylated interferon (peg-IFN) is considered for use in individuals with evidence of active viral 
replication in combination with an elevated ALT level and histological evidence of active 
disease on liver biopsy.  Active viral replication is defined as a HBV DNA level of greater than 
20,000 IU/mL in cases of HBeAg positive disease and a VL of greater than 2,000IU/mL in 
individuals with anti-HBe disease (32). 
 
Treatment response to peg-IFN is defined by either seroconversion to anti-HBe, a reduction in 
quantitative HBV DNA level or HBsAg seroconversion.  Treatment outcomes can be observed 
either at completion of forty-eight weeks of therapy or within twenty-four weeks of 
treatment cessation.  The efficacy of peg-IFN, used as both a single agent and in combination 
with lamuvidine has been compared in several large multicentre studies (96,97).  In the study 
by Janssen et al, HBeAg positive participants were assigned to treatment either with peg-IFN 
monotherapy or interferon in combination with lamuvidine (96).  HBeAg loss occurred in 
approximately one third of patients treated, with no significant difference in the rates of 
clearance observed between the monotherapy and combination therapy cohorts (96).  Here, 
HBsAg loss occurred in seven percent of participants, again no superior outcome was 
observed in the combination therapy cohort (96).   
 
In a further study of 814 patients with HBeAg positive disease conducted by Lau et al, 
participants were randomised to three treatment arms and observed for outcomes.  The 
treatment arms were peg-IFN monotherapy, interferon with lamuvidine and lamuvidine 
monotherapy (97).  Suppression of viral load occurred more frequently in individuals that 
received combination therapy, however HBeAg seroconversion twenty-four weeks after 
treatment cessation was observed most frequently in the cohort of participants receiving Peg-
IFN monotherapy, occurring in thirty-two percent of cases (97).  In this trial, surface antigen 
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clearance was observed in three percent of all participants receiving peg-IFN either as 
monotherapy or in combination with lamuvidine (97).   
 
In a clinical trial, designed to assess response to peg-IFN therapy in individuals with anti-HBe 
disease (98), peg-IFN was compared to lamuvidine.  Outcomes measured included 
normalisation of ALT level and reduction in VL to less than 20,000 IU/mL.  Superior outcomes 
were observed in the peg-IFN monotherapy cohort with ALT normalisation and HBV VL 
reduction observed in fifty-nine and forty-three percent of cases respectively, compared to 
forty-four and twenty-nine percent in the lamuvidine monotherapy cohort (98).  Loss of 
HBsAg occurred in three percent of participants that received peg-IFN therapy, with no cases 
of viral clearance observed in the lamuvidine monotherapy cohort (98).   
 
Factors associated with virological and biochemical response to interferon include female 
gender, young age, high pre-treatment ALT in combination with low pre-treatment HBV VL 
and genotype A, B and C disease (99,100).  Individuals infected with genotype D have a less 
favourable response to peg-IFN therapy (101).   
 
1.3.4.2 Nucleos(t)ide analogues 
Nucleos(t)ide analogues (NAs) are the other main class of agents used in the treatment of 
chronic HBV.  Their mode of action is inhibition of HBV DNA polymerase activity, thereby 
suppressing viral replication.  NAs have no impact on existing cccDNA reservoirs within 
infected hepatocytes.  Five NAs have been approved for the treatment of chronic HBV and 
due to their optimum resistance profiles, the two main agents used in the UK are tenofovir 
and entecavir.  Treatment response to NAs is defined as an undetectable HBV DNA level by 
polymerase chain reaction (PCR) assay (32).   
 
NAs are favourable compared to peg-IFN in terms of dosing regimen, side effect profile and 
patient tolerance.  However, treatment, once initiated is often long-term and there is 
potential for the emergence of drug resistance mutations due to the rapid replication rate of 
the virus coupled with the lack of an effective proofreading mechanism as discussed 
previously.  A finite treatment regimen with NAs may be considered for individuals with 
HBeAg positive disease as the indication for treatment, in cases of seroconversion with 
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subsequent normalisation of serum ALT and reduction in VL to less than 2,000IU/mL (32).  
Sustained off-treatment response rates following HBeAg seroconversion with NAs vary 
considerably though depending on the trial reviewed.  High durability of seroconversion has 
been reported in follow-up studies conducted by Dienstag and Poynard et al (102,103).   One 
of these studies however is only available for review in abstract format.  Conversley, high 
relapse rates have been reported in cases of NA treatment withdrawal in studies by Song and 
Reijinders et al.  The authors of these studies concluded that seroconversion as a result of NA 
therapy is a transient rather than permanent event (104,105).  Higher off-treatment success 
rates were observed in studies performed in Western countries with relapses observed more 
frequently in Asian populations suggesting that HBV genotype may impact on long-term 
outcomes observed in the setting of NA therapy.  In addition to this, the length of 
consolidation therapy with NAs varied between the studies and this may have contributed to 
the differences observed.  Finally, the definition of relapse varied between studies, with some 
only classifying relapse as recurrence of HBeAg positive disease, not taking into account the 
presence of a detectable HBV VL after withdrawal of therapy.   
 
HBsAg clearance has been documented in individuals receiving long-term NA therapy, 
although this outcome does not occur as frequently as in cases treated with peg-IFN.  A 
retrospective study of long-term clinical outcomes in individuals receiving NA therapy 
observed an annual seroclearance rate of 0.33% (106).  It is debatable whether HBsAg loss 
experienced with NA therapy truly represents viral clearance.  In this study, nearly one 
quarter of patients with negative HBsAg status had on-going low level detectable HBV (106).  
This finding however is not solely observed in cases treated with NA, with comparable 
findings observed in cases of spontaneous HBsAg clearance (107,108).  This finding suggests 
that HBsAg loss observed in the setting of NA therapy actually reflects a decrease in surface 
antigen production as a result of suppression of viral replication.  Independent of surface 
antigen status, long-term treatment with NA has been associated with an improvement in 
histological fibrosis score and reversal of cirrhosis has been observed (109–111). 
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1.4 Hepatitis C 
With an estimated 130-170 million cases of infection worldwide, chronic HCV is a significant 
global health problem (2).  HCV has a high predilection for establishing long-term infection, 
resulting in persistent hepatic inflammation that culminates in liver cirrhosis with or without 
development of HCC.  In developed countries, HCV related disease is now the most common 
indication for OLTx (112).  Development of highly effective antiviral therapies have 
revolutionised the treatment of a disease that for more than two decades, with the exception 
of interferon, had very few therapeutic options.  Unlike HBV, a vaccine to reduce the spread 
of disease is yet to be developed.      
1.4.1 Discovery of the virus 
Hepatitis C, initially referred to as Non-A Non-B hepatitis, was discovered in 1989 following 
the emergence of a high number of sero-negative cases of hepatitis, observed predominantly 
in blood transfusion recipients and people who injected drugs (PWID)(113).  The complete 
genome was coded in 1991 and six phenotypically distinct virus genotypes were identified.   
Multiple quasispecies of the HCV virus exist however, due to errors made by the viral-RNA 
dependent RNA polymerase during replication (114).  Worldwide, genotype 1 is the most 
prevalent strain of virus, accounting for up to forty-six percent of all HCV infections (115).  
Genotypes 1, 2 and 3 are predominantly responsible for cases of HCV infection in the United 
States of America, Australasia and Europe (115).  Genotype 4 is prevalent in North Africa and 
the Middle East, genotype 5 in South Africa and genotype 6 in individuals residing in South 
East Asia (115).   
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Figure 2: The global distribution of HCV genotypes 
 
 
A map depicting the relative prevalence of each HCV genotype by global burden of disease (GBD) region. The size of 
the pie charts is proportional to the number of seroprevalent cases as estimated by Hanafiah et al (116).  Image 
reproduced from and credited to Messina et al (117). 
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1.4.2 Hepatitis C virus lifecycle 
Hepatocytes are the host cells predominantly used by HCV for replication, however 
replication may also occur in peripheral blood mononuclear cells (118).  HCV is comprised of a 
nucleocapsid core surrounded by a host derived membrane containing the envelope 1 (E1) 
and envelope 2 (E2) glycoproteins that mediate cell entry (119).  Host cell entry is through a 
complex interaction involving glycosaminoglycans, the low density lipoprotein receptor, the 
high density lipoprotein receptor scavenger receptor class B type 1, tetraspanin CD81 and 
tight junction proteins claudin-1 and occludin (120).    
 
Once inside the cell, HCV dissolves its outer coating, releasing a single positive strand of RNA 
into the cell cytoplasm, this travels to the rough endoplasmic reticulum (RER).  Ribosomal 
subunits associated with the RER serve as translation units, converting the positive strand 
viral RNA genome into a single large polyprotein of approximately 3011 amino acids.  The 
polyprotein is cleaved by host and viral proteases to produce three structural and seven non-
structural (NS) proteins (121).  The primary function of the NS proteins is to support viral 
replication.  Non-structural 4B protein (NS4B) with non-structural 5A protein (NS5A) are 
primarily responsible for formation of the site of HCV viral replication by assembling the 
membrane associated replication complex responsible for synthesising RNA and then by 
recruiting the genomic RNA into the complex.  Although all NS proteins are essential for HCV 
replication, NS5B encodes the RNA-dependent RNA polymerase.  During viral replication, a 
negative strand HCV RNA is produced from the positive strand RNA.  These combine to form a 
double stranded intermediate that serves as a template for the production of further copies 
of the viral genome.  The new positive strand RNA is then packaged to form new HCV virions 
that mature in the host cell golgi apparatus prior to release from the hepatocyte by 
exocytosis. 
 
Rapid viral replication in addition to a high error rate in the NS5B coded RNA-dependent RNA 
polymerase results in mutations and a heterogeneous collection of virus quasispecies within 
each viral genotype (122).  Mutations occurring in the hypervariable region of the genome 
that code for the HCV envelope proteins result in failure of the host T-cells to respond to new 
virus epitopes which in turn results in high rates of chronic infection through a phenomenon 
known as original antigenic sin (123). 
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Figure 3: Hepatitis C virus replication 
 
 
A diagram demonstrating a replication cycle of HCV as described in the text above.  Image taken from ‘Unique ties 
between hepatitis C replication and intracellular lipids’ with full credit to  Herker & Ott (124). 
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1.4.3 The epidemiology of hepatitis C 
1.4.3.1 Worldwide prevalence 
For a multitude of reasons, the global prevalence and true extent of the associated burden of 
disease related to HCV will probably never be established.  The documented global 
prevalence of HCV derived from reviews of published data is two to three percent (115). 
Several factors influence the validity of results derived from HCV prevalence studies, and 
these are discussed below.  Firstly, in prevalence studies, screening assays for antibodies to 
hepatitis C (anti-HCV) form the basis of testing.  The presence of anti-HCV is not diagnostic for 
chronic HCV, it remains positive in the setting of both spontaneous viral clearance and 
eradication following administration of antiviral agents (125). The use of this test is therefore 
likely to overestimate the prevalence of disease in the populations approached for testing 
(126).  Prevalence studies that perform PCR testing to confirm chronic infection in individuals 
with a positive anti-HCV test therefore more accurately reflect the true magnitude of the HCV 
pandemic.  The second factor influencing results relates to the type of immunoassay used by 
prevalence studies.  Advances in medicine have resulted in improved sensitivity of 
immunoassays used to screen for HCV.  Anti-HCV prevalence therefore may have been 
overestimated with the use of first generation immunoassays (127).  In addition to this, any 
prevalence estimates derived from retrospective studies performed on stored sera need to be 
interpreted with caution due to the increased reporting of weakly positive antibody tests in 
‘aged’ blood samples (128). Currently prevalence studies use third generation immunoassays 
to screen for anti-HCV and these demonstrate both a high sensitivity and specificity (129–
131).   
 
Conversely, as opposed to over-estimating prevalence, historically, prevalence studies may 
have underestimated the true burden of disease predominantly because of the cohorts of 
individuals selected to participate in testing.  There are a paucity of published studies focusing 
on HCV prevalence in high-risk populations, namely in PWID and incarcerated individuals 
(132).  One key example of this is prevalence estimates of chronic HCV infection in the USA in 
a landmark paper from the NHANES III study by Alter et al.  The sample population failed to 
include either homeless or incarcerated individuals and therefore investigators are likely to 
have underestimated the true prevalence of disease in the American population (133).  
Another factor impacting on accurate prevalence reporting relates to the insidious onset and 
often asymptomatic nature of infection with HCV that prevents prevalence studies for chronic 
disease being conducted prospectively using individuals presenting with acute infection (134). 
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Variations in both geographical and temporal trends of chronic HCV infection have been 
identified by studying infected populations originating from different areas of the world (135).  
In America, NHANES III, a large population based study conducted between 1988-1994, 
identified that over half of all chronic HCV infections affected individuals aged between thirty 
and forty-nine who were therefore born between 1945-1965 (133).  The high prevalence of 
disease observed in this age group indicated that the risk of HCV infection was greatest in the 
relatively recent past with transmission occurring in young adults either through IVDU or high 
risk sexual intercourse.  
 
The second pattern of infection, observed in China, Italy, Japan, Spain and Turkey identified 
cases of infection predominantly in individuals of advancing age with low prevalence rates 
observed in children and young adults.  When investigated in Japan, the seroprevalence in 
individuals aged less than twenty was very low, less than one percent compared to more than 
two percent in subjects aged over fifty-five (136).  This finding suggested that transmission of 
HCV started in the 1930s, with infection transmitted through IVDU, unsafe medical 
procedures and blood transfusions (136).   
 
The third pattern observed was high rates of infection across all age groups.  One key example 
of this was in Egypt.  The homogeneity of HCV subtypes in Egypt reflected rapid spread of the 
virus over a very short period of time, likely related to public health initiatives introduced to 
control the spread of schistosomiasis.  This mass immunisation campaign has subsequently 
been described as the world’s largest example of iatrogenic transmission of a blood-borne 
pathogen (137–139). 
 
1.4.4 Routes of infection 
The routes of transmission of HCV vary depending on the population studied.  In developed 
countries, transmission of the virus is predominantly through injecting drug use.  In 
developing countries however, unsafe medical practices including the use of contaminated 
healthcare equipment and the transfusion of unscreened blood products are implicated in the 
spread of HCV. 
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1.4.4.1 Hepatitis C in people who inject drugs 
Globally, ninety percent of new HCV infections are attributed to IVDU (140).   International 
estimates of the incidence of HCV infections in PWID range from eleven to forty-two per one 
hundred person years, highlighting this as an important risk factor for HCV acquisition (141–
143).  Independent predictors of HCV infection in PWID include new injectors, in particular 
individuals with an injecting history of less than twelve months, female gender, a partner who 
also injects drugs, use of shared needles, assistance required to inject, commercial sex work, 
incarceration, and concurrent use of intravenous cocaine (141-143).  The geographic location 
of each study, the age of individuals recruited, the duration of each person’s injecting history 
and changing patterns in injecting behaviours are likely to be responsible for variations in the 
incidence of HCV infections observed in these studies.  A systematic review and meta-
regression of published literature pertaining to HCV infection in PWID residing in developed 
countries estimated a prevalence of infection (anti-HCV positive) of 32.02% [95% CI: 25.31%, 
39.58%] after twelve months of injecting and 53.01% [95% CI: 40.69-65.09%] after five years 
of injecting drug use (144). 
 
1.4.4.2 The transfusion of unscreened blood products 
Recommendations from The World Health Organisation (WHO) are that globally, blood 
transfusion related activities including collection, testing, processing, storage and distribution 
should be coordinated at a national level through integrated blood supply networks.  These 
networks, governed by national blood policies and legislative framework would ensure 
consistency in the quality and safety of blood and blood products.  The WHO Global Database 
on Blood Safety (GDBS) was established to address concerns about the availability, safety and 
accessibility of blood transfusions.  The GDBS collects and analyses data on blood safety with 
the objective of improving blood transfusion services globally.  In 2013, seventy-three percent 
of countries submitting data for analysis had a national blood policy, and sixty-five percent 
had specific legislation for the safety and quality of blood transfusions.  Of the one hundred 
and eight countries with specific legislation in place, seventy-nine percent were classified as 
high-income, sixty-four percent middle-income and forty-one percent low-income.  
As part of its policies on blood safety, the WHO recommended that mandatory testing for 
human immunodeficiency virus (HIV), HBV, HCV and syphilis be performed on all blood 
donations prior to use.  Data obtained from one hundred and fifty-six countries through the 
GDBS identified that sixteen countries were still not able to screen all donated blood for one 
or more of the above infections (145).  The most commonly reported barrier to screening for 
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infections was the irregular supply of kits to perform testing (145).  In high-income countries, 
eighty-one percent of blood screening laboratories were monitored through external quality 
assessment schemes, compared to fifty-five percent in middle-income countries and as few as 
thirty-four percent in low-income countries (145).  These data support the transfusion of 
unscreened blood products as one of the major causes of HCV infection in low-income or 
developing countries 
 
Table 2: Prevalence of transfusion-transmissible infections in blood donations 
The prevalence of transfusion-transmissible infections in blood donations in high, middle, and 
low income countries, reproduced from WHO fact sheet: Blood safety and availability (145). 
 
 HIV 
Median, range 
HBV 
Median, range 
HCV 
Median, range 
High-income 
countries 
0.003% 
(0.001%-0.040%) 
0.030% 
(0.008% – 0.180%) 
0.020% 
(0.003% – 0.160%) 
Middle-income 
countries 
0.120% 
(0.020% – 0.340%) 
0.910% 
(0.280% – 2.460%) 
0.320% 
(0.090% – 0.690%) 
Low-income 
countries 
1.080% 
(0.560% – 2.690%) 
3.700% 
(3.340% – 8.470%) 
1.030% 
(0.670% – 1.800%) 
 
1.4.4.3 Unsafe medical practices 
Historically, in developing countries, medical therapies were commonly administered using 
injections, with data suggesting that the number of injections administered per person per 
year ranged between 1.2-8.5, with a mean of 1.5 per annum (146).  In this study, in the 
majority of cases, the indication for injection therapy was often unjustified (146).  Despite 
increasing knowledge about HCV, misconceptions regarding injection safety, repeated use of 
medical equipment without sufficient sterilisation and poor sharps waste management still 
exist in low-income countries (147).  
 
Injection therapy was considered to be ‘the gold standard’ for medicine administration in low-
income countries.  The reasons for this were public perception regarding the efficacy of 
injection therapy, increased income attached to injection therapy and the use of injections by 
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traditional and untrained healthcare workers (146,148). The most powerful example of the 
relationship between unsafe injections and transmission of HCV was observed in Egypt 
following parenteral anti-schistosomiasis therapy (138).  The findings of this study were 
supported by a case-control study performed in Pakistan.  Here, a significant association was 
identified between injection use and positive anti-HCV status. One limitation of the study was 
the authors collected information on exposure to HCV after participants had been informed 
of their anti-HCV result and this may have resulted in re-call bias (149). 
 
1.4.4.4 Sexual and vertical transmission 
Large prospective studies that have been performed in heterosexual couples in monogamous 
relationships confer that risk of sexual transmission of HCV is low (150, 151)  In the HCV 
partners study, new cases of anti-HCV were discovered in less than five percent of partners 
included (148).  In forty percent of individuals included in the study that had developed 
antibodies to HCV, the genotype or subtype isolated differed from that of their partner 
indicating that the infection must have been acquired via an alternative route (151).  Another 
prospective study that recruited more than eight hundred monogamous heterosexual couples 
identified only three new cases of anti-HCV.  In all cases, the viral isolate was not consistent 
with sexual intercourse as the mode of transmission (150).  Factors increasing the risk of 
transmission of HCV include promiscuity, a history of sexually transmitted infections, 
intercourse without condoms and co-infection with HIV (152-155).  
A systematic review and meta-analysis of twenty studies of pregnant women with chronic 
HCV infection determined that the risk of vertical transmission of HCV was approximately five 
percent in children born to HCV positive, HIV negative mothers and ten percent in children 
born to HIV/HCV co-infected mothers (156). 
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1.4.5 The natural history of hepatitis C 
1.4.5.1 Acute infection 
Acute infection with HCV, much like HBV, is either asymptomatic or marked by vague 
constitutional symptoms including malaise and loss of appetite.  Symptomatic acute infection 
with jaundice occurs in approximately fifteen percent of cases.  The silent onset of HCV 
renders studies relating to the acute phase of infection and rates of persistence extremely 
challenging, with selection bias likely to occur and impact the results obtained.  In the 
majority of cases, HCV infections are detected during post exposure surveillance (134). 
 
Laboratory diagnosis of HCV is performed using two classes of assays; serologic and 
molecular.  Serologic assays detect anti-HCV with a high degree of sensitivity (129).  In acute 
infection, anti-HCV rises at approximately week eight; therefore this is not the test of choice 
for diagnosis in the initial weeks following exposure to the virus.  However, once detectable 
anti-HCV remains positive throughout all subsequent stages of infection including cases of 
chemical eradication or spontaneous clearance (128).  During the first two weeks of infection, 
HCV RNA is present in the blood, rising rapidly up to a level of 10
8
IU/mL by week eight (128).  
Chronic infection is confirmed by detection of HCV RNA in blood six months after the episode 
of acute infection. 
 
Detection and quantification of HCV RNA is performed with molecular assays.  The COBAS-
TaqManHCV test version 2.0 (Roche Molecular Systems, Pleasanton, CA) targets the highly 
conserved 5’ non coding region of the HCV genome, generating amplification products 
detected real-time by a sequence specific TaqMan probe during amplification. 
 
1.4.5.1.1 Factors influencing spontaneous clearance of HCV 
As discussed previously, research to establish the rates of spontaneous clearance of HCV in 
individuals is hampered by the asymptomatic nature of the acute phase of infection.  Studies 
conducted, attempting to establish the rates of spontaneous viral clearance have produced a 
wide range of results, suggesting that both host and environmental factors including the 
route of acquisition influence viral clearance.   In one study, 173 out of 632 individuals cleared 
HCV during twelve months of follow-up, with higher rates of clearance observed in female 
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subjects (157).  In a second study following a heterogeneous cohort of sixty-seven individuals 
with acute infection, a spontaneous clearance rate of eighteen percent was identified.  In this 
study again, spontaneous eradication was seen more frequently in female subjects (158).  
Studies conducted in homogenous groups of infected individuals - pregnant women receiving 
contaminated anti-D immune globulin during pregnancy and children with post-transfusion 
associated hepatitis demonstrated even higher rates of spontaneous viral clearance.  In these 
studies, only  fifty-five percent of individuals with anti-HCV had evidence of chronic infection 
(159, 160).  The factors identified that influence spontaneous clearance of HCV are discussed 
below. 
1.4.5.1.2 Age at the time of infection 
The impact of age on developing chronic infection has been investigated in several studies. In 
the NHANES III study, detection of RNA positive HCV in the anti-HCV positive population aged 
over twenty was 75.6% [95% C.I: 67.3-84.9%] compared with 30.1% in individuals aged less 
than twenty [95% CI: 9.8-92.8%].  A small sample size is likely to be responsible for the wide 
confidence interval and raises suspicion about the validity of this finding; the prevalence of 
chronic infection may not be as high as two and a half times in the older age group (133).  The 
association between age and chronicity of HCV infection was further demonstrated in a larger 
cohort in the DIONYSOS study.   Persistence of HCV infection in subjects aged less than forty-
five years of age was fifty-six percent compared to seventy-two percent in those aged over 
forty-five (161). 
1.4.5.1.3 Gender 
Conflicting evidence exists regarding the role that gender plays on the rate of persistent 
infection in individuals with HCV.  Two observational studies in females exposed to 
contaminated anti-D immune globulin during pregnancy identified that only fifty-five percent 
of subjects with positive anti-HCV had chronic HCV infection (159, 162).  Female gender was 
also associated with spontaneous clearance in studies performed on heterogeneous cohorts 
(157, 158).   Larger population studies however have produced conflicting results. In these 
follow-up studies, gender was only demonstrated to be significant in non-Hispanic subjects 
(133).  One explanation for the high rate of spontaneous clearance in females in the infected 
anti-D cohort may be the specific characteristics of the individuals.  Oestrogen has been 
associated with increased rates of viral clearance in the setting of interferon therapy in 
women aged less than forty years of age (163).  In pregnancy, oestrogen is a key hormone 
responsible for uterine expansion, relaxation of pelvic ligaments and the prevention of 
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uterine contraction. In addition to this, in both of the anti-D immune globulin follow-up 
studies there was no male sex cohort for viral clearance comparison.   
1.4.5.1.4 Ethnicity 
Black ethnicity has been associated with statistically significant lower rates of viral clearance 
(133). In the NHANES III population study, the prevalence of HCV RNA positivity among anti-
HCV positive participants in non-Hispanic blacks was eighty-six percent compared to sixty-
seven percent in non-Hispanic whites (p=0.02)(133).  In a study of PWID in Baltimore, again 
higher rates of viral clearance were observed in white ethnic groups, with chronic HCV 
infection identified in ninety-five percent of African-Americans included (164).   
 
The higher rates of viral persistence  in Black and African-American ethnic groups is related to 
the single nucleotide polymorphism rs12979860 upstream of the IL28B gene (165).  Enhanced 
viral clearance and response to treatment is observed in individuals with the IL28 CC 
genotype, with individuals being three times more likely to clear HCV compared to the other 
genotypes CT/TT.  The C allele is less frequently observed in individuals of African descent, 
explaining the higher rates of persistent infection (165).   
1.4.5.1.5 Immune status 
Co-infection with HIV increases the rate of viral persistence in HCV.  In a study of individuals 
with altered immune status, namely co-infection with HIV paired with low CD4 cell counts of 
less than 200 x 10
6
/L, observed episodes of spontaneous viral clearance of HCV were lower 
compared to non-infected subjects [odds ratio (OR) 2.19 CI 1.26-3.47] (166).   
1.4.5.1.6 Symptomatic acute infection 
The final predictor of spontaneous clearance is the presence of jaundice complicating the 
acute phase of infection (162, 164). 
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1.4.5.2 Chronic HCV infection 
Chronic infection with HCV causes persistent hepatic inflammation resulting in parenchymal 
liver damage characterised histologically by fibrosis score.  The end point of chronic infection 
with HCV is liver cirrhosis with or without the development of HCC.  In the context of cirrhosis 
secondary to HCV, the annual risk of HCC development is between one and four percent (167, 
168).  
 
The natural history of HCV is still largely unknown.  The insidious onset and often 
asymptomatic nature of HCV makes it difficult to perform prospective longitudinal follow-up 
studies in order to determine fibrosis progression.  Results obtained from retrospective 
studies that have attempted to establish fibrosis progression have produced conflicting 
results and this may be due, in part to the characteristics of participants recruited.  Published 
data on fibrosis progression to cirrhosis varies significantly from between two to three 
percent to fifty-one percent after a duration of twenty years of infection (162,169).  One 
possible explanation for the large difference in reported progression rates are the study 
populations.  In the study by Tong et al, individuals infected with HCV from blood transfusions 
were recruited after presenting for assessment to a tertiary hepatology unit, implying a 
cohort consisting of more unwell, symptomatic individuals.  In this study, the mean age at the 
time of infection was thirty-five, established by participant recall (169).  Wiese et al studied 
fibrosis progression in a cohort of women with very similar characteristics, exposed to HCV 
during pregnancy.  These individuals were diagnosed with HCV after been recalled for testing 
due to the potential risk of infection from contaminated blood products, thereby implying a 
more asymptomatic cohort, unlike in the study by Tong et al (162). 
 
A number of modifiable and non-modifiable risk factors that result in an accelerated 
progression of fibrosis have been identified and include advancing  age  at the time of 
infection, male gender, hepatic steatosis and  insulin resistance, co-infection with HBV or HIV, 
and excess alcohol consumption (170-172).  Genotype 3 infection has also been associated 
with an accelerated course of fibrosis (173).   
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Data used to estimate fibrosis progression has been obtained from studies that have used 
either a single or paired liver biopsy design (170,174,175).  Retrospective studies using data 
from single liver biopsies, with the duration of infection established by participant recall have 
suggested that progression of fibrosis in HCV infection is linear with an increase in fibrosis of 
between 0.12 and 0.19 units per year (170,174).  In these studies, the median duration of 
time between infection and the onset of cirrhosis was thirty years in the absence risk factors 
for accelerated progression (170,174).  In the single liver biopsy studies from which these 
conclusions were drawn, an assumption was made that the rate of progression of fibrosis in 
HCV infection is consistent, however this is not supported in other single and paired liver 
biopsy studies (176–178). A prospective study that compared data obtained from paired liver 
biopsy samples taken from a group of individuals not treated for HCV strongly disagreed with 
the concept that fibrosis progression in HCV is linear and furthermore, that it can be predicted 
from duration of infection with the use of a single liver biopsy (175).  In the study by Ryder et 
al, the two independent factors that influenced fibrosis progression were the presence of 
fibrosis on the index biopsy and the age of the individual at the time of infection (175). 
 
In addition to hepatic dysfunction, significant morbidity and mortality has been associated 
with extra-hepatic manifestations in HCV.  A large Australian community-based study 
conducted retrospectively in individuals with HCV identified an increase in all-cause as well as 
in liver-related mortality in the cohort infected with HCV compared with the general 
population of New South Wales (179).   In this study, death from liver-related causes was 
identified more frequently in individuals of advancing age, and this is likely to be related to 
the duration of infection with HCV.  Conversely, in young adults, especially in females infected 
with HCV, the risk of dying from complications of drug use exceeded liver-related deaths.  The 
findings of this study are consistent with other studies looking at outcomes in HCV infected 
PWID (180, 181).  
 
The increased number of liver-related deaths in individuals of advancing age identified by 
Amin et al supports the use of antiviral therapies in these age groups to prevent 
complications associated with long-term infection (179).  There were however limitations 
associated with the data collected and presented in this study.   Firstly, individuals with HCV 
were only followed by investigators for five years; this period is inadequate in duration to 
observe all complications associated with HCV.  Secondly, the study design was retrospective, 
therefore all data collected for interpretation was death registry data, increasing the 
possibility of both incomplete and inaccurate data sets. 
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Through targeted testing for viral hepatitis in primary care, HepFree will identify a cohort of 
individuals, infected with HCV that are unaware of their diagnosis, thereby implying an 
asymptomatic cohort.  All individuals enrolled in HepFree found to have chronic HCV infection 
will undergo fibrosis assessment at the time of diagnosis with subsequent long-term follow-
up for clinical outcomes.  The data collected from this screening trial will augment the pre-
existing evidence base both for fibrosis progression and morbidity and mortality associated 
with chronic HCV.   
 
1.4.6 Quality of life in hepatitis C infection 
Historically, chronic HCV infection was thought to be predominantly asymptomatic, with signs 
and symptoms arising only in cases of advanced disease complicated by the presence of 
cirrhosis (182).  This differs from other diseases that are characterised by the presence of 
persistent inflammation.   The significance of extra-hepatic manifestations in chronic liver 
disease of other aetiologies, in particular the impact of fatigue on quality of life in primary 
biliary cirrhosis (PBC) has been recognised.  In PBC, it is widely recognised that symptoms 
experienced by patients correlate poorly with both biochemical markers of severity and the 
degree of hepatic fibrosis present (183–185).   A plethora of studies exist that have identified 
symptoms in individuals infected with HCV.  These studies, the symptoms reported and the 
subsequent impact on quality of life are discussed below. 
 
1.4.6.1 Fatigue 
Fatigue is the most commonly reported symptom in individuals with chronic HCV (169,186–
188).  The subjective nature of fatigue, combined with the lack of specific therapies available 
for treatment makes it arguably one of the more distressing manifestations associated with 
the disease (189).  In observational studies of individuals infected with HCV, high rates of 
fatigue have been reported;  67% of individuals infected with HCV from contaminated blood 
and 81% infected from contaminated anti-D immune globulin respectively (159,169).   In a 
study assessing symptoms with the use of questionnaires, performed in a hepatology 
outpatient department, identified that fatigue in individuals with HCV was more significant 
compared to liver disease of other aetiologies (186).  In a large study by Poynard et al, fatigue 
was more prevalent in females of advancing age, but there was no correlation identified 
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between symptom severity and the degree of histological fibrosis observed  (187).  The major 
limitation of the studies performed to investigate fatigue in HCV is the absence of a control 
group for comparison. 
 
1.4.6.2 Cognitive impairment 
Hepatic encephalopathy (HE), first described by Sherlock et al, is the neuropsychiatric 
syndrome most commonly associated with hepatic failure (190,191).  Latent sub-clinical 
minimal hepatic encephalopathy (MHE) is the term used to describe the constellation of 
symptoms and signs characterised by selective impairments of psychomotor speed, visual 
perception and attention with persevered verbal ability.  MHE can occur in individuals with 
cirrhosis with no appreciable signs of HE (191,192). 
 
Due to the frequent complaint of ‘mental clouding’ in the context of chronic HCV infection, 
studies have attempted to investigate the effects of HCV on cognitive functioning in 
individuals with both non-cirrhotic and cirrhotic liver disease (193–197).  Cordoba et al 
assessed cognitive functioning by using a series of neurophysiologic tests.  In this study, 
individuals were classified as having either mild disease, compensated or decompensated 
cirrhosis and the findings obtained in each cohort were compared to healthy controls (196).  
Exclusion criteria for the study included a history of excess alcohol consumption, psychotropic 
drug use, illiteracy and marked cognitive impairment.  In this study, neurological 
abnormalities were identified solely in the cohort of individuals with decompensated cirrhosis 
(196).   
 
The direct effect of HCV on the central nervous system has been investigated in cohorts of 
individuals that have no evidence of liver cirrhosis.  The hypothesis of subclinical cognitive 
impairment in HCV was studied by performing a series of sensitive electrophysiologic tests of 
cognitive processing by Kramer et al (195).  Findings from this study demonstrated sub-clinical 
impairment of cognitive brain function in the HCV infected cohort (195).  The results obtained 
occurred independent of the degree of histological or biochemical activity of hepatitis and 
also independent of the severity of fatigue observed within the same cohort (195).   The 
results of this study were supported by findings from a study by Forton et al, and confirmed 
that mild cognitive impairment is a feature of chronic HCV infection (193).  In these studies, 
the authors addressed the potential negative effect of a history of substance misuse on 
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cognitive impairment in addition to the potential negative effects of depression and fatigue; 
two conditions prevalent in HCV infected populations.  Independent of the aforementioned 
factors, the study detected a decrease in concentration as well as a reduction in working 
memory speed (193).  Within the study design, a sub-group of seventeen individuals with HCV 
as well as a control group of healthy volunteers underwent further tests with cerebral proton 
magnetic resonance spectroscopy (MRS).  The results of these tests demonstrated 
significantly elevated choline/creatine ratios in the basal ganglia and white matter of the HCV 
infected cohort compared to the healthy controls (193).  A subsequent imaging study by the 
same lead author confirmed that chronic HCV results in neurological damage (198) .  In this 
study, MRS was performed on three cohorts of individuals; individuals with chronic HCV with 
no histological evidence of advanced disease, individuals with evidence of previous exposure 
to HCV, and a group of healthy controls.  Mean myoinositol/creatine levels were higher in 
HCV positive cohort compared to the healthy control group with a strong association 
established between elevated levels and prolonged working memory reaction times, p=0.002 
(198). 
 
1.4.6.3 Depression 
Depression is frequently reported in quality-of-life (QOL) studies performed in individuals 
with chronic HCV; however there is wide variation in the incidence of symptoms reported 
depending on the study referred to.  In an interview based trial performed in 157 individuals 
referred to a tertiary Hepatology unit, depression resulting in a reduction in QOL was 
reported in more than fifty percent of individuals (199).  This study population contained a 
large number of participants with cirrhosis. The authors however stated that no significant 
difference in depression reporting rates were observed between the cirrhotic and non-
cirrhotic subjects interviewed (199).  In this study, depression was associated with a reduction 
in health related quality-of-life (HRQL).  A correlation was identified between HRQL scores 
and both knowledge and understanding of the disease, therefore raising the possibility that 
depression in HCV arises as a result of fear of the condition and the implications of long-term 
infection, rather than as a direct effect of the virus itself.   
 
In studies investigating the incidence of depression in HCV by Dwight and Fontana et al, 
depression was observed in twenty-eight percent and thirty-five percent of individuals 
respectively.  There was a positive correlation observed between the severity of fatigue 
reported and degree of depression observed (200,201).  With the exception of one study, 
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once again, the lack of a healthy control cohort for comparison was the major limitation of 
the studies described. The one exception was a large Italian study conducted by Carta et al 
that demonstrated an increased incidence of depressive disorders in patients with chronic 
HCV compared to two other cohorts; subjects both chronic HBV and healthy controls (202). 
 
1.4.6.4 Musculoskeletal pain 
In a study analysing data collected from 239 questionnaires completed by individuals 
attending a hepatology outpatient department, the most frequently reported symptom was 
musculoskeletal pain, in particular backache.  Additional symptoms included myalgia, muscle 
stiffness and neck pain (186).  In the HCV cohort interviewed, the incidence of both fatigue 
and musculoskeletal pain was significantly higher compared to cohorts of individuals with 
liver disease of other aetiologies (186).  In observational longitudinal follow-up studies 
conducted in individuals infected with HCV during pregnancy in Ireland and Germany, 
arthralgia and myalgia were also frequently reported (159,162).  The results of these studies 
however do have to be interpreted with caution due to the financial provisions available for 
individuals with long-term health problems arising as a result of infection with HCV. 
 
1.4.6.5 Health-related-quality-of-life in the setting of chronic HCV 
Investigators have used HRQOL questionnaires to explore the impact of chronic HCV on an 
individual’s well-being, including any effects that treatment and subsequent cure might have.  
Several large studies have identified that irrespective of the severity of liver disease, infection 
with HCV causes symptoms that result in a reduction in QOL (203,206).   Difficulty remains 
however in determining whether reduction in QOL occurs as a direct consequence of viral 
infection or whether it is multifaceted, influenced by symptoms, pre-existing knowledge and 
anxiety surrounding the diagnosis as well as fear about the long-term implications of 
infection.  In a study by Foster et al, the Short Form 36 (SF-36) questionnaire was used to 
assess the impact of symptoms on QOL in individuals with HCV (207).  This study enrolled two 
cohorts infected with chronic HCV infection, differentiated by the presence or absence of a 
history of substance misuse.  The purpose of this trial design was to address and reduce any 
potential bias arising from drug-use and any associated behaviours that may have had an 
adverse effect on QOL, some of which have previously been described(208,209). SF-36 
outcomes from participants with HCV were compared to outcomes collected from a cohort of 
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individuals infected with chronic HBV and a cohort of healthy controls (207).  In the two HCV-
infected cohorts, scores related to mental and physical health were significantly reduced 
compared to the non-HCV populations (207).  There was only a small difference in QOL 
observed between the drug-using and non-drug using cohorts (207).  The findings of this 
study, supported by a study conducted by Poynard et al, concluded there was no correlation 
between QOL reported and the histological degree of inflammation observed in HCV (187).  
These findings were also supported by studies from Carithers, Davis and Ware et al 
(203,204,206).   
 
The effects of treatment with peg-IFN and SVR on QOL have been studied (205,210–214). 
Prior to anti-viral therapy, irrespective of the severity of liver disease, all individuals included 
in these studies were identified to have a reduction in HRQOL compared to healthy 
individuals.  Marked improvements in both QOL and functioning were observed in individuals 
that obtained an SVR following treatment.  The improvement observed in the SVR cohort was 
more significant than any changes in QOL noted in the cohorts of individuals that received 
anti-viral therapy but in whom treatment was unsuccessful (205,210-214).   
 
A study by Rodgers et al however disagrees with the concept that reduction in QOL observed 
in individuals with HCV arises as a direct consequence of viral infection and therefore 
improves with eradication of the virus following administration of anti-viral therapy.  The 
Australian study aimed to investigate the impact of pre-existing knowledge of HCV on an 
individual’s perceived QOL and well-being (215).  In this study, QOL was assessed in two 
cohorts of individuals with chronic HCV, one containing individuals aware of their diagnosis 
and one cohort blinded (215).  In the cohort with pre-existing knowledge of their disease 
status, data obtained from the QOL assessment tools used were comparable to results 
published by Carithers, Davis, Foster and Ware et al, with a reduction identified in seven out 
of eight questionnaire domains (203,204,206,207).  In contrast to this, in the cohort blinded 
to their disease status, reduction in QOL was only observed in three domains and importantly, 
any reduction in emotional or physical health reported by this cohort did not perceive that 
the reduction impacted on either their overall functioning or on activities of daily living (215).   
 
The reduction in QOL observed in the cohort blinded to their diagnosis, although not as 
severe, does support the argument that symptoms in HCV do not arise purely in response to 
psychological distress associated with knowledge of the virus.  The study by Rodgers et al did 
however highlight two major limitations with the other trials reviewed.  The first limitation 
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relates to the sample populations studied. In the trials discussed, all symptom assessment 
tools and questionnaires were performed in individuals that had been referred to either a 
secondary or tertiary care centre for assessment.  The locations selected for participant 
recruitment could infer a more ‘unwell’ population and the prevalence of symptoms in 
individuals seeking medical care are more likely to be greater than in individuals who have 
either not yet been referred for specialist input, or in individuals in whom the disease was 
detected through routine screening based solely on ‘risk’ of infection.  The second limitation 
was that all questionnaires were performed in cohorts of individuals aware of their diagnosis.  
The authors have therefore failed to consider the potential psychological impact of a 
diagnosis of HCV on both symptom and QOL reporting (216). 
 
Although many studies have examined the impact of chronic HCV on individuals diagnosed 
with HCV no study has, to-date, examined the impact of undiagnosed HCV infection on 
healthcare utilisation.  We hypothesised that if HCV infection per se, rather than knowledge 
and anxiety regarding the diagnosis, is responsible for the observed changes in QOL then 
patients with undiagnosed chronic HCV should present to their general practitioners with 
complaints of fatigue more frequently than uninfected controls.  The HepFree study provided 
a unique opportunity to examine this.  
 
The primary aim of the HepFree sub-study was to explore the impact of undiagnosed HCV on 
healthcare utilisation in a primary care setting.  The sub-study design was a retrospective 
case-control study.  Cases consisted of individuals with a positive test for HCV, identified 
through targeted testing in high-risk populations in the HepFree trial and controls consisted of 
individuals that attended for screening and tested negative for both HBV and HCV through 
HepFree.  Controls were matched to cases using the following criteria: age, gender, ethnic 
origin, country of birth and length of time resident in the UK.  This sub-study was unique in its 
design and aimed to enhance pre-existing knowledge on symptomatology in chronic HCV.   
 
In the sub-study, primary care data including number of GP appointments and presenting 
clinical complaint were collected for individuals in both cohorts up to the point of enrolment 
and viral hepatitis testing through HepFree.  Similar to the study by Rodgers et al, in the HCV 
infected cohort, individuals included in the sub-study were blinded to their diagnosis prior to 
the date that the screening test was performed, giving us the opportunity to explore 
symptoms that occur in individuals with undiagnosed HCV without having to adjust for either 
reporter bias, recall bias or having to take into account any potential psychological impact of a 
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diagnosis of chronic HCV.  The HepFree sub-study was also unique in its design because of the 
location selected for data collection.  Previous studies investigating symptoms have been 
conducted in subjects referred to secondary and tertiary care centres; however individuals 
included in the HepFree sub-study were identified through ‘routine’ testing in a presumed 
healthy population that have risk factors for chronic viral hepatitis. 
 
1.4.7 Treatment of chronic hepatitis C 
The goal of treatment in chronic HCV is to reduce both liver related complications including 
end-stage liver disease and/or HCC in addition to all-cause mortality by achieving a cure, 
otherwise known as SVR.  The definition of SVR is aviraemia twenty-four weeks following 
completion of antiviral therapy and is considered a cure in more than ninety-nine percent of 
cases (217).  Multiple benefits associated with SVR include a decrease in liver inflammation as 
reflected by a decrease on serum aminotransferase levels as well as a reduction in the rate of 
progression of liver fibrosis (218).  Treatment and cure has also been associated with a more 
than seventy percent reduction in the risk of HCC and a ninety percent reduction in the risk of 
liver- related mortality and transplantation (219,220).  
 
Treatment for HCV consists largely of antiviral agents, with liver transplantation reserved for 
individuals with end-stage liver disease that either cannot tolerate medical therapy, or those 
with HCV related complications namely HCC.  As discussed, the development of DAAs has 
revolutionised HCV treatment.  In this thesis, treatment options and outcomes pre and post 
the introduction of DAAs will be discussed.   
 
Prior to 2011, there were limited therapeutic options available for HCV and treatment 
consisted of peg-IFN and ribavirin.  Peg-IFN was used because of its potent antiviral and 
immunomodulatory properties, however its exact mode of action in treating HCV remains 
unknown (221).   Duration of treatment with these agents varied, depending on genotype and 
VL in addition to host characteristics including age, race, body mass index (BMI), stage of 
hepatic fibrosis and presence of co-infection with HIV(221).  In the largest paired liver biopsy 
study of HCV/HIV co-infected individuals, one third of individuals had evidence of fibrosis 
progression of at least one METAVIR stage at a median interval of two and a half years, and 
nearly one half of individuals that had no fibrosis on their index biopsy had evidence of 
histological progression (222). 
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In 2011, the first generation direct-acting antiviral therapies with NS3 protease inhibitors (PIs) 
boceprevir and telaprevir were licensed for use in genotype 1 infection.  Prior to the era of 
PIs, genotype 1 was considered the most resistant to medical therapy.  Phase III trials 
conducted using these agents in combination with peg-IFN and ribavirin demonstrated an 
increase in SVR rates from between forty to fifty percent to between sixty-five and seventy 
percent making clinicians optimistic about the future treatment of their genotype 1 infected 
populations (223,224).   
 
1.4.7.1 Hepatitis C treatment: The past 
Early treatment with interferon monotherapy provided somewhat disappointing response 
rates.  Twenty-four week SVR rates varied between six to twelve percent in subjects that 
received six months of therapy and between sixteen to twenty percent in individuals treated 
for twelve months (225).  Combination therapy consisting of the guanosine anologue ribavirin 
and peg-IFN was the next approved treatment for chronic HCV (226).   
 
Combination therapy was associated with higher SVR rates, ranging between forty-two and 
forty-six percent in genotype 1 infection and between seventy-six to eighty percent in 
genotypes 2 and 3 infection (227,228).  Duration of treatment with combination therapy was 
response guided according to VL, with treatment terminated prematurely in the event of 
either no response in VL, termed null response or an initial response followed by a relapse 
and subsequent increase in VL(221).The terms that were used in combination therapy 
treatment are detailed in Table 3.  Approximately one-third of individuals who received 
combination therapy were classified as null responders (221).  Poor predictors of response to 
antiviral therapy included infection with genotype 1 virus, male gender, African American 
race, advancing age, advanced hepatic fibrosis, IL28 TT genotype and the presence of insulin 
resistance (229). 
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Table 3: Responses to combination therapy in hepatitis C virus infection 
Definitions used to describe an individual’s response to combination therapy with peg-IFN 
and ribavirin in HCV infection.  Original classification credited to Feld & Hoofnagle. 
Term Definition 
Rapid Virologic Response (RVR) Undetectable HCV RNA at week four of treatment.   
Obtaining RVR was identified as one of the strongest 
predictors of successful virus eradication with SVR in 
all gentoypes (230,231). 
Extended Rapid Virologic Response(eRVR) Undetectable HCV RNA level from week four to week 
twelve. 
Early Virologic Response (EVR) Undetectable serum HCV RNA at week twelve of 
therapy. 
Failure to achieve an EVR was identified as the most 
accurate negative predictor of SVR in individuals 
receiving combination therapy (230).  Failure to 
achieve an EVR was an indication to prematurely stop 
combination therapy in genotype 1 infection. 
Null response (NR) Failure to suppress serum HCV RNA by at least 2 log10 
by week twelve of treatment. 
Treatment was discontinued in this group of 
individuals as soon as this non-response pattern was 
recognised (232). 
Partial response (PR) A reduction in HCV RNA by at least 2 log10 at week 
twelve of treatment but detectable levels of HCV RNA 
at week twenty-four. 
Virologic Breakthrough Detectable HCV RNA in a patient with previous HCV 
RNA suppression whilst still receiving combination 
therapy. 
End of Treatment Response (ETR) Undetectable HCV RNA at the end of combination 
therapy. 
Sustained Virologic Response (SVR) Undetectable HCV RNA levels twenty-four weeks after 
treatment discontinuation.  A twenty-four week SVR 
represents HCV eradication in 99-100% of patients  
(233). 
Virologic Relapse Recurrence of HCV RNA in a patient with an end-of 
treatment response. 
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1.4.7.2 Treatment indications and side effects 
This section refers specifically to side-effects related to HCV treatment prior to the 
development of DAAs.  In the new, rapidly changing landscape of HCV treatment, it is 
arguably easier to treat infected populations because courses of therapy are shorter, easier to 
tolerate, and require less monitoring.  These desirable qualities do however come at a greater 
cost to the NHS. 
 
For combination therapy, EASL produced guidance recommending consideration of treatment 
in all individuals with compensated cirrhosis and without contraindications to peg-IFN therapy 
(234).  Individuals with histological evidence of advanced fibrosis (METAVIR score F3 or 
above) or those with clinically significant extra-hepatic manifestations of HCV were given 
priority.  These guidelines did not provide comprehensive instructions relating to the timing of 
treatment in individuals with HCV infection and evidence of minimal fibrosis on histological 
assessment and with no identifiable risk factors for rapid disease progression.   
 
Contraindications to peg-IFN therapy include pre-existing evidence of uncontrolled 
depression, psychosis, epilepsy, autoimmune thyroid disease, retinal disease, decompensated 
liver disease and pregnancy (234).  For individuals termed intolerant to peg-IFN, prior to the 
development of all oral therapies, treatment options were scarce. 
 
1.4.7.3 Combination therapy side effects 
The side-effect profiles of peg-IFN and ribavirin are vast, ranging in severity from influenza- 
like symptoms, headache, fatigue and fever to anaemia, depression and psychosis (235). It is 
reasonable to suggest that peg-IFN did, and does continue to act as a relative barrier to 
effective treatment of HCV either because individuals are reluctant to seek treatment 
because of the perceived side-effect profile or stop therapy prematurely due to side effects 
experienced (12). 
 
In a large retrospective study documenting adverse outcomes in individuals receiving peg-IFN 
therapy, thyroid dysfunction, diabetes and psychiatric presentations were the most common 
non-hepatic disorders observed (236).   
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The relationship between peg-IFN therapy and development of psychiatric symptoms is well 
recognised, occurring either de-novo or in individuals with a documented personal history of 
mental health disorders.  In a cohort of individuals followed for adverse events in the setting 
of peg-IFN therapy, ten discrete episodes of psychiatric disturbance were observed, and all 
occurred in individuals without a prior personal history of mental health problems (236).  An 
increased risk of recurrence of depression or psychiatric disturbance during peg-IFN therapy 
has been documented in several studies (237–239).  In addition to this, case reports 
documenting suicide in individuals receiving peg-IFN therapy have been published (236,240).  
 
Conflicting evidence regarding the risk of recurrence or worsening of symptoms in individuals 
with psychiatric comorbidities does exist.  In a study by Schaefer et al, no increased risk of 
recurrence or exacerbation of symptoms in individuals with a past history of psychiatric 
disorders was identified (241).  The trial design may however have influenced the findings 
observed.  Participants included in the trial were reviewed by a psychiatrist twice a week for 
the first eight weeks of peg-IFN therapy and once a month thereafter.  Any changes in mood 
identified in trial participants prompted a comprehensive mood assessment to be performed 
and either antidepressant therapy commenced or psychiatric medication modified.  In the 
trial, the frequency that depressive episodes occurred was not significantly increased in the 
cohort of participants with pre-existing mental illness compared to the control group, but the 
severity of the depressive episodes were more significant.  The investigators commented that 
all suicidal thoughts ‘disappeared under psychiatric care’.  In this trial, intensive psychiatric 
input, enabling early recognition of symptoms and use of therapeutic agents is likely to have 
accounted for the outcomes observed.   
 
The role of peg-IFN in the development of type 2 diabetes mellitus (T2DM) in cohorts of 
individuals with HCV is a little less clear.  Insulin resistance is a well-recognised extra-hepatic 
manifestation of chronic HCV (242).  Studies, including a meta-analysis that have explored the 
relationship between HCV infection and T2DM have demonstrated an increased prevalence of 
diabetes in individuals with chronic HCV compared to non-infected subjects  (243,244).  The 
development of type 1 diabetes mellitus (T1DM) in the setting of peg-IFN therapy has also 
been described; firstly by Fabris et al, and later by several other authors (245–248).  In Japan, 
a nationwide cross-sectional study identified a prevalence of T1DM of 0.34% among patients 
receiving peg-IFN therapy with anti-islet antibodies identified in more than ninety percent of 
cases (249).  In addition to the development of T1DM in individuals receiving peg-IFN, other 
autoimmune disorders including autoimmune thyroiditis, autoimmune hepatitis, rheumatoid 
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arthritis, systemic lupus erythematous, autoimmune thrombocytopenic purpura and immune 
mediated dermatological disorders have also been identified (236,250,251).  
 
Observational studies performed in individuals receiving peg-IFN therapy have identified 
additional non-immune mediated, non-hepatic disorders including cardiovascular disease, 
seizures, impotence, peripheral neuropathy and haemolytic anaemia (250).  In these studies, 
disorders resolved spontaneously following withdrawal of the drug, and a relationship 
between the frequency of side effects and both dose and duration of therapy administered to 
individuals were established (236,250).   
 
The overall incidence of fatal or life-threatening side effects associated with interferon 
therapy in the Italian cohort were low with the trial authors concluding that the risk of death 
from peg-IFN was not increased compared to an individual’s risk of death from complications 
related to chronic viral hepatitis in the presence of poor predictors of survival (236).   
 
As the majority of side-effects related to peg-IFN appeared to be duration dependent, the 
development of newer treatments that resulted in a reduction in the duration of therapy with 
peg-IFN inevitably resulted in an improvement in the safety profile of the drug. 
 
1.4.7.4 Advances in medical therapy 
In 2011, the introduction of first generation NS3 PIs improved SVR rates in adults with 
genotype 1 infection.  The new agents at that time, boceprevir and telaprevir worked by 
directly inhibiting HCV proteins required for intracellular replication.  In both treatment naïve 
(TN) and treatment experienced (TE) patients, SVR rates with triple therapy were superior to 
peg-IFN and ribavirin combination therapy, 63-66% and 58.6-66.5% respectively (224,252).  
 
Despite the introduction of triple therapy leading to overall improvements in SVR rates, the 
side-effect profile as well as the risk of drug-drug interactions and potential for adverse 
outcomes associated with PI therapy made the management of individuals on anti-viral 
therapy much more complex (253,254).  The introduction of first generation PIs did not herald 
the start of an era of well-tolerated anti-viral therapy. 
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First generation PIs inhibit cytochrome P450 3A (CYP3A).  When used in conjunction with 
drugs highly dependent on CYP3A for clearance can result in serious or life-threatening 
interactions.  Because of the significant risk of drug-drug interactions, extra care was required 
during the assessment period of genotype 1 patients prior to treatment.   
 
Well documented side-effects with PIs included a rash associated with telaprevir therapy and 
dysgeusia associated with boceprevir (253).  In addition to these, anaemia, often 
multifactorial in origin was commonly observed in individuals receiving treatment. 
 
Further advances in the understanding of the HCV genome resulted in the development of 
new DAA therapies.  These agents target HCV encoded proteins that are vital for virus 
replication.  These agents as well as being better tolerated had superior efficacy against HCV.  
Due to the rapidly changing recommendations for HCV treatment that are occurring in 
response to new DAAs, in this section I will discuss the agents that were available for use to 
treat chronic HCV during the time period that the HepFree trial was active.  The four classes 
of DAAs used were available in both interferon-containing and interferon-free ‘all-oral’ 
regimens. 
 
1.4.7.5 Non-structural protein 3 (NS3)/Nonstructural protein 4A (NS4A) protease inhibitors 
(PIs) 
The mode of action of these molecules is inhibition of the NS3/NS4A serine protease enzyme 
that is involved in the post translational processing and replication of HCV. During HepFree, 
the agent available for use as part of a combination regimen was simeprevir.  Therapy with 
simeprevir was generally well tolerated, with very few individuals needing to discontinue 
therapy due to side effects.  The two side effects related to the drug include photosensitivity 
and rash, in addition to mild elevations in serum bilirubin, occurring in response to inhibition 
of the hepatic transporters OATP1B1 and MRP2 (255). 
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1.4.7.6 Non-structural protein 5A (NS5A) inhibitors 
During HCV replication, NS5A is involved in both viral replication and modulation of the 
physiology of the host cell (256).  Inhibition of NS5A interrupts viral replication, assembly and 
virus secretion (257).  NS5A inhibitors are very well tolerated.  In clinical trials using 
daclatasvir as part of a combination regimen, the most commonly reported side effects were 
headache, fatigue and nausea ranked mild to moderate in severity (258).  The agents that 
were available for use in combination therapy included ledipasvir and daclatasvir. 
1.4.7.7 Non-structural protein 5B (NS5B) inhibitors 
NS5B is an RNA-dependent RNA polymerase that initiates complementary negative-strand 
RNA synthesis.  The negative-strand RNA then acts as a template enabling this protein to 
synthesise positive-strand RNA(259).  The molecules developed that inhibit NS5B are 
classified as either nucleotide polymerase inhibitors (NPIs) or non-nucleotide polymerase 
inhibitors (NNPIs).   
 
NPIs target the catalytic site of NS5B resulting in chain termination.  Once inside the 
hepatocyte, NPIs are activated through phosphorylation to nucleoside triphosphate.  This 
competes with nucleotides and results in chain termination during RNA replication of the 
genome.  NNPIs induce conformational changes in the NS5B polymerase enzyme by binding 
to its various allosteric sites.  They have a low barrier of resistance and are genotype specific.  
The NS5B inhibitor available for use was the sofosbuvir.  Side effects experienced by 
individuals using sofosbuvir occurred as a result of concurrent treatment with interferon and 
ribavirin.  
 
1.4.7.8 Direct acting antiviral treatment regimens 
In this section I will review clinical trials that have been conducted in TN and TE individuals 
using the drugs described above.   
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1.4.7.8.1 Genotypes 1 and 4 
In phase III trials conducted in TN individuals with genotype 1 infection, simeprevir was used 
in combination with peg-IFN and ribavirin for twelve weeks, followed by either twelve or 
thirty-six weeks of consolidation therapy with peg-IFN and ribavirin.  SVR rates following 
response guided therapy, were between eighty and eighty-one percent(260,261).  Less 
favourable outcomes were demonstrated in individuals with genotype 1a infection with the 
Q80K mutation present at baseline testing.  In this cohort, SVR rates decreased to between 
fifty-two and seventy-five percent (262).  In phase III trials conducted in Japan, this treatment 
regimen produced even more successful results.  This may be related to characteristics of 
participants included in the trials.  Almost all included had genotype 1b infection and the 
Q80K mutation is much less prevalent in this strain of infection.  Furthermore, participants 
selected for inclusion were non-cirrhotic (263). 
 
Simeprevir was also licensed for use in individuals with genotype 4 infection,  a trial of both 
TN and TE patients, with a primary end point of SVR twelve weeks following completion of 
therapy (SVR 12), demonstrated an overall SVR rate of eighty-three percent  Sub-group 
analysis of the TE cohort revealed less favourable SVR rates of forty, sixty and eighty-six 
percent in prior null-responders, prior partial responders and prior relapsers respectively 
(264). 
 
For individuals with genotypes 1 and 4, sofosbuvir was available for use in combination with 
peg-IFN and ribavirin.  In the single-group, open-label study NEUTRINO, sofosbuvir was used 
in combination with peg-IFN and ribavirin in 327 patients infected with HCV genotypes 1, 4, 5, 
and 6. SVR 12 was achieved in ninety percent of the trial population, with no significant 
difference observed between genotypes; ninety-two, eighty-two, and ninety-six percent for 
genotypes 1a, 1b and 4 respectively.  A reduction in SVR12 was observed in the presence of 
cirrhosis; eighty percent compared to ninety-two percent in the non-cirrhotic cohort, 
however the authors noted that at the time of its development and use, this treatment 
regimen still had the highest efficacy of any on the market for patients with cirrhosis (265). 
 
The phase III, multicentre, randomised, open-label trial ION-1 used sofosbuvir and ledipasvir 
without peg-IFN.  The trial assessed the impact of varying the duration of therapy as well as 
the addition of ribavirin on treatment outcomes.  The genotype 1 TN cohort received fixed 
dose ledipasvir and sofosbuvir administered once daily and were then randomised to four 
treatment arms in order to investigate the trial objectives.  The treatment arms were: 
ledipasvir/sofosbuvir for twelve weeks, ledipasvir/sofosbuvir plus ribavirin for twelve weeks, 
 
 
70 
 
ledipasvir/sofosbuvir for twenty-four weeks, ledipasvir/sofosbuvir plus ribavirin for twenty-
four weeks.  SVR rates among the four cohorts varied between ninety-seven to ninety-nine 
percent with no superior outcomes identified either by the addition of ribavirin, or 
prolongation of treatment duration (9). 
 
The same trial design was conducted in a cohort of TE individuals, with randomisation 
stratified according to genotype (1a versus 1b), the presence or absence of cirrhosis and 
response to prior therapy; relapse or virologic breakthrough versus null response(266).  
SVR12 rates in individuals receiving twelve weeks of therapy, with or without ribavirin were 
ninety-six and ninety-four percent respectively and ninety-nine percent in those receiving 
twenty-four weeks of therapy.  The presence of cirrhosis did impact on SVR rates with 
different durations of therapy.  In the cirrhotic cohort, the overall SVR 12 was ninety-two 
percent, however  a reduction was identified in the cohort assigned to twelve weeks of 
treatment, SVR 12 was eighty-six percent without and eighty-two percent with ribavirin.  In 
the non-cirrhotic cohort SVR rates were ninety-five percent and one hundred percent 
respectively.  In individuals receiving twenty-four weeks of treatment, response rates were 
similar irrespective of cirrhosis status.  The authors concluded that extending the duration of 
therapy from twelve to twenty-four weeks in the presence of cirrhosis had a statistically 
significant superior effect, p=0.007 (266).  Subsequent results from the phase III ION-3 trial 
suggested that TN, non-cirrhotic patients could be treated with an even shorter course of 
sofosbuvir and ledipasvir for eight weeks with no inferior outcomes in terms of SVR12 rates 
(10). 
 
The combination of sofosbuvir with daclatasvir was also available for use in individuals with 
genotypes 1 and 4 disease that were deemed interferon intolerant.  In the open label phase II 
trial AI444040, 126 TN and 41 TE genotype 1 participants were randomly assigned to receive 
one of the following treatment regimens: one week of sofosbuvir ‘lead in’ followed by 
daclatasvir and sofosbuvir for twenty-three weeks, daclatasvir and sofosbuvir for twenty-four 
weeks, or daclatasvir, sofosbuvir, plus ribavirin for twenty-four weeks (267).  Overall SVR12 
rates of ninety-eight percent were observed in the genotype 1 cohorts, with no superior 
effect observed in the setting of ribavirin therapy (267). 
 
The phase IIb trial COSMOS examined SVR 12 rates in both TN and TE patients with genotype 
1 disease treated with sofosbuvir plus simeprevir with or without ribavirin for either twelve or 
twenty-four weeks (268).  One cohort consisted of previous treatment non-responders with 
no evidence of cirrhosis, and a second cohort consisted of a combination of both TN and TE 
patients with evidence of advanced fibrosis/cirrhosis.  The primary end point of the trial was 
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SVR12.  Overall SVR12 using this combination of therapy was ninety-two percent; ninety 
percent in the TE cohort and ninety-four percent in individuals with advanced fibrosis (268).       
 
1.4.7.8.2 Genotypes 2 and 3 
During HepFree, sofosbuvir was licensed for use in combination with peg-IFN and ribavirin in 
individuals infected with genotypes 2 and 3 HCV that had previously failed therapy (TE).  
LONESTAR-2, a small phase IIb trial demonstrated SVR rates of 96% in TE genotype 2 
participants receiving twelve weeks of therapy, and 83% in the genotype 3 cohort(11).  SVR 
rates were not influenced by the presence of cirrhosis, however the study population was 
small and so findings had to be interpreted with caution (11). 
 
The phase III FISSION trial examined the efficacy of interferon free therapy,  Here, cirrhotic 
and non-cirrhotic TN individuals with genotype 2 and 3 disease were treated with twelve 
weeks of sofosbuvir in combination with ribavirin (265).  Treatment outcomes on this 
combination of therapy were non-inferior compared to outcomes following twenty-four 
weeks of the traditional combination regimen including peg-IFN and ribavirin, with SVR12 
rates of 67% in both groups.  The SVR rates in genotype 2 participants included in this trial 
were far superior compared to genotype 3;  97%, and 56% respectively (265).   
 
FUSION investigated the efficacy of this treatment regimen in TE individuals that had not 
previously responded to an interferon-containing regimen.  FUSION was a blinded, active-
control study and approximately 30% of individuals enrolled had evidence of compensated 
cirrhosis at the time of screening for recruitment.  SVR rates in genotype 2 participants 
enrolled were 86% and 94% for treatment durations of twelve and sixteen weeks 
respectively, and 30% and 62%  in genotype 3 (269).   
 
Given that genotype 3 appeared to be the more resistant virus, in VALENCE, an un-blinded 
phase III trial, the duration of treatment with sofosbuvir and ribavirin in both TN and TE 
genotype 3 patients was increased to twenty-four weeks, with improved SVR rates of 91% in 
the cohort without evidence of cirrhosis and 68% in those with cirrhosis (270).  In all trials, 
excellent SVR rates were observed in genotype 2 cohort (269–271).     
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In the interferon-free trials described above, an inferior response to treatment was observed 
in individuals with genotype 3 disease.  Results from the small phase II LONESTAR-2 trial 
suggested that sofosbuvir in combination with Peg-IFN and ribavirin was an effective regimen 
for use in genotype 3 infected individuals and therefore a large phase III trial was conducted 
to compare the efficacy and safety of sofosbuvir in combination with ribavirin, with and 
without peg-IFN in TE cirrhotic patients with genotype 2 HCV and in TN and TE patients with 
genotype 3 HCV (272).  The multicentre, phase III open-label trial BOSON randomised patients 
in a 1:1:1 ratio to one of the three following treatment regimens: sofosbuvir with ribavirin for 
16 weeks, sofosbuvir with ribavirin for 24 weeks, or sofosbuvir with ribavirin and peg-IFN for 
12 weeks (272).  The primary efficacy end point was SVR 12.  The trial recruited 
predominantly genotype 3 patients; 92% versus 8% genotype 2.  Baseline characteristics were 
similar to previous trials, predominantly white males of which 31% of all genotype 3 and 32% 
of genotype 2 participants had compensated cirrhosis (272).  SVR 12 rates were similar across 
all treatment groups; 87% in the 16 week sofosbuvir and ribavirin cohort, 100% in the 24 
week sofosbuvir and ribavirin treatment group and 94% in the group receiving sofosbuvir and 
ribavirin in combination with peg-IFN (272).  In the genotype 3 cohort, SVR 12 rates were 71% 
in the 16 week treatment arm, 84% in the 24 week treatment arm and 93% in the peg-IFN 
arm and this was statistically superior.  Virologic relapse rates were also lower in the peg-IFN 
cohort compared to the two groups receiving sofosbuvir and ribavirin; 5% versus 28% and 
13% in the 16 and 24 week treatment groups respectively (272).  Results from the BOSON trial 
provided clear evidence that in individuals with no contraindications to peg-IFN, a regimen 
consisting of sofosbuvir, ribavirin and Peg-IFN provided a promising option for treatment in 
genotype 3 infected individuals. 
  
 
 
73 
 
1.4.7.8.3 Real-world data 
Trials that assessed SVR12 outcomes in both interferon-containing and interferon-free DAA 
HCV regimens produced very promising results.  These results may have solely been due to 
the efficacy of the combination of agents used, but may have been influenced by a 
combination of factors including the controlled environment in which medical trials are 
performed and the characteristics of the individuals selected to participate.  Trial participants, 
in addition to being both motivated and engaged are often less complex in terms of both their 
physical and psychological health needs.  Therefore real-world outcomes observed when 
using the same regimens are often inferior to trial outcomes.  A good example of this is the 
comparison between trial outcomes and real-world outcomes for individuals with genotype 1 
HCV treated with telaprevir and boceprevir.  Real-world outcomes were complicated by 
significant rates of premature treatment discontinuation due to the side-effect profile of the 
first generation PIs and SVR rates as a result were lower (273). 
 
HCV-Target, a multicentre prospective observational study was performed to evaluate 
treatment outcomes in individuals with genotype 1 HCV treated with ledipasvir and 
sofosbuvir with or without ribavirin.  The trial was conducted by the Hepatitis C Therapeutic 
Registry and Research Network.  In the trial 154 individuals received eight weeks of therapy 
and 527 received twelve weeks, both without ribavirin.  Treatment regimens were selected by 
the responsible clinician and therapy was administered in accordance with local 
protocols(274).A second study obtained data for analysis through Trio’s Health Innovation 
Platform (275).Data was collected from 895 TN, non-cirrhotic patients with genotype 1 HCV 
that were treated with ledipasvir and sofosbuvir for either eight or twelve weeks.  SVR was 
determined by intention to treat (ITT) analysis (276). 
 
In both trials, SVR rates exceeded 94% across all sub-groups, with little difference identified 
between response rates in genotype 1a versus 1b and between the eight and twelve week 
regimens.  The SVR rates observed were consistent with outcomes observed in the ION-1 and 
ION-3 trials.  Furthermore, the real-world studies demonstrated low rates of discontinuation 
as a result of adverse effects, re-emphasising both the safety and tolerability profiles of DAAs 
(277).  One limitation in using these studies as real-world data for comparison is that the 
participants included did not have cirrhosis nor any of the associated complex medical 
problems, therefore SVR rates demonstrated here may still be higher than would be expected 
when clinicians start to treat complex individuals that have previously been deemed either 
unsuitable for, or who have failed therapy with interferon-containing regimens. 
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Welzel et al assessed the safety and effectiveness of daclatasvir in combination with 
sofosbuvir with or without ribavirin in a large real-world cohort of individuals diagnosed with 
advanced liver disease.  Criteria for inclusion included adults with HCV and a high risk of 
either decompensation or death within twelve months, with treatment  carried out as part of 
a European compassionate use programme (278).  The regimen recommended for use was 
daclatasvir and sofosbuvir for twenty-four weeks, with the addition of ribavirin at the 
discretion of the responsible clinician.  The primary outcome measured was SVR12.  In this 
study, eighty percent of participants recruited had liver cirrhosis, forty-six percent with a 
Model of End-Stage Liver Disease (MELD) score of more than ten.  The majority of individuals 
recruited were TE, and unsurprisingly the most prevalent genotypes were 1 and 3, thirty-nine 
percent and twenty-one percent of the study population respectively (278).  Ribavirin was 
used in three quarters of cases.  The ITT SVR rate in the study population was in excess of 
ninety percent.  On-treatment deaths occurred in two percent of the study population and a 
further four percent died during the period of follow-up.  Given the severity of liver disease 
required to meet the inclusion criteria, these outcomes were probably not to be unexpected 
and may not have occurred as a direct consequence of the treatment administered in the 
trial(273).  The authors concluded that treatment with daclatasvir and sofosbuvir was well 
tolerated even in individuals with advanced liver disease and high SVRs were achievable in 
these populations (278). 
 
An expanded early access programme (EAP) was also available through NHS England for 
individuals with HCV of all genotypes that were at significant risk of death or irreversible 
damage within twelve months as a result of hepatic or extra-hepatic manifestations of HCV.  
Clinicians had the choice to treat eligible patients with sofosbuvir in combination with either 
ledipasvir or daclatasvir, with or without the addition of ribavirin for a fixed duration of 
twelve weeks.  Individuals that fulfilled the criteria of the EAP were enrolled into the UK 
hepatitis registry, HCV research UK.  A  paper by Foster et al examined whether antiviral 
therapy was beneficial in unselected patients of all HCV genotypes with decompensation 
compared to individuals with equivalent stage disease enrolled into the same registry for at 
least six months prior to the start of the EAP.  Through EAP, 480 patients received antiviral 
therapy and data was available on 467.  Those treated had advanced liver disease; eighty-
eight percent of cases had decompensated cirrhosis and/or a Childs-Pugh score was more 
than seven and nine percent of patients had previously undergone liver transplant for HCV 
with evidence of aggressive recurrence in the graft (279).  Similar to the study by Welzel et al, 
the majority of individuals enrolled were male, Caucasian and were TE (279).  The spread of 
genotypes treated were fairly equal, 54.6% versus 45.4%.   
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Analysis of the data identified a predilection for treatment with sofosbuvir and ledipasvir in 
the genotype 1 cohort and for daclatasvir with sofosbuvir in the genotype 3 cohort.  In ninety-
one percent of cases, ribavirin was added to treatment regimens.  In 10.9% of cases viral 
response was followed by a subsequent relapse, 0.43% had no response to antiviral therapy, 
3.6% died and a further 3.4% were lost to follow up.  Large variations were seen in SVR rates 
between genotypes.  SVR 12 in genotype 1 participants was 90.5% compared to 68.8% in 
genotype 3, p<0.0001.  In terms of the safety profile and tolerability of DAAs in this complex 
group of individuals, treatment was discontinued prematurely in 5.6% of cases, and 7 patients 
died whilst on treatment (279).  An improvement in MELD was identified in the cohort 
receiving antiviral therapy, when compared to the untreated cohort.  In addition to this, rates 
of new episodes of decompensation were significantly reduced in the treatment cohort.  No 
significant differences were observed in either episodes of sepsis, the development of HCC, or 
deaths between the treated and untreated cohorts (279). 
 
1.4.8 Liver transplantation in hepatitis C 
Worldwide, cirrhosis secondary to chronic HCV is the most common indication for liver 
transplantation (OLTx) (280).  Graft re-infection has been documented in all cases of OLTx 
performed in RNA positive recipients (281).  Fibrosis progression in the graft occurs at an 
accelerated rate compared to in the native organ with cirrhosis present in up to one third of 
transplant recipients at five years (282).  Multiple factors including high VL pre and early in 
the post-transplant course, advancing donor age, prolonged ischaemic time, co-infection with 
cytomegalovirus and/or HIV, in addition to aggressive post-transplant immunosuppression 
may all contribute to rapid progression of fibrosis (283).  Fibrosing cholestatic hepatitis (FCH) 
occurs in approximately ten percent of individuals that are transplanted with chronic HCV.  
FCH causes rapid liver dysfunction resulting in graft loss, usually within two years of the 
transplant (284). 
 
1.4.9 Chronic hepatitis C virus infection in England: past and present 
In England, the number of deaths attributed to HCV has quadrupled and the number of 
registrations for OLTx due to HCV related cirrhosis has increased nearly threefold between 
1996 and 2014 (285).  In 2002, in response to the growing burden of disease associated with 
HCV, a government publication was produced, aimed at intensifying actions with regards to 
the prevention of spread of the disease, the diagnosis of and subsequent treatment of HCV in 
 
 
76 
 
high-risk populations (286).  HCV testing facilities were set up in genitourinary medicine 
(GUM) clinics, GP surgeries, prisons and in drug treatment centres.  A pilot scheme was 
launched in prisons that distributed both disinfectant tablets and injecting equipment with 
clean needles to IVDUs.  A public awareness raising campaign, ‘faCe it’ was developed by the 
Department of Health and education booklets were distributed to all general practitioners.  
Despite these interventions, results from a survey completed by primary care clinicians in 
London in 2003 demonstrated that knowledge surrounding HCV, in particular risk factors for 
acquiring the virus, diagnosis and management principles remained very low (287).  In a later 
review of implementation of HCV services in 2008 it was identified that only one-third of 
primary care trusts had adopted, and were following the  HCV action plan and  fifteen percent 
of primary care trusts had failed to adopt the plan at all (288). Awareness of viral hepatitis is 
improving though.  The 2015 Public Health England report on HCV in the UK demonstrated an 
increase in both awareness of, and testing and diagnosis of HCV in high-risk populations(285).  
There was a five-fold increase in the number of laboratory confirmed reports of HCV between 
1996-2014 and a twenty-one percent increase in testing in primary care between 2012-2014 
(285).  Sentinel surveillance data has indicated an increase in testing in black and ethnic 
minority groups in particular in Asian ethnicity groups (285).  An increase in testing in these 
other high-risk populations has been attributed to targeted awareness-raising campaigns in 
migrant communities.  The prevalence of disease in the south Asian and eastern European 
populations from the sentinel surveillance data was reported as two percent and five percent 
respectively, highlighting the significant burden of disease in these groups and emphasising 
the need for focused case-finding programmes to be developed and implemented.   
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1.4.10 Screening programmes for chronic HCV 
Primary prevention of HCV concentrates on activities aimed at reducing or eliminating the 
potential risk of transmission of the virus.  Secondary preventative measures predominantly 
focus on developing and implementing screening programmes to identify infected individuals 
in order to reduce the potential burden of chronic disease.   
 
When screening for any disease is considered, general principles that need to be evaluated 
include whether the disease in question poses an important public health problem, whether 
the natural history of the disease is understood, whether there is a latent stage of infection 
and finally whether effective treatments are available for use (289).  The case for widespread 
screening for HCV is an area with contrasting views and opinions.   
 
Historically, HCV screening was recommended for all individuals at an increased risk of 
infection; therefore anybody that had been exposed to the virus.  The Centers for Disease 
Control (CDC) recommended screening in the following groups of individuals: anybody who 
originated from a country where HCV was endemic, PWIDs, individuals in receipt of a blood 
transfusion prior to 1992 and individuals requiring renal replacement therapy (290). 
 
In 2012, guidance was modified to include one-time screening for anyone born between 
1945-1965 because it was recognised that the highest burden of disease was concentrated in 
this age group (291).  This change in screening policy has not been fully supported.  There are 
several arguments discouraging the notion of widespread screening for HCV.  One argument 
is that there is insufficient evidence available to support the progression of chronic HCV to 
end-stage liver disease (292).   
 
In a review of screening recommendations, authors questioned the appropriateness of 
screening given that there is a paucity of data available to fully explain the natural history of, 
and therefore progression of fibrosis in HCV.  Koretz et al proposed that in order to establish 
whether there are clear benefits to screening and subsequently treating HCV, a prospective 
study be conducted in order to document fibrosis progression from the point of infection 
(292).   Although ideal in its approach, this prospective study would be difficult, if not 
impossible to perform given the previously discussed asymptomatic nature of acute HCV 
infection.  In the literature, it is generally accepted that the incidence of cirrhosis 25-30 years 
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after infection with HCV ranges from between fifteen to thirty-five percent (293).  Duration of 
virus exposure and resulting chronic liver disease is supported by the high cirrhosis-mortality 
rates observed in middle aged men and women living in Egypt (294).  As previously discussed, 
there are few studies available to establish whether a relationship exists between duration of 
infection and progression of fibrosis due to a paucity of data in individuals with both a known 
duration of infection and paired liver biopsies for histological assessment.  
 
In studies that have been performed to investigate the natural history of fibrosis in HCV, 
samples collected for histological analysis have often been obtained from individuals that 
have presented with symptoms prompting investigation.  There is a lack of data available to 
evaluate progression of fibrosis in individuals with asymptomatic disease.  There is therefore 
an element of selection bias in studies that have been conducted with the primary aim of 
investigating fibrosis progression and the natural history of HCV.   
 
Data collected from individuals recruited to the HepFree trial will attempt to increase the 
understanding of fibrosis progression in asymptomatic cohorts of individuals infected with 
chronic HCV.  In HepFree, data on fibrosis stage has been collected using a combination of 
both non-invasive and invasive techniques in all individuals with a positive test for HCV.  This 
unique dataset will contain fibrosis scores for individuals that were tested and diagnosed with 
HCV through targeted testing in a population deemed as ‘at-risk’, implying a healthier cohort 
of individuals.  As with pre-existing fibrosis progression studies, the major limitation of the 
HepFree data set is the unknown duration of infection.  However because the programme 
targets individuals born outside of the UK, in most cases we assume that the virus was 
acquired in the first few years of life.   
 
In the review of widespread HCV screening, Koretz et al stated that in the majority of cases of 
chronic infection with HCV, individuals remain asymptomatic and do not die from liver-related 
complications.  If this was the case, they speculated that in addition to the costs associated 
with screening, diagnosis and treatment, risks associated with antiviral therapy outweigh any 
benefit derived from viral eradication (292).  Reduction in QOL in individuals infected with 
chronic HCV and subsequent improvements following SVR have previously been discussed 
and disagree with Koretz et al.  Evidence also exists that suggests higher mortality rates from 
both hepatic and extra-hepatic complications in anti-HCV seropositive patients compared 
with anti-HCV seronegative individuals even in the absence of end-stage liver disease 
(179,295).  As discussed, HCV treatment has evolved from interferon monotherapy with poor 
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SVR rates and multiple side-effects to an era of interferon free all–oral DAA regimens.  The 
vast improvement in SVR rates observed with new safe to use and easily tolerated agents 
support case finding initiatives.    
 
In both Canada and the USA, cost analyses of screening programmes have been conducted 
(296,297).  These studies considered both the cost of HCV treatment using both traditional 
and novel therapies together with costs associated with HCV related deaths and quality 
adjusted life years. In each of these analyses, screening was shown to be cost effective 
(296,297). 
 
Currently, EASL and the National Institute for Clinical Excellence (NICE) recommend targeted 
HCV screening in the following groups of individuals (298,299) 
 PWIDs or individuals with a past history of injecting drug use. 
 Individuals in receipt of a blood transfusion prior to 1991 or blood products prior to 
1986. 
 Migrants originating from a country with a prevalence of viral hepatitis of more than 
two percent. 
 Children born to mothers infected with HCV. 
 Prisoners and young offenders. 
 Looked-after children and young people in care homes. 
 The homeless and people living in hostels. 
 HIV positive men who practice sex with men. 
 Close contacts of a known HCV carrier. 
 
1.4.10.1 Screening for viral hepatitis in PWID 
Drug policies in England recognise the need for a harm reduction approach in PWIDs. This 
approach is facilitated by the provision of opioid substitution programmes, key worker 
support in substance misuse centres, needle and syringe programmes as well as information 
available on the transmission of blood borne viruses (BBVs). Guidance exists recommending 
screening in all service users accessing drug services.  Screening in this population can be 
performed either by venepuncture or alternative testing methods including dry blood spot 
(DBS) and mouth swabs in individuals with difficult venous access (298).  Post screening, it is 
recommended that all service users be offered vaccination against HBV and annual HCV tests 
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in those with an on-going risk factors for infection (298).  Opt-out testing for BBVs in prisons 
began in England in April 2014 following a National Partnership Agreement between the 
National Offender Management Service (NOMS), NHS England (NHSE) and Public Health 
England.  
 
1.4.10.2 Screening in immigrant populations 
Currently in the UK, testing for viral hepatitis in immigrant populations is the responsibility of 
healthcare professionals, namely those operating in primary care.  Guidance recommends 
that testing is offered to all adults and children at increased risk of infection, in particular 
migrants originating from medium or high risk prevalence countries, at the point of 
registration with a new GP (298).   
 
The prevalence of viral hepatitis in migrants residing in the UK is not known.  Investigators 
have previously attempted to establish whether prevalence data from immigrants’ countries 
of origin can be used to predict the prevalence of disease in migrants residing in host 
countries.  Authors of HBV screening studies performed in Asian and Somali immigrants living 
in New York City and Minnesota concluded that disease prevalence in immigrants reflected 
the prevalence in their country of origin (7,8).  This was not the case in HCV screening studies 
performed in immigrants from the former Soviet Union residing in New York and in south 
Asian immigrants living in England (300,301).  One reason for the variation in findings may be 
the validity of prevalence data available for interpretation; epidemiological studies are 
expensive to perform and the results obtained are very dependent on the characteristics of 
the individuals recruited.   
 
Outreach studies previously performed in migrant populations have demonstrated that case-
finding for viral hepatitis in these populations is feasible  (301–304).  These studies employed 
both a variety of different invitation approaches and locations for testing.  Events were 
advertised using posters and flyers placed in shops, barbers and community centres.  In 
addition to the written adverts, religious leaders were approached and recruited to help to 
both increase the profile of hepatitis testing and to attempt to overcome barriers associated 
with screening.   
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There were several limitations associated with the methodology of the aforementioned 
studies.  The first limitation relates to the methods used to invite individuals for testing.  In 
these studies, viral hepatitis testing was only performed in individuals that self-presented in 
response to the advertising campaign.  This method of recruitment could have potentially 
resulted in selection bias, with testing performed more frequently in individuals with higher 
levels of knowledge regarding viral hepatitis and the implications of chronic infection who 
self-selected themselves for screening.  The second limitation relates to the locations selected 
to perform testing by the studies.  Screening was predominantly performed in public areas; 
individuals may have had reservations about attending and participating in a public place such 
as a community centre if they perceived that this act may be witnessed and reported 
negatively within their community because of stigma associated with HCV. 
1.4.10.3 Barriers to screening in immigrant populations 
It is widely accepted that chronic viral hepatitis affects disproportionately high numbers of 
the most deprived and marginalised communities worldwide.  In these populations, there are 
multiple barriers that prevent individuals from engaging with both screening for viral hepatitis 
as well as any subsequent assessment and treatment that may be required.  In addition to 
obstacles in engaging these populations, it is clear that challenges also exist in engaging 
health professionals to promote and facilitate testing in these groups (287).   
 
The success of a screening programme is dependent on how well the target population is 
engaged (305).  Ideally for a population to be engaged, they would possess awareness, 
knowledge and understanding of the disease being screened for, in addition to knowledge 
about both the risks and implications of leaving the disease both unidentified and untreated 
in the long-term.  Engagement by immigrant populations in viral hepatitis screening can be 
predicted to a certain extent by reviewing attendance data at pre-existing preventative 
screening programmes.  Historically, both socio-economic deprivation and migrant status 
have been associated with non-engagement with pre-existing preventative care strategies 
(306,307).  In England, research has demonstrated that attendance by migrant populations at 
breast, cervical and colorectal screening programmes is poor, in particular by groups of 
individuals originating from south Asia and the Indian subcontinent (308–310).   Inaccurate 
screening registers, frequent changes of address by individuals and extended periods of 
overseas travel have all been implicated as reasons for poor attendance amongst migrant 
groups (308).  In addition to these, language and communication barriers impact on both 
engagement in screening programmes as well as access to healthcare services on a larger 
scale (311,312). 
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Illiteracy is prevalent in migrant populations residing in England, with the highest rates 
observed in first generation immigrants, in females, and in individuals of advancing age (313).  
It has been estimated that more than half of all Bangladeshi and Pakistani women and nearly 
a quarter of men aged over fifty are illiterate in any language, and less than one third of 
women from these ethnic groups are able to read and understand English (313).  In these 
populations, written invitations to participate in preventative screening strategies are 
particularly ineffective and the high rates of illiteracy in all languages prevent the use of 
translations (313).  Another factor that might be associated with poor engagement in 
preventative care strategies by migrant populations is clinician-patient relationship. Research 
has identified that black and ethnic minority groups have a lower level of trust in their 
clinician compared to individuals of Caucasian origin (314,315).  This lack of confidence in 
healthcare providers may impact on an individual’s decision to participate in preventative 
care interventions offered to them (315,316). 
 
Research conducted in America, Australia and the Netherlands has focussed specifically on 
the attitudes of migrants towards testing for viral hepatitis.  Data from these studies 
augments pre-existing knowledge of the potential obstacles facing screening programmes 
(317–321).  Key themes including low levels of awareness about viral hepatitis, little 
knowledge pertaining to the potential routes of transmission of the viruses, symptoms 
associated with the diseases and the long-term implications of chronic infection were 
identified (317–321).  In this research, the insidious onset, as well as the asymptomatic nature 
of infection had a negative impact on individuals accepting the offer of testing.  Absence of 
symptoms has previously been associated with reluctance to attend for, and participate in 
preventative care screening strategies (322).  Stigma was also found to influence an 
individual’s decision to participate in viral hepatitis testing.  In developed countries, there is a 
well-established relationship between IVDU and a positive diagnosis of viral hepatitis, 
therefore an association exists between a viral hepatitis and socially unacceptable behaviours.  
Fear about how an individual might be perceived and subsequently treated by other members 
of their community if they are seen participating in testing might impact on their decision to 
engage with testing strategies (323).  Interestingly however, in specific viral hepatitis studies 
by Coronado et al and Nguyen et al clinician recommendation for testing had a positive effect 
on subsequent engagement rates (324–326). 
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1.5 Objectives of the investigation 
Through the HepFree trial and the associated sub-study, I aimed to explore the following: 
1. The feasibility of utilising electronic records in primary care in order to identify 
immigrants at risk of viral hepatitis that would benefit from screening for viral 
hepatitis. 
2. The acceptability of setting up a screening programme for viral hepatitis in primary 
care. 
3. The preferred method for inviting first and second generation immigrants to attend 
for testing, specifically whether a targeted invitation letter has value when compared 
to a standard, generic invitation letter. 
4. The demography and prevalence of viral hepatitis in first and second generation 
immigrants residing in culturally diverse area of England (Bradford). 
5. Whether undiagnosed chronic HCV results in increased utilisation of healthcare 
resources in primary care. 
 
In the following chapters I will describe the methods used to explore the above objectives, 
present and discuss the research findings, critique the methodology used by HepFree and 
make some recommendations for future research. 
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2. Materials and Methods 
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Within this chapter I will describe the methods used to conduct the HepFree trial including 
trial design, hypotheses, trial set up, participant identification, selection and invitation, 
participant enrolment and data collection. Statistical methods used for the exploratory 
analysis will also be discussed. 
 
2.1 Trial design 
HepFree is a cluster randomised controlled trial conducted in GP practices in four areas of 
England: north-east London, south-east London, Bradford and Oxford.  The trial was designed 
to invite up to 48,000 eligible participants from fifty GPs that had been recruited to 
participate and subsequently randomised to the intervention arm of the trial.  A further eight 
practices were recruited and assigned to the control arm of the trial.  HepFree set out to 
examine and test the following hypotheses that were included in the protocol: 
 That targeted case-finding for viral hepatitis in first and second generation 
immigrants in primary care is superior to opportunistic testing in identifying 
individuals with viral liver disease.  
 That providing additional information on the condition of viral hepatitis encourages 
individuals to enroll in the study and take up the offer of a screening blood test. 
 That providing treatment and follow-up for individuals who test positive for viral 
hepatitis in the community is superior, in terms of compliance and adherence to 
therapy, compared to treatment and follow up in secondary care (standard care). 
 
The study included two nested interventions within the intervention arm. One intervention 
involved randomising practices to either community care or standard, hospital based care in 
the event of a positive diagnosis of hepatitis. The other investigated the hypothesis that an 
‘enhanced’ invitation letter was more valuable than a ‘standard’ letter.  The ‘standard’ letter 
invited the recipient to take part in a research project that aimed to establish the best way of 
identifying individuals infected with viral hepatitis from those who are deemed at risk, based 
on their own, or parents country of birth.  The ‘enhanced’ invitation letter included an 
additional page of information on the viruses been tested for, the implications of chronic 
infection and reasons why the participant had been selected to participate in the trial.  A copy 
of both invitation letters used in the trial are available in Appendix 3.  From the fifty practices 
that were randomised to the targeted case-finding arms of the trial, twenty-one were 
assigned to standard care follow-up and twenty-nine to community care follow-up.  Eighteen 
out of the fifty practices were assigned to the intervention arm that sent a simplified 
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‘standard’ invitation letter to all eligible participants, and the remaining thirty-two invited 
participants used the ‘enhanced’ trial invitation letter.  The eight practices randomised and 
assigned to the control arm provided information on testing rates and subsequent 
engagement with treatment in a further 4,000 individuals.  Trial randomisation was 
performed using the method of minimisation (Peacock & Simon, 1975).  The programme 
managing allocations was web-based, and developed using Java at Queen Mary University 
London. 
 
Although the broad principles are similar, there are differences between case finding 
(targeted testing) and screening.  Case finding (or targeted testing) is a strategy used for 
targeting resources at individuals or a population based on the presence of risk factors.  It 
involves performing a systematic search to identify the ‘at- risk’ population followed by an 
invitation to attend for testing, as opposed to waiting for individuals to present with signs and 
symptoms relating to the disease of interest.  This is very similar to screening in that both 
processes risk stratify a population prior to further investigation.  The primary purpose of 
screening is to detect early disease in large numbers of asymptomatic or ‘healthy’ individuals.  
There are several principles that must be fulfilled before a testing strategy can be adopted as 
a screening programme, these principles are referred to as Wilson’s criteria. 
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Figure 4: The HepFree cluster randomised controlled trial design 
 
 
 
 
 
 
 
 
 
 
 
 
A flow chart summarising the HepFree trial design.  Comparing testing rates in GP surgeries performing targeted 
testing (coloured blue) with opportunistic testing in control practices (coloured green)  will investigate whether 
targeted case-finding for viral hepatitis in first and second generation immigrants in primary care is superior to 
opportunistic testing in identifying patients with viral liver disease.  Within the targeted case-finding arm (blue) there 
were two nested interventions; the first to investigate whether providing additional information on the condition of 
viral hepatitis encourages individuals to participate in testing, and the second to determine whether community 
based treatment improves compliance and engagement with treatment.  Practices in the red boxes sent an enhanced 
invitation including an additional information sheet to their eligible population and practices in the white boxes sent 
a standard invitation letter.  Participants with a positive test for viral hepatitis registered at a GPs assigned to the 
yellow boxes in the flow chart above were assessed and treated in hospital (standard of care) and participants with a 
positive test registered at GPs assigned to the purple boxes on the flow chart were assessed and treated in satellite 
hepatology clinics based in the community. 
 
*At the time of enrollment into the trial, participants were blinded to their treatment location 
allocation in the event of a positive viral hepatitis test result.  A second-stage consent was 
sought from all participants who had a positive test result at the time of their diagnostic 
assessment in secondary care.  Once the second-stage consent had been obtained, 
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participants were un-blinded and informed of their treatment and monitoring allocation, 
either hospital treatment and follow-up, referred to as standard care or treatment and 
follow-up at a satellite clinic in the community.  Any participant that withdrew consent for the 
second-stage of the trial was treated as per standard care.  Treatment allocation was 
concealed until after the initial consent to participate in the trial had been obtained, in an 
effort to prevent bias from being created between recruitment in the two arms of the trial. 
 Comparison of testing results in control and intervention practices; coloured green 
and blue respectively will investigate hypothesis one, that targeted case-finding for 
viral hepatitis in first and second generation immigrants in primary care is superior to 
opportunistic testing in identifying patients with viral liver disease.  
 
 Comparison of case-finding outcomes in practices inviting eligible individuals using 
the enhanced invitation with outcomes in practices using the standard invitation 
letter; coloured red and white respectively on the flow diagram will investigate 
hypothesis two, that providing additional information on the condition of viral 
hepatitis encourages individuals to enroll in the study and take up the offer of a 
blood test. 
 
 Comparison of the engagement and treatment outcomes in participants receiving 
standard of care versus care in the community; coloured orange and purple on the 
flow chart respectively will investigate hypothesis three, that providing treatment 
and follow-up in a community setting increases patient engagement, adherence and 
compliance with both appointments and therapy. 
 
2.2 The HepFree Trial 
2.2.1 The trial team 
The HepFree trial team involved the CI, a dedicated trial manager in addition to a part-time 
data manager and statistician. This team was based in London and responsible for both the 
submission of the ethics application and initiation of the trial.  The process of trial set up, 
which was conducted by the London team, is described below. 
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2.2.2 Trial set up 
HepFree, following a grant application from Professor Foster, was funded by the NIHR 
through the Programme Grants for Applied Research.  A copy of the trial protocol, written by 
the CI with support from the trial coordinator, is attached in Appendix 1.  The trial was set up 
by the team in London prior to me joining the group in October 2013.  Set-up involved several 
processes described below.   
 
In order to apply for sponsorship from the Bart’s Health NHS trust and Queen Mary University 
London, an Integrated Research Application System (IRAS) form for the trial was completed, 
and all documents submitted for internal peer review at the Blizard Institute, 4 Newark 
Street, London, City of London, E1 2AT and external review by the Bart’s Health NHS Trust 
Research Development team, Joint Research Management Office, Queen Mary Innovation 
Centre, Lower Ground Floor, 5 Walden Street, London, E1 2EF.  Once provisional sponsorship 
had been granted by the Joint Research Management Office for Bart’s Health NHS Trust and 
Queen Mary University London, Mile End Road, London, E1 4NS, the trial documents were 
submitted for central ethics review to the National Research Ethics Service, HRA NRES Centre 
Manchester, Barlow House, 3
rd
 Floor, 4Minshull Street, Manchester, M1 3DZ.  Following 
central ethics approval, full sponsorship was provided by Queen Mary University London and 
at this point the CI site was able to distribute study specific information to the research teams 
at the local coordinating sites in Bradford, Oxford and south-east London. 
 
2.2.3 Trial modifications 
Modifications were made to the HepFree trial protocol once permissions had been granted 
and sites were being recruited and randomised.  During randomisation, it was evident that 
practices had far larger numbers of potential study participants registered than had been 
predicted.  This observation was related to changes in primary care whereby small, single 
handed practices were encouraged to merge to form larger collective practices.  This would 
have had a negative effect on both the trial design and the study budget.  The trial 
methodology was therefore amended and a ‘cap’ introduced.  Practices that were recruited 
to the trial following the protocol amendment were instructed to invite only five hundred 
individuals at random from the list of all potential study participants registered in the 
practice. 
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This modification meant that the trial conducted participant recruitment using two different 
methods as described below.  Practices either invited all potential study participants who 
were registered there, referred to as comprehensive enrolment, or they invited five hundred 
potential participants selected at random from the list of all potential study participants.  The 
second method of recruitment was referred to as selective enrolment.  Of the fifty practices 
recruited to perform targeted case-finding in London and Bradford, sixteen practices utilised 
the comprehensive enrolment methodology, and thirty-four performed selective enrolment.  
The methods used to pre-select participants are discussed within the section titled Participant 
Retrieval.  
 
A second modification was made to the trial once sites had been opened and recruitment had 
commenced.  Staff within the practices provided feedback to the trial team regarding the low 
response rates to the trial letter invitations that had been sent as well as historically low 
response rates observed in migrant populations to written invitations for other established 
screening programmes.  In response to this, a further amendment was made to the trial 
protocol that allowed members of staff to approach potential study participants that 
attended the practice for another clinical reason to offer the viral hepatitis test.  This method 
of recruitment was referred to as opportunistic testing.  Within the amendment, the trial 
team was given permission to design and activate an electronic alert on the clinical computer 
systems in the practices.  The alert, once created, was linked to the trial report that contained 
a list of all potential study participants. From this point, whenever the electronic medical 
record of an eligible individual was retrieved by a member of staff within the practice 
(receptionist, healthcare assistant, practice nurse, clinician) a pop-up alert appeared on the 
home page of the record prompting them to enquire as to whether the individual would like 
to participate in the trial. If the individual did wish to participate following the verbal prompt, 
a copy of the patient information sheet (PIS) both in English and in their native language, if 
available, was provided and the individual was given the opportunity to read it prior to 
undergoing testing, which occurred either on the same day or at a future appointment 
arranged by the practice. 
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2.3 Trial methodology 
2.3.1 The control arm 
Practices randomised to the control arm of the trial received detailed written information 
pertaining to the trial aims, objectives and methods.  This was delivered in the form of the 
research protocol which was included as part of the trial site file.  The control practices 
received a single face to face meeting with the clinical fellow working on the HepFree 
research team, known as the site initiation visit (SIV), during which the trial aims, objectives 
and methodology were discussed.  The SIV was attended by general practitioners, the 
practice manager, practice nurse and healthcare assistants.  In the meeting, the clinical fellow 
delivered an education session on viral hepatitis that included indications for testing and 
consequences of long term infection.  The education session was delivered with the aid of a 
power-point presentation and all in attendance received a handout of the slides.  Throughout 
the presentation, members of staff present were encouraged to ask questions.  A copy of the 
handout provided at the teaching session is included in Appendix 2.The purpose of the 
education session was to encourage practitioners to offer testing to individuals considered at 
risk of viral hepatitis, individuals who would have been eligible if the practice had been 
randomised to perform targeted case-finding.  Clinicians were encouraged to consider 
offering the viral hepatitis blood test to eligible individuals who attended the practice for 
either a consultation, or when registering as a new patient.  The purpose of this was for the 
trial to be able to assess the impact of education on subsequent opportunistic case-finding for 
viral hepatitis in ‘high-risk’ individuals. 
 
2.3.2 The targeted case-finding (intervention) arms 
In practices assigned to perform targeted screening, potential study participants were invited 
to attend for screening using one of the two trial invitation letters, depending on the outcome 
of randomisation.  The trial invitation letters are included in Appendix 3.  The invitation letter 
provided each individual with the opportunity to attend their practice to consent to 
participate in the trial, and undergo a viral hepatitis screening test. During the SIV for targeted 
screening practices, members of staff received the same education session that was provided 
to control practices, as well as teaching on additional techniques and processes required to 
conduct the trial.   
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Administrative staff were taught how to generate and distribute personalised screening 
invitation letters using the clinical computer system within the practice.  Allied healthcare 
professionals were taught how to obtain consent, perform blood sampling for analysis, 
complete the sample request form, and how to locate and complete the trial specific 
template that had been published on the electronic records system used by the practice.  
Finally staff were taught to input Read codes denoting the results of the screening blood tests 
on to each participants electronic medical record and instructions were given on how to refer 
a participant to the HepFree trial team (myself for Bradford patients) in the event of a positive 
screening test result. 
 
In targeted screening practices, successful enrollment into the trial involved asking the trial 
participant to read, understand, and sign an up-to-date version of the consent form; copies of 
the patient information sheet and consent form are in Appendices 4 and 5.  Once consent had 
been obtained, six millilitres of venous blood was obtained by venepuncture and sent in a 
Serum Clot Activator VACUETTE
® 
sample tube with a study specific proforma requesting for 
the sample to be tested for HBsAg and anti-HCV to the local virology laboratory.  For Bradford 
the selected laboratory was The Old Medical School, Leeds General Infirmary, Thorseby Place, 
Leeds, West Yorkshire, LS1 3EX.  A contract was set up and agreed between the official 
sponsor of the trial Queen Mary University, Whitechapel, London, E1 2AN and the Leeds 
Teaching Hospitals NHS Trust for processing and reporting of trial blood samples.  To facilitate 
identification of study samples I created a study specific sample request proforma, available 
in Appendix 6.   
 
Practice payment 
Practices received monetary incentives for trial related activities.  For time taken to set up the 
trial and to produce a data extract, control practices received £250 from the HepFree trial 
budget.  In practices performing targeted screening, as the trial has been adopted by the 
NIHR Clinical Research Network (CRN) portfolio, financial support was provided by them.  
Table 4 summarises the payments made to targeted screening practices for trial related 
activities in Bradford.  
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Table 4: HepFree study support costs  
Study support costs paid to targeted testing practices participating in the HepFree trial by the 
Clinical Research Network 
Trial related activity Cost (pound sterling) 
Set up costs 475.28 
GP check on participant list for suitability 160.00 
Reminder set up 12.44 
Text Message reminder service set up 11.00 
Consent and Screening 7.32 
Book appointments (per appointment) 2.07 
Invites (per invite) 0.41 
Exclusions Nurse 0.37 
Text message reminder (per SMS) 0.15 
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2.4 HepFree trial inclusion criteria 
Potential study participants included anyone registered within one of the designated targeted 
screening practices that: 
 Originated from a country with a prevalence of viral hepatitis of more than 2% (List 
of countries available in Appendix7). 
 Had a parent who originated from a country with a prevalence of viral hepatitis of 
more than 2% 
 Was eighteen years of age or older. 
 Had capacity to consent to participate. 
 Had no documented evidence of previous viral hepatitis screening within the last five 
years. 
 Did not have a pre-existing diagnosis of viral hepatitis. 
 
Due to uncertainty surrounding whether subjects had historically been screened for HBV 
infection prior to immunisation, we did not exclude anyone that had previously been involved 
in a HBV immunisation programme. 
 
2.5 The HepFree trial in Bradford 
 
I joined the HepFree trial team in October 2013.  Once full sponsorship for the trial had been 
granted in London, my first role was to set up Bradford as a coordinating trial site.  In order to 
do this, I facilitated the development and implementation of a contract between Barts Health 
NHS Trust, The Royal London Hospital, Whitechapel, London E1 1BB and Bradford Teaching 
Hospitals NHS Foundation Trust, Bradford Royal Infirmary, Duckworth Lane, Bradford, BD9 
6RJ.  Once the contract had been finalised, site feasibility was completed and an agreement 
produced between the Research Development team at Bradford Teaching Hospitals and the 
Research Management Group at the Bradford District Care NHS Foundation Trust to enable 
the screening trial to be performed in GPs in the community.  The trial approval letters are 
available in Appendix 8. 
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Prior to commencing recruitment of sites in Bradford where the trial would be conducted, I 
had to establish the methods that would be used to interrogate primary care clinical 
computer systems in order to identify potential study participants.  Moreover, I had to 
establish the methods that we would use to collect both demographic and disease status data 
on participants that consented to, and participated in the screening trial.  As described within 
Participant Retrieval, the trial team had decided to identify potential study participants, also 
known as eligible individuals to participate in screening based on pre-existing demographic 
data stored in the form of Read codes, within their electronic medical records.  These ‘Read 
code searches’ were initially established in London for use on GP electronic records stored in 
the EMIS web system. In Bradford an alternative system, SystmOne (S1) was used.  I was 
responsible for designing and creating the specific reports used to identify and record data 
from potential study participants in Bradford.   
 
In order to establish the Read codes to be included in the trial reports, also referred to as 
‘eligibility reports’, I applied for a research passport.  This allowed me to gain access to a 
S1unit in a GP surgery in Bradford.  Here, I interrogated the clinical coding catalogue that is 
published and available for use by members of staff that code clinical information in patient 
records.  Interrogation consisted of performing multiple searches using different Read codes 
pertaining to ethnicity, country of birth, and main spoken language in order  to understand 
how best to identify individuals who were already registered within the practice.  As well as 
designing and running reports using Read codes, I performed surname analysis to identify 
participants who were likely to belong to particular ethnic groups of interest to the trial.  I 
then accessed and reviewed the Read codes used in the patient demographic section of the 
S1 record to gain a better understanding about the way in which practices use Read codes to 
store demographic data relating to ethnicity, country of birth and main spoken language.   
 
Once I was satisfied with the list of Read codes that I had acquired from my preliminary 
searches on S1 that would be used in the eligibility reports for the trial, I arranged a meeting 
with the data quality team at the Yorkshire and Humber Commissioning Support Unit, 
formerly The West and South Yorkshire and Bassetlaw Commissioning Support Unit, West 
Yorkshire Office, Douglas Mill, Bowling Old Lane, Bradford, West Yorkshire, BD5 7JR.  Here, 
with the help of one of the members of the data quality team, I devised and built the 
eligibility reports that were published on S1 for use by practices that we recruited to HepFree. 
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Once the eligibility searches had been published on S1, I began the process of practice 
recruitment.  Recruitment, site initiation, training and all support required by practices during 
the period of screening were performed solely by me in Bradford. 
 
Once practices had been recruited, opened and screening had commenced, all participants 
with a positive hepatitis screening test were assessed, clinically managed and followed-up by 
the trial team, either in secondary care or in the community, depending on the randomisation 
outcome of the practice at which they were registered. In Bradford, I arranged and conducted 
all assessments and follow-up appointments for participants with a positive screening test.  In 
addition to this I also captured and entered all trial related data in the trial eCRF, a form I had 
assisted in the development and testing of, alongside the clinical fellow and data manager in 
London. 
 
In the following sections I discuss in detail the methods of practice selection and recruitment, 
the study specific training that was delivered to practices at the time of the site initiation and 
the methodology of participant retrieval.  Finally I discuss the exploratory analysis 
methodology. 
2.5.1 Practice selection and recruitment 
Twenty-one GPs were recruited from two Clinical Commissioning Groups (CCG); Bradford City 
and Bradford District. Eighteen practices were randomised to the targeted screening arms 
and three to the control arm of the trial. Within the targeted screening practices, ten were 
allocated to comprehensive enrolment and eight to selective enrolment.  Data from the ten 
practices performing comprehensive enrolment were included in the exploratory analysis.  
The distribution of the practices is illustrated below. 
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Figure 5: The HepFree trial design in Bradford 
 
A flow chart summarising the numbers of practices randomised to each arm of the HepFree trial in Bradford.  
Comparing testing rates in GP surgeries performing targeted testing (coloured blue) with opportunistic testing in 
control practices (coloured green)  will investigate whether targeted case-finding for viral hepatitis in first and second 
generation immigrants in primary care is superior to opportunistic testing in identifying patients with viral liver 
disease.  Within the targeted case-finding arm (blue) there were two nested interventions; the first to investigate 
whether providing additional information on the condition of viral hepatitis encourages individuals to participate in 
testing, and the second to determine whether community based treatment improves compliance and engagement 
with treatment.  Practices in the red boxes sent an enhanced invitation including an additional information sheet to 
their eligible population and practices in the white boxes sent a standard invitation letter.  Participants with a positive 
test for viral hepatitis registered at a GPs assigned to the yellow boxes in the flow chart above were assessed and 
treated in hospital (standard of care) and participants with a positive test registered at GPs assigned to the purple 
boxes on the flow chart were assessed and treated in satellite hepatology clinics based in the community. 
 
Practice recruitment  
In order to increase awareness of the trial and assess clinician interest, two meetings were 
arranged by the research team in Bradford for general practitioners and practice managers.  
The meetings were hosted by a consultant hepatologist, two research nurses and theHepFree 
trial manager who visited from London.  The meetings were advertised both in the CCG 
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newsletter and in an electronic mail (email) that was sent to all clinicians by a central 
coordinator at the CCG.  At the meeting, contact details were taken for all clinicians who 
expressed an interest in participating in the trial, and these practices were prioritised when 
trial recruitment began in January 2014. 
 
In Bradford I was responsible for recruiting all practices to participate in the trial.  Practices 
that had expressed an interest in participating in the trial at the time of the HepFree meetings 
were prioritised and contacted in the first wave of recruitment.  Once this list had been 
exhausted, a list of GPs in both the Bradford City and Bradford District CCG was accessed from 
the internet.  The terms ‘Bradford City CCG’ and ‘Bradford District CCG’ were entered into the 
internet search engine Google to access the following websites: www.bradfordcityccg.nhs.uk 
and www.bradforddistrictccg.nhs.uk.  From the homepages of the websites there was a link 
for ‘Your services’.  On this page there was a list of all GP practices within the CCG with 
addresses and telephone numbers.  From this list, I contacted practices, prioritising them 
based on their geographical location and ethnicity data available from the census, offering 
trial places to practices within the postcode districts BD7, BD8 and BD9 first as these areas 
had high ethnic diversity.  
 
 Initial contact with practices was made by a telephone call to the practice manager in which 
the trial aims, objectives, and methods were discussed.  The telephone call was followed up 
immediately with an email that provided a brief summary of the telephone discussion, a short 
trial synopsis and contact details of the trial team in Bradford, so a face to face meeting with 
myself and one of the hepatology research nurses at a mutually agreeable time could be 
requested.  The face to face meeting, unlike the site initiation visit was not mandatory, but 
provided practices with the opportunity to meet the trial team prior to agreeing to participate 
if they wished, in addition to providing them with opportunity to discuss any issues related to 
the trial that might have arisen.  At the face to face meeting if the practice decided that it 
would like to adopt the trial, the specific search that had been designed to identify potential 
study participants (also known as the participant eligibility search) was accessed and run on 
S1.  If practices did not want to participate in the initial face to face meeting, then verbal 
instructions on how to locate and run the participant eligibility search were provided over the 
telephone.  The number of potential study participants in the practice, data derived from the 
participant eligibility report was required in order for the practice to be randomised and 
entered into HepFree.  Once this information was available, a randomization proforma was 
completed by myself, and submitted to the trial statistician via email.  A copy of the 
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randomisation proforma is available in Appendix 9.Once the outcome of randomization was 
known, the practice was informed and a time arranged to conduct the SIV.   
 
Due to the nature of how we were recruiting practices, there was no formal trial contact and 
initiation procedure, however all practices that failed to respond to the email that was sent to 
them following the first telephone call, or those that did not make contact with the trial team 
to disclose the outcome of their decision to participate in the trial within one week of the first 
telephone call were re-contacted by me. Practices were contacted either by email or 
telephone call, and this process was repeated at a frequency of at least once per week until 
an outcome regarding participation had been established.   All practices that declined the 
invitation to participate in the trial when contacted were offered a face to face meeting with 
the research fellow (myself) to discuss any potential barriers that may have been preventing 
them from participating in the trial.   
 
After four months of recruitment using the methods described above, a third meeting was 
organised by the hepatology research team in an attempt to improve engagement by 
clinicians in primary care with the trial.  Again, this meeting was advertised, and the invitation 
extended to all clinicians, practice managers, and practice staff working in general practice 
within the two CCGs.  Despite the third meeting, we were still not able to recruit the required 
number of practices for the cluster trial design and so a different approach was adopted.  I set 
up and attended a meeting with the head of the CCG in order to discuss the trial aims and 
objectives as well as the difficulties we were encountering with recruitment of sites in primary 
care.  The head of the CCG personally contacted all clinicians that they felt would be both 
willing, and able to incorporate the trial into their workload and run it efficiently.  This email 
lead to the recruitment of two more practices, but this did not complete recruitment for 
Bradford and so recruitment via telephone and email strategy continued until the required 
number of practices had been recruited. 
2.5.2 Trial specific training 
Once the outcome of randomisation was known, the SIV was arranged by me, with the 
practice, in order to deliver the trial specific training required for the practice to be able to be 
opened for recruitment. At the SIV, the lead clinician in the practice, practice manager, 
practice nurse and/or healthcare assistant were in attendance. I conducted all SIVs with 
assistance from a member of the data quality team from the Commissioning Support Unit.  
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The data quality team member attended the meetings to provide training on the S1 data 
management system, discussed below.  
 
As discussed previously, the visit started with an education session delivered by the clinical 
fellow (myself in Bradford) with the aid of a PowerPoint presentation.  This session was 
delivered in an informal manner with time for discussion, and provided an overview of the 
current and projected burden of disease associated with viral hepatitis in addition to the aims 
and objectives of the trial, the trial design and methodology.  There were also slides relating 
to good clinical practice, including data protection, consent, and reporting of adverse events.  
Of particular importance for practices randomised to the community arm of the trial, but also 
pertinent for all practices, cluster allocation bias was discussed by the clinical fellow and the 
lead clinician was asked to sign a contract, available in Appendix 10,that stated that they 
understood and agreed to avoid the introduction of bias related to treatment allocation.   
 
2.5.3 Generating the trial invitation letter 
As stated in the methodology, potential study participants were invited to participate in the 
trial using one of two invitation letters both of which are available in Appendix 3.  Practices 
were advised to personalise the letter by adding their letter head to the top of the letter as 
well as their contact details in the body of the text that would provide the recipient with 
details to enable them to book an appointment for testing.   
 
In order to generate an invitation letter populated with the study participant’s details, the 
invitation letter template had to be uploaded onto S1.  At the SIV the member of the data 
quality team taught the practices how to do this.  In addition to generating the letter using S1 
we asked the administrative staff to enter a specific Read code (9OT4) in the electronic 
medical record of each individual at the time when the letter was produced.  This allowed the 
trial team to produce a report containing details about the date and time that each letter had 
generated by the practice for each participant. 
 
Translations of the invitation letter were available in Bengali, Gujurati, Urdu, Polish, French 
and simplified Chinese.  If the staff responsible for distributing the invitation letters were 
aware that the main spoken language of a potential study participant was one of the 
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languages listed above, they were encouraged to send this in addition to the English version 
of the invitation.   
 
During this part of the training session, the data quality team also added the electronic alert 
to S1 and linked it to the list of potential study participants (the eligibility search).  The 
electronic alert was the reminder that would appear each time the medical record of a 
potential study participant was retrieved by a member of staff in the practice, thereby 
enabling them to offer testing opportunistically.  By linking the electronic alert to the list of 
potential study participants, the alert would only appear on the medical records of individuals 
that were eligible to participate in the trial.   
 
2.5.4 Consent training 
This session was delivered by the research fellow (myself) and covered the following 
principles: obtaining and recording consent, sending the blood sample for processing and 
completion of the study template.   The PowerPoint presentation provided an introduction to 
consent, containing an overview of the principles of both capacity and consent.  In this 
additional session, training was provided for the named members of staff within each practice 
that were responsible for taking consent, and included how to confirm participant eligibility, 
the methods involved in obtaining consent, instructions on how to fill the consent form and 
where to store each consent form.  A laminated pre-filled consent template was provided to 
each practice to act as an ‘aide memoire’.  Training was also provided on how to complete the 
study specific blood request proforma and how to complete the trial template that was 
published and available for use on S1.  The template will be discussed further in the section 
titled The Study Template. 
 
2.5.5 Recording case-finding test results 
Staff within each practice that were designated the task of reviewing all viral hepatitis test 
results were taught how to code each result in the electronic medical record of each 
participant.  Members of staff were also instructed how to inform the trial team in the event 
of a positive test result.  The results of all of the trial samples that were received and 
processed by the virology laboratory at Leeds General Infirmary were returned to the practice 
 
 
102 
 
for review by the lead clinicianonS1 using an electronic link.  The clinician or other named 
member of staff then had the task of entering two Read codes into each electronic medical 
record.  The purpose of this was to enable the research team to collect data on anonymised 
test results. The four Read codes available to the practice staff are summarised in Table 5. 
 
Table 5: Read codes to document viral hepatitis test outcomes 
Read codes available within SystmOne that were recommended by the trial for use to 
document the results of the viral hepatitis tests.  Once a Read code was assigned to a test 
result, this anonymised data could be retrieved by the data team. 
XaPEy Hepatitis B screening test positive 
XaPLp Hepatitis B screening test negative 
XaPLI Hepatitis C screening test positive 
XaPLZ Hepatitis C screening test negative 
 
 
If the result of either the HBV or HCV test was positive, the practice was advised to fax a copy 
of the result to a secure facsimile number belonging to the research team at Bradford Royal 
Infirmary, Duckworth Lane, Bradford, BD9 6RJ.  The practice was then instructed to invite the 
participant to the surgery to inform them of this result and to notify them that the research 
team would arrange an appointment for assessment at Bradford Royal Infirmary.  
 
2.5.6 The HepFree site file 
The final stage of the SIV involved reviewing the site file and trial protocol.  All members of 
staff within the practice that were going to be involved with the trial were asked to complete 
a research specific curriculum vitae (CV) that detailed any previous research experience, a 
copy of the research CV is available in Appendix 11.  They were also asked to sign two 
registers, one to indicate attendance at the meeting and a second to state that they had 
received the appropriate training from the trial team to enable them to run the trial.    The 
lead clinician signed the PI agreement page and thereby declared that all research carried out 
in the practice would be performed in accordance with the research government framework 
for Health and Social Care (2005) and the World Medical Association Declaration of Helsinki.  
The PI agreement page is in the trial protocol in Appendix 1. 
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2.5.7 Participant Retrieval 
2.5.7.1 Comprehensive enrolment 
As discussed above, in order to identify potential trial participants using S1, a series of reports 
were designed by myself in Bradford, and built with the assistance of the data quality team at 
the Yorkshire and Humber Commissioning Support Unit, formerly The West and South 
Yorkshire and Bassetlaw Commissioning Support Unit, West Yorkshire Office, Douglas Mill, 
Bowling Old Lane, Bradford, West Yorkshire, BD5 7JR.  The eligibility search consisted of two 
reports that were combined and when run at the same time on S1would create the final list of 
trial participants.  Report one searched for Read codes in electronic medical records that 
related to the following demographic data fields: 
 Country of birth 
 Main spoken language  
 Ethnicity 
 
The second report, report two, was designed to exclude individuals that were eligible based 
on demographic data searched for in report one, but who had either already been diagnosed 
with chronic viral hepatitis or had undergone testing for viral hepatitis in the previous five 
years.  The two reports, when run together on the clinical computer system in the GPs 
produced a final report containing the details of all individuals, registered at that practice that 
fulfilled the criteria for enrolment.  This list was then used by administrative staff within the 
practice when letters were generated and distributed.  Practices recruited to perform 
comprehensive enrolment were instructed to send an invitation letter to all potential study 
participants that appeared within the eligibility report during the eighteen month screening 
period.   
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Figure 6: HepFree eligibility reports on SystmOne 
 
 
A screen-shot providing an overview of the reports created and published on S1 to identify potential study 
participants.  Report one (HepFree study main) searched for Read codes in individual patient electronic medical 
records relating to country of birth, main spoken language and ethnicity of interest to the study.  Report two 
(HepFree C & B Screen positive) excluded individuals that would have been eligible for the trial based on 
demographic data stored within their electronic patient record, but who had either already been diagnosed with 
chronic viral hepatitis or had undergone testing for viral hepatitis in the previous five years.  The two reports, when 
combined in S1 (HepFree potential study participants) produced a final report containing the details of all individuals, 
registered at that practice that fulfilled the criteria for enrolment. 
 
2.5.7.2 Selective enrolment 
For practices recruited to perform selective enrolment, the same process described above, 
was used to identify potential study participants registered at the practice.  Once the list of 
study participants had been generated, a function within S1 was used to produce a list of five 
hundred individuals that were selected at random from the original eligibility report.  An 
additional Read code was entered into the electronic medical record of all five hundred 
participants, and a new search was created in S1 to produce a report using this Read code.  
The report produced was a modified list of potential study participants from which the 
practice could send invitation letters.  The Read code selected for use was 9PZ. 
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Figures 7 and 8: Creating a random list in SystmOne 
 
 
 
 
 
 
 
 
 
 
 
Screen-shots demonstrating the function available within S1 to create a modified list of potential study participants 
for use in GP surgeries limited to inviting only 500 of their eligible patient population to participate in the trial 
following the protocol amendment described in chapter 2.2.3 trial modifications.   Potential study participants were 
selected at random from the original HepFree eligibility report by using the Ad hoc patient list function in S1. 
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The searches used to identify potential study participants were unique to Bradford because of 
the different clinical computer systems used in Bradford and London.  SystmOne, developed 
by the Yorkshire based Software Company; The Phoenix Partnership (TPP), Mill House, Troy 
Road, Leeds, LS18 5TN is the primary care clinical computer system used in all practices in the 
two Bradford CCGs.  In London however, only a minority of practices usedS1, with the 
majority using EMIS web. EMIS web and S1 utilise different versions of Read codes; Read 
version 2, and CTV-3 and therefore the searches and reports had to be unique to each 
particular clinical computer system. 
 
2.5.8 The trial template. 
A trial-specific template was designed by the London team with input by me and was built 
and published on S1 for use by all practices performing targeted testing.  The template was 
used to collect and record specific trial-related activities using Read codes.  The following data 
was recorded in the template either by using a tick box or free text entry.  Read codes were 
attached to all data fields with a tick box.   
 The date the individual either agreed or declined the offer to take part in the trial. 
 The date consent was obtained from the trial participant. 
 The tests requested on the study specific proforma. 
 The ethnicity of the trial participant. 
 The country of birth of the trial participant. 
 The main spoken language of the participant and whether an interpreter was used 
for the trial consent. 
 
There were two fields on the template to record a positive HBV or HCV test result so either 
this could be used or the Read codes could be entered manually, as previously described, the 
second option did not require the template to be opened.  In the first week of every month 
during the testing period, the data quality team initially, but later myself once the contract 
had expired, produced a series of reports containing cumulative testing data for each practice 
including all of the data collected in the template, the number of invitation letters sent, the 
number of individuals that had consented for testing and the results of all viral hepatitis blood 
tests.  The data in these reports was sent to London by secure email for cleansing and storage 
by the trial data manager. 
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Figures 9-11: The HepFree trial template  
 
 
Screen-shots from S1 depicting the trial template and all patient information collected for analysis by the study.  
The template was completed by healthcare staff within the practice at the visit when consent was sought to 
perform the viral hepatitis test.  
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Figure 12: Timeline of HepFree trial related events from October 2013 
 
A flow diagram demonstrating the timeline of trial related events occurring in Bradford from the point that the 
clinical fellow (myself) joined the HepFree trial.  Twenty-one GP surgeries were recruited, randomised and opened 
between January 2014 and April 2015.  Between March 2014 and March 2016, eighteen of the twenty-one practices 
performed targeted testing for eighteen months and opportunistic testing was performed in the three practices 
randomised to the control arm of the trial.  Participants with a positive hepatitis test during the testing period were 
invited to attend for a diagnostic assessment, with second stage consent obtained at the first assessment visit that 
took place in secondary care.  All data from the diagnostic and subsequent visits was collected in eCRFs for 
subsequent analysis.   
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2.5.9 Trial sample analysis 
As discussed in Study Methodology, during the screening visit, six millilitres of venous blood 
was obtained by venepuncture from each participant and sent with a trial specific proforma 
for analysis to the virology laboratory at Leeds General Infirmary.  Each sample was tested for 
HBsAg and anti-HCV. 
 
2.5.9.1 Anti-HCV 
Samples were tested for the presence of anti-HCV using the Abbott ARCHITECT Anti-HCV 
assay (Abbott Laboratories.  Abbott Park, Illinois, U.S.A.).  The ARCHITECT anti-HCV assay is a 
two-step immunoassay that uses chemoiluminescent microparticle immunoassay (CMIA) 
technology for the qualitative detection of anti-HCV in human serum and plasma.  The test is 
designed to detect antibodies to structural and non-structural proteins of the HCV genome.   
 
If the result obtained from the ARCHITECT anti-HCV test was positive, the sample was 
referred for confirmatory testing using the Diasorin Liason XL assay (Via Crescentino snc - 
13040 Saluggia (VC)).  This test also uses CMIA technology for qualitative detection of anti-
HCV.  If there was a discrepancy in the results obtained from the first and second tests, a third 
test was performed on samples using the Orthogenics HCV antibody kit. 
 
HepFree study samples tested for anti-HCV were reported in one of three ways as listed 
below in addition to subsequent actions that were taken as part of the trial. 
 
2.5.9.1.1 Anti-HCV positive 
Samples that tested positive for anti-HCV were automatically referred for RNA testing by the 
virology laboratory to confirm chronic infection status.  This was performed using the COBAS® 
AmpliPrep/COBAS® TaqMan® HCV Test, Roche Molecular Diagnostics (4300 Hacienda Drive, 
Pleasanton, CA 94588, USA).  This is an in-vitro nucleic acid amplification test for the 
quantification of HCV in human plasma or serum. 
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2.5.9.1.2 Anti-HCV negative. 
The blood test for HCV was negative and no further action was needed. 
 
2.5.9.1.3 Low level anti-HCV 
For samples that were reported as low level antibody or antibody indeterminate by the 
virology laboratory, the study participant was recalled for repeat anti-HCV testing after seven 
days.  If the repeat sample was positive for anti-HCV, RNA testing was performed, and if it was 
either negative, or indeterminate again, no further action was taken. 
 
2.5.9.2 HBsAg 
Blood samples were tested for HBsAg using the Abbott ARCHITECT HBsAg qualitative assay, a 
one-step immunoassay for the qualitative detection of HBsAg using CMIA technology.  All 
samples that tested positive for HBsAg using the Abbott immunoassay underwent 
confirmatory testing using the Diasorin Liason XL assay in addition to testing for the following 
markers to confirm chronic infection: total core, core IgM, Hepatitis B e-antigen and hepatitis 
B e-antibody. 
 
2.5.10 HepFree: second stage 
As discussed, all participants with a positive hepatitis result were contacted by a member of 
staff in the practice and an appointment made to discuss the significance of the positive result 
with one of the clinicians within the practice. The trial clinical fellow was informed of the 
positive result by the practice and was responsible for generating a referral for the participant 
to attend secondary care for a diagnostic assessment (myself in Bradford).  The participant 
was notified of this appointment by a letter to their home address and text message 
reminder.   
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Irrespective of the randomisation outcome regarding location of treatment services, all 
participants had their initial diagnostic assessment performed in secondary care.  All 
appointments that occurred following a positive screening test were conducted by me.   
 
On the day of the appointment, once the study participant had arrived in the outpatient 
department at Bradford Royal infirmary, they were introduced to one of the hepatology 
research nurses.  The role of the research nurse was to counsel the participant on the second- 
stage of the trial and seek consent from them to remain in the trial; a copy of the second 
stage consent form is available in Appendix 12.  The participant was informed that if they 
chose to continue in the trial they would be randomised to receive treatment for viral 
hepatitis if required, and would be invited to attend all subsequent follow up appointments 
either in hospital (standard care) or in the community.  Prior to giving consent, participants 
were provided with an information leaflet pertaining to stage-two, included in Appendix 13.   
As HepFree was a cluster trial, GPs were randomised to either standard care or community 
care follow-up and all participants registered within the practice would be randomised to the 
same treatment location.  The process outlined above, whereby a research nurse, associated 
with the trial, but who was unaware of the practice allocation obtained consent from the 
participant to participate in the second-stage of the trial ensured that inadvertent bias was 
avoided and individuals were truly blind to their treatment allocation when they consented to 
participate. 
 
For participants randomised to community care follow-up, after the initial diagnostic 
assessment and any appointments required for radiological examinations that formed part of 
the diagnostic assessment, all follow-up appointments were conducted in the community.  
The one exception to this was when individuals were assessed by a viral hepatitis clinical 
nurse specialist (CNS) with a view to commencing antiviral therapy.  These assessment 
appointments were performed in the secondary care to ensure that the CNS did not identify 
any issues that would prevent an individual from being able to be treated safely with antiviral 
therapies outside of the hospital setting. 
 
2.5.11 Community treatment in HepFree 
One of the objectives of the HepFree trial was to examine the impact of moving the location 
for treatment and follow-up of viral hepatitis from secondary care to the community, 
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measured in terms of patient adherence and compliance.  In Bradford I approached two GPs 
and requested to use a consulting room in each in order to set up a satellite hepatology clinic.  
Practices were reimbursed financially from the trial for the number of hours the room was 
used by a member of the research team. 
 
Practices were selected primarily according to their location.  I selected practices that in 
theory would be easier for participants to access taking into account the distance they would 
have had to travel to the hospital compared to the community clinic.  It was not feasible to 
calculate the distance for each individual from their home address to the hospital so we 
calculated distance from their base GP surgery and selected locations that were both closer 
than Bradford Royal Infirmary in distance, and that had facilities for the study participants to 
use free of charge, such as parking. 
 
2.6 Exploratory analysis of findings from practices performing comprehensive enrolment. 
Data obtained from ten practices assigned to perform comprehensive enrolment that had 
completed eighteen months of testing by March 2016 were used in an exploratory analysis 
performed by myself, and presented in this thesis.  I used the data available to investigate the 
feasibility and acceptability of targeted testing for viral hepatitis in immigrant populations in 
primary care.  Of particular interest to me were the demographics of individuals who 
consented to testing, and those who declined the offer, drawing comparisons with the 
populations that were eligible and invited to participate in the trial.  Other objectives I wanted 
to investigate included whether the type of letter invitation used had an impact on response 
rates. In addition to this, I explored the timing of response between the date the invitation 
letter was sent and when the screening test was performed.  Through analysis of this data I 
wanted to gain more information and attempt to draw conclusions on the effectiveness of 
letter invitation in preventative testing strategies in immigrant populations.   
 
The exploratory analysis used a combination of descriptive and inferential statistical tests 
performed using IBM SPSS statistics 23 and Microsoft EXCEL.  Independent T-tests, Chi-square 
tests of independence, Fisher’s exact tests and logistic regression were performed in SPSS. 
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2.7 The HepFree sub-study 
In this section I will discuss the methodology of the HepFree sub-study, designed and 
conducted to investigate symptom prevalence and use of healthcare resources in primary 
care by individuals with a positive HCV screening test.   
 
The HepFree sub-study was a retrospective, observational case-control study investigating 
symptoms and primary care healthcare resource utilisation in individuals with a positive HCV 
test.  It was conducted in participants that had been enrolled into, and consented to testing 
for viral hepatitis in the main HepFree trial in Bradford.  The sub-study was designed to test 
the following hypotheses: 
 Individuals with undiagnosed chronic HCV (RNA positive) use healthcare resources in 
primary care more frequently compared to individuals that have no evidence of 
infection with viral hepatitis (hepatitis B and C). 
 Individuals with evidence of past infection with HCV, but no evidence of on-going 
infection (anti-HCV positive, RNA negative) do not have an increased number of 
episodes of attendance to primary care compared to individuals with no evidence of 
previous infection with viral hepatitis. 
 
 
2.7.1 Sub-study set up 
This retrospective, observational case-control study was designed, developed and run solely 
by the clinical trial fellow (myself) in Bradford. Funding for the sub-study was provided by the 
main HepFree trial.  The HepFree trial CI supervised and oversaw all sub-study activities.I 
designed and wrote the protocol for the sub-study and completed and submitted the IRAS 
form.  Sub-study documents were submitted for review by the Bart’s Health NHS Trust 
Research Development team, Joint Research Management Office (JRMO), Queen Mary 
Innovation Centre, Lower Ground Floor, 5 Walden Street, London, E1 2EF and subsequently 
underwent internal peer review at the Blizard Institute, 4 Newark Street, London, City of 
London, E1 2AT.  Provisional sponsorship was sought from the Joint Research Management 
Office for Bart’s Health NHS Trust and Queen Mary University London, Mile End Road, 
London, E1 4NS.   Once sponsorship had been agreed, sub-study documents were submitted 
for central ethics review to the London-West London & GTAC Research Ethics Committee, The 
Old Chapel, Royal Standard Place, Nottingham, NG1 6FS.  Following a committee meeting at 
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the Hammersmith Hospital, London, W12 0NN, central ethics approval was granted and 
Queen Mary University London subsequently provided full sponsorship.  Once all agreements 
were in place, data collection began in all practices performing targeted screening in 
Bradford. 
 
2.7.2 Sub-study Methodology 
2.7.2.1 Participant selection: cases 
 
All cases and controls included in the sub-study had been recruited, consented and 
undergone testing for viral hepatitis as part of the main HepFree trial between March 2014 
and February 2016.  In order to test the hypotheses described above, data for analysis on 
healthcare utilisation was collected on two cohorts of cases; 31 cases of chronic HCV infection 
(characterised by anti-HCV positive, RNA positive) and 23 cases with evidence of previous HCV 
infection associated with spontaneous clearance (characterised by anti-HCV positive, RNA 
negative without prior antiviral therapy or medical intervention).  Cases were diagnosed using 
the ABBOTT ARCHITECT Anti HCV chemiluminescent microparticle immunoassay (Abbott 
Laboratories.  Abbott Park, Illinois, U.S.A) and RNA positive using the Roche COBAS 
Ampliprep/COBAS Taqman HCV test (Roche molecular diagnostics, 4300 Hacienda Drive, 
Pleasanton, CA 94588, USA).  A detailed description of the definitions of cases is listed below.   
 
 
As discussed previously, in the main HepFree trial, all participants with a positive HCV test 
were invited by the research team for assessment in secondary care.  At this appointment, for 
individuals with evidence of previous infection with HCV, a thorough medical history was 
taken to ensure they had not received eradication therapy; this was an exclusion criterion for 
the sub-study.  Separate consent was not obtained from participants for the sub-study as 
permission was sought during the initial consent process. 
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2.7.2.2 HepFree sub-study definitions 
Cases of chronic HCV infection were diagnosed by the presence of both anti-HCV and HCV 
RNA.  Cases with evidence of previous infection associated with spontaneous clearance were 
diagnosed by a positive anti-HCV test, but a negative RNA test. 
 
2.7.2.3 Sub-study criteria for enrolment 
Individuals that were identified as cases and included in the sub-study fulfilled the following 
criteria: 
 Registered at a HepFree targeted screening GP surgery. 
 Enrolled, consented and tested for viral hepatitis as part of the HepFree trial 
between March 2014 and February 2016. 
 Had a blood test result consistent with either chronic HCV or evidence of previous 
infection with HCV. 
 
Exclusion criteria for the sub-study were as follows: 
 
 Anti-HCV positive cases in whom the individual had previously received antiviral 
therapy for the treatment of HCV. 
 Individuals with an indeterminate anti- HCV antibody test result. 
 Individuals that did not engage with follow-up in the HepFree trial (also known as 
lost to follow up). 
 Individuals that died during follow-up in the HepFree trial 
 Individuals that withdrew consent to continue in the HepFree trial. 
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2.7.2.4 Participant selection: controls 
For the purpose of the sub-study, a control participant was defined as an individual that had 
been recruited, consented and had undergone testing for viral hepatitis as part of the 
HepFree trial.  The control must have tested negative for both HBV and HCV.  Controls were 
matched to cases using the following criteria: 
 Gender 
 Age; documented date of birth within six months 
 Country of birth 
 Ethnicity 
 Length of time living permanently in the UK: documented date of entry of the control 
within six months of the case. 
 
Participants selected to act as controls were identified and matched to cases by creating and 
running a report in S1.  All eighteen GP practices that were performing targeted testing in the 
HepFree trial were used to search for participants to act as controls. 
 
In HepFree, each participant that was consented and had a viral hepatitis blood test as part of 
the trial had a trial specific proforma completed by a member of staff within the practice 
(described in section 2.5.8).  As previously discussed, this proforma contained demographic 
details for each participant in addition to information relating to the date and time that they 
underwent testing.  Data entered into the proforma was recorded as Read codes in each 
patient electronic medical record.  A report could therefore be created and run on S1 to 
identify all individuals registered in each HepFree practice that had a Read code within their 
electronic records stating that they had undergone testing through HepFree.   
 
The list of participants generated by the report was then broken down by gender and age to 
create a final list of participants.  Once eligible controls had been identified based on age and 
gender, as described above, the clinical fellow reviewed the demographic data stored on 
within the patient electronic medical record on S1 to validate eligibility based on the 
remaining matching criteria (country of origin, length of time resident in the UK) and 
confirmed that the viral hepatitis diagnostic test results were negative.  A control was 
excluded if the clinical fellow was not able to fully match them to a case using information 
stored in the electronic medical record.  This process of selecting a control subject for a case 
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was repeated on each clinical computer system in all of the practices performing targeted 
screening.   
 
In cases when more than one eligible control participant was identified using the criteria for 
matching stated above, a randomisation programme on Microsoft EXCEL was used to select 
the final participant that would act as the control.  In S1, demographic data is stored in a 
separate area to the journal, where details of consultations are documented so the clinical 
fellow was blinded to any clinical information until after the control participant had been 
selected and prevented selection bias from being introduced.  Cases were matched to 
controls using a 1:1 ratio. 
 
In the event that a suitable participant to act as a control could not be identified using the 
above criteria,  the six month matching rules for date of birth and/or length of time in the UK 
were extended, with controls selected that fulfilled the matching criteria as close as possible. 
 
2.7.3 Sub-study data collection 
In order to test the hypotheses, data was collected on the total number of episodes of care 
sought by cases and compared to controls, up to, and including the visit when the individual 
was enrolled into the HepFree trial.  An episode of care was defined as any documented 
contact with a healthcare professional within the GP practice.  A healthcare professional for 
the purpose of this sub-study was defined as a doctor, specialist nurse practitioner, practice 
nurse, community nurse, district nurse or healthcare assistant. For each episode of care that 
was documented within the electronic patient record, the following information, where 
available was collected: the date of attendance and the diagnosis or outcome of the episode 
of care.   
 
 
For participants that had lived in the UK prior to 2005, data was collected from 01/01/2005.  
This cut-off date was selected as from this point; attendances to primary care were recorded 
and available to view in the electronic medical record on S1.  For participants that entered the 
UK after 2005, data collection commenced from the time of the new-patient registration 
appointment.   
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Sub-study data was anonymised using the strategic identifier (ID); a pseudoanonmyised 
number generated by the clinical computer system in primary care at the point of enrolment 
into the HepFree trial.  All data collected for analysis was stored using this number in a 
Microsoft EXCEL database on a secure hospital information technology (IT) server.  
Supplementary demographic data collected by the HepFree trial was accessed for the sub-
study.  The flow diagram in Figure 13 summarises participant selection for the HepFree sub-
study. 
 
2.7.4 Statistical analysis 
Descriptive analysis was carried out in Microsoft EXCEL.  Statistical analysis was performed by 
an independent statistician.  Poisson and negative binomial based generalised linear models 
were fitted in STATA 14 using Generalised Estimating Equations with an autoregressive 
correlation matrix of order 1 (AR1).  Relative risks were estimated using the univariate 
negative binomial model. 
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Figure 13: Participant selection for the HepFree sub-study 
  
Participants consented into the HepFree trial 
Positive (+ve) HCV test 
HCV RNA +ve Anti HCV 
+ve/RNA -ve 
Negative (-ve) HBV/HCV test 
‘Healthy’ controls matched to cases 
using 
1. Gender 
2. Date of birth 
3. Ethnicity 
4. Country of birth 
5. Length of time in the UK 
Randomisation using Microsoft Excel  
Data collection and analysis 
A flow chart summarising participant selection in the HepFree sub-study.  Individuals with a positive test for 
HCV diagnosed through the HepFree trial were identified and screened against the inclusion criteria for the 
sub-study.  If eligible, they were divided into two groups; RNA positive chronic HCV and anti-HCV positive, 
RNA negative (previous infection with spontaneous clearance of HCV). Individuals recruited to HepFree with 
a negative test for HBV and HCV (healthy controls) were matched to cases in a 1:1 ratio using the criteria 
detailed in the green box.  If more than one healthy control was identified as a match, a programme in 
Microsoft Excel was used to select a participant at random to act as the healthy control.  Once controls had 
been matched to all cases, the electronic medical records of each participant were accessed to collect data 
for analysis.   
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3. Results: Demography of the area. 
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3.1 Overview 
In this Chapter I will review both the demography of Bradford and the practices participating 
in HepFree.  In Bradford, twenty-one GP practices were recruited and randomised to rake 
part in the HepFree trial. 
Figure 14: The city of Bradford and surrounding areas 
 
A map of Great Britain with a pin denoting the location of Bradford and its surrounding areas. 
 
3.2 Bradford: census summary.   
Information accessed from UK census data. 
Bradford is a city and metropolitan borough located in West Yorkshire, England.  According to 
the Office for National Statistics, it has a population of 528, 200, making it the fourth most 
populous metropolitan district, and sixth most populous local authority district in England.   
 
The city of Bradford is situated on the edge of the Pennines, bound to the east by the city of 
Leeds, to the west by the Pendle borough of Lancashire, to the north by the boroughs of 
Craven and Harrogate, and to the south by the metropolitan boroughs of Kirklees and 
Calderdale. 
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Bradford rose to prominence as an international centre of textile manufacture, in particular 
wool, during the 19
th
 century.  This later fell into decline in the mid-twentieth century.   
Similarly to other post-industrial areas in the north of England, Bradford has faced the 
challenges of deindustrialisation, social unrest and economic deprivation as a result of this 
decline in industry. 
 
Bradford has a long history of immigration, making it one of the north of England’s most 
culturally and ethnically diverse cities.  Data from the 2011 census suggested that 20.4% of 
Bradford’s population were of Pakistani origin.  There has been a rise in the settlement of 
people of Pakistani origin since the last census in 2001, in which only 14.5% of the city’s 
inhabitants belonged to this ethnic group.  In the 2011 census, 76.6% of Bradford’s population 
held a UK passport, 3.9% held a passport from either an Asian country or country in the 
Middle East, 2.8% held one from a country within the European Union, and 16.3% of the 
population held no passport. 
 
More recently, a rapid increase in the number of migrants residing in Bradford has been 
observed.  Between 2001 and 2011, 40, 975 (45.7%) of non-UK born residents arrived in the 
city to live, and of these, 32,290 arrived after 2004. 
 
In 83.1% of households included in the 2011 census, all residents aged sixteen or over had 
English listed as their main spoken language.  In 8.4% of households, at least one adult could 
speak English, in 1.5% of cases, no adults could speak English but one or more children could 
speak English, and in 7.1% of households, none of the residents were able to speak English.   
 
Almost 25% of Bradford’s population listed their primary religion as Muslim.  A reduction in 
the number of residents with Christianity as their chosen religion has been observed, from 
60.1% in 2001 to 45.9% in 2011.  In 20.7% of cases participants had no religious preference 
and in 6.2% of cases the question was not answered. 
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Areas of Bradford are among the worst in the UK in terms of the level of social deprivation.  
According to the census occupancy rating, nearly 10% of households were classed as 
overcrowded.  Within West Yorkshire, Bradford has the fewest number of economically active 
residents aged between sixteen and seventy-four.  At the time of the last census there were 
210,000 residents aged between sixteen and seventy-four in employment, corresponding to 
an employment rate of 57.3%, compared to a regional rate of 60.0% and a rate in England of 
62.1%.  The largest industry in Bradford was noted to be retail/wholesale, with 17.7% of 
Bradford’s employed residents working within this field. 
 
3.3 GP practices in Bradford 
There are two CCGs in Bradford; Bradford City comprising twenty-seven GP practices that 
serve the local population, and Bradford District consisting of forty practices.  Permission was 
granted to recruit practices from within both CCGs to conduct the HepFree trial. GP practices 
in the postcode districts BD7, 8 and 9 were prioritised in terms of recruitment as census data 
demonstrated that large groups of ethnically diverse individuals resided within these areas; 
individuals that would fit the inclusion criteria of HepFree.  Figure 15 demonstrates the 
locations of GP practices recruited to participate in the HepFree trial. 
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Figure 15: Locations of HepFree in Bradford 
 
 
 
A map of GP surgeries that were recruited to the HepFree trial in Bradford.  Red pins demonstrate the location of 
practices within each postcode district.  GP surgeries in BD8 were prioritised during practice recruitment as these 
areas have high numbers of ethnically diverse populations residing within them.      
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In August 2013, prior to the trial permissions being granted, a meeting with clinicians from GP 
practices within both CCGs was held by the research team to raise awareness and assess 
interest in the trial.  Contact details were taken for clinicians interested in participating at the 
time of the meeting.  When recruitment commenced in January 2014, these practices were 
approached in the first wave of recruitment. 
 
As previously discussed in Materials and Methods, each practice was contacted via telephone 
to assess interest and offer them a place in the trial, followed by an email summarising the 
key points of the discussion as well as details of a member of the research team to contact in 
the event of further questions.  This email was sent immediately after the telephone call.  In 
Bradford, I as the clinical fellow was solely responsible for recruiting the twenty-one practices 
included in the trial.   
 
In the majority of cases, due to the work pressures, it was not possible to speak directly to the 
clinician with regards to participating in the trial.  Often the practice manager acted as the 
spokesperson for the practice.  In most cases, the practice manager agreed to discuss the trial 
on our behalf, at the practice meeting, where the clinicians would be present.  This meeting 
would occur either once per week or once per fortnight.  If the time between the initial 
telephone call and the practice meeting was more than seven days, I would endeavour to 
speak to the practice manager again to ensure that the trial was added to the meeting’s 
agenda.  
 
Response to trial recruitment efforts was variable; from the list of clinicians that expressed an 
initial interest in the trial in August 2013, 82% of practices agreed to become trial sites.  GP 
practice recruitment commenced in January 2014 and was completed in April 2015. 
 
3.4 Summary of recruitment 
In five out of the twenty-one practices (24%) that were recruited and opened, the research 
team was approached by the practice managers of the sites.  In these cases, the practices had 
positive feedback from other trial sites that were already open and recruiting participants into 
HepFree.  In two cases (9.5%), the practices had previously been approached regarding 
recruitment by the clinical fellow, but had declined.  However, during the period of 
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recruitment between January 2014 and April 2015, the practice managers in charge of the 
practices changed, enabling the sites to be subsequently recruited by the clinical fellow.  As 
discussed in Materials and Methods, at the time of the telephone call the research team 
offered to attend the practice to discuss the trial in more detail.  Alternatively, if this was not 
required and the site agreed to participate, details required for randomisation were collected 
by the practice staff using the HepFree eligibility searches that had been published on S1 and 
were available to access by the practice staff.  The eligibility searches, as described in 
Materials and Methods, were the series of reports created by the research team that enabled 
potential study participants in each practice to be identified.   
 
Once the outcome of randomisation was known, the practice was contacted to arrange a 
mutually agreeable time for the SIV.  Table 6 summarises the time between first contact with 
practices and site initiation, including the number of episodes of contact that were initiated 
by the clinical fellow within the research team. 
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Table 6: GP surgeries recruited to the HepFree trial 
Recruitment details for practices that agreed to participate in HepFree including the number 
of episodes of contact between the practice and the research team and the number of days 
that elapsed between the first episode of contact and the site initiation visit.  The average 
number of episodes of contact between the research team and practice was 8, range 2 – 22. 
 
Practice Date of first 
contact 
Date of sign 
up 
Date site 
opened 
Number of 
episodes of 
contact 
No. of days 
elapsed from 
first contact to 
site initiation 
1 13/11/2013 13/11/2013 14/04/2014 3 152 
2 13/01/2014 24/01/2014 07/04/2014 6 83 
3 14/01/2014 20/01/2014 08/04/2014 7 84 
4 14/01/2014 13/02/2014 02/04/2014 5 78 
5 14/01/2014 04/02/2014 10/03/2014 4 55 
6 15/01/2014 10/02/2014 07/05/2014 14 112 
7 16/01/2014 11/02/2014 07/05/2014 17 111 
8 04/02/2014 01/05/2014 02/05/2014 8 87 
9 04/03/2014 27/03/2014 05/08/2014 22 155 
10 21/03/2014 28/03/2014 30/04/2014 4 40 
11 21/03/2014 01/04/2014 22/05/2014 5 65 
12 31/03/2014 01/04/2014 01/05/2014 4 30 
13 01/04/2014 03/04/2014 01/05/2014 3 31 
14 03/04/2014 14/04/2014 02/05/2015 7 397 
15 03/04/2014 04/07/2014 09/06/2015 13 432 
16 09/04/2014 09/04/2014 30/04/2014 2 21 
17 08/07/2014 24/07/2014 09/10/2014 8 93 
18 19/09/2014 19/09/2014 16/10/2014 3 27 
19 12/01/2015 28/01/2015 17/04/2015 9 95 
20 13/02/2015 08/03/2015 10/04/2015 7 56 
21 13/02/2015 08/03/2015 10/04/2015 7 56 
AVERAGE    8 108 
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On average, eight episodes of contact by the clinical fellow were required to recruit a practice 
and 108 days elapsed between first contact and site initiation. Practice 1 was the first site 
recruited and this was used to evaluate both recruitment and trial procedures.  Specifically, 
the trial statisticians, once formal ethics and Research and Development office approvals 
were in place, tested the randomisation programme using data from this practice to ensure it 
was functioning prior to full recruitment commencing. Up until the approvals were in place, 
all testing of the randomisation programme had been conducted on dummy data.  Due to the 
practice being used to test trial related processes, there was a prolonged delay between first 
contact and site initiation.  In addition to practice 1, practices 2, 3, 4 and 5 were contacted by 
the fellow and all agreed to participate in the trial prior to R&D permissions being granted; 
however none of the practices were opened until all required permissions were in place.  
Hence some of the delay from site contact to initiation that was observed was due to trial 
related logistical concerns.   
 
The reason for delayed site initiation in the cases of practices 6 and 7 were staff sickness 
within the practices.  When practice 8 was approached by the trial team, the offer to 
participate was initially declined because of long-term vacancies in staff posts; however the 
practice manager later contacted the trial to make enquiries regarding HepFree and was 
subsequently recruited.   
 
The time between first contact and site initiation exceeded 150 days in practice 9.  The 
reasons for this delay were initially because the practice moved locations to a new site and 
building within Bradford.  Secondly, this practice was one of the few recruited that would 
ordinarily not send blood samples to Bradford Royal Infirmary for analysis, but to another 
hospital laboratory within the region.  As the trial had an agreement in place with Leeds 
Teaching Hospitals for analysis and reporting of trial samples, a bespoke agreement had to be 
created with the practice to ensure the safe and confidential transfer of all study bloods to 
Bradford as opposed to the other laboratory.  The pathology laboratory at Bradford Royal 
Infirmary then organised the safe and secure transfer of all samples to Leeds for testing.   
 
Practices 14 and 15 were opened more than twelve months after the point of first contact by 
the study team.  This was because these practices were recruited to also participate in a sub-
study associated with the main trial that assessed individuals pre-existing knowledge of and 
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attitudes towards viral hepatitis.  For the sub-study, all eligible participants registered in the 
practices were contacted prior to receiving the invitation for testing and given the 
opportunity to participate in this additional study.  If an individual decided to participate in 
the sub-study, a questionnaire was completed with them over the telephone.  Practice 17 was 
initially also approached to conduct the sub-study, however it was later not required, and so  
subsequently opened to recruit for the main trial only.  Practices 16, 18, 19, 20 and 21 
approached the trial clinical fellow and requested to take part and be randomised.   
 
In the initial cluster design, Bradford was designated 18 sites to recruit and open, however 
due to difficulties with recruiting sites to perform HepFree in London, additional trial sites 
were allocated to Bradford and this allowed the research team the opportunity to offer places 
for practices 19, 20 and 21.  For reasons stated above, there was no typical trial contact and 
initiation procedure and it is difficult to draw general conclusions from these data about the 
logistical difficulties that would be involved in any general role out of GP based screening. 
However the myriad of contractual and logistical issues, not all of which were trial related, 
indicate that any large scale screening programme would require considerable logistical 
support.  Table 7 summarises the outcomes for practices that were contacted by the trial 
fellow but declined to participate in HepFree.  
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Table 7: GP surgeries that declined HepFree participation 
Details of practices that declined the invitation to participate in the HepFree trial including 
the number of episodes of contact between the trial team and the GP approached and 
reasons provided by the practice for declining.   
 
Practice Date of 
first contact 
Date practice 
declined to 
participate 
No. of 
episodes of 
contact 
Comments 
22 15/01/2014 15/01/2014 1 Single attempt to speak to practice 
manager, advised to contact by email.  
Trial synopsis and contact details sent.  
Email declining the offer to participate 
received from the practice manager on 
the same day that first contact was made. 
23 10/02/2014 24/02/2014 3 Trial discussed with practice manager on 
the phone.  Two further emails sent 
offering a face to face meeting, trial place 
declined. 
 
24 
01/04/2014 13/05/2014 6 Trial discussed with practice manager on 
telephone who agreed to discuss at the 
practice meeting.  Four email reminders 
sent.  Study discussed 13/05/2014, trial 
team contacted by practice manager to 
explain that the trial place had been 
declined by the clinicians due to 
increased perceived work load associated 
with the trial.   Declined offer of a face to 
face meeting to explore concerns 
25 01/04/2014 No formal 
response from 
practice 
4 Trial discussed with practice manager on 
the phone.  Three follow up emails sent 
with no response.   
26 07/04/2014 07/04/2014 1 Single attempt to speak to practice 
manager, advised to contact by email.  
Trial synopsis and contact details sent 
with email response from the practice 
manager received on the same day.   
27 07/04/2014 08/04/2014 2 Trial discussed with practice manager on 
telephone who agreed to discuss at the 
practice meeting on the following day.  
Contacted by practice manager to explain 
that the trial place had been declined by 
the clinicians, no reason for refusal stated 
in email.  Declined offer of a face to face 
meeting to explore potential concerns. 
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Table 7: GP surgeries that declined HepFree participation 
Details of practices that declined the invitation to participate in the HepFree trial including 
the number of episodes of contact between the trial team and the GP approached and 
reasons provided by the practice for declining.   
 
Practice Date of 
first contact 
Date practice 
declined to 
participate 
Number of 
episodes of 
contact 
Comments 
28 08/04/2014 25/04/2014 4 Telephone call and email sent to practice 
manager.  Two further email reminders 
sent regarding the study.  Declined to 
participate due to pre-existing work 
pressures within the practice. 
29 14/04/2014 13/06/2014 7 Trial discussed with lead GP on telephone 
who expressed an interest in 
participating.  Subsequent difficulty 
engaging the practice to enable trial 
randomisation.  Five follow up emails sent 
and one further telephone call with lead 
clinician of practice who declined due to 
perceived increased work load associated 
with the trial.  Declined offer of a face to 
face meeting to explore concerns. 
30 14/04/2014 01/05/2014 7 Three attempts to speak to practice 
manager by telephone, unsuccessful.  
Contacted CCG lead who discussed with 
the practice on behalf of the trial.  Face to 
face meeting with lead GP and practice 
manager.  Declined offer of trial place 
with ‘cap’ of only inviting 500 
participants. 
31 14/01/2014 14/01/2014 1 Trial discussed with practice manager, 
declined due to problems with long-term 
vacancies.  Declined offer of a face to face 
meeting. 
32 21/04/2014 21/04/2014 2 Trial discussed with practice manager, 
declined due to perceived increased work 
load associated with study.  Declined 
offer of a face to face meeting to further 
explore concerns 
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From R&D approvals, it took fourteen months to engage and recruit twenty-one practices to 
the trial.  From all practices approached, 38.9% participated in the trial. 
 
Once practices had been recruited, randomised and opened, the locations for the community 
clinics were decided.  As discussed in Materials and Methods, one of the objectives of the 
HepFree trial was to examine, by measuring patient adherence and compliance to both 
appointments and therapies, the impact of moving the location for treatment and follow-up 
of viral hepatitis from secondary care to the community.  In Bradford I approached two 
practices that had been recruited to the trial and requested to use a consulting room in each 
one in order to set up a satellite hepatology clinic.  Practices were chosen primarily on their 
location, selecting practices that would be closer in distance for participants to access 
compared to the hospital.  As it was not feasible to cater for all participants by calculating the 
distance from their home address to the hospital, we decided to calculate distance using the 
address of their base GP to both the community clinic and the hospital, as patients have to 
live within a certain catchment distance of their surgery.  In addition to selecting locations 
closer in distance compared to the hospital, we ensured there were facilities available for the 
trial participants to use free of charge, including parking.  What we failed to consider when 
selecting the locations for community clinics were the public transport links that would be 
available for use by patients randomised to this arm of the trial. 
  
The distances of practices randomised to the community arm of the trial to both of the 
satellite clinics and the secondary care centre (hospital) are displayed in Table 8. 
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Table 8: Locations of all HepFree GPs in relation to secondary care and community based 
hepatology satellite clinics 
The distances in miles from each HepFree practice to Bradford Royal Infirmary, Duckworth 
Lane, Bradford, BD9 6RJ (the location used to perform follow-up of positive participants 
assigned to standard of care) and the two GPs where satellite hepatology services were set up 
for use by the HepFree trial.  The ‘designated community centre’ is the satellite clinic where 
participants would be followed-up in the event that their practice had been randomised to 
the community follow-up nested intervention.   
 
Practice Satellite clinic 
1  
(miles) 
Satellite clinic 
 2 
(miles) 
Secondary care 
(hospital) 
(miles) 
Designated 
community 
centre 
A 2.3 0.8 3.1 2 
B 2.5 1.3 3.3 2 
C 2.7 2.6 2.7 2 
D 0.3 3.0 1.1 1 
E 0 2.9 1.0 1 
F 1.3 2.1 2.2 1 
G 2.1 1.0 3.0 2 
H 3.6 2.0 4.4 2 
I 1.6 3.0 2.2 1 
J 2.9 0 3.7 2 
 
3.5 Discussion 
The purpose of HepFree was to determine whether or not it would be feasible to implement a 
screening programme for viral hepatitis in GP.  The data presented here demonstrates that 
the task of recruiting and persuading practices in primary care to test immigrants is by no 
means trivial.   
 
A recruitment rate of less than 40% in all practices approached regarding HepFree indicates 
that staff within practices were somewhat reluctant to adopt the trial and offer testing for 
viral hepatitis to the high-risk populations registered there.  Although in this thesis I will not 
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comment specifically on recruitment methods and subsequent uptake rates in London, similar 
difficulties were encountered there and resulted in the trial increasing the number of sites in 
Bradford.   
 
As mentioned above, it is important to consider the amount of effort required to engage the 
practices that did eventually become trial sites.  It took an average of eight episodes of 
contact, ranging from a minimum of two to a maximum of twenty-two, and an average time 
of 108 days elapsed from the first point of contact with a practice to the site been opened for 
recruitment.  Although some extenuating circumstances were identified including delays 
related to study approvals from R&D, in the majority of cases, the delays encountered were 
due to routine problems frequently encountered in the work place, including staff sickness, 
and post vacancies.  In Bradford, one of my main roles in HepFree initially was to recruit and 
set up practices, and therefore I was able to dedicate a large amount of time and effort to this 
task.  This ensured that we had sufficient sites recruited to fulfil the study design.   
 
It became evident early in the process of recruitment that attempting to implement a 
protocol that could be used to engage and recruit practices would be difficult.  This was 
probably, largely due to the fact that we were asking practices to adopt and conduct the trial 
on our behalf, and therefore we had to be mindful of both the pre-existing work load within 
the practice as well as the demands already placed on practice staff. Analysis of recruitment 
outcomes in Table 6 demonstrated that there was no typical contact and initiation procedure, 
and bespoke methods were employed in order to recruit practices.   
 
Despite the study providing financial incentives, it was not possible to engage some GP 
practices with the case-finding project.  Taking all of this into account, if the combined results 
of the HepFree trial recommend universal screening for viral hepatitis in migrant populations 
in primary care, it would be beneficial to conduct further qualitative research in a selection of 
practices, ideally including practices that both adopted the trial in addition to some that 
declined to participate.  The research should attempt to establish what the perceived and real 
barriers to performing screening were from a primary care perspective, and what adaptations 
could be made to make the task of screening more acceptable. 
 
In the past in Bradford, multiple initiatives have been performed to increase public awareness 
of, education about, and testing for viral hepatitis in migrants.  In 2008, a large community 
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study was conducted in mosques and community centres in Bradford, offering testing for viral 
hepatitis to people of south Asian origin (296).  Although only an anecdotal observation, it is 
interesting that the majority of staff and clinicians within the practices approached by the 
HepFree research team were of south Asian origin.  Yet, despite this, engagement rates by 
GPs in the trial were low.   
 
These findings might suggest that case identification of viral hepatitis in immigrant 
populations is still not a priority, furthermore, given that these are the observations in an area 
of England that is densely populated with migrants, it would be reasonable to speculate that 
implementing a widespread screening programme for viral hepatitis in primary care in areas 
of England with lower numbers of immigrant populations would be even more challenging.   
 
Conversely however, the obstacles encountered in trying to engage practices and set up 
HepFree may be related to the fact that HepFree was a research trial and not an established 
screening programme.  Following discussions with clinicians, it was evident that practices feel 
adequately equipped to facilitate pre-existing NHS preventative screening programmes.  This 
is because although the practical procedure is performed by a member of staff at the 
practice, for which they are reimbursed, all reporting of results and subsequent referrals to 
secondary care is done by a central body.  Clinicians within practices are notified of the 
outcomes of screening tests but are not expected to initiate the pathway for assessment and 
treatment if required.   
 
The HepFree trial as described in Methods and Materials was considerably more labour 
intensive, with practices responsible for performing the searches on S1 to identify potentially 
eligible participants, generating and distributing the invitation letters, booking the 
appointments, performing consent and collecting the blood samples for analysis as well as 
reviewing all test results and notifying the trial team in the event of a positive result.  It may 
therefore be feasible to reproduce HepFree on a larger scale, and lead to greater engagement 
by practices if changes were made to HepFree to make the work load more closely resemble 
other established preventative screening strategies both in terms of the way individuals are 
invited, the way results are reported and follow-up arrangements made. 
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4. HepFree results: Participant eligibility. 
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4.1 Introduction 
One of the objectives of the HepFree trial was to assess the feasibility of accessing and using 
pre-existing medical records in GP surgeries in primary care to identify individuals at risk of 
viral hepatitis based on their demographics, including country of birth, ethnicity and main 
spoken language.  In this chapter I will present the results of the eligibility searches that were 
designed and created to identify ‘high-risk’ individuals based on pre-existing Read codes 
contained within individual patient electronic medical records. 
 
As discussed in Materials and Methods, I was responsible for designing and helping to build 
the electronic searches that were uploaded and published onto the clinical computer systems 
in primary care, with the help of the data quality team at the Yorkshire and Humber 
Commissioning Support Unit, Douglas Mill, Bowling Old Lane, Bradford, West Yorkshire, BD5 
7JR. 
 
In this chapter I will present eligibility data from ten of the eighteen practices that were 
performing targeted testing as part of the HepFree trial that had completed eighteen months 
of testing by February 2016, when data for this thesis was collated.  This chapter does not 
include any data obtained from control practices.  The reason for this is that at the time of 
writing this thesis the HepFree study was incomplete and therefore data from control 
practices had not been analysed.   
 
In subsequent chapters, analysis of data from participants that both consented to participate 
and declined the offer of testing in these practices will be presented.   
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4.2 Results 
As outlined in Materials and Methods, data were analysed by IBM SPSS statistics 23 and 
Microsoft EXCEL. 
 
In the ten practices that had completed targeted testing for HepFree, the potential study 
participant population consisted of 21,982 individuals, of which 20,478 (93%) were sent an 
invitation letter.  In total 7,302 participants were recruited and underwent testing for viral 
hepatitis, accounting for 35.7% of the potential study participant population.  Figure 16 is a 
summary of targeted testing activity in the ten practices included in the analysis. 
 
Figure 16: A summary of participant recruitment in targeted testing practices based in 
Bradford 
 
 
A flow chart summarising trial recruitment in GP surgeries that were randomised to perform targeted testing in 
Bradford and included in this analysis.  From an eligible population of 21,982, 7302 individuals attended for testing, 
representing an uptake rate of 33.2%.  Targeted testing was performed more frequently in practices randomised to 
send standard invitation letters, 44% compared to those sending enhanced invitation letters, 25%. 
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As discussed within Materials and Methods, at the time of the SIV practices were instructed 
to generate and send by second class mail, a modified and personalised trial invitation letter.  
Letters were modified to include the practice name and contact details that could be used to 
book an appointment to attend for screening.  Administrative staff were advised to send a 
letter to all potential study participants registered at the practice.  A potential study 
participant, also referred to as an eligible individual, was anyone registered at a practice 
assigned to perform targeted testing that fulfilled the trial inclusion criteria (see Methods).  
Study participants were identified using eligibility searches that had been created and 
published on S1 units. 
 
One of the trial objectives was to establish the feasibility of integrating targeted testing for 
viral hepatitis into primary care, and therefore the trial protocol stipulated that all trial 
related activities, including the distribution of invitation letters were to be performed by staff 
within the practice, without additional input from the research team.  From an eligible 
population of 21, 982, 93% were sent an invitation letter.  From discussions with practices, 
staff shortages related to long-term sickness in addition to full-time vacancies and the 
demands of pre-existing practice work were three of the main obstacles that prevented 
invitation letters from being distributed and resulted in non-contact of 7% of potential study 
participants. 
4.2.1 Demographics of the eligible population 
The results of the eligibility searches conducted to identify potential study participants in each 
of the targeted testing practices are set out in Tables 9-11 and Figures 17-19.  In each of the 
Tables, the number of potential study participants (eligible participants) is expressed as a 
percent of the total potential study population and as a percent of the total number of 
patients (both eligible and ineligible) registered in all ten HepFree practices included in this 
thesis.   
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Table 9: The demographics of the HepFree potential study population  
 
The countries of origin of all potential study participants registered and eligible to be invited 
for testing in HepFree practices.  Data are expressed as a total number, percent of the total 
eligible HepFree population and as a percent of all patients registered in Bradford practices 
performing HepFree (eligible and ineligible).     
 
Country of origin No. of eligible 
participants 
Percent of total 
eligible population 
Percent of all patients 
in HepFree practices 
Africa 358 1.6 0.6 
Asia-Pacific 7415 33.7 12.5 
Eastern Europe 1737 7.9 2.9 
Latin America & 
Caribbean 
79 0.4 0.1 
Western Europe & 
others 
2298 10.5 3.9 
Not known 10095 45.9 17.0 
TOTAL 21982 100.0 36.9 
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Table 10: The demographics of the HepFree potential study population 
 
The main spoken languages where available, of all potential study participants registered and 
eligible to be invited for testing in HepFree practices.  Data are expressed as a total number, 
percent of the total eligible HepFree population and as a percent of all patients registered in 
Bradford practices performing HepFree (eligible and ineligible).   
 
Main spoken 
language 
No. of eligible 
participants 
Percent of total 
eligible population 
Percent of all patients 
in HepFree practices 
English 1958 8.9 3.3 
Urdu/Punjabi 9278 42.2 15.6 
Gujurati 381 1.7 0.6 
Polish 923 4.2 1.6 
Bengali 925 4.2 1.6 
Others 2362 10.7 4.0 
Not known 6155 28.0 10.3 
TOTAL 21982 100.0 36.9 
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Table 11: The demographics of the HepFree potential study population 
 
The recorded ethnicities of all potential study participants registered and eligible to be invited 
for testing in HepFree practices, where available.  Data are expressed as a total number, 
percent of the total eligible HepFree population and as a percent of all patients registered in 
Bradford practices performing HepFree (eligible and ineligible).   
 
Ethnic group No. of eligible 
participants 
Percent of total 
eligible 
population 
Percent of all patients 
in HepFree practices 
White 1457 6.6 2.4 
Mixed/Multiple ethnic 
groups 
260 1.2 0.4 
Asian/British Asian 17556 79.9 29.5 
Black: African/Caribbean/ 
British 
655 3.0 1.1 
Other ethnic group 1055 4.8 1.8 
Not known 999 4.5 1.7 
TOTAL 21982 100 36.9 
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Figure 17: The demographics of the HepFree potential study population 
The numbers on the bars represent the number of participants eligible for testing within each 
category. 
 
 
A column chart summarising the countries of origin of all potential study participants registered in GP surgeries 
recruited to perform targeted testing in the HepFree trial.  In 46% of cases, due to deficiencies in data collection in 
primary care, the country of origin of individuals was not known.    
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Figure 18: The demographics of the HepFree potential study population 
 
A column chart summarising the main spoken languages of all potential study participants registered in GP surgeries 
recruited to perform targeted testing in the HepFree trial.  In Bradford, Urdu/Punjabi was most frequently 
documented as the main spoken language in the potential study population.  This finding is in keeping with the 
majority of potential study participants originating from countries within Asia-Pacific. 
 
Figure 19: The demographics of the HepFree potential study population 
 
A column chart summarising the ethnicity of all potential study participants registered in GP surgeries recruited to 
perform targeted testing in the HepFree trial.  80% of potential study participants were Asian/British Asian.    
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As described in Materials and Methods, the eligibility searches identified individuals 
registered within each practice that had one or more of the pre-selected Read codes in their 
medical record that suggested that they originated from an area of high-risk for viral hepatitis 
but had not previously been tested, or given a formal diagnosis of hepatitis.  Table 12 
illustrates the total number of individuals eligible to participate in the ten HepFree practices, 
broken down by ethnicity.  Data are expressed as a percent of the total number of patients 
registered within the same practices and compared with data collected in the 2011 census for 
Bradford.  The overall percentage figures for the two classifications are 36.9% (HepFree) and 
35.6% (census).  This shows that the two groups are similar, with small differences likely to 
represent changes in patterns of migration in the time since the last census was performed.  
From this analysis it can be assumed that the sample invited for testing in the HepFree 
practices is representative of the wider population in Bradford. 
 
Table 12: The ethnicity of potential HepFree study participants compared to Bradford census 
data 
 
The documented ethnicity of individuals identified as eligible to participate from HepFree 
search results.  Data are expressed as a percent of the total number of patients registered 
within the HepFree practices (eligible and ineligible) and compared with the 2011 census for 
Bradford. 
 
Ethnic group No. of eligible 
participants 
Percent of all 
patients in HepFree 
practices 
Percent of 
respondents 2011 
census data 
White (other) 1457 2.4 3.0 
Mixed/Multiple ethnic 
groups 
260 0.4 2.5 
Asian/British Asian 17556 29.5 26.8 
Black: African/Caribbean/ 
British 
655 1.1 1.8 
Other ethnic group 1055 1.8 1.5 
Not known 999 1.7  
Total 21,982 36.9 35.6 
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In the ten practices from which data were collated for this thesis, a total of 59, 524 patients 
were registered.  The eligibility searches identified that 21,982 (36.9%) were potential study 
participants, therefore the remaining 37,542 (63.1%) patients were considered ineligible for 
participation in HepFree. 
 
The doughnut diagram (Figure 20) demonstrates the combinations of Read codes that 
potential study participants were identified by in the eligibility searches.  In 48.4% of cases, 
electronic patient records were comprehensively completed and contained Read codes 
pertaining to all search criteria; ethnic group, country of origin and main spoken language.  
The demographic field for country of birth was completed least efficiently, with an absent 
field in 45.9% of records.  In these cases it was not possible to establish whether the potential 
study participant was a first or second generation immigrant.  
 
The results of the eligibility searches highlighted inconsistencies in demographic data 
collection and recording in primary care.  The results of the searches further demonstrated 
that in order to identify individuals at risk of viral hepatitis by using pre-existing databases, 
searches needed to be sophisticated enough to be able to identify an individual using several 
demographic categories.   
 
Within the Bradford cohort of GP practices, the ethnic category with the largest number of 
potential study participants was Asian/British Asian.  Black African/Caribbean/British 
individuals were represented least in the population sample. 
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Figure 20: Read code combinations within electronic medical records of eligible participants 
in HepFree practices 
 
 
 
The combinations of Read codes contained within the electronic medical records of eligible participants in HepFree 
practices.  In 48.4% of cases, electronic patient records were comprehensively completed and contained Read codes 
pertaining to all search criteria; ethnic group, country of origin and main spoken language (orange).   
 
Because ethnicity was the most comprehensively filled demographic field, Table 13 
summarises potential HepFree trial participants registered in each GP practice by ethnicity.  In 
the table, the number of eligible participants in each ethnic group is expressed as a number, 
as a percent of the total study population (also known as eligible population) and as a percent 
of the total patient population within each practice (also known as list size). 
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Table 13: The ethnicity of eligible HepFree participants in Bradford 
Ethnicity data obtained through SystmOne from each practice recruited to the study.  The list size (total number of patients registered at the practice) as 
well as number of eligible study participants in each practice is included.  For each ethnic group of interest, the number of individuals registered at each 
practice is stated and data  expressed as a percent of the total number of eligible participants within the practice as well as a percent of all of patients 
registered (list size).     
 
 
 
 
 
 
 
 
 White Mixed/Multiple Asian/Brit Asian Black Other & Unknown 
Practice List 
size 
Total No. 
of eligible 
participants 
No. % of 
eligible 
% of 
total 
list 
No. % of 
eligible 
% of 
total 
list 
No. % of 
eligible 
% of 
total list 
No. % of 
eligible 
% of 
total 
list 
No. % of 
eligible 
% of 
total list 
1 5461 3539 190 5.4 3.5 12 0.3 0.2 3147 88.9 57.6 37 1.0 0.7 153 4.3 2.8 
2 5080 3237 110 3.4 2.2 38 1.2 0.7 2700 83.4 53.1 54 1.7 1.1 335 10.3 6.6 
3 6191 1942 77 4.0 1.2 29 1.5 0.5 1659 85.4 26.8 70 3.6 1.1 107 5.5 1.7 
4 4119 2557 105 4.1 2.5 11 0.4 0.3 2324 91.0 56.4 33 1.3 0.8 84 3.2 2.0 
5 4840 2384 397 16.7 8.2 19 0.8 0.4 1436 60.2 31.7 36 1.5 0.7 496 20.8 10.2 
6 6399 3170 38 1.2 0.6 21 0.7 0.3 2913 91.9 45.5 25 0.8 0.4 173 5.5 2.7 
7 7401 685 45 6.6 0.6 36 5.3 0.5 475 69.3 6.4 58 8.5 0.8 71 10.4 1.0 
8 7114 945 138 14.6 1.9 33 3.5 0.5 506 53.5 7.1 102 10.8 1.4 166 17.6 2.3 
9 8778 1182 305 25.8 3.5 41 3.5 0.5 577 48.8 6.6 86 7.3 1.0 173 14.6 2.0 
10 4141 2341 52 2.2 1.3 20 0.9 0.5 1819 77.7 43.9 154 6.6 3.7 296 12.6 7.1 
TOTAL 59524 21982 1457 6.6 2.4 260 1.2 0.4 17556 79.9 29.5 655 3.0 1.1 2054 9.3 3.5 
Abbreviations 
Asian/Brit: Asian & British Asian, Black: Black African/Caribbean/ British 
 
 
149 
 
49 
 
 
In Bradford, irrespective of postcode district, the greatest proportion of potential study 
participants in each GP practice were of Asian/British Asian ethnicity, ranging from 48.8% of 
potential participants in practice 9 to 91.9% of the potential study population in practice 6.   
 
Table 14 provides a summary of the populations tested in each HepFree practice by ethnicity. 
  
 
1
5
0
 
 
 
Table 14: The ethnicity of HepFree study participants in Bradford 
Data on the ethnicity of participants recruited to the HepFree trial in Bradford.  For each practice performing targeted testing that is included in this analysis, 
the number of individuals from each ethnic group that participated is expressed as a percentage of the number of individuals that were eligible to 
participate. 
 
 White Mixed/Multiple Asian/Brit Asian Black Other & Unknown TOTAL 
Practice No. 
eligible 
No.  
tested  
(%) 
No. 
eligible 
No.  
tested  
(%) 
No. 
eligible 
No.  
tested  
(%) 
No. 
eligible 
No.  
tested  
(%) 
No. 
eligible 
No.  
tested  
(%) 
No. tested 
 
No. eligible 
population 
per practice 
(%) 
1 190 76 (40.0) 12 4 (33.3) 3147 1551 (49.3) 37 20 (54.0) 153 26 (17.0) 1677 47.4 
2 110 46 (41.8) 38 23 (60.5) 2700 1744 (64.6) 54 24 (46.2) 335 64 (19.1) 1901 58.7 
3 77 28 (36.3) 29 13 (44.8) 1659 838 (50.5) 70 26 (37.1) 107 32 (30.0) 937 48.2 
4 105 12 (11.4) 11 0 (0.0) 2324 486 (20.9) 33 3 (9.1) 84 12 (14.3) 513 20.1 
5 397 181 (45.6) 19 9 (47.4) 1436 852 (59.3) 36 23 (63.9) 496 28 (5.6) 1093 45.8 
6 38 7 (18.4) 21 2 (28.6) 2913 516 (17.7) 25 2 (8.0) 173 2 (1.2) 529 16.7 
7 45 9 (20) 36 4 (11.1) 475 47 (9.9) 58 4 (6.9) 71 8 (11.3) 72 10.5 
8 138 13 (9.4) 33 3 (9.1) 506 44 (8.7) 102 7 (6.9) 166 1 (0.6) 68 7.2 
9 305 35 (11.5) 41 7 (17.1) 577 94 (16.3) 86 14 (16.3) 173 4 (2.3) 154 13.0 
10 52 4 (7.7) 20 2 (10.0) 1819 331 (18.2) 154 16 (10.4) 296 5 (1.7) 358 15.3 
TOTAL 1457 411 (28.2) 260 67 (25.8) 17556 6503 (37.0) 655 139 (21.2) 2054 182 (8.9) 7302 33.2 
Abbreviations 
(%): Percent of the eligible population by ethnic group in each practice who attended for testing 
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Trial participation was highest amongst individuals of Asian/British Asian ethnicity, with 37.0% 
of all potential study participants consented for testing belonging to this ethnic group.  In 
contrast, trial participation was lowest in individuals that had no documented country of 
birth.  This finding may be indicative of a communication barrier between the practice and 
this group of individuals, preventing both demographic data from being collected and 
preventing discussions about the trial from being conducted.  Alternatively this finding may 
reflect a global lack of engagement from this group of individuals with primary care services. 
 
In order to explore whether the size of the potential study participant population, and the 
total number of patients registered at each practice (practice list size) had an impact on case-
finding performance, a comparison was made between the total number of patients 
registered at each practice (practice list size), the number of individuals identified as potential 
study participants from the trial searches and total number of participants tested at each 
practice (Table 15  and Figures 21 and 22). 
 
Table 15: HepFree recruitment data in per GP surgery in Bradford  
Data on the number of patients registered at each practice (list size), the number of potential 
study participants registered and the number recruited to participate in the study. 
Practice List size No. of potential 
study participants 
registered 
No. of potential  
participants 
recruited 
No. recruited as a 
percent of total 
potential study 
participants 
No. recruited 
as a percent 
of total list 
size  
1 5461 3539 1677 47.4 30.7 
2 5080 3237 1901 58.7 37.4 
3 6191 1942 937 48.2 15.1 
4 4119 2557 513 20.1 12.5 
5 4840 2384 1093 45.8 22.6 
6 6399 3170 529 16.7 8.3 
7 7401 685 72 10.5 1.0 
8 7114 945 68 7.2 1.0 
9 8778 1182 154 13.0 1.8 
10 4141 2341 358 15.3 8.6 
TOTAL  21,982 7,302   
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Figure 21: A scatter plot of potential study participants per GP practice and participant 
recruitment to HepFree. 
 
 
 
A scatter plot of the relationship between the number of potential study participants registered at a HepFree practice 
performing targeted screening (x-axis) and the percentage of potential study participants subsequently recruited to 
the HepFree trial (y-axis).  A non-significant positive correlation was identified between the number of potential 
study participants registered at each practice and testing performance, Pearson correlation coefficient, r = 0.6236, n 
= 10, p = 0.054. 
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Figure 22: A scatter plot of practice list size and participant recruitment to HepFree. 
 
 
 
A scatter plot of the relationship between GP practice size (x-axis) and the percentage of potential study participants 
recruited to the HepFree trial (y-axis).  No correlation was demonstrated between practice list size and testing activity 
in HepFree.  Targeted testing was performed least frequently in practices with the largest numbers of patients 
registered.  Pearson correlation coefficient, r = -0.4214, n = 10, p = 0.225.   
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Discussion 
Two of the objectives of the HepFree trial were to assess the feasibility of using information 
stored in electronic medical records in GPs in primary care in order to identify individuals at 
risk of viral hepatitis, and secondly to explore whether practices would be able to implement 
a case-finding programme for viral hepatitis in ‘high-risk’ populations registered within their 
practices.   
 
As discussed within chapter three, although recruitment of the required number of practices 
was eventually completed, persuading GPs to adopt HepFree was often difficult with multiple 
obstacles encountered that needed to be overcome.  The methods and procedures used to 
contact, recruit and finally initiate practices varied greatly, usually because the trial team 
encountered a myriad of different logistical difficulties in each of the practices approached.   
 
On reflection, it is possible that some of the obstacles that we encountered when trying to 
engage practices occurred as a result of the fact that HepFree was a research trial.  Despite 
the main objective of the trial being to test ‘at-risk’ populations to detect potentially curable 
diseases, in the current financial climate with budget cuts, GP practices may have been wary 
of additional costs associated with viral hepatitis testing in their practice population.  
Although the study provided financial re-imbursement for both trial administrative duties in 
addition to allied healthcare professionals time used for trial related visits as well as the cost 
of the blood test, we did not take into account the financial impact of either the additional 
appointment required for a clinician to discuss the results with a patient in the event of a 
positive result, or the cost of both the new-patient referral and all subsequent follow-up 
visits.   
 
Concerns of a similar nature were raised by clinicians in primary care when approached and 
asked about providing targeted testing for viral hepatitis in immigrant populations in a 
qualitative research project performed prior to HepFree commencing by Sweeney et al (327).  
Following discussions with local clinicians, the reason why practices are able to facilitate NHS 
preventative screening programmes is that although the procedure is performed by a 
member of staff at the practice, for which they are reimbursed, all reporting of results and 
subsequent referrals to secondary care is performed by a central body, it does not add to the 
work-load of the individual practice.  It may therefore be feasible to reproduce HepFree on a 
larger scale, with greater engagement from GPs if changes were made to the methodology, in 
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particular the way that positive test results were reported both to the practice and to the 
patient.  One option may be to explore employing and training a team of ‘specialist nurses’ 
whose role would be to process results, inform individuals of positive results and organise on-
going management when required. 
 
In the ten practices performing targeted testing from which data were collated for this thesis, 
a total of 59, 524 patients were registered, of which 21, 982 (36.9%) individuals were 
identified as being eligible to participate in targeted testing, the remaining 37, 542 (63.1%) 
patients were not eligible for HepFree.  As discussed previously, these figures, when 
compared to ethnicity data provided by respondents to the 2011 census demonstrate that 
the practices selected to perform HepFree were very typical of the ethnic makeup of 
Bradford.  In the 2011 census, White British/Irish and Gypsy Irish traveller represented 
64.43% of the total respondents, with 35.57% made up of Other White, Asian/British Asian, 
Black/Black British, mixed or other ethnic groups (Table 12). 
 
In the practices recruited to perform HepFree, trial specific searches were used to identify 
potential study participants from the total list of patients registered.  Participants were 
identified by Read codes that had previously been recorded in their electronic records.  The 
results of these searches demonstrated that the demographic field denoting ethnicity was 
completed most comprehensively, with only 4.5% of potential study participants that were 
identified from another demographic Read code having an absent field for ethnicity.   
 
Historically, within primary care, financial incentives were provided in return for recording of 
ethnicity data through the Quality and Outcomes Framework (QOF) and this resulted in 
dramatically increased recording to levels of over 90% for all newly registered patients (328).  
The results from our eligibility searches for HepFree support this data and confirm the high 
rate of recording of ethnicity data.  In their study, Mathur et al also investigated the quality 
and accuracy of ethnicity data recorded in primary care.  In this study, ethnicity data obtained 
from primary care was compared with data collected and stored by secondary care.  In 85% of 
cases, ethnicity data was consistent across both databases however discrepancies were 
identified more frequently in data recording in ethnic minority patients.  Validation of 
ethnicity data could be performed by using name recognition software such as Onomap or 
Nam Penchan.  These software programmes are not completely accurate though as they 
cannot account for ethnic mixing and inter-racial marriage, both of which result in surname 
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changes.  In HepFree we did not develop a method for validating the results obtained from 
the eligibility searches. 
 
The relationships between the sizes of the potential study participant populations in each 
practice versus targeted testing performance as well as practice list size versus targeted 
testing performance were examined in Table 15 and Figures 21 and 22.  A non-significant 
positive correlation was identified between the number of potential study participants 
registered at each practice and testing performance (Figure 21).  For the two variables list size 
and testing performance, a negative correlation was demonstrated (Figure 22).   
 
In practices with small numbers of potential study participants, recruitment and testing rates 
were particularly low (practices 7, 8 and 9).   The opposite was observed in practices with 
large numbers of eligible individuals registered; in these practices testing was performed on a 
greater scale (practices 1, 2 and 5).  One possible explanation for the patterns observed is that 
practices with large numbers of potential study participants encountered their target 
population more frequently in a clinical setting and were therefore able to offer testing 
opportunistically compared to practices with small numbers of potential study participants.  
Another explanation may be that in the practices with smaller numbers of eligible participants 
registered, practice staff were not encountering potential study participants very frequently 
so they may have felt less familiar with trial recruitment procedures and less equipped to deal 
with potential questions from participants that were being offered the viral hepatitis test and 
therefore were reluctant to offer testing opportunistically. 
 
Although no correlation was demonstrated between practice list size and testing activity in 
HepFree (Figure 22), the scatter plot demonstrates that targeted testing activity was lowest in 
practices with the largest numbers of patients registered (eligible and ineligible).  These 
practices may have performed inferiorly in terms of trial recruitment due to an increased 
work load generated by a large patient population.  An alternative explanation for trial 
recruitment performance in practices with large populations is that potential study 
participants encountered difficulties when attempting to obtain an appointment for testing 
due to high demand on practice resources.   
 
In order to determine why some practices were more effective in engaging patients than 
others, once the targeted testing element of the HepFree trial has been completed at all sites 
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in England, a qualitative sub-study will commence.  Here, various members of staff from 
within practices that have performed trial related activities as part of HepFree will be invited 
to participate in interviews aimed at assessing attitudes towards case-finding for viral 
hepatitis in primary care.  In addition to data obtained from these semi-structured interviews, 
baseline data including practice staff to patient ratios, staff to room ratios, participant 
recruitment levels and the presence of onsite phlebotomy services will be collected.  The 
researchers will attempt to explore the motivations and challenges of running a screening 
programme in primary care as well as any practical obstacles encountered.   
 
Previous research has attempted to understand factors that both hinder and promote the 
uptake of complex interventional trials, like HepFree by GPs and have attempted to 
understand variations observed in testing performance observed in these trials (329).  In a 
retrospective analysis of performance by practices participating in a complex intervention trial 
that introduced rapid HIV testing to patients in primary care, the diffusion innovations model 
developed by Greenhalgh et al, was used.  This model is widely recognised, providing a 
framework for analysing implementation processes (330).  The authors identified five aspects 
of the model that explained the performances observed in practices participating in the HIV 
‘screening’ trial.  These five aspects were, system antecedents for innovation, system 
readiness for innovation, adopter characteristics, implementation process and, reinvention 
and local customisation.   In the HIV trial, high-recruiting practices were often innovative, 
characterised by strong leadership, good managerial relations, a readiness for change and 
that had time available to implement new processes.  Furthermore, staff within these 
practices believed in the beneficial value of performing the intervention and were confident 
in the procedures required to perform testing.  In this trial, a positive test result appeared to 
reinforce staff commitment to participant recruitment.  The opposite was observed in 
practices with poor testing performances.  Here, less effective managerial relations were 
observed and time constraints preventing practices from engaging fully with the trial resulted 
in a lack of familiarity with testing procedures (329).  Performing a retrospective analysis of 
high and low performers in HepFree will provide invaluable information prior to widespread 
implementation of a screening programme for viral hepatitis, if the final trial results support 
this. 
 
From analysis of HepFree data, it was evident that participation in testing varied between 
participants of different ethnicities (Table 15).  The highest proportion of respondents to the 
study were of Asian/British Asian ethnicity, 37%, compared to 8.9% in individuals with either 
no documented ethnicity or no meaningful ethnicity recorded.  The absent field denoting 
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ethnicity may be a surrogate marker reflecting a global lack of engagement between this 
group of individuals and primary care services.   
 
Non-engagement in testing may be the result of linguistic and/or literacy barriers, access to 
healthcare ‘user ignorance’ or due to cultural perceptions and stigma relating to a diagnosis 
of viral hepatitis.  In qualitative research performed using focus groups that helped to inform 
the trial design of HepFree by Sweeney et al, several barriers were identified that would 
prevent engagement by individuals with a primary care based screening programme.  These 
barriers included a lack of knowledge about the disease been tested for, language and 
communication barriers, limited time to attend for testing, lack of adequate social support to 
deal with a positive diagnosis and low levels of trust and confidence in general practice based 
care (327).  Interestingly in the focus group interviews, although key informants from the 
Pakistani and Chinese communities expressed that individuals with a family member that had 
been affected by hepatitis would have increased awareness of the conditions been tested for, 
they felt that this group still lacked specific knowledge relating to viral hepatitis.  In this focus 
group, key informants from Eastern European and African communities demonstrated very 
low levels of understanding relating to viral hepatitis (327).   
 
In order to explore in more detail, factors that impact on an individual’s decision to engage 
with testing, a sub-study by Owiti et al was designed and conducted in conjunction with the 
HepFree trial.  In this sub-study, potential study participants were contacted by a member of 
the research team prior to being invited for testing to collect information on attitudes as well 
as perceived barriers towards testing for viral hepatitis.  This research was performed via semi 
structured interview over the telephone using a population-based survey of knowledge of 
viral hepatitis in conjunction with other questionnaires including Patient Health Questionnaire 
(PHQ-9) and the Generalised Anxiety Disorder 7-item (GAD-7) questionnaire. 
 
 
 
 
  
 159 
 
 
 
 
 
 
 
 
 
 
 
 
5. HepFree results: Recruitment and targeted testing 
outcomes 
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5.1 Introduction 
In this chapter, demographic data from both the eligibility searches that were conducted to 
identify potential study participants, as well as data collected in the trial-specific template 
completed at the time of testing will be analysed to in order to gain information on the 
demography of individuals that engaged with our case-finding programme.  Within the cohort 
of individuals that consented for testing through HepFree, I will initially explore the methods 
of engagement that were used by practices to recruit participants as well as investigate 
factors associated with trial participation. 
 
5.2 Results 
In targeted testing practices that were included in the analysis, 7,302 individuals were 
recruited, consented and underwent testing for viral hepatitis.  This figure represents 35.7% 
of the potential study participant population that received an invitation letter to participate in 
the trial. 
 
The population that engaged with the study consisted of 4173 females (57.1%), median age 
39 (IQR 30); and 3123 males (42.8%), median age 43 (IQR 33).  The gender of 6 participants 
was not known (0.1%).    A chi-square test performed to examine the relationship between 
gender and testing was highly significant X
2
 (1) = 155.651, p <.0001 identifying that females 
were more likely to attend for testing compared to males. 
 
Table 16 summarises the characteristics of the eligible population, with information obtained 
from the eligibility searches, compared to characteristic of individuals that were recruited to 
HepFree.   
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Table 16: Characteristics of potential study participants and individuals recruited to HepFree. 
The characteristics of the eligible study population registered in HepFree practices compared 
to the characteristics of individuals that consented to participate in the trial.  Data obtained 
from SystmOne. 
 Potential study 
participants 
Consented 
Participants (%) 
Gender 
Male 
Female 
Not known 
 
10719 
11256 
7 
 
3123 (29.1) 
4173 (37.1) 
6 
Generation 
First 
Second 
Not known 
 
9589 
2298 
10095 
 
5319(55.5) 
1875(81.6) 
108 (1.1) 
Median age (IQR) 
Male 
Female 
Not Known 
 
36 (28) 
35 (27) 
47 (35) 
 
43 (33) 
39 (30) 
42.5 (33.5) 
Age groups 
18-29 
30-39 
40-49 
50-59 
60-69 
70+ 
 
6862 
6200 
4122 
2130 
1439 
1229 
 
1434 (20.9) 
1941 (31.3) 
1693 (41.1) 
995 (46.7) 
707 (49.1) 
532 (43.3) 
Ethnic group  
White 
Mixed 
Asian/British Asian 
Black  
Other ethnic group 
Not known 
 
1457 
260 
17556 
655 
1055 
999 
 
411 (28.2) 
67 (25.8) 
6503 (37.0) 
139 (21.2) 
166 (15.7) 
16 (1.6) 
Country of birth  
Africa 
Asia-Pacific 
Eastern Europe 
Latin America/Caribbean 
Western Europe/others 
Not known 
 
358 
7415 
1737 
79 
2298 
10095 
 
126 (35.2) 
4676 (63.1) 
465 (26.8) 
42 (53.2) 
1911 (83.2) 
82 (0.8) 
Main spoken language  
English 
Urdu/Punjabi 
Gujurati 
Polish 
Bengali 
Other 
Not known 
 
1958 
9278 
381 
923 
925 
2363 
6155 
 
1739 (88.8) 
4100 (44.2) 
98 (25.7) 
160 (17.3) 
425 (45.9) 
648 (27.4) 
132 (2.1) 
Abbreviations: 
Mixed: Mixed or multiple ethnicities, Asian/Brit: Asian & British Asian,  
Black: Black African/Caribbean/ British 
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Figures 23-25 demonstrate the countries of birth, ethnic groups and main spoken languages 
of individuals recruited for viral hepatitis testing through HepFree. 
 
 
Figure 23: The demographics of individuals recruited to the HepFree trial 
 
 
 
 
A column chart summarising the countries of origin (x-axis) of individuals recruited and tested for viral hepatitis 
through the HepFree trial.  Data are expressed as both numbers tested (figures on the columns) and as a percent of 
the total tested population (y-axis).  For individuals with a documented country of origin, testing was most frequently 
conducted in individuals originating from countries within Asia-Pacific (n=4676).   
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Figure 24: The demographics of individuals recruited to the HepFree trial 
 
 
 
A column chart summarising the documented ethnicity (x-axis) of individuals recruited and tested for viral hepatitis 
through the HepFree trial.  Data are expressed as both numbers tested (figures on the columns) and as a percent of 
the total tested population (y-axis).  37% (n=6503) of individuals recruited and tested through HepFree in Bradford 
were Asian/British Asian ethnicity.   
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Figure 25: The demographics of individuals recruited to the HepFree trial 
 
 
 
 
A column chart summarising the documented main spoken language (x-axis) of individuals recruited and tested for 
viral hepatitis through the HepFree trial.  Data are expressed as both numbers tested (figures on the columns) and as 
a percent of the total tested population (y-axis).  In 56.1% of cases, testing was performed in individuals with a main 
spoken language of Urdu/Punjabi.   
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5.2.1 Method of engagement 
To determine the impact of the invitation letter on trial engagement, we examined the timing 
of response by individuals to the letter.  Invitation letters were generated for 93% of the 
eligible population by administrative staff within the GP practices (See Materials and 
Methods).  A total of 8,206 standard invitation letters were sent by practices assigned this 
intervention arm, and 12,272 enhanced invitation letters (additional information leaflet) were 
sent out by the remaining practices. 
 
 
5.2.1.1 Assumption 
 
In order to determine whether the invitation letter was responsible for an individual engaging 
with testing, the following assumption was made: If recruitment into the trial, defined by the 
presence of a signed consent form and completed electronic template on SystmOne, occurred 
between days 1-31 from the date the letter was sent, then recruitment was considered to be 
associated with the invitation letter.  Consent taken on the same date that the letter was 
generated or after 32 days from the date the letter was generated and sent was considered to 
be as a result of opportunistic recruitment. 
 
 
In 81.3% of cases, testing occurred as a result of the opportunistic method of recruitment.  
The median number of days between the letter being sent and recruitment was 51, IQR 169, 
range 616, mode equal to 0 days.  Table 17 summarises the data pertaining to the number of 
days between the invitation letter been sent and consent to the trial obtained.   
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Table 17: Duration of time between trial invitation and recruitment 
Grouped data demonstrating the time interval between the trial invitation letters being sent 
and subsequent participant recruitment.  Data are expressed as a number and as a percent of 
the total recruited.  In 81.3% of cases, recruitment occurred either on the same day that the 
letter was generated, or after 32 days, suggesting opportunistic recruitment.   
 
No. of days to consent Frequency Percent (%) Cumulative percent 
Day 0* 1759 24.1 24.1 
1-31 1364 18.7 42.8 
32-61 753 10.3 53.1 
62-91 644 8.8 61.9 
92-121 464 6.4 68.3 
122-151 311 4.3 72.5 
>152 2007 27.5 100.0 
TOTAL 7302 100.0  
*Letter generated and participant consented on the same day. 
 
 
In order to further investigate factors that may be associated with recruitment, we examined 
the impact of the type of invitation letter received on recruitment outcomes.  In the trial,  
7,302 individuals were recruited and tested for viral hepatitis; 56.0% (4,091) of these had 
been invited using the standard invitation letter and 44.0% (3, 211) had been invited using the 
enhanced invitation letter.   
 
 
Using the previously stated assumption, in the trial 1,364 participants were recruited and 
testing performed between days 1- 31 of the invitation letter been sent by the GP practice, 
and it was this group where we considered that the letter was directly responsible for 
participant recruitment.  Analysis of data from this participant cohort (n= 1,364) suggests that 
the type of letter received was highly significant in determining whether testing was 
performed.  
 
 
952 (29.6%) of the 3,211 individuals that received an enhanced invitation letter consisting of 
an invitation letter in addition to an information sheet on viral hepatitis, including the 
consequences of untreated infection, attended for testing between days 1-31 compared to 
412 (10.1%) of the 4,091 individuals that were invited using the standard invitation letter that 
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did not contain the additional information sheet on hepatitis.  In summary, individuals that 
received the enhanced invitation were more likely to participate in testing compared to 
individuals who received a standard invitation (OR 3.76; 95% CI: 3.31 – 4.27, p<0.0001).    
 
 
5.2.2 Participant age 
In order to establish whether targeted viral hepatitis testing is considered acceptable and 
accessed by individuals of all ages, participant age was examined.  Establishing the prevalence 
of viral hepatitis in different age groups will also provide information on whether universal 
screening of all first and second generation immigrants irrespective of age is justified.   
 
The ages of all participants recruited and tested through HepFree is summarised in Table 18. 
Although the age group with the highest number of individuals tested was 30-39, as a 
proportion of the total potential study participant population, testing occurred more 
frequently in adults of advancing age (Table 19). 
 
  
 168 
 
 
Table 18: Grouped data on ages of participants recruited to the HepFree trial 
 
Grouped data on ages and genders of individuals recruited to HepFree.  Data are expressed as 
a figure and percent of total number recruited to the trial.   
 
Gender Age group No. of participants 
tested 
Percent of total number 
tested 
Male 18-29 516 7.1 
 30-39 753 10.3 
 40-49 806 11.0 
 50-59 466 6.4 
 60-69 328 4.5 
 >70 254 3.5 
 Total 3123 42.8 
Female 18-29 918 12.6 
 30-39 1185 16.2 
 40-49 886 12.1 
 50-59 528 7.2 
 60-69 379 5.2 
 >70 277 3.8 
 Total 4173 57.1 
Gender unknown 18-29 0 0.0 
 30-39 3 0.0 
 40-49 1 0.0 
 50-59 1 0.0 
 60-69 0 0.0 
 >70 1 0.0 
 Total 6 0.1 
Total 18-29 1434 19.6 
 30-39 1941 26.6 
 40-49 1693 23.2 
 50-59 996 13.6 
 60-69 707 9.7 
 >70 532 7.3 
 Total 7302 100.0 
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Table 19: HepFree trial recruitment by age group 
 
The number of individuals in each age group recruited to HepFree.  Data expressed as a 
percent of the total number of eligible participants.  Trial recruitment was more successful in 
individual aged 40 and over.   
 
 
Age group No. of potential study 
participants 
No. of participants 
tested 
Percent of total 
potential participants 
tested 
18-29 6862 1434 20.8 
30-39 6200 1941 31.3 
40-49 4122 1693 41.1 
50-59 2130 995 46.7 
60-69 1439 707 49.1 
>70 1229 532 43.3 
TOTAL 21982 7302  
 
 
Independent T – tests were performed to examine the mean ages of participants grouped by 
gender and by generation.  Unsurprisingly, individuals that originated from outside the UK 
and attended for testing (first generation) were older than second generation study 
participants.  The difference in mean ages between the two groups was statistically 
significant; first generation (Mean =47.28, SD = 15.499) and second generation (Mean =32.66, 
SD = 9.875), t (3056.378) = 33.767, p ≤ .05, 95% CI 13.769, 15.467.  Cohen’s effect size (d = 
1.13) suggested a moderate to high practical significance.   
 
 
The mean ages of males and females that participated in testing was also examined.  Females 
attending for testing were younger than males and again the results were statistically 
significant; males (Mean =44.89, SD = 15.504) and females (Mean =42.69, SD = 15.787), t 
(5936) = 5.413, p ≤ .05, 95% CI 1.402, 2.994. Cohen’s effect size (d = .14) was small in this 
case, suggesting that the significant result may be due to the degrees of freedom with 
significant results occurring more frequently when large sample sizes are tested. 
 
 
Data was further analysed to establish which, if any factors impacted on trial participation.  
Due to differences in cultural behaviours and beliefs, individuals were analysed according to 
ethnicity.  Due to the relatively low number of non-Asian subjects participating in the trial in 
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Bradford, a finding that is likely to have occurred as a consequence of the ethnic composition 
of the community where the HepFree trial was conducted, participants were grouped for 
analysis as ‘Asian’ and ‘non-Asian’.  Participants with no documented ethnicity were excluded 
from the analysis. 
5.2.3 The impact of ethnicity on trial recruitment 
5.2.3.1 Asian Ethnicity 
Testing themes in the Asian cohort were reflective of testing activity patterns observed in the 
overall trial.  In this ethnic group, a greater number of females were recruited and tested 
compared to males (Table 20).  A chi-square test of independence was significant, rejecting 
the null hypothesis that gender and trial participation to undergo testing are independent, 
therefore concluding that there was an association between gender and testing rates;  X
2
 (1) 
=140.607, p=<.0001. The odds of females attending for testing were 1.43 times higher than 
males. 
 
 
Table 20: Factors influencing the uptake of testing for hepatitis through the HepFree trial: 
gender 
 
The impact of gender on recruitment to HepFree in individuals of Asian ethnicity.   
 
 
Gender No. of potential 
study 
participants 
No. 
recruited 
Percent of 
potential study 
population (%) 
Univariate 
 OR (95% CI) P 
Female 8987 3704 41.2 1 (ref) 
Male 8565 2796 32.6 .691 (.649-
.735) 
<.0001 
Unknown 4 3   
TOTAL 17556 6503 37.0 
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Table 21: Factors influencing the uptake of testing for hepatitis through the HepFree trial: age 
 
The impact of participant age on trial recruitment in individuals of Asian ethnicity.  As a 
percent of the total eligible study population, testing was performed more frequently in all 
age groups compared to 18-29 year olds.  Univariate analysis demonstrated that testing rates 
were significantly higher in all age groups compared to 18-29 year olds.   
 
 
 
Age 
category 
No. of potential 
study 
participants 
No. 
recruited 
Percent of 
potential study 
population (%) 
Univariate 
 OR 
(95% CI) 
P 
18-29 5459 1295 23.7 1 (ref) 
30-39 4848 1713 35.3 1.757 
(1.613-
1.914) 
<.0001 
40-49 3321 1507 45.4 2.671 
(2.435 – 
2.930) 
<.0001 
50-59 1636 850 52.0 3.477 
(3.099 – 
3.902) 
<.0001 
60-69 1251 647 51.7 3.444 
(3.033 – 
3.912) 
<.0001 
>70 1041 491 47.2 2.871 
(2.504 – 
3.291) 
<.0001 
TOTAL 17556 6503 37.0  
 
 
Participation in HepFree was greatest in individuals aged 50 and older; in these age groups, 
50.6% of the eligible population were recruited and tested for hepatitis compared to 33.5% of 
adults aged 18-49.  Testing was performed least frequently in individuals aged 18-29 (Table 
21).  Univariate analysis demonstrated that testing rates were significantly higher in all age 
groups compared to 18-29 year olds.   
In order to investigate whether gender influenced attendance and participation in individuals 
of different ages, a comparison was made of testing rates by age groups in females and males 
(Tables 22 &23). 
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Table 22: Factors influencing the uptake of testing for hepatitis through the HepFree trial:  
female age 
The impact of participant age on trial recruitment in females of Asian ethnicity.  In females, 
increasing age was associated with attendance for viral hepatitis testing through the HepFree 
trial.   
 
Age 
group 
No. of 
potential study 
participants 
No.  
recruited 
Percent of 
potential study 
population (%) 
 
Univariate 
OR 
(95% CI) 
P 
18-29 2792 821 29.4 1 (ref) 
30-39 2527 1043 41.3 1.687  
(1.506 – 
1.890) 
<.0001 
40-49 1622 790 48.7 2.28  
(2.008 – 
2.588) 
<.0001 
50-59 826 448 54.2 2.845  
(2.426 – 
3.337) 
<.0001 
60-69 652 345 52.9 2.698  
(2.267 – 
3.211) 
<.0001 
>70 568 257 45.2 1.984  
(1.650 – 
2.385) 
<.0001 
TOTAL 8,987 3704 41.2  
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Table 23: Factors influencing the uptake of testing for hepatitis through the HepFree trial:  
male age 
The impact of participant age on trial recruitment in males of Asian ethnicity.  In males, 
increasing age was associated with attendance for viral hepatitis testing through the HepFree 
trial. 
 
 
Age 
group 
No. of 
potential study 
participants 
No. 
recruited 
Percent of 
potential study 
population (%) 
 
Univariate 
OR 
(95% CI) 
P 
18-29 2667 474 17.8 1 (ref) 
30-39 2319 668 28.8 1.872 
(1.673 – 
2.140) 
<.0001 
40-49 1699 717 42.2 3.378 
(2.942 – 
3.879) 
<.0001 
50-59 809 402 49.7 4.57 
(3.856 – 
5.416) 
<.0001 
60-69 599 302 50.4 4.705 
(3.897 – 
5.680) 
<.0001 
>70 472 233 49.4 4.510 
(3.671 – 
5.542) 
<.0001 
TOTAL 8,565 2796 32.6   
 
 
In nearly every age cohort reviewed, in males, testing was performed less frequently 
compared to females.  In individuals of advancing age, testing rates by gender were 
comparable.  These results suggest that the HepFree screening strategy is not effective in 
engaging males aged between 18-29 in screening, in this age group, less than 20% of the 
eligible population were recruited.   
 
 
To establish whether hepatitis testing rates were influenced by an individual’s ability to speak 
English, trial participation by English speakers were compared to non-English speakers.   
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Table 24: Factors influencing the uptake of testing for hepatitis through the HepFree trial:  
main spoken language 
 
The impact of main spoken language; English versus non-English on trial recruitment in 
individuals of Asian ethnicity.  A significant positive association was demonstrated between 
English as a main spoken language and attendance for testing, OR = 11.0135, 95% CI: 9.3653 – 
12.9517, p<.0001. 
 
 
 
Language 
No. of 
potential 
study 
participants 
No. 
 recruited 
Percent of 
potential study 
population (%) 
Univariate 
OR 
(95% CI) 
P 
English 1698 1526 89.9 1 (ref) 
Other 10902 4864 44.6 .091 
(0.077 – 
0.107) 
<.0001 
Unknown 4956 113 2.3 .003 
(.002 - 
.003) 
<.0001 
TOTAL 17556 6503 37.0  
 
 
Analysis of recruitment and hepatitis testing by main spoken language identified that testing 
was performed less frequently in individuals in whom English was not the main spoken 
language; 44.6% versus 89.9% in English speakers.  There was a significant positive association 
demonstrated between English as a main spoken language and recruitment to HepFree, OR = 
11.0135, 95% CI: 9.3653 – 12.9517, p<.0001 (Table 24). 
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5.2.3.2 Non- Asian Ethnicity 
 
The same analysis was performed in HepFree participants with a documented ethnic group 
other than Asian/British Asian. 
 
 
Table 25: Factors influencing the uptake of testing for hepatitis through the HepFree trial: 
gender 
 
 
A table demonstrating the impact of gender on recruitment to HepFree in individuals of non-
Asian ethnicity.  In this cohort, a greater proportion of females that were invited to 
participate in HepFree attended for testing compared to males; 25.8% versus 19.6%. 
 
 
Gender No. of 
potential 
study 
participants 
No. 
recruited 
Percent of 
potential study 
population (%) 
Univariate 
OR 
(95% CI) 
P 
Female 1780 460 25.8 1 (ref) 
Male 1646 322 19.6 .698 (.594 
- .820) 
<.0001 
Unknown 1 1   
TOTAL 3427 783 22.8  
 
 
Similar to patterns observed in the analysis of the Asian cohort, there was a significant 
negative association between male gender and testing rates in individuals of non-Asian 
ethnicity.  The odds of females attending for testing in this cohort were 1.43 times higher 
than for males, p = <.0001. 
 
 
As a proportion of the total eligible population, recruitment into HepFree was much lower in 
individuals of non-Asian ethnicity, compared to Asian ethnicity; 22.8% versus 37.0%.  A chi-
square test of independence was significant, rejecting the null hypothesis that ethnicity and 
attendance for viral hepatitis testing were independent, thus concluding that there was an 
association between Asian ethnicity and attendance for testing as part of the HepFree trial;  
X
2
 (1) =254.216, p=<.0001.   
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Table 26: Factors influencing the uptake of testing for hepatitis through the HepFree trial: age 
 
 
The impact of participant age on trial recruitment in individuals of non-Asian ethnicity.  As a 
proportion of the total eligible study population, testing was performed more frequently in all 
age groups compared to 18-29 year olds.  Univariate analysis demonstrated that testing rates 
were significantly higher in all age groups compared to 18-29 year olds.   
 
 
Age 
group 
No. of 
potential study 
participants 
No. 
 recruited 
Percent of 
potential study 
population (%) 
Univariate 
OR 
(95% CI) 
P 
18-29 1051 135 12.8 1 (ref) 
30-39 1005 226 22.5 1.971 
(1.560 – 
2.49) 
<.0001 
40-49 640 182 28.4 2.696 
(2.101 – 
3.46) 
<.0001 
50-59 416 142 34.1 3.516 
(2.680 – 
4.613) 
<.0001 
60-69 160 58 36.3 3.858 
(2.666 – 
5.583) 
<.0001 
>70 155 40 25.8 2.360 
(1.578 – 
3.530) 
<.0001 
TOTAL 3,427 783 22.8  
 
 
Lower rates of attendance for hepatitis testing were observed in all age groups of non-Asian 
individuals compared to individuals of Asian ethnicity (Table 26).  Although slightly higher 
testing rates were observed in participants of advancing age, only 32.8% of all eligible 
participants aged 50 and above participated in the trial.  As was observed in the Asian cohort 
there was a negative association between youth and attendance for hepatitis testing, OR = 
0.516, 95% CI = 0.43-0.61, P= <.0001.   
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Table 27: Factors influencing the uptake of testing for hepatitis through the HepFree trial:  
female age 
 
A table investigating the impact of participant age on trial recruitment in females of non-Asian 
ethnicity.  In this population, increasing age was associated with attendance for viral hepatitis 
testing through the HepFree trial.  
 
 
Age 
group 
No. of 
potential study 
participants 
No.  
recruited 
Percent of 
potential study 
population (%) 
Univariate 
OR 
(95% CI) 
P 
18-29 595 95 16.0 1 (ref) 
30-39 512 140 27.3 1.981 
(1.478 – 
2.655) 
<.0001 
40-49 308 95 30.8 2.347 
(1.694 – 
3.254) 
<.0001 
50-59 203 79 38.9 3.353 
(2.346 – 
4.794) 
<.0001 
60-69 78 32 41.0 3.661 
(2.217 – 
6.047) 
<.0001 
>70 84 19 22.6 1.539 
(.882 – 
2.683) 
.129 
TOTAL 1780 460 25.8  
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Table 28: Factors influencing the uptake of testing for hepatitis through the HepFree trial:  
male age 
 
The impact of participant age on trial recruitment in males of non- Asian ethnicity.  In this 
cohort, a significant association was identified between increasing age and attendance for 
viral hepatitis testing through the HepFree trial. 
 
Age 
group 
No. of 
potential study 
participants 
No. 
recruited 
Percent of 
potential study 
population (%) 
Univariate 
OR 
(95% CI) 
P 
18-29 456 40 8.8 1 (ref) 
30-39 492 85 17.2 2.172 
(1.456 -
3.24) 
.0001 
40-49 332 87 26.2 3.693 
(2.46 – 
5.54) 
<.0001 
50-59 213 63 29.6 4.368 
(2.819 – 
6.769) 
<.0001 
60-69 82 26 31.7 4.829 
(2.739 – 
8.514) 
<.0001 
>70 71 21 29.6 4.368 
(2.387 – 
7.992) 
<.0001 
TOTAL 1646 322 19.6  
 
 
Participation in testing was particularly low in males aged less than 39 in the non-Asian 
cohort, with only 13.2% of the eligible population consenting for testing.  Of note, in the non-
Asian cohort, testing was performed in less than 10% of the eligible population in males aged 
between 18-29.  Participation in HepFree was significantly higher in all age groups compared 
to ages 18-29, p=<.0001. 
 
Within the non-Asian cohort, further analysis of recruitment rates according to ethnicity was 
performed.  Through exploring testing rates in each individual ethnic group, it may be 
possible to establish whether non-attendance was more frequently observed in particular 
ethnic groups, enabling the methodology of the trial to be reviewed and adapted to try and 
overcome this problem and increase subsequent engagement.  Table 29 summarises the 
testing rates in each ethnic group contained within the non-Asian cohort. 
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Table 29:  HepFree recruitment rates in ethnic groups within the non-Asian cohort 
 
 
Rates of attendance for viral hepatitis testing in HepFree by individuals with a documented 
ethnicity other than Asian/British Asian in Bradford.  Data expressed as a proportion of the 
total number of individuals registered at practices that were eligible to participate in the trial.   
 
Ethnic 
category 
No. of potential 
study participants 
No.  recruited Percent of potential study 
population (%) 
White 1457 411 28.2 
Mixed 260 67 26.2 
Black 655 139 21.2 
Other 1055 166 15.7 
TOTAL 3427 783 22.8 
Abbreviations:  
Mixed: Mixed/multiple ethnicities, Black: Black African/Caribbean/ British 
 
 
Individuals with a Read code in their electronic medical record that did not give a clear 
indication of their ethnic origin engaged least frequently with testing through the trial.  One 
such example of a Read code is ‘other ethnic group’.  In all other ethnic groups included in this 
sub-analysis, testing rates exceeded 20%.  In order to try and gain additional information 
about the group of individuals with no meaningful code recorded to describe their ethnic 
origin, country of birth was explored.    There was a Read code denoting country of birth in 
470 of the 1,055 potential study participants with no documented ethnicity (44.5%).  The 
countries of birth that were recorded in the electronic medical records of these individuals 
are summarised in Table 30. 
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Table 30: Country of origin of eligible individuals with no documented ethnicity on SystmOne 
The country of origin of individuals identified as eligible for participation in HepFree in whom 
no meaningful ethnicity was documented on SystmOne.   
Country of origin No. of participants 
Afghanistan 6 
Albania 4 
Argentina 1 
Azerbaijan 1 
Bahrain 1 
Bangladesh 1 
Brunei 3 
Burkina Faso 1 
Burma 1 
Central African Republic 1 
Czech Republic 37 
Egypt 1 
Estonia 2 
Georgia 1 
Ghana 1 
Greece 3 
India 2 
Iran 7 
Iraq 25 
Italy 1 
Kuwait 2 
Latvia 20 
Lebanon 2 
Libya 6 
Lithiuania 7 
Malawi 1 
Morocco 10 
Nepal 4 
Nigeria 3 
Oman 1 
Pakistan 36 
Poland 74 
Portugal 2 
Romania 9 
Russia 6 
Saudi Arabia 5 
Seychelles 1 
Slovakia 159 
Somalia 1 
Spain 1 
St Kitts and Nevis 1 
Sudan 1 
Syria 7 
Thailand 1 
Tunisia 2 
Turkey 1 
Ukraine 1 
Venezuela 1 
Vietnam 1 
The former Yugoslavia 2 
Zimbabwe 1 
Yemen 1 
TOTAL 470 
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More than 50% of the 470 individuals with a country of birth, but no ethnicity recorded, 
originated from countries within Eastern Europe.  This raises the possibility that although 
these individuals were born in countries within Eastern Europe, their ethnicity originates from 
another part of the world, and they do not consider themselves as ‘white European’ ethnicity. 
 
Once again, in the non-Asian cohort, recruitment and testing rates in English speakers were 
compared with non-English speakers.     
 
 
Table 31: Factors influencing the uptake of testing for hepatitis through the HepFree trial:  
main spoken language 
 
The impact of main spoken language; English versus non-English on trial recruitment in 
individuals of non-Asian ethnicity. 
 
Language No. of 
potential 
study 
participants 
No. 
recruited 
Percent of 
potential study 
population (%) 
Univariate 
OR 
(95% CI) 
P 
English 255 208 81.6 1 (ref) 
Other 2058 557 27.1 .084 
(.060 - 
.117) 
<.0001 
Unknown 1114 18 1.6 .0037 
(.00021 - 
.0065) 
<.0001 
TOTAL 3,427 783 22.8  
 
 
An analysis of testing rates by main spoken language in non-Asian participants produced the 
same results as were observed in the Asian cohort.  Hepatitis testing was performed less 
frequently in individuals with a documented main spoken language other than English, 27.1% 
versus 81.6%.  Again, English as a main spoken language had a statistically significant 
association with attendance for testing, OR 11.926, 95% CI: 8.564 – 16.61, p<.0001.  The wide 
confidence interval is likely to be attributed to the sample sizes included in the analysis.   
 
 
From analysis of participants recruited into HepFree based on ethnicity, similar themes in 
screening occurred in both the Asian and non-Asian cohorts.  In HepFree, engagement rates 
were higher in females, in individuals of an advancing age and in those with English 
documented as a main spoken language. 
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5.2.4 Individuals declining the offer of screening 
 
As summarised in Figure 15, 20,478 individuals were invited to attend for hepatitis testing in 
the ten HepFree practices included in this thesis.  The uptake of testing in the invited 
population was 35.7%.  Within the trial specific proforma published on S1, there was the 
option for a member of staff in the GP surgery to document occasions when potential study 
participants either contacted the practice on receipt of the invitation letter to formally decline 
the offer of participation in the trial and subsequent testing, occasions when potential study 
participants were offered the test face to face and declined, or occasions when potential 
study participants attended to consent for the trial but ultimately declined prior to testing 
been performed.  If the section of the trial specific proforma labelled ‘declined to participate 
in research’ box was ticked, a Read code was recorded in the electronic medical record of that 
individual, and this data was available for collection by the trial team.   
 
During the eighteen months that the trial was active within the practices, there were 1,065 
episodes when the Read code ‘declined to participate in research’ was entered in an 
electronic record in a targeted testing practice.  This figure represents 5.2% of the invited 
population. 
 
5.3 Discussion 
In this chapter, the methods used by practices to engage participants in HepFree were 
analysed.  For the purpose of the analysis, an assumption was made that if consent and 
hepatitis testing occurred between days 1-31 of the invitation letter being sent, then 
recruitment was considered to be associated with the invitation letter.  In the ten practices 
performing targeted testing, in 81.3% of cases, recruitment occurred either on day zero (the 
same day that the letter was generated) or after thirty-one days, in these participants, 
recruitment was therefore considered to be opportunistic.  In the HepFree trial, opportunistic 
recruitment testing was proven to be more effective than letter invitation to attend for 
testing. 
 
 
We do however recognise that it is rarely possible to apply such an arbitrary assumption to a 
real life situation.  There are a multitude of factors that exist and that may influence an 
individual’s decision to participate in testing that cannot be taken into account when simply 
measuring the number of days that have lapsed between an invitation letter being sent and 
an individual attending for testing.  Cultural, social and economic factors, in addition to first-
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hand experience of the consequences of hepatitis may all influence a person’s decision 
making with respect to engaging in testing.  As observed here, although in the majority of 
cases the letter may not have been the sole driving force prompting an individual to book an 
appointment for testing, the letter may have contributed to their decision to participate in 
some way.  In view of this, we feel that the results of this analysis alone are not powerful 
enough to conclude that letter invitation is ineffective in future screening programmes 
directed at immigrants.   
 
 
The results do however highlight the importance of modifying methods used to invite the 
target population in future targeted testing strategies, in order to optimise engagement by 
‘non-responders’, The rigorous and efficient use of Read codes may help to facilitate this.  It is 
arguable that generating an invitation letter is less onerous on members of staff compared to 
phone-calls, so as an initial method of invitation it is reasonable to continue to use this.  
Inputting a Read code at the time that an individual responds to the invitation would then 
allow the practice to be able to review ‘non-responder’ records and determine the next most 
appropriate method of invitation.  The addition of an alert or prompt to the records of all 
‘non-responders’ would act as a reminder to staff to discuss the testing/screening strategy if 
they have an episode of contact with them.  If however, on reviewing the records of ‘non-
responders’ it is clear that they rarely engage with primary care, a SMS or telephone call may 
be more effective.  By coding each engagement method used and performing regular reviews 
of uptake rates in response to each method, an evaluation of the effectiveness of different 
interventions could be performed. 
  
 
In Bradford, as a proportion of the population that were invited to participate in HepFree, 
higher rates of attendance were observed in females compared to males, 37.1% versus 
29.1%.  The majority of participants recruited for testing through HepFree were first 
generation immigrants, 72.8% versus 25.7%.  It would have been both interesting and 
valuable to have been able to establish the uptake rate amongst all first and second 
generation immigrants that were eligible to participate from the ten practices.  This was not 
possible however due to deficiencies in data available relating to country of origin for all 
potential study participants.  From the data that was available for analysis, just over half of all 
cases (54%) had a documented country of birth; 43.6% were born outside of the UK and 
therefore first generation and 10.4% were second generation immigrants.  
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The increased attendance at hepatitis case finding initiatives  by first generation immigrants 
observed is consistent with previous viral hepatitis studies conducted in migrant populations 
(301,303,304,331,332).     
 
 
In order to investigate the impact of factors including gender, age and main spoken language 
on attendance for testing, depending on an individual’s ethnicity, analysis was performed on 
two cohorts, Asian and non-Asian.  Similar themes with regards to testing were identified in 
both of the cohorts analysed.  Irrespective of ethnicity, it was evident that the HepFree trial 
failed to engage males to the same extent as females; in particular young males.   
 
 
The pattern of recruitment observed in HepFree was not surprising.  There are several 
possible explanations for the findings observed.  In immigrant populations, unemployment 
rates are more prevalent in females, making it easier for this group to access appointments at 
the GP surgery during the day to engage with the HepFree trial.  In addition to this, although 
not proven, as this group of individuals do not have work commitments, they may be more 
likely to socialise with other members of their community where they may be influenced by 
the views and opinions of their peers with regards to testing.  Finally a report has 
demonstrated that ethnic minority females are more likely to report a limiting long-term 
illness compared to both white females and males of the same ethnicity and may therefore 
be more likely to attend appointments in primary care, increasing the number of available 
opportunities for trial recruitment to occur through opportunistic methods (333). 
 
 
The pattern of recruitment observed in HepFree also reflects the demographics of the 
individuals that access primary care services in England.  Apart from at extremes of age, 
females access medical services in primary care more frequently than males.  In terms of the 
trial, this results in an increased number of opportunities for practice staff to engage with 
these potential study participants (334,335).  In order to engage men more effectively in 
testing for hepatitis, one possibility may be to adapt the trial methodology and increase the 
number of locations used to perform testing, perhaps to include both places of worship, as 
well as places of work that employ large numbers of migrant workers in conjunction with 
testing in primary care.  
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In HepFree, recruitment and subsequent testing was observed less frequently in individuals 
that did not have English documented as a main spoken language.  There are several possible 
explanations for why this finding might have occurred.  Firstly, it may be related to the 
methods used by HepFree to invite potential study participants.  Although the potential 
impact of a language barrier was addressed during the trial design and translations of both 
the invitation letter and patient information sheet produced, even with these modifications, 
letter invitation does not cater to individuals who are either illiterate in all languages, or those 
who speak and read a local dialect.  In addition to difficulties in inviting potential participants 
due to language barriers, the consent form used at the time of recruitment into HepFree was 
written in English.  This may have resulted in individuals that could not read English been 
reluctant to sign to participate in the trial. 
 
 
Participation in HepFree by non-Asian participants was lower than in Asian participants.  This 
finding may have occurred for multiple reasons discussed below.  Firstly, it could be related to 
the ethnic composition of Bradford.  Of the potential study participants invited to participate 
in the trial, 17,556 were Asian/British Asian ethnicity compared with 3,427 non-Asian.  An 
alternative explanation is that this finding reflects awareness levels of viral hepatitis within 
the two cohorts.  Due to the high prevalence of viral hepatitis in south Asian countries, in 
particular Pakistan, individuals of Asian ethnicity may be both more aware, or have more first-
hand experience of the consequences of viral hepatitis.  In addition to this first-hand 
experience, as previously discussed, several viral hepatitis awareness campaigns have 
previously been launched in Bradford, aimed in particular at south Asian communities.  The 
finding of lower rates of engagement observed in the non-Asian cohort may be a reflection of 
this group of individuals’ perceived risk of infection.  Individuals of non-Asian ethnicity may 
either have a lower level of awareness about viral hepatitis and the consequences of long-
term untreated infection, or alternatively may not be as concerned about their risk of 
infection compared to age-matched Asian individuals.   
 
 
The differences in trial recruitment rates between the cohorts may also be a reflection of the 
overall health and health-needs of individuals within the non-Asian cohort.  We established 
that engagement with the HepFree trial was predominantly the result of opportunistic 
recruitment methods; therefore, if non-Asian patients do not attend the practice as 
frequently for medical appointments, there would be fewer opportunities available to offer 
testing opportunistically to this cohort. 
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In 5.2% of cases, a Read code was entered into the electronic medical record of a potential 
study participant signifying that they had formally declined the offer to participate in the 
HepFree trial.  This data does however have to be interpreted with caution.  Firstly, the Read 
code used by the trial to record an individual’s decision to not participate in the trial was not a 
‘HepFree specific’ Read code.  The Read code was a generic one, available in the catalogue of 
Read codes published and available for use on SystmOne.  It is therefore possible that the 
Read code may have been used to document an individual’s decision not to participate in 
another trial that was being conducted at the same time as HepFree.  As well as potential 
inaccuracies with the Read code, the Read code data is not comprehensive as it fails to take 
into account individuals that received the letter but failed to respond.  Failure to respond is 
highly suggestive that an individual has declined the offer of participation in the trial, 
therefore the number of potential study participants declining to participate  in hepatitis 
testing could have been as high as 13,176.    
 
In order to accurately establish the number of potential study participants that were invited 
and then subsequently declined the offer of hepatitis testing through HepFree, processes 
would have to be implemented to firstly ensure that all potential study participants received 
their invitation letter.  A subsequent episode of contact would have to be made with each 
individual to confirm that those who had not booked an appointment for testing did not wish 
to participate.  By doing this, an outcome for all participants that were invited would be 
recorded. 
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6. HepFree results: Prevalence of viral hepatitis in 
immigrant communities in Bradford. 
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6.1 Introduction 
In this chapter I will present data on the prevalence of viral hepatitis in immigrant populations 
in Bradford acquired from the GP based case-finding trial HepFree.  In particular I will describe 
the demographics and characteristics of study participants that tested positive for viral 
hepatitis.  I will explore the prevalence of anti-HCV and HBsAg in different ethnic groups, 
genders and age groups, and aim to establish which groups are at highest risk of infection, 
and would therefore benefit most from implementation of a universal viral hepatitis 
screening programme. 
 
 
For each participant that was tested as part of the HepFree trial, blood was taken and 
analysed to test for the both presence of HBsAg and anti-HCV.  As discussed previously, the 
presence of HBsAg in serum indicates chronic infection with HBV.  Anti-HCV, if present, 
indicates that an individual had been exposed to HCV, and requires further investigation with 
an RNA test to determine whether there is evidence of chronic infection. 
 
 
6.2 Results 
HepFree recruited 7,302 participants in Bradford and 14, 604 results were reported.  From all 
viral hepatitis tests performed, 145 results were not available; this accounts for 1% of all tests 
performed (Figure 26).    In 72 cases the laboratory failed to report both the HBsAg and anti-
HCV result for subjects tested, and in one further case, the HBsAg result was available but the 
anti–HCV result had not been reported.  Results were not generated by the laboratory for the 
following reasons; inadequate sample volume sent for analysis, sample haemolysis, incorrect 
labelling of the sample sent for analysis, and discrepancies in participant information between 
the sample bottle and sample request form. 
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Figure 26: The results of targeted testing for viral hepatitis in the HepFree trial in Bradford  
 
 
 
 
A flow chart summarising the results of viral hepatitis tests requested in the HepFree trial population included in this 
analysis.  7,302 individuals were consented and underwent testing.  There were 61 cases of chronic HBV and 68 cases 
with a positive test for anti-HCV.  
 
 
The prevalence of viral hepatitis, defined as either the presence of anti-HCV or HBsAg in the 
tested population was 1.77%; anti-HCV 0.9% and HBsAg 0.8% respectively.  In first generation 
immigrants undergoing testing, the prevalence of anti-HCV was 1.2%, and HBsAg was 1.1%.  In 
second generation, the results were 0.32% and 0.27% respectively.  First generation 
immigrants had 3.72 times the risk of having viral hepatitis compared to second generation 
immigrants, 95% CI 2.010 – 6.887.  Expressed as a percent relative effect, first generation 
immigrants had 272% increase in risk of being infected with viral hepatitis compared to 
second generation immigrants. 
 
 
All participants with a positive viral hepatitis test were referred for review in a secondary care 
outpatient clinic.  Subjects with a positive anti-HCV test had a subsequent HCV RNA test 
performed automatically by the laboratory to establish chronic infection status.  During the 
diagnostic assessment in secondary care it became apparent that 18 individuals with a 
positive test for anti-HCV had previously received antiviral therapy for chronic HCV.  Within 
this previously treated cohort, there was no recurrence of disease.  In individuals with no 
prior history of treatment with antiviral therapy, RNA positive chronic hepatitis C was 
identified in 25 cases (50%) and spontaneous virus eradication had occurred in the remaining 
25 cases (50%). 
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6.2.1 The demography of individuals with a positive viral hepatitis test  
 
Figures 27 to 29 summarise the demography of participants with a positive test for hepatitis.  
In all figures, the coloured bars represent the following values: 
 
 Test positive for viral hepatitis 
 
 Test positive for Anti-HCV  
 
 Test positive for HBsAg 
 
 
 
Figure 27: The prevalence of viral hepatitis in individuals according to ethnicity   
 
Note the change in the axis scale. 
 
 
 
A column chart summarising the prevalence of disease according to documented ethnicity.  The highest prevalence of 
viral hepatitis was identified in individuals with ‘mixed’ ethnicity however this is likely to be a consequence of the 
sample size.  
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Figure 28:  The prevalence of viral hepatitis in individuals according to country of birth   
 
 
 
 
 
 
A column chart summarising the prevalence of disease according to documented country of birth.  The lowest 
prevalence was identified in individuals originating from countries within Western Europe; this is likely to reflect the 
second generation population tested as part of the trial. 
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Figure 29: The prevalence of viral hepatitis in individuals according to main spoken language 
 
 
 
 
 
A column chart summarising the prevalence of viral hepatitis according to documented main spoken language.  The 
highest prevalence of viral hepatitis was identified in individuals with a main spoken language of Urdu/Punjabi and 
was lowest in individuals with a documented main spoken language of English.   
 
Positive screening tests were most frequently observed in individuals with a documented 
main spoken language of Urdu/Punjabi (Figure 29). This is an important finding as the results 
of the analysis performed on factors that influence uptake of testing demonstrated that non-
English speakers were less likely to engage with the trial compared to English speakers, 
therefore we could be under-diagnosing viral hepatitis in this group of migrants. 
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Figure 30: The prevalence of viral hepatitis in individuals according to gender 
 
 
 
A column chart summarising the prevalence of viral hepatitis in the trial cohort according to gender.  The highest 
prevalence was identified in males that attended for testing; 2.1% versus 1.5%. 
 
 
The overall prevalence of viral hepatitis was higher in males recruited to the trial compared to 
females, despite more females engaging with testing through HepFree.  Interestingly the 
prevalence of HBV in males was 1.2% compared to only 0.6% in females.  This finding is 
discussed in more detail below.  The prevalence according to gender highlights the 
importance of adapting the methodology of a future screening programme to encourage 
participation by male immigrants. 
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Figure 31: The prevalence of viral hepatitis in individuals according to generation; first versus 
second. 
 
 
 
A column chart summarising the prevalence of disease in the HepFree population according to generation.  The 
highest prevalence of disease was identified in individuals born outside of the UK, also known as first generation; 
2.2% versus 0.6%. 
 
 
Consistent with results from previous screening studies, viral hepatitis was identified more 
frequently in first generation immigrants, compared to second generation immigrants. 
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Figure 32: The prevalence of viral hepatitis in individuals according to age (Grouped Data)  
 
 
 
 
A column chart summarising the prevalence of disease in the HepFree population according to age (grouped data).  
The prevalence of disease increased with advancing age (>40 years). 
 
  
 
Finally, when exploring the prevalence of disease in different age groups, there was a higher 
prevalence of disease identified in individuals of advancing age.  This is consistent with the 
finding that more cases of infection were identified in first generation immigrants.  In 
HepFree, first generation immigrants engaging with the trial were older than second 
generation immigrants (Figure 32). 
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A more in depth analysis was performed on the cohorts of participants with viral hepatitis in 
order to gain a better understanding about the demographics of individuals that should be 
targeted by future screening programmes because of an increased risk of viral infection.  Data 
obtained was analysed by ethnicity, age group and gender.  Cases of HBV and HCV infection 
were analysed individually. 
 
The following trial participants were excluded from this analysis: 
1. Individuals with no viral hepatitis result reported. 
2. Individuals that participated in the trial with an unrecorded gender. 
3. Individuals that participated in the trial with an unrecorded ethnicity. 
6.2.2 The demographics of the Hepatitis C positive cohort 
6.2.2.1 Ethnicity 
 
An equal proportion of positive anti-HCV tests were observed in individuals of White, 
Asian/British Asian and Black African/Caribbean/British ethnicities (Table 32).  A higher 
prevalence of anti-HCV positive tests were identified in individuals that attended for testing 
with a Read code denoting ‘mixed/multiple’ ethnicity in their electronic medical record.  
There were no positive anti-HCV tests in the cohort of individuals with an absent field for 
ethnicity.  In both the ‘mixed/multiple’ ethnic category and the cohort of individuals with no 
ethnic code documented, the numbers of individuals participating in testing were very low 
and therefore the results obtained are likely to be outliers, reflecting the small sample size.  
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Table 32: The prevalence of anti-HCV in trial participants according to ethnicity 
 
The prevalence of anti-HCV in the tested population in each ethnic group of interest.   
 
 
Ethnic group Number 
eligible 
Number 
tested 
Number 
positive 
Percent 
of total 
tested 
Percent 
of total 
eligible 
Univariate 
OR 
(95% 
CI) 
P 
White 1457 399 3 0.8 0.2 1 (ref) 
Mixed/Multiple 260 66 2 3.0 0.8 4.135 
(.678 – 
25.233) 
.124 
Asian/Brit Asian 17552 6451 62 1.0 0.4 1.284 
(.401 – 
4.109) 
.422 
Black 654 135 1 0.7 0.2 .988 
(.102 – 
9.575) 
.991 
Other ethnicity 1055 161 0 0 0 .352 
(.0181 – 
6.846) 
.490 
Total 20,978 7,212 68 0.9 0.3  
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6.2.2.2 Age 
 
Testing for the presence of anti-HCV appeared to be particularly beneficial in individuals aged 
between 40 and 59; the prevalence of a positive test in this cohort was 1.2%.  The role of 
future screening strategies in young adults aged 18-29 is dubious given the very low 
prevalence observed.   
 
The low rate of infection identified in this age group is likely to be related to the country of 
birth of participants included within it.  As discussed previously, in the trial, second generation 
immigrants were younger than first generation so it is likely that testing in this age group was 
primarily focussed on second generation immigrants (Table 33). 
 
Table 33: The prevalence of anti-HCV in trial participants according to age (grouped data) 
 
The prevalence of anti-HCV in the tested population organised by age group.  A very low 
prevalence was identified in individuals aged 18-29, likely a reflection of their country of 
origin (first versus second).  
 
Age 
group 
Number 
eligible 
Number 
screened 
Number 
positive 
Percent of 
total 
tested 
Percent 
of total 
eligible 
Univariate 
OR 
(95% CI) 
P 
18-29 6862 1414 4 0.3 0.1 1 (ref) 
30-39 6200 1917 21 1.1 0.3 3.904 
(1.337 – 
11.399) 
.012 
40-49 4122 1677 20 1.2 0.5 4.255 
(1.451 – 
12.477) 
.008 
50-59 2130 980 13 1.3 0.6 4.739 
(1.541 – 
14.577) 
.007 
60-69 1439 700 5 0.7 0.3 2.536 
(.679 – 
9.473) 
.166 
>70 1229 524 5 1.0 0.4 3.396 
(.908 – 
12.695) 
.007 
Total 21,982 7,212 68 0.9 0.3  
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6.2.2.3 Gender 
Table 34: The prevalence of anti-HCV in trial participants according to gender 
 
The prevalence of anti-HCV was similar in both females and males 0.4% versus 0.3% of the 
total eligible population and 1.0% versus 0.9% of the total population recruited and tested 
through HepFree.  
 
Gender Number 
eligible 
Number 
screened 
Number 
positive 
Percent 
of total 
tested 
Percent 
of total 
eligible 
Univariate 
OR 
(95%CI) 
P 
Female 11,256 4128 40 1.0 0.4 1 (ref) 
Male 10,719 3084 28 0.9 0.3 .936 
(.576 – 
1.521) 
.791 
Total 21,975 7,212 68 0.9 0.3  
 
There was no statistically significant difference identified between the prevalence of infection 
in females and males included in the sample, p = .791. 
 
6.2.2.4 Binomial logistic regression 
 
A binomial logistic regression was performed to understand whether a positive HCV test could 
be predicted based on an individual’s age, country of birth and gender.  For the purpose of 
this analysis due to the small sample size, country of birth was categorised as either ‘Asia 
Pacific’ or ‘Other’.  Table 35 demonstrates the odds ratios and significance of the predictor 
variables.  Of the variables entered into the model, only country of origin was statistically 
significant.  Individuals originating from Asia-Pacific were 3.129 times more likely to be anti-
HCV positive, 95% C.I 1.554-6.301.  For both gender, and the continuous variable age, 95% 
confidence intervals contained 1.0; therefore the association was not significant at the .05 
significance level. 
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Table 35: Binomial logistic regression HCV 
 
A binomial logistic regression using data collected from individuals with a positive anti-HCV 
test.   
 
Independent 
variable 
B S.E Sig Exp(B) 95% CI for EXP (B) 
Lower Upper 
Age -.001 .008 .922 .999 .983 1.015 
Gender -.075 .249 .762 .927 .570 1.510 
Country 1.141 .357 .001 3.129 1.554 6.301 
Constant -5.426 .433 .000 .004   
 
 
6.2.3 The demographics of the hepatitis B positive cohort 
6.2.3.1 Ethnicity 
The highest prevalence of chronic hepatitis B was identified in Black African/Caribbean/British 
participants that attended for testing; 2.2%.  Similar to the results of the HCV screening test, 
no cases of infection were identified in subjects with no meaningful ethnicity documented. 
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Table 36: The prevalence of HBsAg in trial participants according to ethnicity 
The prevalence of anti-HCV in the tested population in each ethnic group of interest.   The 
highest prevalence of HBV was identified in Black African/Caribbean/British participants 
attending for testing. 
 
Ethnic group Number 
eligible 
Number 
screened 
Number 
positive 
Percent 
of total 
tested 
Percent 
of total 
eligible 
Univariate 
OR 
(95% CI) 
P 
White 1457 399 6 1.5 0.4 1 (ref) 
Mixed/Multiple 260 66 0 0 0 0.455 
(.0253-
8.176) 
.593 
Asian/Brit Asian 17552 6451 52 0.8 0.3 .532 
(.227-
1.247) 
.147 
Black 654 135 3 2.2 0.5 1.489 
(.367 – 
6.036) 
.578 
Other ethnicity 1055 161 0 0 0 .187 
(.011 – 
3.347) 
.255 
Total 20,978 7,212 61 0.8 0.3   
 
6.2.3.2 Age 
 
As in the anti-HCV cohort, the prevalence of HBsAg in young adults aged 18-29 who attended 
for testing was very low; 0.6%.  There was a statistically significant increase in the prevalence 
of HBsAg in participants aged 60-69 compared to the baseline group for comparison which 
was 18-29.    
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Table 37: The prevalence of HBsAg in trial participants according to age (grouped data) 
The prevalence of HBsAg in the tested population organised by age group.  A very low 
prevalence was identified in individuals aged 18-29, likely a reflection of their country of 
origin (first versus second).  
 
 
Age 
group 
Number 
eligible 
Number 
screened 
Number 
positive 
Percent of 
total tested 
Percent of 
total 
eligible 
Univariate 
OR 
(95% CI) 
P 
18-29 6862 1414 9 0.6 0.1 1 (ref) 
30-39 6200 1917 12 0.6 0.2 0.983 
(.413– 
2.340) 
.97 
40-49 4122 1677 19 1.1 0.5 1.789 
(.807 – 
3.967) 
.152 
50-59 2130 980 8 0.8 0.4 1.285 
(0.494 – 
3.342) 
.0607 
60-69 1439 700 10 1.4 0.7 2.262 
(.915 – 
5.594) 
.008 
>70 1229 524 3 0.6 0.2 .899 
(.242 – 
3.33) 
.873 
Total 21,982 7,212 61 0.8 0.3  
 
 
6.2.3.3 Gender 
 
There was a statistically significant increase in the prevalence of HBV in the male population 
that attended for screening compared to the female population, OR 2.229, p=.003.  This 
finding may be a consequence of other screening initiatives which exist for females in the UK 
(Table 38). 
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Table 38: The prevalence of HBsAg in trial participants according to gender 
The prevalence of a positive test for HBsAg was significantly higher in males tested through 
HepFree compared to females, p = <.003.  
 
Gender Number 
eligible 
Number 
screened 
Number 
positive 
Percent 
of total 
tested 
Percent 
of total 
eligible 
Univariate 
OR 
(95%CI) 
P 
Female 11,256 4128 23 0.6 0.2 1 (ref) 
Male 10,719 3084 38 1.2 0.4 2.227 
(1.324 – 
3.745) 
.003 
Total 21,975 7,212 61 0.8 0.3  
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6.2.3.4 Binomial logistic regression 
 
A binomial logistic regression was performed to understand whether a positive HBV test could 
be predicted based on participant age, country of birth and gender.  For the purpose of this 
analysis due to the small sample size, country of birth was categorised as either Asia Pacific or 
other.  Table 39 demonstrates the odds ratios and significance of the predictor variables.  Of 
the variables entered into the model, only male gender was statistically significant.  In this 
population, males were 2.209 times more likely to be HBsAg positive, 95% C.I (1.311-3.721) as 
shown in Table 39.  For both country of origin and the continuous variable age, 95% 
confidence intervals contain 1.0, therefore the association is not significant at the .05 
significance level. 
 
Table 39: Binomial logistic regression in HBsAg 
 
A binomial logistic regression using data collected from individuals with a positive HBsAg test.   
 
 
Independent 
variable 
B S.E Sig Exp(B) 95% CI for EXP (B) 
Lower Upper 
Age .004 .009 .666 1.004 .987 1.021 
Gender .792 .266 .003 2.209 1.311 3.721 
Country .508 .325 .118 1.661 .879 3.140 
Constant -5.678 .434 .000 .003   
 
 
6.2.4 Staging of disease in HepFree participants 
All participants with chronic viral hepatitis diagnosed through HepFree were invited to attend 
a diagnostic assessment with subsequent appointments for investigations in secondary care in 
order to stage the severity of their disease and to help guide management.  For participants 
with chronic HCV, staging was primarily performed using either transient elastography 
(Fibroscan®), a percutaneous ultrasound guided liver biopsy, or a combination of the two.  
For participants with chronic HBV, in addition to Fibroscan® and USS guided liver biopsy, 
disease activity was established by serum liver function testing and HBV VL analysis.  In HBV, 
active disease is defined as a HBV VL of more than 2000IU/mL in combination with an 
elevated ALT.   
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In the trial, one hundred percent of participants with chronic HCV attended both the 
diagnostic and disease staging assessment visits.  In the cohort of participants diagnosed with 
chronic HBV, 16 individuals (26%) were already known to secondary care and engaged with 
follow up and a further 7% did not engage with follow-up through the trial.  Results will 
therefore be presented for forty-one participants with a new diagnosis of chronic HBV that 
engaged with HepFree follow-up. 
 
Table 40: Baseline characteristics of participants with chronic HCV diagnosed through 
HepFree 
The baseline characteristics and fibrosis assessment outcomes for trial participants diagnosed 
with RNA positive chronic HCV. 
 
Gender 
(M/F) 
Age Country of origin HCV 
genotype 
Fibroscan® kPa 
(Metavir stage) 
Ishak  
fibrosis stage 
F 27 Pakistan 3 5.0 (0-1)  
F 29 Pakistan 3 4.2 (0-1) 1 
M 59 Czech Republic 1 48 (4)  
F 41 Pakistan 3  2 
F 70 Pakistan 3 8.4 (1-2)  
F 45 Pakistan 3 16.5 (4) 3 
F 51 Pakistan 1 3.6 (0-1)  
M 27 Pakistan 3  5 
M 46 Pakistan 3 4.8 (0-1) 1 
F 28 Pakistan 3 5.9 (0-1)  
M 35 Pakistan 3  2 
F 51 Pakistan 3 6.1 (0-1) 2 
F 82 Pakistan 3 13.1 (3-4)  
M 73 Pakistan 3  2 
M 39 Pakistan 3 10.8 (3)  
F 40 Pakistan 3 7.4 (1-2)  
F 37 Pakistan 3 6.5 (1)  
M 43 Pakistan 3 6.0 (0-1) 1 
F 37 Pakistan 3 5.8 (0-1) 1 
M 40 Pakistan 3 9.9 (3) 6 
F 38 Pakistan 3 6.1 (0-1)  
M 31 UK 1  2-3 
M 38 Pakistan 3 7.3 (1-2) 1-2 
M 37 Pakistan 3 7.4 (1-2) 2 
M 27 Pakistan 3 6.2 (0-1) 1 
 
 
In 20% (5/25) of cases diagnosed with chronic HCV through the HepFree trial there was 
evidence of advanced fibrosis on either transient elastography or percutaneous liver biopsy 
(eKPa 12.5, Metavir stage 4, Ishak stage 5/6).   
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Figure 33: Transient elastography assessment in HepFree participants with chronic HCV  
 
 
 
A scatter plot of participant age (x-axis) and transient elastography liver stiffness score (kPa) (y-axis) in HepFree 
participants with chronic HCV that underwent fibrosis assessment using Fibroscan®.  The horizontal red line at 
12.5kPa denotes cirrhosis.  In this scatter plot, no correlation was identified between participant age and severity of 
disease; Pearson correlation coefficient, r = 0.3841, n = 20, p = 0.0095.  Data from the one outlier kPa 48.0 was 
excluded from this figure. 
 
 
In the HepFree cohort of participants with chronic HCV no correlation was identified between 
participant age and severity of disease using transient elastography liver stiffness score. 
 
The severity of liver disease in different age groups of individuals with chronic HCV is 
displayed in Figure 34.  Liver disease severity was classified as mild, moderate and severe 
using the following criteria: 
 
Severity of liver disease Metavir fibrosis score 
Mild 0-1 
Moderate 2 
Severe ≥ 3 
 
Due to the small number of individuals identified through HepFree screening it is difficult to 
draw conclusions pertaining to the severity of disease and duration of infection.  In this 
cohort, mild disease was more frequently observed in individuals aged 18-30, individuals in 
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this age group also had evidence of severe fibrosis suggesting that long-term infection with 
the virus for more than twenty years is a risk factor for the development of cirrhosis. 
 
 
Figure 34: The severity of liver disease in individuals diagnosed with chronic HCV 
 
 
 
A column chart comparing participant age (grouped data, x-axis) and severity of liver disease, according to Metavir 
fibrosis score (frequency of diagnosis, y-axis) in individuals with RNA positive chronic HCV diagnosed through 
HepFree.  Mild disease was more frequently observed in individuals aged 18-30, however there were cases of severe 
fibrosis in this age group suggesting that long-term infection with the virus for more than twenty years is a risk factor 
for the development of cirrhosis. 
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Table 41: Baseline characteristics of participants with chronic HBV diagnosed through 
HepFree 
The baseline characteristics and fibrosis assessment outcomes for trial participants newly 
diagnosed with chronic HBV who attended for diagnostic assessment in secondary care. 
 
Gender 
(M/F) 
Age 
(yrs) 
Country of 
Birth 
HBV 
genotype 
eAg 
status 
 
HBV VL  
(IU/mL) 
ALT 
(IU/L) 
 
Fibroscan® 
kPa 
(Metavir 
stage) 
Treatment 
indicated 
M 46 Pakistan D1 Neg 1.1 x 10
3
 27 4.1 (0-1)  
M 22 UK D1 Pos 1.7 x 10
8
 92 4.6 (0-1) Y 
M 36 Pakistan  Neg 1.3 x 10
2
 23 4.9 (0-1)  
F 53 Lithiuania D1 Neg 3.2 x 10
2
 24 5.9 (0-1)  
M 34 Bangladesh D2 Neg 2.8 x 10
2
 44 5.8 (0-1)  
M 35 Gambia A1 Neg 4.7 x 10
2
 32 8.7 (2)  
M 55 Pakistan  Neg <20 62 11.4 (3)  
M 21 Pakistan D1 Neg 1.6 x 10
3
 32 5.6 (0-1)  
F 62 Pakistan  Neg <20 26 8.2 (2)  
F 48 Pakistan D1 Neg 6.3 x 10
2
 23 5.0 (0-1)  
M 48 Pakistan  Neg 10. x 10
2
 28 4.0 (0-1)  
M 58 Pakistan D1 Neg 3.4 x 10
3
 40 6.8 (0-1)  
F 27 Pakistan D1 Neg 3.4 x 10
3
 20 5.6 (0-1)  
M 63 Pakistan  Neg 1.3 x 10
2
 24 6.8 (0-1)  
M 47 Bangladesh D2 Neg 1.1 x 10
3
 23 5.4 (0-1)  
F 61 Pakistan  Neg 46 19 4.1 (0-1)  
M 60 Pakistan D1 Neg 2.0 x 10
2
 32 2.0 (0-1)  
F 67 Pakistan D1 Neg 1.2 x 10
3
 23 8.9 (2-3)  
F 52 India  Neg <20 18 4.9 (0-1)  
F 56 Pakistan D1 Neg 1.0 x 10
3
 21 4.1 (0-1)  
M 62 Pakistan  Neg 7.2 x 10
2
 22 4.5 (0-1)  
M 41 Pakistan D1 Neg 2.0 x 10
3
 21 3.3 (0-1)  
M 40 Pakistan  Neg 1.4 x 10
2
 21 7.8 (1-2)  
M 39 Pakistan  Neg 71 79 9.4 (2-3)  
M 48 Pakistan D1 Neg 7.5 x 10
2
 24 3.2 (0-1)  
M 28 Pakistan  Neg <20 54 4.0 (0-1)  
M 38 Pakistan  Neg 83 20 5.3 (0-1)  
M 42 Pakistan D1 Neg 1.5 x 10
3
 28 5.8 (1)  
M 42 Pakistan  Neg 27 34 12.6 (3) Y 
F 59 India D1 Neg 1.3 x 10
3
 23 4.2 (0-1)  
M 57 Pakistan  Neg 5.4 x 10
2
 21 6.4 (0-1)  
M 22 UK   Neg 4.9 x 10
2
 24 4.7 (0-1)  
M 25 UK   Neg 20 26 4.8 (0-1)  
F 45 Pakistan  Neg 2.9 x 10
2
 19 5.3 (0-1)  
F 44 Pakistan  Neg <20 18 3.3 (0-1)  
M 39 Ghana E Neg 1.6 x 10
3
 34 4.7 (0-1)  
F 32 Pakistan D1 Neg 6.1 x 10
3
 20 4.8 (0-1)  
M 83 Bangladesh  Neg <40 13 6.1 (0-1)  
M 33 Bangladesh D1 Neg 1.1 x 10
3
 36 7.8 (2)  
M 48 Poland A2 Neg 3.7 x 10
4
 53 10.1 (2-3) Y 
M 42 Pakistan D1 Neg 8.4 x 10
2
 21 5.4 (0-1)  
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In the cohort of newly diagnosed individuals with chronic HBV that attended for assessment, 
98% (40/41) had undergone seroconversion and were anti-HBe positive.  A genotype was 
available in 54% of cases (22/41).  In individuals with sufficient viral load to enable 
genotyping, the most prevalent genotype in this was D (46.3%).  This result was unsurprising 
given the high number of participants originating from countries in the group Asia Pacific.  
In 15% of cases (6/41) the VL was elevated over 2000IU/mL.  Of those participants with an 
elevated VL, 33% (2/6) also had an elevated ALT above the upper limit of normal (reference 
range 40IU/L) suggesting active disease requiring regular monitoring in addition to 
interpretation of the fibrosis score obtained from transient elastography or from USS guided 
liver biopsy to establish whether antiviral therapy would be required.  
 
 
Figure 35: Hepatitis B viral load and serum ALT measurement in individuals with chronic HBV  
 
 
 
 
A scatter plot of HBV viral load and serum ALT measurement in individuals with chronic HBV who attended for 
assessment.  No correlation was identified between HBV viral load and serum ALT, Pearson correlation coefficient, r = 
0.2521, n = 40, p = 0.117. 
 
No correlation was identified between HBV viral load and ALT measurement in individuals 
with chronic HBV in the HepFree cohort.  This demonstrates that serum ALT alone cannot be 
reliably used as a marker of activity in HBV.   
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Figure 36: Transient elastography assessment in HepFree participants with chronic HBV 
 
 
 
 
A scatter plot of participant age (x-axis) and transient elastography liver stiffness score (kPa) (y-axis) in HepFree 
participants with chronic HBV that underwent fibrosis assessment using Fibroscan®.  The horizontal red line at 12.5 
kPa denotes cirrhosis.  In this scatter plot, no correlation was identified between participant age and severity of 
disease using transient elastography liver stiffness score; Pearson correlation coefficient, r = 0.0857, n = 41, p = .5942. 
 
 
In this cohort of individuals with chronic HBV no correlation was identified between 
participant age and severity of disease using transient elastography liver stiffness score. 
 
 
According to EASL guidelines (32), treatment is indicated in individuals with chronic HBV that 
fulfil the following criteria: 
HBeAg positive HBV Anti-HBe positive HBV HBV associated cirrhosis 
HBV DNA >2.0 x10
3
IU/mL 
and/or ALT >ULN with 
histological evidence of 
moderate to severe disease 
on liver biopsy 
HBV DNA>2.0 x10
3
IU/mL 
and/or ALT>ULN with 
histological evidence of 
moderate to severe disease 
on liver biopsy 
Compensated  
Any detectable level of HBV 
DNA. 
Decompensated 
Any detectable level of HBV 
DNA. 
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Treatment was indicated in 5% of individuals that were diagnosed with chronic HBV in 
Bradford.  The relatively small number requiring treatment may be related to the ethnic 
profile of individuals attending for testing.  In Bradford, testing was predominantly performed 
in individuals of Pakistani origin, and D was the prevalent genotype identified in this group.  
Adverse clinical outcomes including the development of cirrhosis and/or HCC are more 
frequently associated with genotypes B and C, therefore the number of individuals tested 
through HepFree that require treatment may be higher in areas of the UK conducting the 
study where there are higher numbers of migrants residing that originate from other 
countries within Asia and Africa. 
 
6.3 Discussion 
 
In medicine, screening is a strategy employed within a population to identify the presence of 
an undiagnosed disease in individuals without signs or symptoms.  The aim of targeted testing 
in viral hepatitis is to identify individuals early, prior to the onset of complications that arise 
as a result of long-term infection enabling interventions to be performed that reduce 
morbidity and mortality associated with the disease.  HepFree trial results in Bradford have 
suggested that the prevalence of viral hepatitis is higher in immigrants residing in the UK 
compared to the indigenous population.  Analysis of the HepFree dataset identified a 
prevalence of viral hepatitis of 2.2%, with disease more commonly identified in individuals 
with a main spoken language other than English.  This result is particularly important for 
several reasons.  Firstly, it is well documented that language barriers can result in inadequate 
access to appropriate healthcare services by users.  In terms of the trial methodology, the use 
of letter invitations may have resulted in exclusion of individuals unable to speak and read 
English.   
 
The prevalence of viral hepatitis in immigrants attending for screening who were born in 
England (second generation) was low, with rates of detection comparable with the rates of 
infection in the non-immigrant population.  There is an argument therefore that future 
screening efforts that concentrate solely on first generation immigrants would be more 
beneficial.  Adapting the methodology of future screening trials to reflect this however may 
result in missed cases of infection.  It is feasible that children born to first generation migrants 
will spend prolonged periods of time overseas in countries where the risk of infection is much 
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greater, either visiting or caring for relatives and this group would therefore still be at an 
increased risk of acquiring the infection. 
 
Our results demonstrated that individuals that attended for testing through HepFree engaged 
with subsequent follow up.  One hundred percent of individuals with a positive anti-HCV test 
attended secondary care for diagnostic assessment.  Although the numbers of individuals 
recalled due to a positive test were low, it is an important finding as there would be little 
benefit in performing widespread screening strategies if the populations targeted were not 
motivated in engaging with follow-up and treatment if required. 
 
If long-term infection with viral hepatitis results in an increased burden of disease, the 
argument for widespread screening and early detection is strengthened.  In the HepFree 
cohort, twenty percent of individuals diagnosed with chronic HCV had evidence of significant 
fibrosis, defined as fibroscan liver stiffness score eKPa >12.5, METAVIR 4, Ishak fibrosis score 
of greater than or equal to 5.  In immigrant populations we suspect that in the majority of 
cases, viral hepatitis is acquired either vertically, or horizontally during the first few years of 
life.  In the small HepFree cohort with chronic HCV, no correlation was identified between 
age, and therefore presumed duration of infection and the degree of fibrosis observed.  One 
important finding that this analysis did identify though, was that there was evidence of 
advanced fibrosis in individuals infected with HCV and aged less than 30.  It is difficult in these 
cases to determine whether the advanced degree of fibrosis was solely caused by HCV virus 
infection or a combination of factors, but this finding does support pre-existing research on 
fibrosis progression to cirrhosis after twenty years of infection (162, 169).   
 
For the cohort of individuals diagnosed with HBV through HepFree, although relatively few 
individuals fulfilled the criteria for treatment, identifying the disease is beneficial for several 
reasons.  Detection of the disease enables monitoring to be performed and this continued 
monitoring of viral load, liver function tests and degree of fibrosis enables adverse prognostic 
markers to be identified and modified by commencing antiviral therapy.   In addition to this, 
disease detection enables contact tracing and screening of relatives and household contacts 
of the affected individual to be performed.  For relatives and contacts that have negative 
contact tracing tests, a course of vaccinations can then be offered to reduce the risk of 
subsequent spread.  This is especially important as currently in the UK, universal vaccination 
against HBV has not been adopted.   
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7. HepFree sub-study results 
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7.1 Introduction 
 
Despite the traditional view that HCV is asymptomatic until an individual develops 
complications in the form of chronic liver disease, there is an increasing body of evidence 
exploring symptoms in individuals infected with the virus in the absence of cirrhosis.  The 
major limitation of much of the pre-existing research is that it has been conducted in 
individuals aware of their diagnosis, and therefore results may be hindered by recall bias and 
the Hawthorne effect.   
 
Anecdotal observations made of individuals infected with chronic HCV in an outpatient setting 
prompted me to design the Hep-Free observational sub-study.  This was a retrospective case 
control study designed to investigate the impact of chronic HCV on healthcare utilisation.  The 
sub-study allowed us to explore symptoms and episodes of care arising as a result of those 
symptoms in individuals who were not at that time aware if their hepatitis C status. 
 
We hypothesised that compared to healthy individuals with no history of viral hepatitis 
infection, individuals with undiagnosed chronic HCV would have a greater number of 
attendances to primary care as a result of symptoms occurring secondary to the virus.  We 
further hypothesised that evidence of prior infection with HCV, but no evidence of ongoing or 
active infection, would not result in greater use of primary care resources compared to 
healthy individuals.  
 
7.2 Methods 
 
With supervision from the HepFree trial CI, I designed and wrote the protocol for the sub-
study and completed the IRAS form, a copy of the protocol is available in Appendix 14.  Sub-
study documents were reviewed by the Bart’s Health NHS Trust Research Development team, 
Joint Research Management Office (JRMO), Queen Mary Innovation Centre, Lower Ground 
Floor, 5 Walden Street, London, E1 2EF and subsequently underwent internal peer review at 
the Blizard Institute, 4 Newark Street, London, City of London, E1 2AT.  Provisional 
sponsorship was sought from the Joint Research Management Office for Bart’s Health NHS 
Trust and Queen Mary University London, Mile End Road, London, E1 4NS.   Once sponsorship 
had been agreed, trial documents were submitted for central ethics review to the London-
West London & GTAC Research Ethics Committee, The Old Chapel, Royal Standard Place, 
Nottingham, NG1 6FS.  Following a committee meeting at the Hammersmith Hospital, 
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London, W12 0NN, central ethics approval was granted and Queen Mary University London 
subsequently provided full sponsorship.  Once all agreements were in place, data collection 
began in all practices performing targeted testing in Bradford. 
 
 
The sub-study included all individuals with a positive anti-HCV test that had consented to 
participate in the HepFree trial in Bradford between March 2014 and February 2016.  
Participants with a positive anti-HCV test (the cases) were divided into two groups dependent 
on the outcome of the RNA test.  Controls were matched to cases using a 1:1 ratio and 
comprised of individuals that had consented to the HepFree trial and tested negative for both 
HBV and HCV. 
 
Controls were identified by using the trial screening log and matched to cases using the 
following criteria:  
 Age 
 Gender 
 Ethnicity 
 Country of birth 
 Duration of time residing in the UK. 
 
In the event of more than one control being identified, the trial participant to be included was 
selected at random using Microsoft EXCEL random function. 
 
The following cases were excluded from analysis: 
 Participants with a positive test that failed to engage with subsequent trial related 
activities, also known as lost to follow up. 
 Participants with anti-HCV positive status that had previously received anti-viral 
therapy for the treatment of chronic HCV. 
 Participants that withdrew consent to continue in the HepFree trial. 
 Participants that died during the trial follow-up period. 
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For the case-control study, participants were divided into four groups for analysis as follows: 
 Group 1: Chronic HCV: anti-HCV positive, RNA positive. 
 Group 2: Group 1 matched controls. 
 Group 3: Evidence of previous HCV with spontaneous clearance: anti-HCV positive, 
RNA negative. 
 Group 4: Group 3 matched controls. 
 
 
Demographic data, in addition to clinical information of year on year GP attendances, was 
collected from SystmOne (S1).  As described previously, S1 is a clinical computer system 
containing electronic patient records used in primary care.  Data on each attendance was 
collected from the point of arrival in the UK, or from 1
st
 January 2005 for individuals that had 
resided in the UK prior to this date.   
 
 
During data collection, the clinical fellow (myself) reviewed each clinical encounter that had 
been recorded within the patient journal on S1.  For the purposes of data collection,  the 
diagnosis, or outcome of the clincal encounter was then coded, to enable analysis,using the 
Wonca Internation Classification Committee, International Classification of Primary Care 
Second Edition (ICPC), available in Appendix 15.  This classification contains seventeen 
categories and was selected for use as it enables classification of the patient’s reason for 
encounter, the problems or diagnoses that are present, in addition to general health care 
interventions that are routinely performed in primary care.  The ICPC has been accepted 
within the  WHO Family of International Classifications.   
 
 
Descriptive analysis was carried out in Microsoft EXCEL and I was the sole contributor to this 
section of the results.  Statistical analysis using the data was performed by an independent 
statistician with my assistance.  Poisson and negative binomial based generalised linear 
models were fitted in STATA 14 using Generalised Estimating Equations with an 
autoregressive correlation matrix of order 1 (AR1).  Relative risks were estimated using the 
univariate negative binomial model. 
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Statistical considerations 
 
The HepFree sub-study was an exploratory study performed using individuals identified 
through the main HepFree trial.  Given the small numbers of participants with a positive 
screening test for HCV, the sub-study was clearly underpowered and therefore all results 
obtained need to be interpreted with great caution. 
 
An independent statistician was consulted with regards to a power calculation.  They 
concluded that power could be calculated based on the number of appointments per year for 
each study group.  The total number of appointments over the course of the study, per group, 
should converge to a normally distributed variable by the central limit theorem.  Therefore 
the mean appointments per year also does.  The size of N required for convergence is not 
known. 
In Group 1, N=73.3 with sd = 52.7 and in Group 2, N=61.6 with sd = 46.1. 
Using the inbuilt power function in STATA 15 (STATAcorp, college station, TX USA) we find a 
power of 12.3% assuming an alpha level of 0.05, with a required sample for 80% power of 283 
per group and a required sample for 90% power of 377 per group.     
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7.3 Results 
There were 108 participants included in the analysis; 54 individuals with either chronic HCV or 
evidence of previous infection with spontaneous eradication, and 54 healthy controls, 
individuals with no evidence of past or current infection with viral hepatitis.  Tables 42-45 
contain descriptors for participants in each group including age, gender, ethnicity, cumulative 
number of visits, interval of follow up and average number of visits per year for each 
participant.  The column chart in Figure 37 demonstrates the number of participants by age 
group in each of the groups included in the analysis.    
 
There were 31 participants in group 1; the cohort identified to have chronic HCV through 
testing in the HepFree trial.  The cohort consisted of 18 females; median age 41, SD 15.6 and 
13 males; median age 39, SD 11.3.  96% were first generation immigrants of Pakistani origin, 
and 3% (1/31) was second generation of British-Pakistani ethnicity.  In this cohort, the total 
number of visits in 303 years of follow-up was 1622; 1150 appointments in 185 years of 
follow-up for females compared to 472 in 118 years of follow-up in males. 
 
 
The cohort of healthy controls selected at random from all HepFree participants that fulfilled 
the matching criteria consisted of 18 females; median age 41, SD 15.7 and 13 males; median 
age 38, SD 11.4.  The ethnic composition of group 2 was identical to that of group 1.  In this 
cohort, the total number of appointments in 297 years of follow-up was 1569; 1158 
appointments in 185 years of follow-up for females and 411 in 112 years for males. 
 
 
Group 3 consisted of individuals with evidence of previous infection with HCV associated with 
spontaneous clearance.  There were 23 participants in group 3; 18 females; median age 46.5, 
SD 11.2 and 5 males; median age 43, SD 11.8.  The total number of years of follow-up was 
210, and the total number of appointments 1686.  The cumulative number of visits in female 
participants was 1417, in 159 years of follow-up compared to 269 appointments over 51 years 
in males.  The ethnic composition of this group was marginally more diverse; 78% were of 
Pakistani origin, 9% (2/23) were second generation British Pakistani and the remaining 
participants were of Bangladeshi, Black African and Polish descent. 
 
 
The healthy controls in group 4 were closely matched to group 3; 18 females; median age 
46.5, SD 11 and 5 males; median age 41, SD 12.1.  In 208 years of follow-up, participants had 
accessed services in primary care on 1417 occasions; females 979 in 158 years of follow-up 
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and males, 438 in 50 years of follow-up.  Due to significant difficulties in matching participants 
using the criteria set out in Materials and Methods, the ethnic composition of group 4 varied 
slightly from group 3; 13% (3/23) of participants were of British Pakistani ethnic origin. 
 
 
In summary, the majority of the total study population were of Pakistani origin, and female; 
88% and 65% respectively.   The mean age of participants in groups 1 and 2 was lower than in 
groups 3 and 4; 43 years versus 48 years (Table 46).  The breakdown of participants included 
in the sub-study by gender and age group is demonstrated in Figure 38.   
 
 
Participants in groups 3 and 4 provided 210 and 208 patient years of data compared to 303 
and 297 for groups 1 and 2.  The number of attendances observed per patient was higher in 
groups 3 and 4 as demonstrated in the pie chart in Figure 39. The total number of recorded 
appointments per patient ranged from 0-42 in a single year and from 2-230 overall.  Follow up 
for participants ranged from 1-12 years. 
 
 
Expected trends in the usage of GP services were seen in all age groups and for female 
patients compared to males.  The year on year attendance was proportionally increased for 
age groups 41-65 and 65 years and over when compared to the baseline age group 18-40 
(Table 47).  The data shows that attendance for people of Bangladeshi ethnicity was greater 
than of Pakistani ethnicity, with Bangladeshi patients having mean usages of 144.5 (Table 48).  
It is important to note however the very small sample size on which this comparison was 
made, Bangladeshi patients n=2. 
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Table 42: HepFree sub-study group 1 participant characteristics 
 
Table 42 contains descriptors for participants in group 1 (individuals with chronic HCV) 
including age, gender, ethnicity, cumulative number of visits, interval of follow up and 
average number of visits per year. 
 
 
Participant Gender Age Ethnicity Total no. 
of visits to 
the GP 
Years of 
follow-up 
Average 
visits/yr 
1 F 33 Pak 85 11 7.7 
2 F 42 Pak 116 10 11.6 
3 F 40 Pak 134 11 12.2 
4 F 83 Pak 115 10 11.5 
5 F 47 Pak 35 11 3.2 
6 M 48 Pak 51 11 4.6 
7 F 51 Pak 55 10 5.5 
8 F 71 Brit-Pak 103 10 10.3 
9 M 32 Pak 11 11 1.0 
10 F 46 Pak 36 10 3.6 
11 F 51 Pak 111 10 11.1 
12 F 30 Pak 65 10 6.5 
13 M 73 Pak 40 11 3.6 
14 M 41 Pak 33 11 3.0 
15 F 29 Pak 48 10 4.8 
16 M 47 Pak 160 10 16 
17 M 37 Pak 64 11 5.8 
18 M 43 Pak 27 11 2.5 
19 F 38 Pak 40 11 3.6 
20 F 23 Pak 13 11 1.2 
21 F 49 Pak 27 11 2.5 
22 F 37 Pak 35 11 3.2 
23 F 28 Pak 56 9 6.2 
24 F 38 Pak 35 8 4.4 
25 M 35 Pak 28 8 3.5 
26 M 40 Pak 10 9 1.1 
27 M 27 Pak 21 2 10.5 
28 F 69 Pak 41 11 3.7 
29 M 39 Pak 3 6 0.5 
30 M 27 Pak 2 5 0.4 
31 M 36 Pak 22 12 1.8 
Total 31   1622 303 5.3 
Abbreviations- Pak: Pakistani ethnic origin; Brit-Pak: British Pakistani ethnic origin   
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Table 43: HepFree sub-study group 2 participant characteristics 
 
Table 43 contains descriptors for participants in group 2 (healthy controls matched to group 
1) including age, gender, ethnicity, cumulative number of visits, interval of follow up and 
average number of visits per year. 
 
 
 
Participant Gender Age Ethnicity Total no. 
of visits to 
the GP 
Years of 
follow-up 
Average 
visits/yr 
32 F 32 Pak 60 10 6.0 
33 F 40 Pak 17 10 1.7 
34 F 83 Pak 178 11 16.2 
35 F 52 Pak 63 10 6.3 
36 F 71 Pak 84 10 8.4 
37 M 32 Brit-Pak 27 11 2.5 
38 F 46 Pak 84 11 7.6 
39 F 30 Pak 36 10 3.6 
40 M 40 Pak 22 11 2.0 
41 F 29 Pak 34 11 3.1 
42 M 47 Pak 50 10 5.0 
43 M 36 Pak 44 10 4.4 
44 F 38 Pak 55 11 5.0 
45 F 50 Pak 37 11 3.4 
46 F 36 Pak 46 10 4.6 
47 F 28 Pak 105 10 10.5 
48 F 38 Pak 20 7 2.9 
49 M 34 Pak 21 8 2.6 
50 M 39 Pak 32 7 4.6 
51 M 27 Pak 6 2 3.0 
52 F 47 Pak 84 11 7.6 
53 F 22 Pak 46 10 4.6 
54 M 47 Pak 18 11 1.6 
55 F 42 Pak 73 11 6.6 
56 F 51 Pak 28 11 2.5 
57 F 68 Pak 108 10 10.8 
58 M 43 Pak 31 10 3.1 
59 M 74 Pak 112 10 11.2 
60 M 38 Pak 13 5 2.6 
61 M 28 Pak 16 6 2.7 
62 M 36 Pak 19 11 1.7 
Total 31   1569 297 5.3 
Abbreviations- Pak: Pakistani ethnic origin; Brit-Pak: British Pakistani ethnic origin   
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Table 44: HepFree sub-study group 3 participant characteristics 
 
Table 44 contains descriptors for participants in group 3 (spontaneous clearance of HCV) 
including age, gender, ethnicity, cumulative number of visits, interval of follow up and 
average number of visits per year. 
 
 
Participant Gender Age Ethnicity Total no. 
of visits 
to the GP 
Years of 
follow-up 
Average 
visits/yr 
63 F 33 Pak 29 10 2.9 
64 F 53 Pak 55 10 5.5 
65 F 71 Pak 176 10 17.6 
66 F 38 Brit-Pak 88 10 8.8 
67 M 58 Pak 92 11 8.4 
68 M 61 Bangladeshi 59 11 5.4 
69 F 44 Pak 60 10 6.0 
70 F 50 Pak 126 10 12.6 
71 F 37 Pak 91 10 9.1 
72 F 45 Pak 42 11 3.8 
73 F 44 Pak 133 10 13.3 
74 F 50 Pak 216 10 21.6 
75 F 62 Pak 117 10 11.7 
76 F 73 Pak 47 10 4.7 
77 M 38 Pak 15 7 2.1 
78 F 40 Pak 3 1 3.0 
79 F 44 Black African 31 5 6.2 
80 M 43 Polish 46 10 4.6 
81 F 56 Pak 42 8 5.3 
82 F 48 Pak 67 11 6.1 
83 F 35 Pak 87 11 7.9 
84 M 30 Brit-Pak 57 12 4.8 
85 F 59 Pak 7 2 3.5 
Total 23   1686 210 8.0 
Abbreviations- Pak: Pakistani ethnic origin; Brit-Pak: British Pakistani ethnic origin   
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Table 45: HepFree sub-study group 4 participant characteristics 
 
Table 45 contains descriptors for participants in group 2 (healthy controls matched to group 
3) including age, gender, ethnicity, cumulative number of visits, interval of follow up and 
average number of visits per year. 
 
 
 
Participant Gender Age Ethnicity Total no. 
of visits 
to the GP 
Years of 
follow-up 
Average 
visits/yr 
86 F 34 Pak 51 10 5.1 
87 F 53 Pak 51 10 5.1 
88 F 38 Brit-Pak 43 10 4.3 
89 F 45 Pak 33 10 3.3 
90 F 50 Pak 61 10 6.1 
91 F 37 Pak 43 11 3.9 
92 F 44 Pak 102 10 10.2 
93 F 49 Pak 63 10 6.3 
94 F 72 Pak 90 10 9.0 
95 M 39 Pak 80 8 10.0 
96 F 40 Pak 2 1 2.0 
97 M 61 Bangladeshi 230 11 20.9 
98 F 71 Pak 108 10 10.8 
99 M 58 Pak 42 11 3.8 
100 F 61 Pak 47 10 4.7 
101 F 54 Pak 42 8 5.3 
102 F 46 Pak 85 11 7.7 
103 F 47 Pak 68 10 6.8 
104 F 41 Black African 10 5 2.0 
105 F 35 Brit-Pak 74 10 7.4 
106 M 41 Polish 41 10 4.1 
107 M 29 Brit-Pak 45 10 4.5 
108 F 59 Pak 6 2 3.0 
Total 23   1417 208 6.3 
Abbreviations- Pak: Pakistani ethnic origin; Brit-Pak: British Pakistani ethnic origin   
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Table 46: Descriptive analysis of case control participants 
 
 
The characteristics of cases and controls selected for the HepFree sub-study.  The majority of 
the study population were female 66.67% versus 33.33%.   The mean age of participants in 
groups 1 and 2 was lower than in groups 3 and 4; 43 years versus 48 years.  
 
 
 
 
 
 
Table 47: GP usage by age and disease status 
 
 
A table of GP services usage by individuals in each age group.  There was an increased use of 
services by individuals of advancing age and by females compared to males. 
 
 
 No. of pts (%) No. of appointments per pt (No. of patients) 
Appointments 
per patient by 
age group 
(no. patients) 
Male Female Group 1 Group 2 Group 3 Group 4 
18-40 21 (19.4) 28 (25.9) 39.5 (17) 34.4 (18) 52.9 (7) 48.3 (7) 
41-65 13 (12.0) 34 (31.5) 65.1 (10) 52.0 (9) 78.1 (14) 62.9 (14) 
65 and over 2 (1.9) 10 (9.3) 74.8 (4) 120.5 (4) 111.5 (2) 99 (2) 
Abbreviations – No.: number; pt: patient 
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Table 48: GP usage by ethnic group 
 
 
GP service usage by individuals included in the sub-study according to ethnicity.  Individuals of 
Bangladeshi ethnicity accessed GP services more frequently compared to all other ethnicities.  
Note small sample size; Bangladeshi patients n=2. 
 
 
 
 
 
 
 
  
 226 
 
 
Figure 37: The ages and disease status of participants included in the sub-study 
 
In the following Figures, the definitions of the groups are listed below: 
 Group 1: Chronic HCV: anti-HCV positive, RNA positive 
 Group 2: Matched healthy controls for Group 1. 
 Group 3: Evidence of previous HCV: anti-HCV positive, RNA negative. 
 Group 4: Matched healthy controls for Group 3. 
 
 
A column chart detailing the ages of participants included within the four groups of the sub-study.  Cases and 
controls between groups 1 and 2, and 3 and 4 were closely matched in terms of age.    
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Figure 38: The range of ages and genders of participants included in the sub-study 
 
 
 
 
A column chart detailing the ages and genders of participants included in the sub-study.  The small sample size of 
men over the age of 65 makes it difficult to draw any conclusions about healthcare utilisation in this group.  
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Figure 39: GP service usage by each sub-study group 
 
 
 
 
 
 
A pie-chart of GP attendances by each group included in the sub-study.  The number of attendances observed per 
patient was higher in groups 3 and 4 (anti-HCV positive, RNA negative and controls) compared to groups 1 and 2 
(RNA positive chronic HCV and controls). 
 
 
 
Details pertaining to each episode of care for all male and female participants included in the 
sub-study are demonstrated in Tables 49 and 50 and a column chart displaying the cumulative 
number of appointments for each ICPC category is shown in Figure 40.  Independent of 
gender and disease status, attendance for a process or procedure was the most commonly 
coded reason for an episode of care; 25.6% of all attendances in men were for this indication 
and 23.8% of attendances in women. 
 
 
Attendances related to the musculoskeletal system were high in all cohorts.  In the HCV 
infected cohort, attendance with a musculoskeletal system related problem was the second 
most common reason for attendance in both males and females; 17.8% of attendances and 
13.0% of attendances respectively.  Attendances for this indication in the HCV infected 
cohorts were slightly higher than in the healthy control groups; 15.8% and 12.1%, but this was 
non-significant, X
2
 (1) = 1.13, p=.288.   A high number of attendances for this indication were 
also observed in the previously infected HCV cohort in both males and females; 13.7% and 
16.1% respectively.  
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In the HCV infected male cohort, 17.2% of attendances were coded as endocrine related, 
compared to 1.0% in the healthy control group.  Attendances for this reason were 
significantly higher in HCV infected males compared to those with evidence of previous 
infection with spontaneous clearance; X
2
 (1) = 25.2, p=<.001. 
 
 
Episodes of care relating to pregnancy, child-bearing and family planning were more 
frequently observed in the HCV infected cohort and their matched healthy controls, 
compared to individuals with evidence of previous infection and their controls; 4.8% of 
attendances versus 2.7%.  This difference is likely to be related to the mean ages of the two 
sets of cohorts in the comparison. 
 
 
In females, presentations with psychological complaints occurred more frequently in healthy 
control participants compared to individuals with undiagnosed chronic HCV; 4.8% versus 
2.5%. 
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Table 49: ICPC coded attendance outcomes for male participants 
 
Details of each episode of care in male participants included in the sub-study, coded using the 
ICPC.   Healthcare utilisation by males in group 4 (healthy controls matched with group 3) was 
far greater; total number of attendances 438 versus 269, and individuals in this group 
frequently presented with complaints related to the digestive system 68 versus 18, and 
respiratory system 77 versus 29.  17% of attendances in individuals with chronic HCV related 
to the endocrine system.   
 
 Group 1 Group 2 Group 3 Group 4 
Total number of males, N=36 
Total number of attendances: 1590 
13 13 5 5 
472 411 269 438 
ICPC code 
Process codes 94 111 74 128 
General and unspecified 13 10 7 8 
Blood, blood forming organs and immune 
mechanism 
0 3 0 2 
Digestive 39 36 18 68 
Eye 3 1 1 2 
Ear 8 12 3 10 
Cardiovascular 0 10 22 6 
Musculoskeletal 84 65 37 56 
Neurological 42 17 6 6 
Psychological 7 6 15 5 
Respiratory 42 54 29 77 
Skin 51 59 37 26 
Endocrine/metabolic and nutritional 81 4 12 33 
Urological 3 11 3 5 
Pregnancy, childbearing, family planning 0 0 0 0 
Female genital 0 0 0 0 
Male genital 5 12 5 6 
Social problems 0 0 0 0 
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Table 50: ICPC coded attendance outcomes for female participants 
 
 
Details of each episode of care in female participants included in the sub-study, coded using 
the ICPC.   The total number of attendances by females in groups 1 and 2 were very similar, 
1150 versus 1158.  Attendances to primary care for procedures were high in all groups 
independent of disease status, as were attendances for disorders relating to the 
musculoskeletal system, digestive system and respiratory system.  
 
 
 
 Group 1 Group 2 Group 3 Group 4 
Total number of females, N=72 
Total number of attendances: 4704 
13 13 5 5 
1150 1158 1417 979 
ICPC code 
Process codes 312 255 326 226 
General and unspecified 54 41 76 54 
Blood, blood forming organs and immune 
mechanism 
11 13 7 5 
Digestive 110 88 171 113 
Eye 9 24 18 8 
Ear 31 49 40 11 
Cardiovascular 15 18 26 6 
Musculoskeletal 150 141 228 122 
Neurological 41 61 52 23 
Psychological 29 56 30 27 
Respiratory 115 117 111 126 
Skin 70 92 101 64 
Endocrine/metabolic and nutritional 50 33 83 28 
Urological 23 55 51 38 
Pregnancy, childbearing, family planning 55 56 27 38 
Female genital 73 58 70 90 
Male genital 0 0 0 0 
Social problems 2 1 0 0 
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Figure 40: ICPC category for each episode of care according to disease status  
 
 
 
 
A column chart detailing the frequency of attendances attributed to each ICPC category in the four groups of 
participants included in the sub-study.  As demonstrated in Tables 49 and 50, episodes of care relating to a 
process/procedure been performed were high, independent of disease status.    
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Figure 41: Time series plots of attendances for selected patients 
 
Figure 41 contains time series plots of attendances for participants included in the HepFree 
sub-study, selected at random using the random function within EXCEL.  No discernible 
pattern was identified.   
 
 
 
 
 
The year-on-year attendance was proportionally increased for age groups 41-65 and 65 and 
over compared to the baseline of age 18-40 (Table 51), for female patients compared to male, 
for Bangladeshi ethnicity vs Pakistani (limited data), and for anti-HCV positive, RNA negative 
versus control patients.  95% Confidence intervals for these estimates that do not include the 
value 1 might be considered statistically significant at the 5% level. 
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7.4 Regression model fitting 
 
Plots of the participant level variance vs mean (appointments per year) suggest that no single 
value of k adequately expresses the relationship var ~mean
k 
for this data (Figure 42).  Poisson 
GEE models including the covariates of age, ethnicity, gender and group (pairwise 1 vs 2, 3 vs 
4) showed a dispersion parameter of ~3.9.   
Poisson GEE regression models therefore show over dispersion.  Negative binomial models 
(dispersion parameter 0.6) with all fitted covariates and robust standard errors (Table 52) 
showed that anti-HCV positive participants had 24% more visits to their GP year-on-year 
when adjusted for other available factors.  This difference was not statistically significant at 
the 5% level.  The statistical significance of these results was found to be sensitive to the 
choice of correlation matrix although convergence problems occur. 
 
Figure 42: A plot of the patient level variance versus mean number of appointments per year 
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Table 51: Cluster adjusted proportional differences in attendance estimates for model 
parameters. 
 
Appointments per year Relative risk 
estimate 
95% confidence interval 
  Lower estimate Upper estimate 
Age group baseline for comparison = 18-40 
Age 41-65 10480 1.137 1.926 
Age 65 and over 2.124 1.564 2.884 
Ethnicity: Compared to Pakistani  
British Pakistani 0.785 0.502 1.229 
Bangladeshi 1.984 0.829 4.744 
Black African 0.653 0.353 1.208 
Polish 0.690 0.598 0.796 
Gender : Compared to male  
Female 1.487 1.065 2.0741 
Group  
Group 3 (HCV Ab pos) 
vs Group 4 (Control 
patients) 
1.217 0.842 1.758 
Group 1 (HCV RNA pos) 
vs Group 2 (control 
patients) 
1.000 - - 
 
 
Table 52: Parameter estimates for Generalised Estimate Equation model fitting, expressed as 
relative risk. 
 
Dependent variable 
=number of 
appointments per 
year per participant 
Parameter 
estimate 
Standard 
Error 
P value 95% CI 
lower 
estimate 
95% CI 
upper 
estimate 
Age group 
Baseline is 18-40 
40-65 1.26 0.25 0.25 0.85 1.87 
65 and over 1.71 0.49 0.06 0.98 2.99 
Gender 
Baseline is male. 
Female 1.19 0.26 0.42 0.78 1.82 
Ethnicity 
Baseline is Pakistani 
Brit Pakistani 1.05 0.28 0.86 0.62 1.78 
Bangladeshi 2.14 0.78 0.04 1.05 4.38 
Black African 0.45 0.21 0.09 0.18 1.14 
Polish 0.64 0.25 0.27 0.30 1.40 
Group 3: HCV Ab 
+ve group 
1.24 0.17 0.124 0.94 1.63 
Constant term 4.49 1.15 0.00 2.72 7.41 
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7.5 Discussion 
The HepFree sub-study was designed to explore the impact of undiagnosed chronic HCV on 
utilisation of healthcare resources.  Given the extensive body of research that already exists, 
we hypothesised that individuals with chronic HCV will access healthcare services in primary 
care more frequently than uninfected ‘healthy’ individuals that have similar characteristics. 
 
Previous research, in addition to identifying that irrespective of the degree of histological 
severity, individuals with HCV feel unwell, has made an association between SVR and 
symptomatic relief in turn resulting in an increased QOL.  With this in mind, in the sub-study 
we included a cohort of individuals with evidence of previous infection with HCV associated 
with spontaneous viral clearance and compared healthcare usage in this group with healthy 
individuals. 
 
The sub-study was a retrospective case-control design.  Information pertaining to previous 
attendances was collected from individual patient electronic records stored on clinical 
computer systems within GPs.  The demography of the sub-study population was largely 
reflective of that seen in the main HepFree trial.  Overall, 67% of participants were female and 
of the total study population, 88% were first generation immigrants of Pakistani origin.  In the 
HepFree trial, testing rates in this ethnic group were far higher than others, with 37% of 
eligible and invited individuals consenting for testing.  
 
As a proportion of the total number of males included in the sub-study, nearly three quarters 
were in cohort 1, comprising 42% of the cohort population, compared to in cohort 3 where 
males only made up 22% of the population.  This finding is likely to be related to the impact of 
gender on spontaneous viral clearance.   
 
The number of attendances observed in cohorts 3 and 4; spontaneous viral clearance and 
healthy controls were higher than in cohorts 1 and 2; chronic HCV and matched healthy 
controls.  This finding may be explained by the increase in the median ages of the two sets of 
cohorts being compared, especially as year on year attendance in the study was found to be 
increased for age groups 41-65 and 65 years and older compared to the baseline group aged 
18-40.  This observation is consistent with the theory that migrants are usually both young 
and healthy on arrival but their health deteriorates with increasing duration of residence.  
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Although the majority of migrants have both lower socioeconomic status as well as poorer 
access to healthcare in their country of birth, on arrival in their host nation, migrants are 
usually relatively healthy and this finding is attributed to the process of self-selection that 
occurs prior to migration.  However, likely as a consequence of both cultural and behavioural 
changes in the host country, migrant heath deteriorates in relation to duration of stay 
(336,337). 
 
Due to the small number of non-Pakistani individuals included in the sub-study it is difficult to 
draw any meaningful conclusions relating to healthcare usage according to ethnicity. 
 
In all cohorts examined in the sub-study, attendance rates were higher in females compared 
to males and there are several possible explanations for this finding.  Firstly, women are 
invited to participate in more preventative screening strategies compared to males, and most 
of these take place in primary care.  The second reason may be that females often require 
more primary care appointments for consultations related to family planning, contraception 
and pregnancy.  Thirdly, migrant females tend to have a lower self-perception of their general 
health compared to native females and males of all ethnicities.  Finally, and perhaps most 
pertinent to the characteristics of the cohorts being studied is the psychological impact of 
immigration on health perception and health related anxiety.  Loneliness and isolation is 
prevalent amongst immigrant populations, and is probably increased in female immigrants.  
Environmental and cultural differences make it difficult for immigrants to settle into 
communities and this is often made worse by a language barrier.  Upon migrating, individuals 
are separated from families and therefore support networks, and are often responsible for 
raising the children due to work commitments of male immigrants.  This combination of 
loneliness and isolation can result in depression and possible somatisation.  A case-control 
study exploring the characteristics of frequent attenders found that low educational 
qualifications and a poor QOL were associated with healthcare usage (338). 
 
Independent of gender and disease status, attendances for a process or procedure were the 
most commonly coded reasons for an episode of care, with nearly one quarter of all 
attendances being for this indication in both males and females. 
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Of particular interest, because of the findings of previous research was the frequency of 
attendances for problems related to the musculoskeletal system.  Attendances for MSK 
problems were prevalent in all cohorts.  In cohort 1, in both males and females, attendances 
for this indication were the second most common reason to consult a primary care 
practitioner. In the HCV infected cohort, attendances for this indication occurred slightly more 
frequently than in the non-infected cohort, but this was non-significant, X
2
 (1) = 1.13, p=.288.   
 
 
The HepFree sub-study failed to identify an increase in healthcare usage in cohorts of 
individuals with chronic HCV compared to age and sex matched healthy controls.  Possible 
reasons for this are discussed in detail in 8.6 HepFree sub-study discussion. 
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8. HepFree discussion 
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8.1 Introduction 
The HepFree trial was designed to determine whether a universal screening programme for 
viral hepatitis should be designed and offered to first and second generation immigrants living 
in England. My role in this national study was to develop and manage the Bradford site.  In 
this thesis I have presented the work that I completed in Bradford in addition to my own 
analysis of the Bradford data. This analysis will be used to inform and develop the analysis of 
the entire study.  In addition I present work from my independent sub-study within the HCV 
cohort.   
 
The study had three broad aims; firstly to examine the feasibility and acceptability of targeted 
testing for viral hepatitis in first and second generation immigrants in primary care, using pre-
existing databases to identify the target population.  The second aim was to establish the 
most effective method of inviting immigrants to attend for testing and finally to gain 
information on the prevalence of viral hepatitis in immigrant populations living in specific 
locations in England.  A better understanding of how to identify, approach and engage ethnic 
minority groups that are at risk of viral hepatitis will help us to successfully diagnose and treat 
those infected individuals.   
 
Currently, for HCV, the end goal of testing and identification of infected individuals is 
treatment with subsequent viral eradication, otherwise known as SVR.  For HBV, the end goal 
of testing is identification of those individuals at risk of HBV associated complications 
including HCC and to commence treatment in those individuals.   
 
At the time of inception, there were no known active studies that were identifying their target 
population using demographic data stored within electronic medical records in primary care, 
nor had widespread case-finding for viral hepatitis in first and second generation immigrants 
using letter invitation been performed in primary care before. The strengths of this study 
were the large scale of the trial with engagement from diverse regions within England and the 
major weakness with the study was the rapidly changing environment (both in NHS systems 
and structures and the development of new drugs). 
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8.2 Review of the Bradford case-finding results 
At the point that data was collected to produce this thesis, ten practices had completed 
eighteen months of targeted testing, and data from those practices was included in the 
analysis.  A total of 7,302 eligible participants had participated in the trial, representing a 
testing rate of 35.7% of the total eligible population that had received an invitation to 
participate.  The study population consisted of 4173 (57.1%) females and 3123 (42.8%) males.  
As a proportion of the total eligible population, testing occurred in 37.1% of females and 29% 
of males.   
 
Attendance and engagement in HepFree was lower than attendance at pre-existing national 
screening programmes in England, but was higher than previous European viral hepatitis 
case-finding projects conducted in immigrant populations. 
 
Attendance data for national screening programmes in the UK is presented as screening 
coverage.  This is defined as the percent of the population that are eligible for screening at 
any given point in time that have been screened adequately within the specified period set 
out by the screening programme.  In 2014/15, screening coverage rates for breast cancer, 
cervical cancer and bowel cancer were 75.1%, 73.5% and 58.2% respectively.  These figures 
are considerably higher than the observed testing rates in our trial.  Difficulty arises however 
in attempting to compare screening rates for these pre-existing screening programmes with 
HepFree, mainly because of the significant variations in the target populations.  In HepFree, 
the eligible population consisted solely of ethnic minority individuals.   
 
Historically, an association has been demonstrated between migrant populations and lower 
or non-attendance at screening programmes (339-342).  In the study by Webb et al, 
researchers in Manchester accessed the electronic screening records of all women eligible to 
participate in cervical screening in order to assess the rate of attendance according to both 
ethnicity and country of birth (339).  In their data set, 9.3% of women were of south Asian 
ethnicity.  Within this cohort, screening was performed significantly less frequently; 69.5% 
compared to 73% in the non-Asian cohort, p =<.0001 (339).  In addition to lower screening 
rates observed in the south Asian cohort, a higher proportion of individuals within this group 
had never attended for screening compared to individuals from other ethnic groups, 14.7% 
versus 10.3% (339).  The study also explored attendance at screening according to country of 
origin.  Here a steep decline in the numbers screened was identified in individuals originating 
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outside of the UK; 57.4% versus 75.6%.  In the cohort of individuals originating from outside 
the UK, nearly one third had never attended for screening, compared to 7.9% of UK nationals 
(339).   
 
Recruitment to HepFree was greater than in other ‘opt-in’ viral hepatitis case-finding projects 
conducted in immigrant populations in Turkey and the Netherlands, and was comparable to 
bowel cancer screening rates in ethnically diverse postcodes in the UK (303,304,331,342).   
 
The highest rates of participation in viral hepatitis case-finding campaigns have been 
observed in an antenatal setting (343,344).  Multiple factors, discussed below may account 
for the differences observed in this specific population.  In the antenatal setting, higher rates 
of engagement may have been observed because of the homogeneity of the trial population; 
individuals targeted by these trials were likely to behave in the same way.  In addition to this, 
the psychological impact of a potential diagnosis may be more profound in these cohorts of 
individuals. Thoughts pertaining to how viral hepatitis might either affect their off-spring, or 
impact on their future health which would in turn impact on their ability to care for their off-
spring may explain the increased level of engagement observed.  Convenience sampling may 
also have impacted on trial participation as well.  In the antenatal targeted testing trials, 
women were already engaged with medical services, undergoing ‘standard of care’ 
investigations, therefore if additional blood tests required for the trial could be taken at the 
same time as standard investigations, meaning no additional effort was required on the part 
of the participant then they may have been more inclined to participate in testing.  
 
It was unsurprising that a higher proportion of female participants were tested through 
HepFree compared to males; there are several possible explanations for this.  It is a common 
observation that higher rates of unemployment exist among ethnic minority females, 
therefore attendance at the GP surgery to participate in the trial would have been easier.  It is 
also plausible that in the absence of time constraints associated with employment, this group 
of individuals would have more time available to socialise and may therefore be encouraged 
to attend for testing by peers and friends.  In addition to these factors, it is well recognised, 
that with the exception of extremes of age, females attend appointments in primary care 
more frequently than males.  This occurs for a variety of reasons including attendance for 
other preventative screening programmes, for consultations related to family planning and 
pregnancy, and also because of a difference in self-perception of their state of health 
(334,335).  Irrespective of the reason for attendance, the increased frequency of 
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appointments increases the number of opportunities available for opportunistic testing to be 
conducted by staff within the practice.  The gender discrepancy in attendance observed in 
HepFree has been identified in previous community based targeted testing programmes 
conducted in locations other than mosques (303,304,331). 
 
In Bradford, trial participation and viral hepatitis testing occurred more frequently in first 
generation immigrants compared to second generation;72.8% versus 25.7% respectively.  This 
finding is consistent with previous viral hepatitis case-finding studies conducted in immigrant 
populations (301,303,304,331,332).  In HepFree, similar to other studies, higher rates of 
engagement with viral hepatitis testing were observed in individuals of advancing age.  This is 
likely to have impacted on the proportions of first and second generation immigrants tested 
as first generation immigrants are more likely to be older (303,304,331). 
 
Previous studies have investigated the effectiveness of different recruitment strategies on 
engagement with screening programmes.  One study evaluating the use of different strategies 
to increase participation in colorectal cancer screening observed that participation was 
greater in both individuals that had consulted a clinician  prior to screening, and in those that 
had received an information leaflet about the process in addition to their invitation letter 
(345).  Another study demonstrated the positive effect of clinician endorsed invitation on 
participation in bowel cancer screening (346).  These findings were taken into account during 
the trial design phase of HepFree, so in addition to participant information sheet, all eligible 
participants received an invitation letter that had been countersigned by their own clinician in 
addition to the trial CI.  In addition to this, during the SIV, training was delivered to clinical 
staff within the practice encouraging them to give all eligible potential study participants the 
opportunity to discuss testing for viral hepatitis each time they attended the surgery. 
 
From analysing the length of time between the invitation letter been sent and recruitment to 
the trial, data suggested that recruitment in HepFree was predominantly via an opportunistic 
approach.  In order to perform this analysis, the assumption was made that if consent and 
testing occurred either on the same day that the invitation letter was given to an individual, 
or more than thirty-one days after the invitation letter had been generated and dispatched by 
the GP practice, then recruitment was not associated with the letter invitation.  Using this 
assumption, 18.6% of accruals for HepFree were attributed to the letter invitation, with 81.3% 
of cases recruited by the opportunistic approach.  
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We do however recognise flaws associated with adopting this assumption.  In real life, 
cultural, social and economic factors, in addition to first-hand experience of the consequences 
of hepatitis may all impact on a person’s decision regarding participation in testing; not simply 
the timing of an invitation letter or a single discussion with a healthcare professional.  
Therefore, although in the majority of cases, the letter may not have been the sole driving 
force prompting an individual to book an appointment for testing; it may have contributed to 
their decision to participate in some way. 
 
In view of this we do not feel that the results of this study alone are powerful enough to 
conclude that letter invitation is ineffective in future screening programmes directed at 
immigrants.  Future research directly assessing the impact of letter invitation versus 
opportunistic invitation on engagement would help to either validate or refute these findings. 
 
In the trial population in Bradford, the overall prevalence of viral hepatitis was 1.77%.  68 
participants tested positive for HCV; 40 females and 28 males, and 61 cases tested positive for 
HBV; 23 females and 38 males.   All participants with a positive hepatitis test were invited to 
be reviewed in a secondary care outpatient clinic.  All participants with a positive anti-HCV 
test underwent further testing to detect RNA in order to diagnose chronic infection that 
would be amenable to treatment.  In 18/68 cases, participants had previously received 
antiviral therapy for the treatment of HCV and there was no evidence of recurrence of disease 
in this cohort.   RNA positive chronic HCV was identified in 25 cases and spontaneous viral 
clearance had occurred in the remaining 25 cases.  One participant tested positive for both 
anti-HCV and HBsAg.  In 91.4% of cases, participants were first generation, and 82% of cases 
originated in people born in countries in Asia-Pacific. 
 
Due to the overall testing rate in Bradford been low, it is difficult to generalise the results of 
the HepFree trial and make assumptions about the prevalence of disease in the larger 
immigrant population residing in this area of England.  It is difficult to establish whether the 
prevalence results obtained from HepFree truly reflect both the disease rate and associated 
burden of viral hepatitis in immigrant populations in Bradford, or whether they are 
representative of the prevalence of viral hepatitis in a self-selected healthy volunteer cohort 
that attended and participated in the trial.  Previous research in general practice has 
demonstrated that populations that are ‘less healthy’ and have risk factors for disease are less 
likely to participate in screening programmes and if they do participate are more likely to 
drop out after displaying an initial interest (347).  This research suggests that the disease 
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prevalence identified by HepFree cannot be used to predict prevalence in other migrant 
populations residing in England.  Research by Hellanius et al however identified that 
individuals with risk factors for poor health were more likely to engage in screening 
performed opportunistically (348).  Therefore in HepFree, although the population recruited 
as a result of letter invitation may have represented a healthier cohort, perhaps this was 
counteracted by the opportunistic testing element of the trial.    
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8.3 Comparisons with other studies. 
8.3.1 Prevalence 
Performing research to establish the prevalence of viral hepatitis in immigrant populations is 
not a new concept.  Multiple previous case-finding studies have been performed, but vary in 
several aspects including the demographics of the cohorts studied, the duration of the trial, 
the methods used to invite eligible participants and the locations used for testing, the 
methods used to consent and to test participants, and finally the viruses tested for (300-
304,331,332,343,344,349,350).  In this section I will discuss in detail the outcomes of the 
HepFree trial and compare our results with data from previous trials. 
 
As discussed in the introduction of this thesis, establishing the true prevalence of anti-HCV 
and HBsAg in any country is difficult, primarily due to the asymptomatic nature of both of the 
diseases and the case-finding initiatives that are currently in operation. The prevalence of any 
disease varies both with time and the demographics of the individuals assessed.  In England, 
multiple initiatives have been developed and implemented to estimate the prevalence of viral 
hepatitis in populations of people who inject drugs.  As a result of this, prevalence data 
derived here will have been influenced by the rigorous testing practices in these sub-groups.  
In England, the overall prevalence of anti-HCV and HBsAg in adults have been estimated at 
0.54% and 0.3% (1,2,351).   In our trial of viral hepatitis prevalence in immigrant populations 
in Bradford, the prevalence of anti-HCV and HBsAg were 0.9% and 0.8% respectively. 
 
HepFree data was further analysed to determine the rates of infection in individuals 
depending on country of origin.  In first generation immigrants, the prevalence of anti-HCV 
and HBsAg was 1.2% and 1.1% compared to 0.32% and 0.27% in second generation 
immigrants.  A previous community based study conducted predominantly in first generation 
south Asian immigrants in Bradford observed a prevalence of anti-HCV and HBsAg of 1.4% 
and 1.6% respectively (301).   
 
In order to determine why two case-finding studies conducted in the same area of England 
detected different rates of infection, trial design, locations selected, eligibility criteria and 
methods used to perform testing must be considered.  There were significant variations in the 
demographics of the populations approached in the two trials.   The target population for 
HepFree included all immigrants registered at a GPs performing targeted testing that had 
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either originated from, or who had a parent that had originated from a country with a 
prevalence of HBV of more than 2%.  In the study by Uddin et al, testing for viral hepatitis was 
offered exclusively to individuals of south Asian ethnicity (301).  The results of our trial 
demonstrated that individuals originating from countries in Asia-Pacific were more likely to be 
infected with anti-HCV; therefore concentrating testing solely in this ethnic group would 
potentially yield an increased number of positive results.  In addition to differences in the 
ethnic origins of individuals invited for testing, unlike in the study by Uddin et al, the HepFree 
study population contained a large number of second generation immigrants.  Although we 
have subdivided testing outcome data by generation, case-finding efforts in HepFree were not 
concentrated solely on first generation immigrants, therefore opportunities may have been 
missed to engage and test this group, in whom we know the rate of infection is higher. 
 
The locations for testing in addition to the methods used to test for viral hepatitis also varied 
quite significantly between HepFree and the study by Uddin et al.  In HepFree, testing was 
performed in GPs with blood taken by venepuncture and sent away for analysis in a 
laboratory.  In contrast to this, in the study by Uddin et al, testing was performed in mosques 
and community centres, with oral fluid obtained for analysis.   
 
In addition to the aforementioned differences, methods of recruitment varied significantly.  In 
HepFree, individuals were sent an invitation letter to which they had to respond and book an 
appointment for the diagnostic test to be performed.  In the study by Uddin et al, individuals 
were approached when attending either the mosque or a community centre; an appointment 
did not have to be made.  As a result of this, it could be argued that in HepFree, recruitment 
and testing occurred in a more health conscious cohort because an individual had to elect to 
book an appointment to participate. 
 
Finally, the study by Uddin et al was performed in the same geographical area as HepFree and 
this may have had a negative impact on prevalence data obtained in HepFree.  The study by 
Uddin et al was performed in the same postcode districts as HepFree, therefore in addition to 
reducing the number of eligible participants for HepFree, the study by Uddin et al may have 
resulted in an increase in both the profile of, and awareness about viral hepatitis, which in 
turn may have led to an increase in subsequent ad-hoc testing in primary care after 2008 
(301).  This theory is supported in part by The Public Health England report into Hepatitis C in 
migrant populations.  This report stated that sentinel surveillance data had identified an 
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increase in HCV testing between 2010-2014, and this increase in testing was attributed to 
targeted awareness-raising campaigns among Asian and British Asian communities (285). 
 
HepFree trial results have once again demonstrated that the prevalence of both HBV and HCV 
in immigrants originating from outside the UK is higher than that in the indigenous 
population.  This finding is consistent with, and supports results obtained from previous case-
finding programmes performed in immigrant populations (300-304,331,343,340,349).  
Although data obtained from HepFree confirms that the prevalence of viral hepatitis is 
greater in ethnic minority groups, our data did not support findings from other studies 
performed in Western countries that suggested that the prevalence of disease in immigrant 
populations reflects their country of origin (349,352).   
 
HepFree data on the prevalence of viral hepatitis in second generation immigrants are 
especially valuable as this is the first time that widespread targeted testing has been 
performed in this cohort of individuals.  Results from the tests performed as part of HepFree 
have demonstrated that the prevalence of disease in this cohort is low, and in fact reflects the 
country of origin of the individuals tested.  These findings are consistent with, and support 
findings from smaller studies that have speculated that infection in immigrants is acquired 
prior to arrival in the UK and that future screening efforts should be focussed on first 
generation immigrants (301). 
 
In HepFree, in the cohort that attended for testing, a higher prevalence of chronic HBV was 
detected in males compared to females.  Historically, in cases of acute hepatitis B, the 
difference in infection rates observed between genders has been attributed to high risk 
sexual activity in both homosexual and heterosexual males.  Interestingly however, the same 
trends in prevalence have been observed in studies concentrating on migrant populations 
where the predominant modes of infection are presumed to either be vertical, or horizontal, 
during the first few years of life (353,354,355).   
 
No clear explanations have been proffered as to why these differences in prevalence rates 
between genders occur.  Although no studies have been conducted that explain why females 
appear to clear the virus more efficiently, associations have been made between the role of 
hormones and HBV related complications.  In a case-control study performed in Shanghai, a 
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relationship was identified between high serum levels of testosterone and the development 
of HCC (356).   
 
In HepFree, 25 cases of RNA positive chronic HCV were identified.  There was evidence of 
previous infection associated with spontaneous viral clearance in a further 25 participants.  In 
the HepFree cohort, disregarding participants that attended for testing despite having already 
received antiviral-therapy, spontaneous eradication occurred in 50% of cases with a positive 
test for HCV indicating previous exposure to the virus.  HCV clearance rates observed here are 
higher than what has previously been reported in a systematic review of longitudinal HCV 
studies.  In this review, spontaneous clearance of HCV occurred in approximately 25% of cases 
of infection (357).  The rate of spontaneous clearance observed in HepFree also differed from 
that observed in the study by Uddin et al, where the rate of chronic infection in 
predominantly genotype 3 infected individuals was 96%.  The authors of this study speculated 
that the genotype of infection may have been responsible for the low rate of spontaneous 
clearance observed, however this is not supported by either the findings of HepFree or a 
study by Lehmann et al (358).  Although we are not able to scientifically prove the genotype 
responsible for infection in individuals no longer infected with HCV, taking into account the 
demographics of the anti-HCV positive RNA negative participants, the favourable genotype 
responsible would also have been 3. 
 
8.3.2 Recruitment 
In the section titled Review of results, comparisons were made between testing rates 
observed in the HepFree trial with both pre-existing preventative screening programmes in 
England and previous viral hepatitis case-finding studies that have been performed both in 
England and overseas.  In this section, further comparisons will be made including the 
methods of recruitment used in order to gain information on both the acceptability of 
targeted testing as well as the superior method of invitation. 
 
With the exception of one pilot study in London, that was terminated prematurely due to 
poor response rate, HepFree was the first viral hepatitis case-finding trial to target immigrant 
populations using a combination of methods including both letter invitation and opportunistic 
recruitment strategies (344).  It was not however the first viral hepatitis prevalence study to 
use letters to invite the target population (331).  In HepFree, more than 80% of individuals 
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were recruited either on the same day that the letter was generated by the GP practice or 
after thirty one days, suggesting that recruitment in these cases was opportunistic. 
 
Previous literature studying response rates to invitation letters in preventative screening 
strategies has suggested that response rates are influenced by a multitude of factors including 
the ethnicity and socio-economic status of the recipient in addition to the condition being 
screened for (306-308,310).  Research into pre-existing preventative screening programmes 
have reported conflicting results with regards the effectiveness of letter invitation in engaging 
ethnic minority groups.  A plethora of evidence exists that suggests participation in pre-
existing preventative screening programmes that use letter invitation including cervical, 
breast and colon cancer is lower in ethnic minority groups (308-310).  These findings however 
were not supported in a study investigating attendance by ethnic minority groups at 
cardiovascular screening in primary care.  In this cross-sectional study by Dalton et al, an 
increased response to letter invitation was observed in individuals of south Asian and mixed 
ethnicity compared to white individuals (359).  The differences in findings observed may 
therefore not be related to the method of invitation but the condition being tested for. 
 
Given that there are both time and financial implications associated with creating, generating 
and distributing letters to invite individuals to participate in preventative screening 
programmes, although we do not feel the results of our study are rigorous enough the claim 
that letter invitation is not effective, we feel that further research is required to directly 
assess the impact of letter invitation on engagement, especially in viral hepatitis testing.  The 
results in this thesis do however suggest that including information relating to the disease 
that is being tested for at the time of the invitation is beneficial. 
 
In HepFree, the combination of recruitment methods resulted in an uptake rate of 35.7%.  As 
discussed previously, this was higher than in other ‘opt-in’ viral hepatitis testing programmes 
that have been performed but lower than what has been observed in both antenatal HBV and 
HCV screening trials (303,304,331,343,344).  In this section I will discuss factors that may be 
responsible for the above findings, including the duration of testing in each trial, the 
populations targeted for testing, the locations where testing was conducted and the methods 
used to consent individuals.   
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Participation rates exceeded 70% in case-finding projects performed in antenatal settings in 
England and Hungary (343,344).  To note, in the trial by Ward et al, testing was not offered 
exclusively to migrant populations, but to all women that attended for antenatal care where 
the trial was being conducted (343). As discussed previously, the populations studied in these 
trials vary significantly from the HepFree trial population; they were homogeneous, both in 
terms of age and gender.  We speculated that trial participation in an antenatal setting may 
have been influenced by both convenience sampling as well as the psychological effect of a 
possible diagnosis of viral hepatitis. 
 
Significant variations were identified between the methods used to obtain consent for testing 
between the antenatal trials and HepFree, making it difficult to draw direct comparisons 
between trial outcomes.  In the trial by Ward et al, verbal consent was taken as opposed to 
written consent. A review of approaches used to improve participation of culturally and 
linguistically diverse populations in clinical trials identified that written consent acted as a 
barrier preventing participation in research (360).  A perceived loss of confidentiality, loss of 
an individual’s right to withdraw or object to treatment, and a lack of understanding of 
complex terms featured within the consent form were all identified as barriers preventing 
participation in studies that require written consent as part of the recruitment process (313).   
 
In addition to the written consent process, multiple other factors have been identified that 
might have impacted on HepFree recruitment.  Within the practices, loss of motivation by 
staff to offer and promote testing due to the relatively long duration of the trial, reduced 
availability of staff to perform administrative tasks including generating invitation letters and 
the potential time implications for staff in performing opportunistic testing could have all 
impacted on HepFree recruitment rates.   
 
Time restraints and a lack of both resources and support have previously been identified as 
factors preventing effective research from being conducted in a primary care setting (361).  In 
England, there has been an increase in the workload experienced in general practice.  Work 
commissioned by the Royal College of General Practitioners (RCGP) identified that the 
number of GP consultations in England had risen from 303 million in 2008/09 to 361 million in 
2013/14, an increase of 19% (362).   In addition to enduring an increase in service use, over 
the past ten years an emphasis has been placed on regulatory requirements in primary care 
including QOF, enhanced services, revalidation and appraisal.  The increased work load has 
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not been reflected in resource allocation; the share of NHS expenditure given to GP fell from 
10.3% in 2004/5 to 8.4% in 2011/12 (362).  
 
As well as practice related barriers, participant factors including difficulty in attending the 
surgery for an appointment due to work or family commitments, difficulty in arranging an 
appointment due to a lack of familiarity with how services operate or a language barrier, and 
the perceived implications of signing a consent form may have all impacted on trial 
recruitment.  
 
As discussed previously, in HepFree, testing occurred more frequently in females compared to 
males. In addition to the reasons that have already been identified and discussed, the 
differences in recruitment rates may have occurred because of factors that prevent men from 
attending appointments in primary care.  A report into the state of men’s health in the 
European Union in 2011 recognised that men are more than twice as likely to work compared 
to women.  This may result in difficulties in organising an appointment, when taking into 
account both working hours and surgery opening times (363).  In addition to this, migrants 
are often employed in low skilled work associated with long and unsociable hours and may 
not be aware of their employee rights to seek time off to attend medical appointments (364).   
The European Commissioning report also identified that men are less likely to know how to 
book an appointment with a doctor, again resulting in decreased attendance (363). 
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8.4 Strengths and weaknesses of the HepFree trial 
8.4.1 Trial location and participant searches 
All prevalence studies are hampered to different degrees by multiple sources of bias.  In this 
section I will discuss potential sources of bias arising from the methodology used in the 
HepFree study.  HepFree was based in primary care, with the target populations identified 
from pre-existing demographic data stored in electronic medical records on clinical computer 
systems within each practice.  The inclusion criteria for the trial were broad, allowing us to 
target a wide and varied cross-section of the community and the trial aimed to invite all 
individuals that fulfilled the inclusion criteria at each practice that had been randomised to 
the intervention arms of the trial. 
 
One potential source of bias in HepFree relates to the locations selected to perform the trial.  
In HepFree the location for testing was the GP surgery, with trial related tasks performed by 
allied healthcare professionals that were permanently employed there.  By conducting testing 
at each GP practice that was recruited to run HepFree, we were able to ensure that all eligible 
individuals that were invited to participate lived within a certain distance of a testing location.   
 
In Bradford, all GPs operate using an appointments based system, with walk-in appointments 
primarily reserved for individuals who are acutely unwell.  The use of appointments for 
testing may have had a negative impact on trial participation if participants were either 
unable to obtain an appointment to attend, or were unaware of how to make an 
appointment at their surgery.  This may be particularly relevant in cases of individuals who 
are either self-employed, or those who work on a shift pattern. 
 
Other disadvantages that have been identified associated with using GPs mainly relate to the 
methods used to identify the study population. As discussed in Materials and Methods, 
searches were created by the trial team to identify the potential study participant population 
from the clinical computer systems in the GP surgeries.  The searches identified individuals 
based on demographic data that already existed in their primary care electronic medical 
record.  However, deficiencies have previously been identified in the recording of diversity 
data in primary care (365).  This would have a negative impact on participant identification in 
HepFree because missing demographic data would result in the eligibility searches omitting to 
identify all individuals registered at the practice that would have been eligible to participate in 
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testing.  An alternative method that could have been considered for use to identify ethnic 
minority groups for research would have been name recognition software such as Onomap 
and Nam Penchan (366,367).  These alternative methods however are not without their own 
limitations.  Previous studies have identified that name recognition software packages often 
produce large numbers of false positive results and this, in turn would impact on the validity 
of the prevalence data obtained (366,367).  In addition to this, these software programmes 
fail to take into account ethnic mixing; individuals that have changed surname, including 
those who have married into another ethnic group and their offspring. 
 
Finally, through basing targeted testing for viral hepatitis in primary care and identifying the 
target population for the study using clinical computer systems, the HepFree  trial has failed 
to address the prevalence and associated burden of disease in a large cohort of migrants that 
are not registered with a GP.  This group of individuals, likely to consist of irregular and 
undocumented migrants may have either been illegally trafficked to the UK or failed to leave 
the UK once their asylum claims had been refused. 
 
8.4.2 Methods of recruitment 
In the original protocol for the HepFree trial, participants were invited to participate using a 
letter invitation that was generated and distributed by staff in each GP surgery.  The protocol 
was subsequently amended to enable participants to be recruited via an opportunistic 
approach.  In this section I will discuss both the letter and opportunistic methodologies used.   
 
The intention of the trial was to send all potential study participants an invitation letter and a 
patient information leaflet about the trial to the home address documented on their medical 
record.  These documents were sent both in English and in the individual’s native language if 
this was known and a translation of the documents was available.  The use of translated 
documents was employed to reduce any selection bias that might have arisen as a result of a 
language barrier. 
 
As part of the trial design, it was the responsibility of the administrative staff within the GP 
practice to personalise, generate, and distribute the invitation letters to their own eligible 
study population.  The trial was designed in this way for two reasons.  Firstly, if targeted 
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testing for viral hepatitis in immigrant populations was found to be cost effective, and 
screening therefore recommended, the trial had to prove that the methods used could be 
replicated by all GPs in England.  Secondly, findings from previous research that has 
investigated the effectiveness of invitation letters in engaging participants in health 
promotion suggested that individuals were more likely to respond to invitation letters 
generated by the primary health care team responsible for providing care, compared to ‘mass 
mailing’ campaigns from a screening programme (368).  This finding was supported by a 
Cochrane review in which analysis of personalised GP invitation letter versus invitation letter 
from other authority sources demonstrated that uptake of screening was higher in the GP 
cohort compared to those receiving letters from programme coordinators (369). 
 
One clear disadvantage of using practice staff to generate and dispatch the letters was that 
the research team could not control the volume or frequency that the letters were sent.  As a 
result of this, some potential study participants did not receive an invitation to participate in 
HepFree and this will have inevitably impacted negatively on trial recruitment data.  An 
alternative and arguably more efficient method of producing the invitations that would have 
also enabled the trial team to control the number sent each month would have been to 
outsource this task to a professional printing company.  This would have improved trial 
efficiency, ensuring that participants received their invitation in a timely manner to enable 
them to attend for testing, but would have prevented us from being able to assess how 
practices coped with the additional administrative work load associated with testing large 
groups of individuals for viral hepatitis.  This may not have mattered however because from 
discussions with clinicians it became evident that it is quite rare for administrative tasks such 
as ‘mass mailing’ invites for example for influenza vaccinations to be performed in the 
practice, now, most practices outsource this task to save time and reduce the administrative 
burden on practice staff. 
 
Following the introduction of opportunistic recruitment and testing, an improvement was 
seen in uptake of the trial.  The opportunistic recruitment methodology also helped to 
reduced bias arising as a result of any of the following: an individual not receiving the 
invitation letter, not been able to read or understand the content of the letter and finally any 
stigma associated with been invited to attend for viral hepatitis testing via written invitation.  
Recruitment to HepFree was not changed solely to opportunistic methods though as this 
would have created bias from convenience sampling, with participants only included in the 
trial if they attended the GP for another reason, thereby potentially resulting in a study 
population comprised of individuals with an increased number of co-morbidities. 
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From trial data collected, it was evident that opportunistic recruitment and testing had been 
performed in some practices.   There were significant variations observed in the numbers of 
participants consented and tested per practice though, suggesting that either some practices 
were more proactive than others in approaching potential study participants to take part in 
HepFree, or alternatively that recruitment had been influenced by selection bias.  Bias may 
have arisen if staff only offered the hepatitis test to individuals that they perceived were at 
high risk of infection, or alternatively if they omitted to offer it to individuals where they felt 
the offer of testing might not be well received.  Potential sources of bias arising from 
opportunistic recruitment and testing at a practice level could have been explored in more 
detail by creating a prompt that documented in the electronic medical record whether testing 
had been offered to an eligible participant in the practice and the outcome of the offer. 
 
One further weakness identified relating to recruitment in HepFree is that the trial collected 
very little information on participants that declined the offer of participating in the trial.  We 
did not have permission to collect any additional information other than aggregate data on 
the number of participants that declined viral hepatitis testing per practice.  It is also 
important to recognise that the group that formally declined the offer of viral hepatitis testing 
and therefore had a Read code demonstrating this in their electronic record does not 
represent the entire cohort that were invited to attend for testing and failed to respond to 
either decline the offer or to participate.  A sub-study linked to the HepFree trial has 
attempted to address attitudes towards testing for viral hepatitis and may help to establish 
why some individuals do not wish to engage with the project. 
 
This qualitative sub-study, conducted through semi-structured telephone interviews, focused 
on individuals attitudes towards testing for viral hepatitis.  It was conducted in two practices 
in Bradford, prior to targeted testing commencing through HepFree.  In the two practices, 
1000 potential study participants were approached and asked to participate in this interview 
that assessed an individual’s knowledge, views and attitudes towards viral hepatitis.  Once the 
interviews had been completed the practice could begin inviting their eligible populations for 
testing.  The data collected will be interpreted alongside recruitment data once all practices 
have completed the eighteen months of recruitment and testing to increase our 
understanding of potential barriers to widespread screening in immigrant populations. 
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8.4.3 Sample collection and interpretation 
In HepFree, venepuncture and blood draw was performed to test individuals for viral 
hepatitis, with samples sent for serologic testing.  Study samples were sent with a study 
specific proforma to a single laboratory for analysis.  The purpose of the study specific 
proforma was to alert laboratory staff in the laboratory that the sample received for testing 
was part of the HepFree trial.  This helped in the event of a problem arising with a study 
sample as the laboratory were aware of a named person for the trial to contact (the research 
fellow, myself).  In addition to this, from a safety point of view, by using the bespoke 
proforma, laboratory staff were aware that the sample was a potential infection risk and to 
ensure that appropriate precautions were exercised. 
 
In the laboratory, each sample was tested for anti-HCV using third generation enzyme 
immunoassays and for HBsAg with enzyme linked immunosorbant assays.  These are the gold 
standards for testing with reported diagnostic sensitivity and specificity in excess of 99% 
(129,131).  All samples confirmed anti-HCV positive were automatically referred for PCR 
testing to establish chronic infection status.  Samples that tested positive for HBsAg were 
further analysed to obtain e-antigen and e-antibody status.     
 
Several disadvantages were identified with regards to the methods of testing selected for 
HepFree.  From a participant point of view, venepuncture can be uncomfortable and may act 
as a barrier to participation, especially in cases of needle phobia.  Secondly, if venepuncture 
was unsuccessful, a participant would need to have a repeat procedure either on the same 
day or at a subsequent visit and this may result in loss of follow up.  Thirdly, sending samples 
for serology incurs a time delay in reporting of results of at least 24 hours.  This delay might 
act as a source of anxiety from a participant perspective. 
 
Alternative methods for BBV testing are available, including point of care tests (POCTs) and 
dry blood spot (DBS) testing.  The major advantages of POCTs are that they can be performed 
in the community without the need for either skilled technical staff or laboratory equipment 
in the first instance.  The tests can be performed on a variety of body fluids including oral 
fluid, thereby offering a non-invasive and potentially more acceptable method of testing from 
a participant point of view.  The results of POCTs are usually available within 5-30 minutes, 
allowing the study participant to be informed of their results during the same visit.  In 
addition to reducing any potential anxiety associated with a delay of results reporting, it 
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would provide staff with the opportunity to counsel participants with a positive result face to 
face and discuss follow-up.  This may help to improve subsequent engagement with 
assessment and treatment (370).   
 
There are however several disadvantages associated with POCTs. Although some assays, for 
example oraQUICK provide results with the same high levels of sensitivity and specificity as 
immunoassays in a laboratory, for other brands, diagnostic accuracy for detection of anti-HCV 
is reduced, ranging from between 79-92%, (370,371).  In addition to this, although POCTs 
have been designed for use on bodily fluids other than blood, reduced diagnostic sensitivity 
has been observed when tests have been performed on oral samples (371).  In addition to 
this, unlike POCTs that are available for HIV testing, that quantify viral load in addition to 
confirming a reactive test, in the event of a positive HCV result, an individual would still 
require a further blood test for confirmatory PCR testing. 
 
In HBV, previous studies have produced conflicting results with regards to the diagnostic 
sensitivity of POCTs.  A systematic review and meta-analysis of diagnostic data has 
demonstrated high pooled accuracy for POCTs in the detection of HBsAg, however the 
diagnostic sensitivity of individual tests varies between 43.5% to 99.8% (372).A reduction in 
the diagnostic accuracy of POCTs in cases of HBV with a low viral load; usually termed the 
inactive carrier phase of HBV infection have been identified and this reduction in diagnostic 
accuracy could result in under-detection of new cases of chronic HBV infection (373,374). 
 
Other factors that need to be taken into account when considering the use of POCTs for viral 
hepatitis testing in primary care are the attitudes of the clinicians responsible for interpreting 
the results, the attitudes of the healthcare professionals performing the tests and the 
attitudes of individuals being offered the test.  A large amount of literature exists relating to 
the use of POCTs in screening trials for HIV. One study that investigated the feasibility and 
acceptability of performing HIV screening using POCTs in GUM clinics and community 
outreach centres demonstrated that both service providers and clients were accepting of this 
form of testing.  Here, more than 90% of clients included in the study stated that they would 
recommend this method of testing to other people.  The authors of the study did recognise 
some of the potential limitations of their study findings.  In this trial, the target population 
consisted of a large proportion of homosexual men, a cohort of individuals that are usually 
both vocal and well informed regarding matters related to HIV including testing, diagnosis and 
access to treatment (375).  This group therefore does differ quite significantly from the target 
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population of HepFree.  In our population, previous studies have demonstrated a poor level of 
knowledge and understanding of viral hepatitis including the implications of a positive result, 
therefore receiving the diagnosis on the same day that the test is performed may be 
overwhelming. 
 
With regards to the attitudes of clinicians and healthcare professionals performing the tests, a 
qualitative study exploring the use of POCTs in primary care identified concerns from 
respondents relating to the accuracy of results obtained from POCTs.  This lack of trust in the 
diagnostic accuracy of tests may result in clinicians either reducing the number of tests being 
performed or being reluctant to counsel a patient on a positive result derived from a POCT 
prior to another method of testing being performed to provide confirmation (376).   
 
A large cluster randomised control trial performed in primary care in Hackney, London 
investigated the impact of ‘opt-out’ rapid tests on the diagnosis of HIV in adults newly 
registering at practices.  Here, the GPs were randomised to either perform the intervention or 
continue standard care.  Trial adoption by GPs was good; 89% of practices approached were 
included in the trial.  In the twenty intervention practices 11, 180 tests were offered and 
4,978 participants accepted a test, corresponding to an uptake rate of 44.5% (377).  
Significant variations occurred in testing performance between practices and this was 
reviewed by the authors in an attempt to establish what factors impacted on screening 
activity (329).  In this follow-up study, interviews were held with members of staff that had 
participated in the trial.  A lack of clinician support for the allied healthcare worker 
performing the test was identified to have a negative impact on recruitment.  A key theme 
evident from the interviews was that although the task of performing the rapid test was easy, 
the potential of diagnosing a stigmatising and potentially life-changing illness made staff more 
wary of the process, especially if a test performed was reactive, indicating active infection.  
Interestingly, although the individuals performing the test reported concerns about the 
prospect of a test being reactive indicating the presence of disease, this event had a positive 
impact on subsequent testing activity.  In HepFree because each study sample was sent for 
laboratory analysis and the result sent back to the lead clinician, feedback of positive results 
to the healthcare workers performing the screening may not have occurred and therefore we 
are unlikely to have observed this effect in our case-finding trial.      
 
Dry blood spot (DBS) offers another alternative method of testing for BBVs.  Similar to POCTs, 
venepuncture is not required; laboratory processing of samples is still required though, 
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incurring a delay in the reporting of sample results.  In addition to this delay, not all 
laboratories in the UK currently offer DBS analysis.  Similar to POCTs, a reduction in diagnostic 
sensitivity has been identified in cases of HBV with  low viral load (378).  Furthermore, 
although DBS testing can be used with confidence to diagnose chronic infection with HCV, a 
systematic review has suggested that it is less accurate in its ability to quantify viral load.  
Contemporary treatments for HCV however do not require pre-treatment viral load 
quantification in order to determine the duration of therapy, so this is probably of less clinical 
importance than previously (379). 
 
 
8.4.4 Reporting of results 
 
One of the mandatory requirements specified in the trial protocol was that Read codes were 
entered in the electronic medical record of each participant undergoing testing  to document 
the results of the tests performed.  The reasons for this were to firstly ensure that the results 
of all study blood tests were reviewed, thereby reducing the chances that positive tests were 
missed, but also it enabled the trial team to produce anonymised reports from each HepFree 
practice containing the following data: the date that the hepatitis test performed, the results 
of the test and demographic data for each individual consented.  The Read codes were 
provided to each practice by the trial team and a suggestion was made that ideally the lead 
clinician, but alternatively a member of the administrative staff took responsibility for 
inputting the Read codes. As well as the lead clinician within each practice receiving a copy of 
the blood test results, the PI in Bradford was also sent a copy of each set of results directly 
from the laboratory. 
 
8.4.5 Generalisability of trial findings 
In Bradford, a large number of individuals attended for testing, and the study population 
included a wide and varied mix of both first and second generation immigrants of different 
ages, genders and ethnic groups.  The characteristics of the study population in addition to 
the trial setting and inclusion criteria helped to increase the generalisability of the trial 
findings.  The only concern regarding generalisability arises around the number of participants 
recruited to the study.  Less than 40% of eligible and invited participants were recruited and 
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therefore it may be difficult to use prevalence data from this cohort to draw conclusions 
about the prevalence of disease in all immigrants residing in Bradford.    
 
One of the primary aims of the trial was to assess the feasibility of performing viral hepatitis 
screening in primary care.  In order to investigate this, the trial team did not intervene or 
assist with either the invitation, or testing of eligible individuals.  Through allowing the 
practices to conduct the study independently, data obtained can be used to draw conclusions 
about the suitability of the location selected for testing, as well as the methods used to both 
identify and invite potential study participants to establish whether this trial would be able to 
be replicated in the future. 
 
In terms of establishing the acceptability of screening for viral hepatitis, we have to be aware 
that by conducting the trial in Bradford, we were performing a targeted testing project in 
both an area of England with a large immigrant population, as well as in a community with a 
large degree of ethnic diversity.  It is possible therefore that the attitudes observed regarding 
acceptability of both offering and performing testing by staff in GP practices, as well as the 
attitudes towards testing observed from participants may differ in areas of England with 
smaller numbers of migrant residents. 
 
8.4.6 Validity of trial findings 
HepFree was a cluster randomised trial.  The use of cluster trials in health-services research is 
increasing because this type of trial design is a well-recognised and pragmatic way of 
measuring the effectiveness of an intervention in this setting.  The major disadvantage of 
cluster trials is that participants within a cluster are more likely to respond in a similar manner 
to one another and therefore cannot be assumed to act independently (380).  Within 
HepFree, the effect of clustering was minimised by blinding all participants to the treatment 
location allocation of their GP practice until the point of the diagnostic assessment in 
secondary care. 
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8.4.7 Blinding 
As discussed above, in order to reduce recruitment bias, all participants undergoing testing 
through HepFree were blinded to the assignment of their practice with regards to where 
treatment would take place in the event of a positive test result.  For all participants that 
required follow- up for a positive hepatitis test, second stage consent was sought at the time 
of the diagnostic assessment in secondary care.  Following consent, if a participant decided to 
remain in the trial, they were un-blinded to their treatment location allocation; standard of 
care versus community care. 
 
8.4.8 Sample size 
Both the number of GP practices and participants within each cluster reduced the risk of 
random error rendering the results invalid.   
 
8.4.9 Statistical analysis. 
In this preliminary analysis of data from one of the four sites in the UK conducting the 
HepFree trial, the effect of clustering was not taken into account.  
 
8.5 Summary 
This is the first viral hepatitis case-finding trial in England to effectively utilise electronic 
medical records in primary care to identify, approach and test immigrant populations that 
have been highlighted as ‘at-risk’ of viral hepatitis because of their demographic 
characteristics.  Through the trial, we identified a high number of newly diagnosed cases of 
both chronic HBV and HCV.   
 
HepFree is not the first case-finding study to identify a higher prevalence of viral hepatitis 
among immigrant populations.  Despite this, to date, no formal recommendations for testing 
in this sub-group have been produced for widespread use.  In the absence of guidance, 
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identification of cases of viral hepatitis in this population often occurs late, with majority of 
cases diagnosed with concurrent chronic liver disease (381,382).   
 
Recruitment figures obtained from HepFree in Bradford suggest that immigrant populations 
find testing for viral hepatitis acceptable, however the methods used to engage this 
population may require some modification.  As discussed before, we do not feel that the 
results of this analysis alone are strong enough to claim that letter invitation for future 
screening (if recommended) in this group of individuals is ineffective.  In HepFree, the median 
number of days between an invitation letter been distributed and consent sought for testing 
was 51, increasing the likelihood that testing occurred as a result of an opportunistic 
approach of recruitment.  Data collected does not however provide any insight into whether 
the letter impacted on an individual’s decision to consent for testing when it was 
subsequently offered.   
 
In HepFree, the number of participants that formally declined the offer of testing through 
HepFree was low, however the proportion of eligible participants that received an invitation 
letter and did not respond was high; 59.1%.  These results suggest that when potential study 
participants were offered the test using an opportunistic approach, they were not averse to 
testing.  The reasons for this might be that when offered a hepatitis test face to face, the 
timing was convenient and did not require personal motivation on the part of the individual 
to arrange an appointment for testing to be performed.  With the exception of screening 
studies performed in antenatal women, the response rate to attend for testing in HepFree 
was comparable to other viral hepatitis case-finding studies.   
 
Future research in this population is still required to address the methods used to engage 
‘difficult to reach’ immigrant population.  One possible method by which this could be done 
would be to assess the impact of performing case-finding for viral hepatitis in the same 
population but in several locations inside and outside of the healthcare setting at the same 
time.  A trial combining both ‘opt-in’ and ‘opt-out’ testing in a variety of locations including 
primary, secondary and tertiary care centres in addition to in the workplace and at religious 
gatherings could result in greater access to and engagement of ‘high-risk’ individuals.  A 
further strategy that could be considered to reduce the number of new migrants entering the 
country with undiagnosed chronic viral hepatitis would be for testing to be performed on 
arrival to the UK, possibly at the same time as tuberculosis testing. 
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8.6 HepFree sub-study discussion 
8.6.1 Introduction 
The HepFree sub-study was designed to investigate the impact of undiagnosed chronic HCV 
on healthcare utilisation in primary care.  This retrospective, observational case-control study 
was designed, developed and run solely by the clinical trial fellow (myself) in Bradford with 
funding provided from the main HepFree trial.  I designed the sub-study, wrote the protocol 
and completed the IRAS form in addition to submitting the study documents to ethics for 
approval.  Once all permissions were in place, participant identification and data collection 
began in all practices that had been inducted and were actively recruiting participants for the 
HepFree trial in Bradford.  In this chapter I will briefly present the sub-study and discuss the 
results obtained.   
 
The sub-study had three broad aims, firstly to investigate whether individuals with PCR 
positive chronic HCV had an increased number of attendances to primary care compared to 
age and sex matched healthy controls.  The definition of a healthy control was no evidence of 
current or past infection with either HBV or HCV.  The second aim was to establish whether 
individuals with evidence of previous infection with HCV, defined by the presence of anti-
HCV, but negative RNA, had a greater number of episodes of attendance to primary care 
compared to age and sex matched healthy controls.  Through studying these cohorts of 
individuals we hoped to ascertain whether either current or past infection with HCV impacts 
on attendance frequency.  Finally through analysis of the symptoms that prompted 
individuals with chronic HCV to present to their healthcare provider we aimed to identify key 
symptoms associated with the virus. 
 
Through obtaining a better understanding of the potential burden of disease associated with 
HCV we may be able to strengthen the justification for widespread screening in high-risk 
populations.  Currently, due to a combination of factors including both the cost of new DAAs 
as well as the workforce required for treatment of infected individuals, EASL recommends 
prioritisation of individuals for treatment based on strict criteria.  EASL criteria currently 
recommend treatment in individuals with evidence of any the following: METAVIR fibrosis 
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score F3-F4, risk factors for progression towards more advanced disease, the presence of 
extra-hepatic manifestations of HCV infection and individuals at risk of HCV transmission.  
This group includes active injecting drug users, men who have sex with men engaging in high-
risk sexual practices, haemodialysis patients and incarcerated individuals (299). 
 
In contrast, there are very few recommendations for the timing of treatment in individuals 
with minimal or no fibrosis in the absence of extra-hepatic manifestations. 
 
If the results of this sub-study identify that, irrespective of fibrosis score, individuals with HCV 
experience symptoms that in turn result in both a reduction in QOL and an increase in 
utilisation of primary care resources, then treatment of the virus in this cohort may ultimately 
be supported as the more cost-effective option. 
 
The major strength of this sub-study was the population included in the analysis.  The 
HepFree trial invited individuals for viral hepatitis testing based on their demographics, and 
therefore were presumed to be asymptomatic.  We had permission to access the electronic 
medical records of individuals that were included in the sub-study in order to review 
attendances to primary care prior to testing and explore symptoms experienced without 
introducing bias.   The major weakness of the sub-study was the relatively small sample size 
included in the analysis. 
 
8.6.2 Review of the sub-study results 
 
In Bradford, the only centre conducting the sub-study, 108 cases were included in the sub-
study; 54 individuals with evidence of active or previous infection with HCV, 31 cases of RNA 
positive HCV and 23 cases with evidence of previous HCV; anti-HCV positive, RNA negative.  
The cases were matched to healthy controls using a ratio of 1:1.  Within the sample there was 
a preponderance of female participants, 67% versus 33% respectively.  The majority of 
individuals included in the sub-study were of Pakistani ethnicity, 88% versus 12% of 
individuals of other ethnicities.  This finding was unsurprising as in the HepFree trial, when 
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expressed as a proportion of the total eligible population, testing occurred most frequently in 
individuals of Pakistani/British Pakistani origin. 
 
The length of follow-up for individuals included in the sub-study was dependent on the length 
of time they had been resident in the UK and ranged from 1 to 12 years.  Individuals with 
evidence of previous HCV infection and their matched healthy controls, labelled as groups 3 
and 4 respectively, provided 210 and 208 patient-years of follow up.  In comparison, the 
number of patient-years of follow up for participants with RNA positive chronic HCV and their 
matched healthy controls (groups 1 and 2) were 303 and 297 respectively.  Per participant, 
the number of attendances was higher in groups 3 and 4, compared to groups 1 and 2. 
 
Expected trends in the usage of GP services were observed in all age groups as well as for 
female participants compared to males.  Year-on-year attendance was proportionally 
increased in each of the following: for the age groups 41-65 and 65 years and over, when 
compared to the baseline age group 18-40, for female participants compared to males, and 
for anti-HCV positive, RNA negative participants compared to healthy controls. 
 
An analysis of the reasons for attendance identified that independent of gender and disease 
status, attendances for either a medical process or procedure was the most commonly coded 
reason for attending for an appointment. In males, 25.6% of all attendances and in females, 
23.8% of all attendances were for this indication. 
 
Attendances for problems relating to the musculoskeletal system were high in all cohorts.  In 
group 1, presentation with a musculoskeletal complaint was the second most common reason 
for attendance in both males and females; 17.8% and 13.0% of attendances respectively.  A 
higher number of attendances for problems relating to the musculoskeletal system were 
observed in the chronic HCV cohort compared to the healthy control cohort, 15.8% versus 
12.1%, however this was not significant, X
2
 (1) = 1.13, p=.288.  
 
Attendances for pregnancy, child-birth and family planning were more frequently observed in 
cohorts 1 and 2, compared to 3 and 4; 4.8% of all attendances versus 2.7%.  This finding is 
likely to be related to the differences in the mean ages of the individuals within the two sets 
of cohorts that were compared. 
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Attendances with a  psychological theme occurred more frequently in the cohort containing 
healthy control participants compared to individuals with undiagnosed chronic HCV; 4.8% 
versus 2.5%. 
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8.6.3 Comparisons with other studies 
At the time of inception, the HepFree sub-study was the first of its kind to retrospectively 
review the electronic medical records of individuals with a positive HCV test to explore both 
the frequency of attendances to primary care and the clinical indication prompting each 
attendance.   
 
A plethora of studies have previously attempted to investigate the impact of chronic HCV on 
quality of life, with results obtained supporting the hypothesis that irrespective of either the 
mode of infection or the severity of disease,  individuals with chronic HCV feel unwell and 
experience a reduction in QOL (196,204,205,206,207,213,383,384). 
 
The impact of SVR on symptoms has also been explored (205,210–214).  In these studies, 
eradication of the virus was associated with an improvement in symptoms.  However, a large 
body of evidence with conflicting results exists.  In these studies, the authors suggest that it is 
knowledge of the disease that impacts on both an individual’s psychological and physical well-
being (215,385-389). 
 
As discussed previously, the HepFree sub-study compared primary care attendances in 54 
participants with a diagnosis of either chronic HCV, or evidence of previous HCV with 54 
healthy control participants.  There was a preponderance of females in the cohorts with a 
positive HCV test, cohorts 1 and 3, 60% and 78% respectively.  This finding is unsurprising and 
reflects overall testing activity in the main HepFree trial.  In HepFree, a greater number of 
females attended and consented for testing compared to males and it was speculated that 
this discrepancy occurred because there were more opportunities available to perform 
opportunistic recruitment in females because of their increased use of primary care services.  
A report of trends in consultation rates in General Practice from 1995-2008 identified that 
apart from at extremes of age, females attended for a consultation more frequently than 
males.  Reasons suggested for this observation included female perception of the state of 
their general health, attendances related to pregnancy, family planning and contraception 
and attendances with sick off-spring (334).  
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Research has suggested that perception of one’s general health can vary depending on the 
ethnicity of the individual in question; therefore ethnicity may impact on primary care 
attendance rates.  A report utilising census data to obtain information on limiting long-term 
illness demonstrated higher rates of illness reporting among Pakistani and Bangladeshi 
women compared to white women in 1991, 2001 and 2011.  This same pattern of illness was 
not however observed in males of Pakistani or Bangladeshi origin (333). 
 
In HepFree, the majority of men with a positive anti-HCV screening test were subsequently 
diagnosed with chronic HCV.  42% of participants in group 1 were male, compared to 22% in 
group 3.  Age at the time of infection, ethnicity, immune status, gender and the presence of 
symptoms during the acute phase of infection have all been found to impact on the chances 
of spontaneous clearance of HCV (133,157-159,161,162,164).  The role of gender in 
spontaneous clearance of HCV is debateable, with previous studies producing conflicting 
results.  Two long-term follow up studies of female subjects infected with HCV from 
contaminated anti-D immune globulin reported spontaneous viral clearance in  45% of 
subjects (159,162).  The rate of spontaneous clearance observed was higher than had 
previously been stated in the literature and did not support findings from larger population 
studies (133).  The findings in the studies by Kenny-Walsh and Wiese et al may therefore be 
related to the homogeneity of the subjects included in the analyses.  Their study populations 
consisted of young females, infected with HCV from contaminated anti-D during pregnancy, 
therefore it is likely that these participants shared very specific characteristics.   
 
In the sub-study, the number of attendances per participant was higher for individuals in 
groups 3 and 4, compared to groups 1 and 2.  This finding may be related to the differences in 
the ages of participants within the cohorts being compared.  The mean age of participants in 
groups 3 and 4 was higher than in groups 1 and 2, 48 years versus 43 years.  A report 
investigating trends in primary care consultation rates identified that the highest rates of 
attendance were observed in adults with advancing age (334). 
 
In the sub-study sample, the mean cumulative visits per participant was higher in first 
generation participants originating from Pakistan compared to second generation participants 
of Pakistani origin, 58.2 versus 49.3.  The relationship between migration and health status is 
complex, influenced by many factors including the process of migration, conditions in the host 
country, conditions in the country of origin, and the self-selecting nature of migrants.  There is 
conflicting data available pertaining to the health of migrants.  Some studies have suggested 
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that migrant groups have lower overall mortality compared to individuals indigenous to the 
host country despite lower socioeconomic status (390).  Other studies however have 
suggested that this ‘healthy migrant effect’ diminishes with time, and the longer the duration 
of residence in the host country, the higher the rate of mortality in migrants (336,391).  In the 
sub-study, attendance patterns observed in first and second generation immigrants were 
consistent with a systematic review of migrant utilisation of somatic healthcare services in 
Europe (392). 
 
In participants with a positive HCV test that were included in this sub-study, attendance data 
prior to the episode of testing did not differ significantly when compared to age and sex 
matched healthy controls with no evidence of HBV or HCV.  Our study findings therefore 
support historical research that suggests symptoms in the presence of HCV occur once the 
diagnosis has been made (215).  The psychological impact of a diagnosis of HCV has previously 
been explored in several studies (215,385,387–389).  Rodger et al identified that individuals 
with pre-existing knowledge of their disease status reported a significant reduction in 
multiple QOL scores.  Individuals with pre-existing knowledge of their diagnosis reported 
greater limitations in their abilities to perform daily activities, as well as an increase in body 
pain, poor social functioning and emotional problems compared to population norms (215).  
Interestingly, in the cohort of individuals included in the study that were unaware of their 
HCV diagnosis, significantly lower QOL scores were reported in areas pertaining to general 
health, vitality and mental health compared to population norms, but subjects did not feel 
that either their emotional or physical health impacted on activities of daily living (215).  The 
authors therefore proposed that the global reduction in QOL observed in the cohort aware of 
their infection may have occurred as a result of labelling (215).   
 
A subsequent cross-sectional study performed to investigate psychological well-being, mental 
health and QOL in women diagnosed with iatrogenic HCV infection supported the findings of 
the study by Rodger et al (385).  In this study, psychological well-being of two cohorts of 
individuals were explored; women with evidence of chronic HCV infection and those with 
previous evidence of HCV infection.  The authors demonstrated a reduction in psychological 
well-being in both groups of women compared to healthy British women (385). The authors 
did not identify any relationship between the degree of hepatic inflammation and well-being 
of the subjects studied and inferred that the results obtained suggested that problems arising 
in subjects with HCV were related to the social impact of a diagnosis, misconceptions 
regarding the route of acquisition of the virus and embarrassment (385).  The authors further 
speculated that embarrassment and stigma were strongly correlated with episodes of 
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depression and anxiety in the context of a positive diagnosis (385).  Interestingly, in this study 
the potential psychological impact of HCV was also observed in the views and beliefs 
expressed by individuals declining to participate.  Non-responders to the invitation to 
participate in the study used the following reasons; a desire not to think about their diagnosis 
and a reluctance to disclose their HCV status (385).   
 
The impact of stigma in HCV infection was evident in a review of the health status of Irish 
individuals with iatrogenic HCV infection.  In this review, illness related stigma was observed 
in 51% of participants surveyed (393).   A more comprehensive investigation of the 
relationship between stigma and a broad range of measures of psychological wellbeing and 
adaptation to illness has also been performed in individuals with HCV (389).  This study 
identified a high prevalence of psychological symptoms in individuals with HCV (389).  The 
researchers identified that even after adjusting for age, gender, route of infection and social 
class, the risk of Diagnostic and Statistical Manual of Mental Disorders, 4
th
 edition (DSM-IV) 
depressive disorders was increased in individuals that perceived HCV-related stigma.  The 
authors identified a relationship between stigma and other aspects of adjustment to illness 
including higher frequency and perceived impact of symptoms and greater perceived 
impairment of thinking and concentration (389). 
 
The results of the studies discussed above, in addition to findings in studies by Cordoba et al, 
have proposed that disease labelling is central to the adverse psychological profile of 
individuals with HCV and conclude that although there are studies that propose alternative 
mechanisms responsible for symptoms experienced by infected individuals, the evidence is 
not compelling (386,387). 
 
The adverse psychological impact of a diagnosis of chronic disease is well recognised in other 
conditions, for example in inflammatory bowel disease, and favourable results in health 
outcomes have been observed following the implementation of strategies aimed at improving 
social support in individuals affected (394,395). 
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In our sub-study, for each participant, the clinical outcome of each attendance was coded 
using the Wonca Internation Classification Committee International Classification of Primary 
Care Second Edition (ICPC).  In previous studies, musculoskeletal pain, fatigue and depression 
have been frequently reported by individuals with HCV (159,162,169,186–188,199,384).  In 
the HepFree sub-study, attendances with a musculoskeletal problem were common in all 
cohorts, independent of disease status.  This finding may be related to the ethnicity of 
subjects included the sub-study.    
 
It is well recognised that musculoskeletal pain is more widespread among ethnic minority 
communities residing in the UK.  In a study of Pakistani immigrants residing in England, there 
was an increased prevalence of musculoskeletal pain compared to individuals of the same 
ethnicity residing in Pakistan (396,397).  In a review of musculoskeletal pain in ethnic minority 
groups of south Asian origin residing in England, authors concluded that there was a lot of 
support for an association between psychological distress and the reporting of symptoms of 
pain (398).   Given that the majority of participants included in the sub-study were of south 
Asian origin, and data collection was performed retrospectively, it would be difficult, if it was 
not documented in the electronic record, to be able to differentiate between true 
musculoskeletal pain and somatisation.  
 
It has been speculated that pain is a frequent presenting complaint in ethnic minority 
individuals because of cultural stigma surrounding mental illness.  Focus groups conducted in 
south Asian communities in London demonstrated the ingrained acceptance of secrecy 
because of shame associated with mental illness (399).  Our sub-study did not identify an 
increased prevalence of psychological disorders in individuals with HCV, with fewer 
attendances observed in the cohorts with a positive HCV test compared to healthy control 
subjects.  
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8.6.4 Strengths and weaknesses of the sub-study 
8.6.4.1 Study design 
The HepFree sub-study was a retrospective case control study, designed to investigate the 
impact of undiagnosed chronic HCV on primary care attendances.  Information on episodes of 
care that had occurred prior to screening was obtained from journal entries in the electronic 
medical records stored on clinical computer systems in GPs.  The major limitation with this 
method of data collection was that information on previous attendances stored within the 
medical records was not collected or recorded specifically for analysis in our sub-study and 
therefore there was variation in the quality of data available. 
 
Read codes are a coded thesaurus of clinical terms that provide a standard vocabulary for use 
by clinicians to record patient findings and procedures in health and social care IT systems.  In 
the medical records accessed for the sub-study, it was evident that Read codes are not used 
exclusively to document the outcomes of clinical encounters by clinicians and other allied 
healthcare professionals.  This finding was supported in research that explored the feasibility 
of creating an ischaemic heart disease (IHD) register by searching for pre-existing Read codes 
in patient electronic records (400).  In this study, authors concluded that from using Read 
codes alone, 31% of patients with IHD were not identified.  Furthermore, 15% of patients that 
did have Read codes related to coronary heart disease within their notes had no evidence of 
the condition of interest clinically (400).   
 
In the sub-study, collecting data pertaining to episodes of care that had been documented 
using Read codes was performed with ease.   For consultations that were recorded using free 
text with no accompanying Read code diagnosis, we had to rely on the observations recorded 
by the clinician that had performed the consultation to establish the reason for attendance.   
Because data collection was performed retrospectively, we were unable to control which 
elements of each consultation were documented by the clinician.  We have recognised that 
this could be problematic, especially in patients that attended primary care frequently for 
review, a group of patients often referred to as frequent attenders.   Frequent attenders, as 
the name suggests, present frequently to primary care to seek medical opinions.  At each 
consultation they often present several problems to the clinician, some of which may be 
psychosomatic in origin.  It is the responsibility of the clinician to differentiate these from true 
pathology.  This group of patients are therefore considered one of the most challenging to 
manage (401).  Due to the high number of, and often unclear nature of problems arising in 
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these consultations, it is possible that not all aspects of each clinical encounter are 
documented.  Therefore, in cases like this, it is possible that some clinical information that 
may have been useful and included in the sub-study for analysis would not have been 
documented and therefore would not be available.   
 
8.6.4.2 Participant selection and recruitment 
The sub-study was conducted using data collected from the electronic medical records of 
participants that had been recruited, consented, and undergone testing for viral hepatitis as 
part of the HepFree trial.  Groups 1 and 3 of the sub-study consisted of individuals with a 
positive HCV test.  Individuals in group 1 had subsequently tested positive for chronic HCV, 
whereas those in group 3 had a negative RNA test indicating spontaneous clearance of the 
virus.  Groups 2 and 4 comprised of individuals that had consented to HepFree and had tested 
negative for both HBV and HCV.  As described in Materials and Methods, control participants 
were matched to cases using the following criteria; gender, age, country of birth, ethnicity 
and length of time resident in the UK.  Healthy controls that matched cases were selected 
from the eighteen GP practices that were performing targeted testing for HepFree.  If more 
than one eligible control was identified using the criteria for matching listed above, a 
randomisation programme on Microsoft EXCEL was used to select the final control that would 
be included in the sub-study.  The clinical fellow that performed participant selection was 
blinded to all clinical information about the control participant until they had been selected to 
prevent any bias from been introduced. 
 
HepFree targeted and invited individuals to undergo testing for viral hepatitis based on 
demographic data stored in their electronic medical records.  An assumption was therefore 
made that blood tests in HepFree were performed in asymptomatic cohorts of individuals, as 
opposed to viral hepatitis testing being performed in individuals that had either sought 
medical attention for investigation of symptoms, or alternatively in a cohort of individuals 
referred to a specialist hepatology unit.  By performing testing in this general setting we had 
the unique opportunity to collect data retrospectively on attendances to primary care that 
had occurred prior to the trial intervention.  This would hopefully enable us to establish 
whether individuals with undiagnosed chronic HCV accessed healthcare services more 
frequently than non-infected individuals prior to testing and diagnosis. 
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8.6.4.3 Data collection 
In contrast to the majority of research performed to investigate symptoms in HCV, this sub-
study collected data on episodes of care that had occurred prior to the diagnosis of HCV been 
made, by accessing individuals electronic medical records in primary care.  By performing data 
collection in this way, we eliminated both recall and reporter bias as well as prevented the 
research findings from been influenced by the Hawthorne effect.   
 
The methods used for data collection and recording were conducted in the same way for each 
participant enrolled into the sub-study.  Prior to commencing data collection, variables that 
were going to be collected and recorded were agreed and documented by the research team.  
In order to minimise intra-rater variability, collection and coding of data relating to episodes 
of care for both cases and controls was performed by a single member of the research team 
(me).   
 
One weakness identified relating to the method of data collection used relates to blinding.  
Ideally the member of the research team responsible for data collection would have been 
blinded to both the purpose of the sub-study and the research questions the investigators 
were attempting to address.  Gearing et al stated that abstractors blinded to the hypothesis 
decrease reviewer bias, specifically the possibility of their assessment being swayed by 
knowledge of others, concern over adversely affecting the study outcome or interpreting 
their abstraction as too lenient or harsh (402).  To reduce any bias that may have arisen 
secondary to the selection of participants to act as ‘non-infected’ controls, Microsoft EXCEL 
was used to select a control at random from the list of eligible and matched participants.  It 
was only after the control had been selected, that the electronic medical record was fully 
accessed to collect data on episodes of care that had occurred prior to HepFree recruitment. 
 
For the sub-study, information on episodes of care were collected either from the time the 
subject entered the UK and was registered with a GP or from 1
st
 January 2005 for subjects 
that had moved permanently to the UK prior this date.  For some participants, their first place 
of residence in the UK was not Bradford.  In these cases we had to assume that GP2GP 
technology had transferred patient electronic medical records directly and securely between 
practices (403).We could not control for periods of time when participants that were included 
in the study visited overseas.  It is common for immigrants to spend prolonged periods of 
time overseas either visiting or caring for family and during this time they may have accessed 
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healthcare services in the country they were visiting and we could not collect data on these 
visits.  This same limitation however does also apply to all cohorts of participants included in 
the sub-study. 
 
8.6.4.4 Generalisability of sub-study findings 
The size of the sample included in the sub-study analysis was small; 54 cases with a positive 
anti-HCV test and 54 controls.  In order to identify this number of cases, 8,973 individuals 
were enrolled and tested for viral hepatitis by the HepFree trial.  There are several 
disadvantages with studies containing small numbers of participants, and these relate to the 
interpretation and significance of results obtained.  In addition to there been difficulties in 
interpreting results obtained, false positive results can occur in studies with small sample 
sizes and it can be difficult to apply the results obtained from a study with a small sample size 
to the larger population. 
 
8.7 Summary 
Whether symptoms and a subsequent reduction in QOL in individuals with HCV arise as a 
direct consequence of the virus, or as a result of knowledge of the condition and the 
implications of long-term infection, failing to recognise and address these ‘extra-hepatic’ 
manifestations of chronic HCV can be distressing for patients.  It is therefore essential that as 
part of the patient assessment, the degree and extent to which the diagnosis of HCV impacts 
on an individual’s QOL should be explored and also be considered when timing of therapy is 
decided.  In this sub-study, we did not identify an increase in healthcare utilisation by 
individuals infected with chronic HCV, however we do recognise that the sample size was 
small.  Future research investigating the impact of targeted support and education 
implemented following a diagnosis of HCV on symptoms and health related quality of life may 
be beneficial in cohorts of infected individuals.   
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9. Summary 
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In this final chapter I aim to explore to what extent the objectives that were set out in this 
thesis have been achieved, contributions that have been made to the existing field of 
research by this piece of work and finally to provide some suggestions about the direction of 
future research in the same field. 
 
Through reviewing the methodology and results obtained from both the HepFree trial and the 
sub-study on healthcare utilisation by individuals with undiagnosed HCV it is clear that 
although valuable in its contribution, modifications to the trial methodology will enable 
further advances to be made with regards to engaging high-risk immigrant populations in 
testing for viral hepatitis. 
 
The broad aims of this thesis were to explore the feasibility of developing and running a 
future screening programme for viral hepatitis in immigrant populations based in primary 
care.  The research questions we attempted to address were: 
1. The feasibility of using electronic medical records held on clinical computer systems in 
primary care to identify the target population to be invited for screening. 
2. The superior method of invitation to successfully engage the target population in 
screening. 
3. The demography and prevalence of viral hepatitis in first and second generation 
immigrant populations residing in Bradford. 
4. Whether undiagnosed chronic HCV results in greater use of healthcare resources in 
primary care. 
 
In addition to this, by reviewing recruitment rates in each practice we hope to be able to 
comment on to what extent it is both feasible and acceptable to design a screening 
programme to be run independently by members of staff within GP. 
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Interrogation of primary care records to identify the target population to invite for screening 
As described in chapters 1.0 and 8.0 at the time of inception, the trial team were not aware of 
any other active studies that were using demographic data that had already been collected 
and stored in electronic medical records in primary care to identify the target population to 
invite for viral hepatitis testing.  The HepFree trial team designed a series of searches that, 
when published and activated on clinical computer systems in GP surgeries would identify 
individuals that fulfilled the trial inclusion criteria.  The searches performed this task by 
identifying Read codes that had previously been recorded by clinical staff to document the 
country of birth, main spoken language and ethnicity of patients registered.  These searches 
were referred to as eligibility searches. 
 
The results of the eligibility searches, described in chapter 4.0, demonstrated that it was 
feasible to identify individuals based on demographic data that had been stored in Read code 
format in electronic records.  The searches were designed to look for Read codes related to 
ethnicity as well as country of birth and main spoken language.  Through these methods we 
aimed to reduce the number of individuals that would have fit the inclusion criteria but would 
not have been identified by the searches due to deficiencies in recording of demographic 
data.  The results of our searches did identify on-going problems with the quality and 
completeness of demographic data recording in primary care.  Although ethnicity recording 
was done very well; in excess of 90% of individuals registered in targeted testing practices had 
a Read code denoting ethnicity; country of birth and main spoken language were not 
completed to the same standard. 
 
Although HepFree was the first viral hepatitis case-finding trial to identify its target 
population by using demographic data stored in primary care databases, it was not the first 
trial to utilise this method for potential trial participant identification.  Read codes related to 
medical conditions have been used to identify a trial population in a study that aimed to 
develop an IHD register in primary care (400). 
 
One of the major limitations in the HepFree methodology was that it failed to include an 
alternative method that would identify individuals that had no demographic data stored in 
Read code format within their record.  Although HepFree demonstrated that electronic 
medical records store large volumes of information that can be interrogated by researchers, 
future research that utilises a similar method for subject identification could consider the 
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additional use of name recognition software to explore whether this increases the eligible 
population identified within practices.  The one potential downside of this is method is that it 
would require a member of staff to manually confirm the results of the searches generated by 
these software programmes as they have previously been associated with large numbers of 
false positives (366,367). 
 
The superior method of invitation used to engage the target population in screening 
As discussed in chapters 1.0, 5.0 and 8.0, many challenges are faced when attempting to 
engage ethnic minority groups in screening programmes.  These challenges arise for a 
multitude of reasons including low levels of knowledge pertaining to the condition being 
screened for, potential fear of stigma associated with a positive diagnosis, uncertainty 
surrounding the implications of infection and how the disease may affect either themselves or 
their family. Further obstacles acting as barriers to screening are related to language and 
literacy, uncertainty about how to organise an appointment to attend for screening, 
availability to attend due to work demands and participant willingness to engage both in 
screening and subsequent follow-up.  In the context of a trial setting, additional fear 
surrounding the methods of consent has also been identified as a barrier to participation.   
 
Previous research has identified that invitation letters endorsed by the clinician responsible 
for an individual’s care improves engagement (345,456,368).  HepFree therefore included the 
practice letterhead in addition to the lead clinician’s signature on all invitation 
correspondence sent.  In HepFree however, letters were not the sole method used to recruit 
potential study participants.  In addition to sending the written invitation, individuals could be 
approached and tested opportunistically.  Our results suggested that the type of invitation 
letter received did impact on an individual’s decision to engage with testing through the trial.  
Nearly one third of individuals attended for testing within thirty-one days of the enhanced 
letter that also included an information sheet on viral hepatitis been sent, compared to only 
ten percent of individuals that received the standard invitation letter.   
 
In the trial, in excess of eighty percent of participants that were recruited to HepFree 
consented for testing either on the same day that the letter was generated by the GP or after 
thirty-one days.  We speculated that in these cases recruitment was opportunistic as opposed 
to the result of receiving the invitation letter.  As discussed in chapter 5.0, although an 
assumption was created for the purpose of the analysis we do not feel that the results of the 
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HepFree study alone are strong enough to conclude that letters are ineffective as a form of 
invitation in ethnic minority groups.  The HepFree trial demonstrated the effectiveness of a 
combination of different invitation approaches in engaging the target population.   
 
Unfortunately due to stipulations in the trial protocol, we did not have the necessary 
permissions to be able to establish the extent to which opportunistic methods of recruitment 
impacted on an individual’s decision to participate in HepFree.  If future research was to be 
conducted in this area, a direct measure of the effectiveness of this approach would be useful 
in helping to decide whether screening programmes in the future should consider stopping 
inviting participants using letters as there are both financial and time implications associated 
with this method of recruitment.  There would however be potential disadvantages to only 
screening individuals approached opportunistically in primary care.  The most obvious 
disadvantage would be that the population included would represent a convenience sample.  
In addition to this, screening success would be solely dependent on members of staff within 
each practice adopting the trial and being motivated to offer screening.  
 
Future research that aims to explore the impact of social media and health advertising 
campaigns on recruitment would be useful.  In the 21
st
 century there has been rapid 
expansion of the social media phenomenon with the proliferation of tools including Twitter 
and Facebook.  Social medial has been identified as a both a platform enabling patients, 
families of patients and caregivers to share their experiences of diseases in addition to raising 
awareness of certain conditions (404).  Therefore adapting the methods used to approach 
target populations may result in greater levels of engagement. 
 
One interesting finding of the study was the extent to which different ethnic minority groups 
engaged with testing for viral hepatitis in Bradford.  The demography of individuals recruited 
into the trial was described in chapter 5.0.  Participation by individuals of Asian ethnicity was 
much higher than by other ethnic groups including white European and ‘other ethnicity’.  This 
may be the result of campaigns that have previously been launched within south Asian 
communities to increase the profile of viral hepatitis and encourage participation in 
screening.  The use of focus groups to enhance our understanding of barriers that prevent 
participation in screening in these more difficult to reach ethnic groups, prior to adapting 
invitation methods may help to guide future research 
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The demography and prevalence of viral hepatitis in first and second generation immigrant 
populations residing in Bradford. 
The HepFree trial design, with its broad inclusion criteria aimed to establish the prevalence of 
viral hepatitis in first and second generation immigrants residing permanently in Bradford.  As 
discussed extensively in chapter 8.0 due to the relatively low response rate to the invitation 
for testing through HepFree, it is difficult to use the findings obtained from this study to make 
assumptions about the prevalence of disease in the larger immigrant population of Bradford. 
 
The results of the trial were however very useful in providing information on the prevalence 
of disease in second generation immigrants in England.  HepFree was the first viral hepatitis 
case-finding trial to engage a large number of second generation immigrants in viral hepatitis 
testing and the results supported those obtained from small studies that have previously 
been conducted.  In 1,875 immigrants tested, the prevalence of anti-HCV and HBsAg were 
0.32% and 0.27% respectively.  These findings suggest that future formal screening efforts in 
ethnic minority groups should be concentrated in first generation immigrants as this is where 
the burden of disease is likely to be concentrated.   
 
From our results, it was clear that higher rates of positive hepatitis tests were concentrated in 
non-English speaking immigrants, in individuals originating from countries within Asia pacific, 
in males, and in individuals of advancing age.  In many ways the demographics of the high-risk 
group share similarities with those considered ‘difficult to reach’.  An analysis of recruitment 
outcomes in HepFree identified that it was more difficult to engage males in screening, and it 
is well recognised that language barriers act as an obstacle preventing individuals from 
accessing appropriate healthcare services. 
 
In the trial, individuals with a positive viral hepatitis test result were invited to attend a 
diagnostic assessment carried out in secondary care that included investigations, both non-
invasive and invasive on order to stage disease.  Twenty percent of the trial population that 
were diagnosed with chronic HCV had evidence of advanced fibrosis/cirrhosis on staging 
investigations, indicating a significant burden of disease related to chronic HCV.  In addition to 
the increased risks associated with treating these individuals with antiviral therapies, even 
after successful treatment they will require on-going surveillance for HCC and remain at an 
increased risk of both liver and non-liver related morbidity and mortality.  
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In the HBV cohort, fifteen percent of cases were found to have an elevated VL that would 
warrant on-going monitoring.  In five percent of cases diagnosed with HBV, there were clear 
indications to commence antiviral therapy in order to try and reduce the incidence of liver 
related complications including HCC.  Even in the small populations that were identified to 
have chronic viral hepatitis through HepFree, the significant burden of disease associated 
with viral hepatitis was evident and should strengthen the case for universal screening. 
 
Whether undiagnosed chronic HCV results in greater use of healthcare resources in primary 
care. 
 
The HepFree sub-study was designed to assess the impact of undiagnosed chronic HCV on 
utilisation of healthcare resources in primary care.  It was unique in its design as it was the 
first time that primary care records had been reviewed retrospectively to establish both 
frequency of attendances as well as reasons for attendance in a group of individuals that were 
not aware of their infection status.  Unfortunately, the major limitation of this sub-study was 
the small number of participants recruited.  Despite performing testing in over 8,000 
individuals, only 54 cases of previous or current infection with HCV were identified. 
 
As discussed in chapter 8.0, previous studies that have attempted to investigate symptoms in 
individuals with chronic HCV have identified an increased prevalence of fatigue, 
musculoskeletal pain including arthralgia and myalgia as well as depression.  The results of 
the sub-study failed to identify an increased prevalence of the above listed symptoms in the 
cohort with undiagnosed chronic viral hepatitis compared to the healthy comparison group.  
This finding may have occurred for several reasons.  Firstly, it may be that the results of this 
sub-study support findings from other research that suggest symptoms occur in individuals 
with HCV as a result of knowledge of the disease as opposed to as a direct consequence of the 
virus itself.  Alternative explanations for the results obtained may be that because in HepFree, 
disease was concentrated in non-English speakers, this group may have been more reluctant 
to engage with medical services even in the presence of symptoms because of the language 
barrier.  Alternatively, because of the vague and often difficult-to-treat nature of symptoms 
that have previously been described in individuals with HCV, individuals may be reluctant to 
seek medical attention because they may perceive that it will not lead to any benefit in terms 
of improvement in symptoms.  The small study population included in the HepFree sub-study 
means that all results obtained from data analysis need to be interpreted with great caution. 
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The feasibility and acceptability of performing targeted screening for viral hepatitis in primary 
care 
 
One of the aims of the main HepFree trial was to establish whether performing targeted 
testing for viral hepatitis in high-risk groups in primary care to identify disease would be cost 
effective and therefore lead to future formal screening programmes being developed.   At the 
time of writing this thesis, some GP sites were still open to recruitment, therefore data has 
not yet been analysed to address the question regarding cost effectiveness.   If the outcomes 
of the trial suggest that it is indeed cost effective, then it is important to have established 
whether the location selected to host the screening programme is appropriate for widespread 
screening in the future.   
 
In order to test this, although the trial in Bradford was overseen by a clinical fellow based in 
secondary care, after site recruitment and initiation, the practices were expected to perform 
the tasks of inviting and testing participants independently. 
 
As discussed in chapter 3.0 considerable challenges were faced when attempting to recruit GP 
sites to perform testing for viral hepatitis through HepFree.  The trial team encountered a 
myriad of logistical and contractual problems when trying to engage practices.  In a large 
number of cases the primary reason given for declining the offer to participate in the trial was 
the perception that it would increase the work load within the practice.  In England multiple 
screening trials are already conducted successfully in primary care and this is probably 
because although allied healthcare professionals within the practice perform the 
investigation, for which they are reimbursed, all other screening activities including inviting 
patients, processing test results and following up on results is performed by individuals 
outside of the practice.  Therefore, the direct impact of these screening programmes on the 
work load of the practice is minimal.  This was not the case with HepFree, therefore by 
modifying the methods to enable support to be provided both for administrative tasks 
including generating and distributing the invitation letters as well as support with processing 
and acting on results, engagement with testing for viral hepatitis by primary care clinicians 
may increase.  Despite this, the results of the HepFree trial did suggest that once practices 
were engaged, they were willing to perform testing for viral hepatitis. 
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There was variation in recruitment between practices participating in HepFree.  A non-
significant positive correlation was identified between the number of potential study 
participants registered at a practice and recruitment performance.  Future research exploring 
the reasons why discrepancies in testing performance were identified would be beneficial for 
future screening initiatives in a primary care setting. 
 
In summary, the HepFree trial has been invaluable in investigating whether or not it would be 
feasible and acceptable to use GPs in primary care to both identify a population at high risk of 
viral hepatitis and then to perform screening in that eligible population.  The results obtained 
from this initial analysis of the Bradford data further support that immigrants find testing for 
viral hepatitis acceptable; however adaptations both to the way that testing  is offered and 
performed in this setting is required in order to increase participation. 
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Appendix 1: The HepFree trial protocol version 7.0 
 
TITLE OF THE PROTOCOL: 
Chronic Viral Hepatitis in First and  Second Generation Immigrants from ‘At Risk’ Countries. A 
controlled randomised cross sectional  cluster trial to assess the impact of  identifying, 
screening and treating immigrants with viral hepatitis.  
 
Short title/Acronym:    HepFree 
 
Sponsor: Queen Mary University of London  
Representative of the Sponsor: 
 Gerry Leonard 
 Head of Research Resources 
Joint Research Management Office 
Queen Mary Innovation Centre   
5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7260 
 Email: sponsorsrep@bartshealth.nhs.uk 
 
REC reference: 12/LO/1768 
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Chief Investigator Agreement Page 
 
 
The clinical study as detailed within this research protocol (Version 7.0, dated  12
th
 March 
2015),or any subsequent amendments will be conducted in accordance with the Research 
Governance Framework for Health & Social Care (2005), the World Medical Association 
Declaration of Helsinki (1996) and the current applicable regulatory requirements and any 
subsequent amendments of the appropriate regulations. 
 
 
 
Chief Investigator Name: 
 
 
 
 
Chief Investigator Site: 
 
 
 
 
Signature and Date: 
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The clinical study as detailed within this research protocol (Version 7.0, dated  12
th
 March 
2015),or any subsequent amendments will be conducted in accordance with the Research 
Governance Framework for Health & Social Care (2005), the World Medical Association 
Declaration of Helsinki (1996) and the current applicable regulatory requirements and any 
subsequent amendments of the appropriate regulations. 
 
 
 
Principal Investigator Name: 
 
 
 
 
Principal Investigator Site: 
 
 
 
 
Signature and Date: 
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STUDY SUMMARY/SYNOPSIS  
 
TITLE Chronic viral hepatitis in first and  second generation immigrants 
from ‘at risk’ countries. A controlled randomised cross sectional  
cluster trial to assess the impact of  identifying, screening and 
treating immigrants with viral hepatitis.  
 
SHORT TITLE HepFree 
Protocol Version Number 
and Date 
 
7.0 dated 12
th
 March 2015 
Methodology 
 
A controlled randomised cross sectional cluster trial to determine 
how to effectively identify and screen immigrants from ‘at risk’ ethnic 
minority communities as well as assessing the impact of primary care 
on engagement of targeted newly diagnosed chronic viral hepatitis 
patients. 
 
Study Duration 
 
5 years  
Study Centre 
 
There will be 56 centres to be utilised over old Primary care trusts 
(including Bradford as well as South and East London), known to have 
a high density of immigrant populations from ‘at risk’ countries ( 
WHO classification of HBV prevalence >2%) 
Objectives 
 
 
Primary objectives  
 To assess the most cost effective method of screening for chronic 
viral hepatitis in primary care patients within ‘at risk’ ethnic 
minority communities. 
 
 To assess the impact of the interventional approach based 
 328 
 
strategy to screening.  
 
 To establish whether the involvement of community therapy is 
likely to have an impact on a patient’s engagement after having 
been positively tested for viral hepatitis. 
 
 To assess differences in treatment adherence between patients 
groups receiving treatment within the community against those 
who have standard hospital care. 
 
Number of Subjects/Patients  It is postulated that up to 48,000 prospective patients could be 
approached to be screened, with demographic data from the 
control practices to be provided for another prospective 4,000 
patients. 
 
 Up to 3500 of these prospective patients will be contacted prior to 
screening by their GP, to try and collect baseline information 
relating to explanatory models of viral hepatitis as well as 
demographics and other contextual variables that relate to 
screening uptake and subsequent treatment engagement, using 2 
different questionnaires.  
 
 Estimates indicate that up to approximately 19,200 will screened 
with 3% testing positive for viral hepatitis.   
 
 Up to approximately 580 infected patients will likely be used to 
assess the impact of community care or standard hospital care for 
patient engagement.    
 
Main Inclusion Criteria 
 
 Female and male patients who have been identified as first 
generation immigrants born in a country of high risk or second 
generation immigrants. Please see appendix 2 – for the complete 
listing of countries that deemed high risk (as outlined by WHO 
classification of HBV prevalence >2%). 
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 >18 years of age. 
 
Statistical Methodology and 
Analysis 
For this clustered trial, it is assumed an intra-cluster correlation co-
efficient of 0.05 for all outcomes and a coefficient of variation of 
cluster size of 0.65.  
We are making three comparisons in this two-stage trial: 
 
Stage 1  
Comparison A: Control vs Interventional screening practices gives 
>80% power to detect a difference from 15% to 40% in testing rates 
at 5% significance level). 
 
Comparison B: Standard invitation vs enhanced invitation gives 88% 
power to detect a difference from 32% to 42% in testing rates at 5% 
significance level). 
 
Stage 2  
Comparison C: Standard hospital treatment vs treatment in 
community gives 90% power to detect a difference from 50% to 70% 
in engagement rates assuming 40% of eligible patients will be 
screened and 3% test positive).  
 
Analyses will use appropriate methods to take account of clustering. 
Because of the nature of the outcomes we anticipate few missing 
values so that generalised estimating equations should produce 
unbiased results. For comparison A we will also conduct a cluster-
level analysis as a sensitivity analysis because of the imbalance in the 
number of clusters per arm.     
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Glossary of Terms and Abbreviations  
 
AE   Adverse Event    
AR   Adverse Reaction 
ASR   Annual Safety Report 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
GAfREC Governance Arrangements for NHS Research Ethics Committees 
HRA Health Research Authority  
ICF   Informed Consent Form 
ISRCTN   International Standard Randomised Controlled Trial Number 
JRMO   Joint Research Management Office 
MA   Marketing Authorisation 
MS   Member State 
Main REC  Main Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
PI   Principle Investigator 
QA   Quality Assurance 
QC   Quality Control 
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Participant  An individual who takes part in a clinical trial 
PCTU   Pragmatic Clinical Trials Unit  
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
TMG   Trial Management Group 
TSC   Trial Steering Committee 
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1. Introduction  
 
1.1  Background  
 
Chronic viral hepatitis is common in people born outside the UK and involves persistent 
infection with either hepatitis B or hepatitis C virus. The disease can cause asymptomatic 
disease that leads to cirrhosis or potentially hepatocellular carcinoma as well as death in a 
large proportion of those who are infected.  
 
Hepatitis C virus is a blood borne single strand RNA virus which exists in a number of different 
genotypes. Chronic infection (defined as infection for more than 6 months) is usually 
asymptomatic and patients usually remain unaware that they are infected until the disease 
has progressed. However, disease progression and severity is highly likely.  
 
Hepatitis B is a blood borne DNA virus that may also be transmitted sexually or by materno-
fetal transmission. Chronic HBV is defined by the presence of hepatitis B surface antigen 
(HBsAg) for six months or more after acute infection.  The disease persists in a number of 
different, convertible phases. The two major phases are defined by the presence or absence 
of the hepatitis B e antigen (HBeAg) in the circulation.  
 
These often asymptomatic diseases require multifaceted diagnostic testing, which includes 
serial testing for antibodies, RNA/DNA as well as liver function tests to ensure patients are 
accurately diagnosed. 
 
The prevalence rate of viral hepatitis currently stands at approximately 0.5% within the UK. 
However, statistics for first and second generation immigrants from ‘at risk’ countries 
indicates a higher prevalence, perhaps approaching 5%.  Current data relating to immigrant 
populations within the UK is limited. However, it is believed that 7 million first and second 
generation immigrants from high prevalence countries currently reside in the UK.  It is 
believed that certain ‘at risk’ communities have a prevalence level similar to their country of 
origin, as demonstrated by studies conducted in the Somali community in Liverpool as well as 
the Pakistani community in London, (Brabin et al., 2002 and Uddin et al., 2010). Hence the 
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prevalence of viral hepatitis is at least ten fold greater in immigrants than in the indigenous 
community. 
 
The UK has one of the lowest rates of therapy for viral hepatitis in Europe and this is 
undoubtedly contributing to the observed rising mortality from liver disease in the UK. This is, 
in contradistinction to the rest of Europe, where mortality from liver disease is decreasing. 
Previous UK studies have shown that access to therapy for patients known to have viral 
hepatitis is poor with only a tiny minority of diagnosed patients going on to receive 
treatment.  
 
Current statistics indicate that of the total UK population that have been infected with 
hepatitis C, only 17% have been diagnosed and less than 2% go on to receive treatment 
(Ryder., S, 2004). Hepatitis B is known to be the cause of 50% of primary liver cancer cases 
within the UK, in which patients are 100 times more likely to develop hepatocellular 
carcinoma than those who are not infected. Strategies culminating in improved access to 
treatment are thought likely to have a major impact on treatment uptake and to reduce 
morbidity. However, currently alternatives to hospital based treatment have not been 
studied. 
 
Current data indicates that approximately 25% of those with chronic viral hepatitis will die in 
their fifth decade as a result of their infection, indicating that up to 50,000 immigrants living 
in the UK may develop cirrhosis and/or liver cancer. The subsequent care of patients with 
these conditions will add a significant financial burden to the NHS. Further analysis of the 
current demographics of the immigrant population shows that over 80% are less than 50 
years old (Foster, G – unpublished data).  It is therefore anticipated that there will be a sharp 
rise in the number of immigrant deaths associated with viral hepatitis over the coming 
decade. 
 
Therapy for chronic viral hepatitis is available and is clinically and cost effective as indicated 
by NICE approval. For chronic HCV infection therapy involves a combination of a long acting 
interferon combined with ribavirin and, increasingly a direct acting antiviral agent (such as 
telaprevir or boceprevir). For chronic HBV infection a number of different treatment options 
are available including interferon based immunomodulatory regimes or perpetual viral 
suppression with a third generation nucleotide derived antiviral agent, either entecavir or 
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tenofovir.  The current model of care involves specialist centres with highly trained staff 
administering therapy at some distance from the patient’s home.  
 
Given the poor uptake of antiviral therapy under current conditions it has been suggested 
that alternative treatment models should be developed but these have not been assessed or 
tested in a large scale.  
 
2.Trial Objectives and Design 
 
2.1    Trial Objectives 
 
The central objective of the study is to determine whether screening for chronic viral 
hepatitis in immigrants living in the UK by testing all registered immigrants in GP 
surgeries is feasible, effective, and cost effective.  
 
We will examine the costs and benefits of screening compared to current ‘standard 
practice’ and evaluate whether an enhanced patient information invitation letter (as 
opposed to ‘standard patient information invitation letter’) enhances engagement as 
well as determining whether local delivery of therapy improves engagement when 
compared to conventional delivery of care. 
 
Prior to the commencement of screening, we will also look at the contextual variables 
and health literacy that will have an impact and influence the uptake of screening and 
subsequent engagement in treatment. This will be done with a population-based 
survey of knowledge of viral hepatitis in conjunction with other questionnaires, Patient 
Health Questionnaire [PHQ-9] and Generalised Anxiety Disorder 7-item [GAD-7] . The 
survey questionnaire is to determine the range and prevalence of different beliefs, 
attitudes and barriers to screening.  
 
The specific study objectives are listed below: 
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Primary Objectives 
 
Stage 1 
 To determine whether interventional screening is more cost-effective than 
control screening in the detection of viral hepatitis in ethnic minority patients 
in primary care.  
 
To determine whether the provision of an enhanced patient information 
invitation letters increases attendance for testing when compared to 
standard information invitation letter. 
Stage 2 
 
 To determine whether community based therapy is superior to conventional 
delivery of treatment (based on referral to local hospital treatment centres) as 
measured by engagement with management.  
 
 Secondary Objectives  
 
 To determine the range and prevalence of different beliefs, attitudes and 
barriers to screening. 
 To assess the impact of contextual variables and demographics as well as 
health literacy in the uptake rate of screening and subsequent treatment 
engagement. 
 To assess treatment adherence between patient groups receiving treatment 
within the community care setting against standard hospital care. 
 To determine the cost effectiveness of the interventions 
 To determine the prevalence of viral hepatitis in different ethnic groups living 
in the UK 
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Primary Endpoint 
 
 The proportion of patients eligible to be screened (determined by a review of 
the number of immigrants registered at the GP practice at the initiation of the 
study)  
 The proportion of potential participants that attend for testing  
 The proportion of potential participants that engage in therapy in the 
different treatment arms. Engagement is defined as:  
o Attending  at least 3 different occasions 
o For patients who are HCV antibody positive or equivocal but HCV 
RNA negative attending the GP practice or the local hospital on two 
separate occasions. 
 
         Secondary Endpoint  
 
 Adherence will be measured upon 80% completion of prescribed therapy, as 
confirmed at 12 month follow up. However, if the participant is under active 
monitoring, adherence will be measured by their level of engagement as 
defined above.  
 
2.2    Trial Design  
 
It is a two stage cluster randomised trial. The first stage (two arms) determines how to 
effectively identify and screen immigrants from ‘at risk’ ethnic minority communities for 
chronic viral hepatitis. Within the first stage of the trial we will determine whether or not 
patients who receive an enhanced patient information invitation letter agree to participate in 
testing at the same rate as patients who receive a standard patient information invitation 
letter. 
The second stage (two arms) investigates if treatment in primary care (community based 
therapy) impacts on the engagement of follow up and treatment. There will be an in-depth 
investigation into a small subset of these participants to assess impact of contextual variables 
and demographics as well as health literacy in the uptake rate of screening and subsequent 
treatment engagement. 
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2.3    Main Study Scheme Diagram  
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3.      Subject Selection 
 
3.1    Number of Subjects and Subject Selection  
 
Stage 1 
 
Up to 48,000 prospective patients from known ethnic minority populations will be contacted 
(interventional screening). First and second generation immigrants from known ‘at risk’ 
communities (as detailed in appendix 2) will be identified utilising GP practice list definitions 
of ethnicity.  
 
Prior to the commencement of screening, up to 8 ‘intervention’ GP practices will be involved 
in generating a representative random sample identified by ethnicity group. The sample will 
reflect the wider population of those that are potentially eligible for screening. Up to 3500 of 
the pool of potential participants will be contacted to take part in the pre-screening survey 
component. 
 
Potential participants from GP practices employing interventional screening will be 
approached in a number of different methods in accordance with local clinical practice. 
Patients will be contacted either by letter, text message or opportunistically when visiting the 
GP. In all circumstances the patient will be given time to consider whether or not they wish to 
participate and patients may choose to re-attend the practice at a later date to confirm 
participation.    Written Informed Consent will be taken from the patient prior to 
commencement of the screening process. Patients will then be tested using standard local 
testing approaches – in practices with on-site phlebotomy we will use local phlebotomy and 
for practices that refer patients for blood testing the usual referral policy will be followed. 
Once the results are available, the patient will be contacted.  If tested positive for viral 
hepatitis, the patient will be invited to re-attend the GP practice to receive their result and 
patients will then be offered appropriate therapy. At this stage patients who have tested 
positive for infection will be offered the choice of continuing with standard management (i.e. 
treatment within hospital) or taking part in Stage 2 of the study in which standard 
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management is compared with community care (see section 4.1.3 for full detail of the 
invitation and consent procedures) 
 
Immigrant demographics from control GP practices for a further 4,000 potential participants 
will be monitored with regards to testing for viral hepatitis and how many engage with 
regards to subsequent treatment. This will be fully anonymised prior to data being exported 
and sent to the data management team for data collection.  
 
Screening and treatment of the identified patients will last for 2 - 3 years with a staggered 
approach to GP site initiations to ensure a consistent flow of patients. 
 
Stage 2  
 
GP practices employing interventional screening will be randomised into two different arms, 
hospital treatment (standard care) or community care treatment. In GP practices that are 
randomised to the hospital treatment arm, participants that are found to be positive for viral 
hepatitis will be treated at their local hospital, as per standard care. In GP practices 
randomised to the community care arm, participants that are found to be viral hepatitis 
positive will be treated for viral hepatitis in a local GP practice by a member of the clinical 
hepatology team. 
 
3.2 Inclusion Criteria 
 
Stage 1  
 > 18 years old  
 First and Second Generation immigrants of appropriate ethnicity (born or born 
to parents that originate from a country of high prevalence (Please see Appendix 
2 for comprehensive list of countries listed by WHO as >2% HBV prevalence) 
Stage 2  
 Inclusion is as for Stage 1 , with the additional criteria: 
 Patient who test positive for viral hepatitis during screening  
 343 
 
 
3.3 Exclusion Criteria 
 
Stage 1 
 <18 years old  
 Lacking capacity 
 
Stage 2  
 Exclusion is as for Stage 1 , with the additional exclusion criteria: 
 Patients that screen negative for viral hepatitis  
 
3.4 Premature withdrawal 
 
Withdrawal of informed consent. 
Data up to the point of withdrawal will be retained and used in the analysis. 
 
 
4.      Study Procedures  
 
4.1 Informed Consent Procedures  
 
4.1.1 Consent for the Pre-screening Component (Survey) 
 
For the subset of participants to be approached for this survey completion, it is proposed that 
verbal consent be sought. The fundamental principles that underlie both verbal and written 
consent are, in essence, the same. The main issue surrounds informing the potential 
participant as to the nature of the research, their rights and safety as participants and making 
explicit that participation is voluntarily and can be revoked at any time without reprisal. From 
our previous work, we discovered that ethnic minorities were often willing to participate but 
concerned about signing anything, perhaps if there literacy problems or concerns about 
‘authorities’ not acting in their interest which is common amongst refugees, for example, or 
recent migrant who may be settling into a new life.  
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There is an element of culturally sensitivity that should be observed within this potential 
participant-population as many will see the signing of forms as an official act with subsequent 
retributions in the future. This may be seen as having negative connotations, bringing about 
considerable scepticism relating to participation. Verbal consent may be deemed as a less 
threatening act. It is known that there is incidence of illiteracy and semi-illiteracy in this 
particular population demographic.  
 
The main concerns are to not discriminate against participation by using a methodology that 
reduced their chances of participation because of language or cultural factors, or issues 
related to social exclusion; for example, postal addresses may chance if the population are 
mobile, or shared accommodation, or loss of post may be factors in non-response.  
 
HRA guidance ‘Consent& Participation Information Sheet Preparation Guidance’ released on 
March 3
rd
 2014, details that participants can give ‘written, oral or non-verbal’ consent. The 
objective is to ensure that the patient’s decision is recorded and that discussions that 
surround this decision  
 
It is likely that the vast majority of the interviews are likely to be conducted via telephone as 
to create minimal intrusion or disruption on account of participation, written consent may not 
be seen as the most practical route of obtaining consent. However, it will be made explicit 
that the consent can be withdrawn at any point during the course of the interview. This 
methodology has been tested previously and worked successfully with ethnic groups in 
primary care.  
 
As detailed by NRES Guidance, Annex 5: Consent and its problems – the stipulation of written 
informed consent could be act as a barrier to recruitment, particularly when there is an 
imperative need  to obtain a representative sample, with the potential benefit deemed 
significant. 
 
The intended mechanism, as discussed with the sponsor, is to use patient information letter 
and using the HRA template consent form as a means of obtaining informed verbal consent, 
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at minimum at the start and the end of the interview. The participant will be allowed to ask 
any further questions to ensure that they have understood what is involved and their 
participation is voluntary, and can be withdrawn at any time. This demonstrates that consent 
an ongoing process and not a one off event. If required, it will be repeated and enforced 
during the course of the interview.  Although, in the first instance, the crucial time points are 
at the commencement of the interview and at the end. This process has been discussed with 
the sponsor, and they have indicated their approval for the research team to proceed. 
 
In each instance, verbal consent will be taken in the presence of an independent witness and 
adequately documented. A similar methodology has been used in previous studies of East 
London immigrants, within a survey in primary care of different ethnic groups (Rudell, K. et 
al., 2009). 
 
4.1.2 Consent for Stage 1 of the Trial 
 
Stage 1 of the trial is investigating two different methods of screening, i.e targeted screening 
which takes place at intervention practices or current standard practice at control practices.  
 
4.1.2.1 Consent for the Screening at Intervention Practices 
 
In the intervention practices, it is the responsibility of the investigator, or a person delegated 
this task by the investigator, to obtain written informed consent from each subject to the 
testing and data collection for further analyses (specifically they will be asked if they agree to 
allow the HepFree trial team to access their medical records and for data held by The Health 
and Social Care Information Centre to be made available to the research team.  The 
investigator will adequately explain the aims, methods, anticipated benefits, and potential 
hazards of these procedures. In the case where the patient is unable to read, an impartial 
witness should be present during the entire informed consent discussion. After the subject 
has orally consented to participation in the trial, the witness’ signature on the form will attest 
that the information in the consent form was accurately explained and understood. The 
investigator or designee must also explain that the subjects are completely free to not to be 
tested or to withdraw consent for data collection at any time. If participants do not wish to 
allow certain aspects of their data to be collected this can be indicated in the consent form. 
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They will still be able to enter the study but in this case only anonymised aggregate data will 
be collected for analysis. 
 
4.1.2.2 Consent for Screening at Control Practices 
 
In control GP practices, fully anonymised demographic data will be collected, with no patient 
identifiable information being collected or viewed outside the direct healthcare team. 
Information collected will be the number of individuals registered at the practice from each 
minority group, the number of these individuals that have been tested for viral hepatitis, the 
number of which tested positive, the number of individuals that engaged in their therapy. 
This is in line with Department of Health’s Advisory Group on Hepatitis, recommending 
systematic case finding in primary care for chronic HBV/HCV infected individuals from 
minority ethnic populations that are born in countries that have intermediate to high 
prevalence of HBV infection. If testing positive, there should be contact tracing of close 
contacts including family members whilst infected individuals will be managed as per 
standard clinical care.  
 
 We are hoping to establish a true and accurate indication of viral hepatitis screening and 
engagement rates in communities of high risk immigrants.  Individual participant informed 
consent will not be sought as it would add a source of contamination bias to the true patient 
screening and engagement rates. This could compromise the scientific integrity of the study if 
this has an impact on their behaviour. 
 
However, no personal or patient identifiable information will be required – all data will be 
fully anonymised and only demographic numbers (as detailed above) will be used as data for 
the study in relation to the control cluster of GP practices.  
 
Patients that test for viral hepatitis in control practices will be counselled by their doctors 
about chronic viral hepatitis (standard medical practice) and they will give verbal consent to 
for this test. Hence there will be minimal differences between the control group and the 
intervention group. 
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4.1.3 Consent for Stage 2 of the trial  
 
Patients eligible for stage 2 of the trial (testing positive for viral hepatitis in the screening 
intervention practices) will be invited to participate by a member of the clinical hepatology 
team. A patient information sheet will provide a comprehensive account of the 
treatment/monitoring phase (stage 2) of the trial enabling the participant to make an 
informed decision as to whether they would like to remain on the trial or not. The patient 
information sheet will not indicate whether the patient’s GP practice was randomised to 
standard care (care in hospital as per standard practice) or intervention (care at a local 
community care practice) arm.  The investigator, or delegated member of the HepFree team, 
consenting the eligible patients will not be aware of the patient’s allocation at the time when 
consent is sought (see section 4.2.4). Participants that consent to take part in this second trial, 
will subsequently be informed of their treatment/monitoring allocation by the doctor or 
health care practitioner who will manage their treatment. Participants that do not wish to 
take part in the second stage of the trial will be treated as per standard care. Treatment 
allocation will be concealed until after consent to participate in the trial has been obtained, in 
an effort to prevent bias between recruitment into the two arms of the trial (community vs 
hospital care).  Patients will be explicitly informed of their right to withdraw from the study if 
they are not comfortable with their treatment allocation at any point.   If a participant 
subsequently withdraws consent to the trial they will be treated as per standard of care (see 
section above).  
 
4.2 Study Procedure Overview 
 
56 GP practices across East London, South London and Bradford will be invited to participate 
within this study. Practice selection will be based on an established patient population of first 
and second generation immigrants from ‘at risk’ countries. The GP practices will either be 
allocated to one of the following five groups: 
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A) Control screening practices 
B) Intervention screening practices with standard hospital treatment, standard 
invitation 
C) Intervention screening practices with standard hospital treatment, enhanced 
invitation  
D) Intervention screening practices with community care to be offered, standard 
invitation 
E) Intervention screening practices with community care to be offered, enhanced 
invitation 
 
In the first stage of the trial to assess screening methods we will compare group A with all the 
others combined. 
In the second stage trial to assess treatment options we will compare groups B & C with 
groups D & E 
In a supplementary analysis to assess the enhanced invitation we will compare groups B & D 
with groups C & E 
 
4.2.1 Pre-screening Component (survey)  
 
A small subset of up to 3500  potential participants from up to 8 of  targeted screening 
practices, form the sample for a population based survey of those eligible for screening, in 
order to assess characteristics of take or decline, at all stages of the project. 
 
The patients will be asked about their illness perceptions and narratives (called explanatory 
models) about hepatitis using an adapted version of the Barts Explanatory Model Interview 
checklists. These have been developed from focus groups and literature review information, 
following the methods set out in the original development for use in common mental 
disorders. Three other validated patient-reported outcomes will be completed by interview: 
patient health questionnaire (PHQ-9) and the generalized anxiety disorder 7-item (GAD-7) 
scale. 
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Some information about the individual will be available from primary care electronic 
databases, that will help establish the need for translated material or not. Potential 
participants will be contacted by a letter of invitation to participate within the survey, with 
further information detailing the project (in English or appropriate translation).  
 
The letter would detail what is involved and that agreement or not to complete 
questionnaires is completely voluntary. In the first instance, telephone interviews will be the 
primary choice used for completion. However, the invitation letter will detail and 
accommodate if the participant prefers to receive an interview face to face, or if they prefer a 
postal survey. The letter will also indicate that contact after 2 weeks will be made to ascertain 
if they would be willing to participate. 
 
After 2 weeks, potential participants will be contacted from the GP practice, via telephone (up 
to 3 times) to confirm if they received the letter and If they have any questions for the GP or 
the research team, indicating that they are happy to continue and participate. 
 
If the participant indicates that they are willing to be interviewed over the phone, verbal 
consent in the presence of a witness will be sought with appropriate language translation (as 
required) and documented. It will be highlighted that participation is voluntary and the 
interview can be stopped at any time, if they do not wish to continue. The interview will be 
concluded with a documented verbal consent. 
 
If the participant details that they would prefer to complete the surveys via post, all 
documents with instructions will be forwarded with a self-addressed envelope with a contact 
telephone number for any enquiries. If, the participant details that they would prefer face to 
face interview, a suitable time will be arranged with appropriate language translation (as 
required) to attend the GP practice. 
 
4.2.2 Screening in Control GP Practices  
 
In the control group arm, existing GP registers of patients will be screened to identify patients 
that fit the HepFree eligibility criteria, by their country of birth or their parents’ country of 
birth. In conjunction with this, a local hepatologist or a trained member of the study team will 
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visit the GP practices, highlighting the study to the GPs and their teams and educating them 
about hepatitis B and C. These practices will continue with their standard care policy relating 
to screening over the 12 – 18 months of screening. 
 
4.2.3 Screening at Intervention Practices 
 
In the intervention practices, existing GP registers of patients will be screened to identify 
eligible patients by recorded ethnicity, country of birth or their parents’ country of birth and 
first language spoken. Potential participants identified as first or second generation 
immigrants without HBV or HCV status, will either be contacted or approached to take part in 
the trial . 
 
Potential participants for screening will be invited by their GP practices to have a blood test 
for viral hepatitis.  The GP, or delegated and trained members of staff, will provide a copy of 
the patient information sheet and informed consent form (in English or appropriate 
translation, if applicable). This will explain the details of the study relating to screening and if 
they test positive for viral hepatitis. 
 
After up to 4 weeks, participants that have been sent an invitation letter may be contacted to 
ensure receipt of the letter. If they wish to attend, an appointment will be made. 
Alternatively, participants can also contact or attend their GP to discuss further and decide 
whether to be tested.  
 
Approximately 48,000 ‘targeted’ patients from ‘at risk’ countries will be approached over a 
maximum18month period. All those screened and tested positive for viral hepatitis will either 
be offered treatment in the specialist out patients clinic in their local hospital or in an 
‘intervention practice’ as part of community care. The location of where patients receive their 
treatment will be dependent on the interventional cluster allocation. 
 
During the screening period, a hepatitis awareness campaign will be set up and conducted by 
a local community group within East London during the screening period. It will involve a 
series of awareness videos to be broadcast on local immigrant channel/ stations as well as 
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producing awareness posters to be displayed in local community centres to try and raise 
awareness and local knowledge about Hepatitis B and C. The impact of this awareness 
campaign will be assessed by looking at screening uptake rates of the practices within the 
area. This awareness campaign will also be fed into the cost benefit analysis of screening. 
 
4.2.4 Participants with Chronic Viral Hepatitis 
 
Participants who test positive for viral hepatitis, and consent to remain on the study, will 
receive treatment/monitoring in the specialist out patients clinic in their local hospital or in 
alocal community care practiceas part of community care. The treatment option for each 
patient will depend on the allocation of their practice, whether to the treatment intervention 
(local community care practice) or control arm (standard hospital). To reduce the chance of 
bias between the two arms, consent to be part of the second stage trial will be sought for 
both arms in the same way, by a member of the direct clinical care team, who, ideally, will be 
blinded to allocation. The status of the person seeking consent will be documented. Consent 
will be sought on the participant’s first visit to see the clinical hepatology team, after 
receiving their positive result for viral hepatitis. If the participant consents to remain on the 
study, they will be unblinded to their treatment allocation.  
 
Patients who test positive for viral hepatitis will be monitored for their level of engagement as 
well as treatment adherence as a secondary study outcome. Engagement will be measured 
relating to the patient’s attendance and we will define ‘engaged’ as:  
- Attending three visits after receiving a viral hepatitis positive result over the first 12 
months 
- OR  
- For patients who are HCV antibody positive or equivocal but HCV RNA negative 
attending the GP practice or the local hospital on two separate occasions 
 
This will allow an assessment of engagement in patients who do not wish to receive or are not 
suitable for antiviral therapy at this time. Attendance at 12 month follow up will be captured 
to ascertain if the patient was engaged and adhered to their care and treatment. Patients 
who undergo therapy will be assessed for adherence by treatment compliance - taking more 
than 80% of the prescribed medication.  
 352 
 
 
Patients will either receive their standard local hospital care upon referral from the 
designated practices, in which case local consultant physicians will manage their treatment 
and monitoring in line with current practice. In ‘community care’ practices, patients who 
agree to undergo therapy in the community will be asked to attend a designated GP practice 
where a specialist viral hepatitis nurse and/or hepatologist will attend and deliver care in the 
community in accordance with a community treatment algorithm established and supervised 
by the local secondary care centre (see section 4.4). 
 
4.3 Screening/Randomisation Procedure  
 
Each GP practice will be randomised to one of the five arms at the outset. See section 4.2 for 
detail. Randomisation is undertaken by the Pragmatic Clinical Trials Unit.56 Practices are to be 
stratified by region in conjunction to be minimised by the number of eligible patients. 
 
4.4   Schedule of Treatment 
Standard therapy for chronic viral hepatitis will be provided as described in Section 4.2.4 
Treatment and any related decisions will be overseen by a named local specialist 
consultant, with GP input and nurse management, in line with usual standard of care.  
 
4.5  Schedule of Assessment  
 
Patients who fit the eligibility criteria will be invited to attend for hepatitis B and C screening. 
If an eligible patient attends their GP practice during the HepFree screening period, they may 
be opportunistically offered hepatitis B and C screening, providing informed consent is 
sought. Once written informed consent is in place, the patient will provide a blood sample for 
testing, following local phlebotomy services and provisions. The patient will be re-contacted 
to receive the test results. To meet the primary objectives of this study the viral hepatitis 
screening outcome will be collected by the research team and this data will be provided to 
the research team in an anonymised format, linked only to an anonymised identifier. Thus the 
participant’s identity could not be deduced from the HepFree database. The identity of the 
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participant will not be known to anyone outside the direct clinical care of the participant, or 
members of the virology team, as per standard practice.  
 
Patients, who test positive will be contacted, to visit their practice to receive their result. If 
unsuccessful, these patients will be recorded as being ‘non-attenders’ 
 
If the patient tests positive, the patient will be treated at either their local hospital specialist 
centre or stay in community care under supervision of the hepatology consultant and nurse at 
the ‘community care practices’. On a regular basis, a member of the team will conduct review 
of specific referral forms or accesses the patient’s electronic records via CRS/PAS/EMIS Web 
as well as review of the appointment system to capture patient engagement as defined in 
section 4.1.3.  
 
For HCV or HBV patients that require immediate therapy, oral and injectable medication 
adherence will be monitored and logged  as detailed by clinical assessment of the patient’s 
condition. Overall assessment of adherence will completed at 12 month follow up by the 
research team. 
 
4.6     Laboratory Assessments(see section 5 for further information) 
 
4.7 End of Study Definition 
The end of study will be defined when the final patient has been assessed for 
engagement, and is documented as attending or not attending their 12 month follow 
up. 
 
4.8    Subject Withdrawal 
 Subjects have the right to withdraw consent at any time and those who do so will have 
no further contact with the study team. Where feasible, reason for withdrawal will be 
documented. 
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4.9 Data Collection and Follow up for Withdrawn Subjects 
Patients that withdraw consent or drop out will be replaced and the withdrawal will be 
documented, e.g. CRF and the medical records.  
 
5.      Laboratories  
5.1 Local Laboratories  
 
 Blood samples will be taken from local sites phlebotomy and sent to local virology 
laboratories for analysis.  
 Blood samples will be measured for HbsAg and Anti-HCV as part of the screening 
process.  
 GP practices and local virology laboratory teams will liaise closely to ensure that 
participants that screen receive their result, as per standard practice. GPs will make the 
virology team aware of patients that consent to the HepFree trial. As the screening 
outcome directly relates to the primary objective of this study, the HepFree research 
team will liaise with both the GP practices and virology laboratories to ensure that 
screening outcome is captured accurately for participants. The identity of the 
participants will not be disclosed to the HepFree research team as the screening results 
will be linked to an anonymised number.  
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6. Safety Reporting 
 
6.1 Serious Adverse Event Reporting  
 
In non-CTIMPs a serious adverse event (SAE) is defined as an untoward occurrence that: 
a) Results in death 
b) Is life threatening 
c) Requires hospitalization or prolongation of existing hospitalization  
d) Results in persistent of significant disability or incapacity 
e) Consists of a congenital abnormality of birth defect 
f) Is otherwise considered medically significant by the investigator 
 
 
An SAE occurring to a research participant should be reported to the main REC (i.e. the REC 
that gave a favourable opinion of the study) where in the opinion of the Chief Investigator the 
event was: 
 
a) Related – that is, it resulted from administration of any of the research 
procedures and 
b) Unexpected – that is, the type of event is not listed in the protocol as an 
expected occurrence 
 
Any hospitalization or other SAE that in the opinion of the CI is related to the trial and 
expected for this population will not be reported to the sponsor or the REC. 
 
SAEs however that are deemed to be related to the trial and/or unexpected will be reported 
to both the sponsor within 24 hours of the CI becoming aware of the event and the REC 
within 15 days of the CI becoming aware of the event. 
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6.2   Adverse event reporting 
 
In non-CTIMPs, an adverse event (AE) is any untoward medical occurrence in a patient or 
clinical investigation subject exposed to a research procedure which does not necessarily 
have a causal relationship with that procedure.  
 
An adverse event can therefore be any unfavourable and unintended sign or symptom of 
disease temporarily associated with their exposure to a research procedure whether or not 
related to that procedure. 
 
7. Statistical Considerations 
7.1   Sample Size 
We have assumed an intra-cluster correlation co-efficient of 0.05 for all outcomes and a 
coefficient of variation of cluster size of 0.65. The sample size is driven by the second stage 
trial, primary comparison, since this involves a smaller number of practices and patients.  We 
assume that 40% of patients will be screened and of these 3% will test positive. To detect a 
difference from 50% to 70% engaged; with 90% power at the 5% significance level requires 55 
practices which also accounts for drop outs. With the number of practices in each of the 
standard care/community care arms, the control practices will be able to detect an increase in 
screening from 15% to 40% with 90% power (first stage of the trial) which will allow for drop 
outs.   
 
7.2    Statistical Analysis 
 
No interim analyses are planned. A 5% level of significance will be used. Due to the nature of 
the outcomes we anticipate few missing values. We will use available case analysis, ie all 
individuals on whom we have outcome data. 
 
Baseline comparisons of both cluster and individual characteristics will be presented. We will 
report separate analyses using generalized estimating equations for the main analyses for our 
three comparisons as follows:- 
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7.3.1 Primary Endpoint Effectiveness Analyses 
 
Stage 1:  
A) Control vs intervention screening, outcome = testing rates 
Generalised estimating equations using logit link to account for binary outcome as primary 
analysis, accounting for region, cluster size (number of individuals eligible to be tested) A 
cluster-level t-test as sensitivity analysis. 
 
B)   Standard invitation v enhanced invitation (outcome = testing rates 
Generalised estimating equations using logit link to account for binary outcome, accounting 
for region, cluster size (number of individuals eligible to be tested). 
 
Stage 2: 
Main comparison: Standard treatment v treatment in community outcome = engagement 
rates. Generalised estimating equations using logit link to account for binary outcome as 
primary analysis, accounting for region and cluster size.  
 
7.4 Secondary Endpoint Effectiveness Analysis  
 
Stage 2 of the trial: Adherence will be analysed using the same principles as discussed in 
section 2.1. 
 
 We will use the intention to treat principle when identifying which clusters and arms to 
analyse individuals in. Thus if patients switch between practices before their test results are 
available they will be analysed in the practice they were in when randomization took place in 
relation to the first stage of the trial comparison and B but in the practice to which they 
moved to in relation to comparison C (because at this stage the trial to test the effect of 
community care on engagement will not have started). 
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8.        Data Handling & Record Keeping 
 
8.1 Data Management 
 
For stage 1 of the trial electronic data capture will be supported by the in-house GP practice 
database, such as EMIS WEB and SystemOne, by a HepFree specific template. Only authorized 
personnel will have access to the EMIS/SystemOne database at the practice level. Data 
relating to the primary outcome will be collected in an identical way between control and 
intervention practices. In intervention practices data from participants who have agreed to 
share personal data with the trial team will be included in the cost effectiveness analysis. 
 
Data files containing HepFree specific data will be transferred from the GP practices to the 
HepFree data management team via a method deemed secure and in accordance to 
information governance policy.   
Once HepFree data files are securely received by the data manager they will be uploaded 
onto a dedicated folder on the secure virtualised environment at the Barts Cancer Centre 
(BCC).  This is where all data analysis of PCTU trial data is carried out.  The BCC environment 
requires a two factor authentication to access the portal via Citrix and the folders where the 
data is stored are only accessible to the appropriate members of the PCTU and HepFree trial 
team. 
 
The data files will be imported into a template Access database, within the BCC network,  
where various data integration steps will be performed to remove any duplication, 
standardise and ensure data quality. 
 
For Stage 2 of the trial, trial specific data will be collected using Case Report Forms within an 
electronic data capture program hosted by a secure online data management system called 
OpenClinica. The CRFs can be accessed via an encrypted and secure uniform resource locator 
(URL) using a unique username and password, which is externally validated, and the details of 
the validation will be held in electronic files by the PCTU. Only authorised members of the 
HepFree team, who are fully trained, will be granted user accounts. A full audit trail will be 
accessible to data managers at the PCTU and relevant members of the HepFree team.  The 
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OpenClinica software is provided by OpenClinica and is hosted on a server by their hosting 
partner in the UK. 
The trial statistician will receive a fully integrated dataset which is blinded to GP trial 
allocation and GP location (South or East London or Bradford).   
 
For the Pre-screening survey paper questionnaires will be used in the first instance. Data from 
these questionnaires will be entered into an OpenClinica database in the same way as 
described for Stage 2 of the trial above. The electronic survey will be designed to mirror the 
paper survey to ensure data is transferred accurately.  
  
The HepFree team will implement a data management plan, which will be approved and 
overseen by the PCTU, to ensure data security, quality and accuracy.  
 
8.1.1     Confidentiality  
 
The Investigator has a responsibility to ensure that patient anonymity is protected and 
maintained. They must also ensure that their identities are protected from any unauthorised 
parties. Information with regards to study patients will be kept confidential and managed in 
accordance with the Data Protection Act, NHS Caldicott Guardian, The Research Governance 
Framework for Health and Social Care and Research Ethics Committee Approval. 
 
All documentation containing patient identifiable data (PID), such as informed consent forms 
and contact details, will be stored separately from case report forms, adverse event logs. 
 
8.2    Study Documents   
 
 A signed protocol and any subsequent amendments 
 Current/Superseded Patient Information Sheets (as applicable) 
 Current/Superseded Consent Forms (as applicable)Indemnity documentation from 
sponsorConditions of Sponsorship from sponsor Conditional/Final R&D 
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Approval Ethics submissions/approvals/correspondence CVs of CI and site 
staff 
 Laboratory accreditation letter, certification and normal ranges for all laboratories 
to be utilised in the study Delegation log Enrolment log  
 Study specific and PCTU SOPs  
 
8.3 Case Report Form 
 
All parameters relating to testing and engagement will be captured on eCRFs 
 
8.4 Record Retention and Archiving 
 
During the course of research, all records are the responsibility of the Chief Investigator and 
must be kept in secure conditions. When the research trial is complete, it is a requirement of 
the Research Governance Framework and Trust Policy that the records are kept for a 
further 20 years. For trials involving BLT Trust patients, undertaken by Trust staff, or 
sponsored by BLT or QMUL, the approved repository for long-term storage of local records is 
the Trust Modern Records Centre which is based at 9 Prescot Street. Site files from other sites 
must be archived at that external site and cannot be stored at the Modern Records Centre. 
 
8.5 Compliance 
 
The CI will ensure that the trial is conducted in compliance with the principles of the 
Declaration of Helsinki (1996), and in accordance with all applicable regulatory requirements 
including but not limited to the Research Governance Framework, Trust and Research Office 
policies and procedures and any subsequent amendments. 
 
8.6    Clinical Governance Issues 
8.6.1      Ethical Considerations 
This protocol and any subsequent amendments, along with any accompanying material 
provided to the patient in addition to any advertising material will be submitted by the 
Investigator to an Independent Research Ethics Committee. Written Approval from the 
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Committee must be obtained and subsequently submitted to the JRO to obtain Final R&D 
approval. 
 
8.7      Quality Control and Quality Assurance 
8.7.1       Summary Monitoring Plan 
 
Will be in accordance with the sponsor based risk assessment and monitoring will follow 
sponsor and PCTUSOPs. 
 
8.7.2      Audit and Inspection 
 
Auditing: Definition “A systematic and independent examination of trial related activities and 
documents to determine whether the evaluated trial related activities were conducted, and 
the data were recorded, analysed and accurately reported according to the protocol, 
sponsor's standard operating procedures (SOPs), Good Clinical Practice (GCP), and the 
applicable regulatory requirement(s).” 
 
A study may be identified for audit by any method listed below:  
1. A project may be identified via the risk assessment process. 
2. An individual investigator or department may request an audit. 
3. A project may be identified via an allegation of research misconduct or fraud or a suspected 
breach of regulations. 
4. Projects may be selected at random. The Department of Health states that Trusts should be 
auditing a minimum of 10% of all research projects. 
5. Projects may be randomly selected for audit by an external organisation. 
 
Internal audits will be conducted by the sponsor as per their SOPs and by the PCTU Quality 
Assurance Management team.  
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8.8 Non-Compliance   
 
A noted systematic lack of both the CI and the study staff adhering to sponsor and PCTU  
SOPs and the protocol leads to prolonged collection of deviations, breaches or suspected 
fraud.) 
These non-compliances may be captured from a variety of different sources including 
monitoring visits, CRFs, communications and updates. The PCTU will maintain a log of the 
non-compliances to ascertain if there are any trends developing which to be escalated. The 
sponsor will assess the non-compliances and action a timeframe in which they need to be 
dealt with. Each action will be given a different timeframe dependent on the severity. If the 
actions are not dealt with accordingly, the JRO will agree an appropriate action, including an 
on-site audit. 
 
9.      Trial Committees  
 
9.1  Trial Steering Committee 
 
There are plans to have a steering committee in place for the study. It is intended that the 
committee will meet at least twice a year to review progress. They will have the authority to 
halt the program for reasons of non-progression or unacceptable ethical/safety issues. 
 
9.2  Trial Management Committee 
 
There will also be a management group put in place for this study which will meet three times 
annually. The management group will monitor progress and will implement any modifications 
the conduct of the study as appropriate, to be submitted to ethics for their approval. 
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9.3  Trial Team Meetings  
 
HepFree team meetings will be scheduled on a weekly basis to review study progress and 
address any issues that may arise. If necessary the trial team will report the Trial 
Management Committee and the Trial Steering Committee.    
 
10.     Publication Policy 
All publications from the study will be published with joint authorship. No member of the 
study team may publish any data from the study without the express consent of the 
management committee. 
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Appendix 1– Information with regards to Safety Reporting in Non-CTIMP Research 
 Who When How To Whom 
SAE Chief 
Investigator 
-Report to 
Sponsor within 24 
hours of learning 
of the event 
 
-Report to the 
MREC within 15 
days of learning 
of the event 
 
SAE Report form 
for Non-CTIMPs, 
available from 
NRES website. 
Sponsor and 
MREC 
Urgent Safety 
Measures  
Chief 
Investigator  
Contact the 
Sponsor and 
MREC 
Immediately 
 
Within 3 days  
By phone 
Substantial 
amendment form 
giving notice in 
writing setting 
out the reasons 
for the urgent 
safety measures 
and the plan for 
future action. 
Main REC and 
Sponsor  
Main REC with a 
copy also sent 
to the sponsor. 
The MREC will 
acknowledge 
this within 30 
days of receipt.  
Progress 
Reports  
Chief 
Investigator  
Annually ( starting 
12 months after 
the date of 
favourable 
opinion) 
Annual Progress 
Report Form 
(non-CTIMPs) 
available from the 
NRES website 
Main REC 
Declaration of 
the conclusion 
or early 
termination of 
the study 
Chief 
Investigator  
Within 90 days 
(conclusion) 
 
Within 15 days 
(early 
termination) 
 
The end of study 
should be defined 
in the protocol 
End of Study 
Declaration form 
available from the 
NRES website 
Main REC with a 
copy to be sent 
to the sponsor  
Summary of 
final Report  
Chief 
Investigator 
Within one year 
of conclusion of 
the Research 
No Standard 
Format 
However, the 
following 
Information 
should be 
Main REC with a 
copy to be sent 
to the sponsor 
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included:- 
Where the study 
has met its 
objectives, the 
main findings and 
arrangements for 
publication or 
dissemination 
including 
feedback to 
participants 
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Appendix 2: The presentation handout distributed to all staff at the site initiation visit 
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Appendix 3: The HepFree trial invitation letters (standard and enhanced) version 1.0 
[GP surgery address/ headed notepaper] 
Dear Sir or Madam, 
 
We are writing to you, from your local GP surgery, to ask if you would take part in a research 
project that we are undertaking.  
 
We know that people who were born outside the UK and their children have a higher rate of 
infection with Hepatitis B and C Virus. Unfortunately, they are often “silent” diseases, and 
people are unaware that they are infected. These viruses can cause more serious liver illness 
that needs treatment. At the moment, we do not know the best way to identify the people 
who have Hepatitis B and C from amongst those who are at risk. This practice has therefore 
agreed to take part in a research project that will try to answer this question. 
 
We are offering you a blood test for Hepatitis B and C. This will involve a short visit to your GP 
where a member of our team will discuss Hepatitis B and C. You can then decide what you 
would like to do. The blood taking itself takes only a few minutes. You will be informed about 
the results of all your tests. Should you be infected you will receive advice and will be 
assessed at your local specialist clinic and offered treatment, if necessary.  
 
If you would like to talk about the project further or ask questions please contact the GP 
surgery. A member of the team may contact you to see if you would like to book an 
appointment to take part in the project, or you can call or attend your GP surgery.  You can 
leave this project whenever you want without giving a reason and this will not affect your 
medical care.  
Yours sincerely,  
 
_________________                                                           _____________________ 
GP       Hep Free/ QMUL rep 
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Appendix 3: The HepFree trial invitation letters (standard and enhanced) version 1.0 
[GP surgery address/ headed notepaper] 
Dear [Name of patient],  
We are writing to tell you that your GP surgery is working on a new project with a research 
team from Queen Mary University of London.The aim of the project is to encourage more 
people in London and Bradford to get a free test for Hepatitis B and Hepatitis C. These are 
viruses that can affect the liver and may need treatment. It is very important that the 
Hepatitis B and C viruses are found and treated early, so that people can live a longer and 
healthier life. Your GP surgery and the research team hope to test people for Hepatitis B and 
C, so that we can offer advice and free treatment to people who test positive for Hepatitis 
B/C. 
 
We would like to offer you the opportunity to have a free, simple blood test for Hepatitis B 
and C organised by your GP surgery.Receiving this letter does not mean that the GP thinks 
you are ill. Many other people from the GP surgery have also received this letter and have 
been offered the test.We hope as many people as possible will take this opportunity for an 
important free health check. 
 
If you agree to have a Hepatitis B/C test, this will involve a 10 minute visit to your GP 
surgery. The GP will discuss hepatitis with you and organise the test. The test will draw a 
small amount of blood from your arm and this blood will only be tested for Hepatitis B/C.  
 
Included on the back of this letter is an information sheet to tell you more about Hepatitis B 
and C. If you would like to talk about the project further or ask questions please contact the 
GP surgery. A member of the team may contact you to see if you would like to book an 
appointment to take part in the project, or you can call or attend your GP surgery.  You can 
leave this project whenever you want without giving a reason and this will not affect your 
medical care.  
Yours sincerely,  
_________________                                                           _____________________ 
GP       HepFree/QMULrep
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WHY HAVE I BEEN INVITED FOR A TEST? 
Receiving this letter does not mean that the GP thinks you are ill. We have 
sent this letter to many other people from the GP surgery in order to encourage 
as many people as possible to have a test for Hepatitis B and C.  
Many people around the world are infected with Hepatitis B and Hepatitis C. 
There are high rates of these viruses in countries in Asia, Africa and 
Eastern Europe, so people who move from these regions to the UK may be at 
increased risk of having these viruses. It is very important that these viruses 
are found and treated, to promote healthy living and save lives. 
 
WHAT WILL HAPPEN IF I GO FOR A TEST? 
If you agree to have a test for Hepatitis B and C, this will involve a 10 minute 
visit to your GP surgery. The GP will discuss hepatitis with you and take a small 
amount of blood to test for Hepatitis B and C. The test will be free of charge. 
 
WHAT WILL HAPPEN AFTER THE TEST? 
Within 3 weeks, you will be contacted by the GP surgery, in order to receive the 
results of your test. If the test shows that you have Hepatitis B or C then 
you will be offered advice and free treatment. Your GP will discuss with you 
whether you will need to take medication to treat or manage the infection. Any 
treatment provided will be free of charge. 
 
CONFIDENTIALITY 
Like all appointments at the GP surgery, if you decide to come for a test for 
Hepatitis B and C, your appointment will be completely confidential. The results of 
your test will be completely confidential and none of your family members or 
anyone else will be told.  
 
 
WHAT IS HEPATITIS B AND C?  
Many people in the world are infected with Hepatitis B and/or Hepatitis C. 
These are viruses that can infect the liver. When some people are infected 
with Hepatitis B or Hepatitis C they recover from the virus, but for many 
people the virus will stay in their body for years. This is then called 
chronic viral hepatitis.  
 
HOW DOES SOMEONE GET HEPATITIS B/ HEPATITIS C? 
If a mother has the Hepatitis B virus, her child may be infected with the 
virus during or after birth. Hepatitis B can also be passed from one person to 
another through sexual contact.  
Both Hepatitis B and Hepatitis C can also be passed from person to person by 
blood- through sharing razorblades, toothbrushes and non-sterilised needles. 
People may get Hepatitis B or C from medical treatment in a country where 
equipment is not properly sterilised.  
 
WHAT DAMAGE DOES HEPATITIS B AND C CAUSE? 
If the Hepatitis B or C virus remains in the person’s body it slowly causes 
damage to their liver and the liver is damaged over many years. If it is not 
treated, eventually it can cause liver cirrhosis (scarring of the liver and 
poor liver function), liver cancer and liver failure. 
 
WHAT ARE THE SYMPTOMS OF HEPATITIS B AND C?  
Some people with Hepatitis B or C might experience symptoms like tiredness, 
but many people who are infected with the viruses do not have symptoms, 
and will not know that they are infected.The only way to know for sure 
whether you have Hepatitis B or C is to have a blood test for hepatitis. 
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Appendix 4: The HepFree trial patient information sheet version 5.0 
 
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ Countries: 
The HepFree study 
Patient Information Sheet for Patient Screening  
 
We would like to invite you to take part in our research study. Before you decide we would 
like you to understand why the research is being done and what it would involve for you. It 
will tell you what will happen if you take part and what the risks might be. One of our team 
will go through the information sheet with you and answer any questions you have.It is 
entirely your choice whether or not you take part. Talk to others about the study if you wish. 
 
1.0 Nature and purpose of the study  
From previous research, we know that people who were born or whose parents were born in 
certain countries are often infected with viruses that can cause liver disease. But many people 
will be unaware of their infection, as the viruses often remain silent. We would like to identify 
people who have these viruses, so we can offer them treatment to try to prevent more 
serious liver disease. We do not yet know the best way to identify within certain ‘at risk’ 
populations, who are infected with chronic hepatitis and who are not, and this study is 
designed to answer this question.  
 
Chronic Viral hepatitis – what is it and what does it do? 
Chronic viral hepatitis is commonly caused by two viruses – hepatitis B and hepatitis C. Both 
of these viruses travel in blood and can be passed on by contact with another person’s blood. 
Both viruses can be passed on by unsterile medical equipment and they can be passed on by 
mothers to their children. Chronic viral hepatitis may be a mild illness that does not cause any 
problems but sometimes chronic viral hepatitis causes liver disease that may need treatment. 
We have drugs that we can use to treat viral hepatitis and these work for most infected 
patients. Unfortunately, chronic viral hepatitis usually causes a silent disease and people who 
are infected often don’t realise that they are infected until serious liver damage has occurred. 
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2.0 Why have I been invited? 
We know from previous work that patients within certain communities have a higher 
likelihood/ are more at risk of having chronic hepatitis. 
 
3.0 Do I have to take part? 
It is up to you to decide to join the study. We will describe the study and go through this 
information sheet. If you agree to take part, we will then ask you to sign a consent form. You 
are free to withdraw at any time, without giving a reason. This would not affect the standard 
of care you receive. 
 
4.0 What will happen to me if I take part? 
In your GP practice, all selected patients will be invited. You may be contacted by your GP 
surgery to book an appointment for testing.  If you would like to participate, one of the 
doctors will talk to you about viral hepatitis. You will then be asked to allow yourself to be 
tested for viral hepatitis. This will involve a small needle prick in one of your veins to draw 4 
teaspoons (5 to 10ml) of blood which will then be sent to a local laboratory for testing. After 
testing the sample will be kept for the duration of the study as well as additional 2 years (to 
allow clinical tests to be performed in line with normal clinical management). Your visit to the 
practice should not take more than 10 minutes all together.Your GP will be informed of the 
results, and patients will be re-contacted to receive their results. If you don’t have viral 
hepatitis no further action is needed. We will test only for viral hepatitis.  
If you do have viral hepatitis you will be asked to attend a clinic where one of the doctors will 
talk to you about further tests that are needed. You may need treatment to protect your liver 
and the doctor who sees you in the clinic will explain this. You will be treated just like every 
other patient with viral hepatitis. 
This is going to be a long term project and we will be collecting data and information held and 
managed by the Health and Social Care Information Centre and other central UK NHS bodies. 
This information may be used to provide information about your health status. This will not 
require us to contact you directly. If you do not wish to have long term data about you 
collected you are free to decline to take part in this part of the study. 
 
5.0 What are the possible disadvantages and risks of taking part? 
The study involves 10 minutes of your time to learn about viral hepatitis and you will be asked 
to allow us to take a blood sample. This is an uncomfortable procedure. You will have to wait 
for the results of the test and this can cause anxiety.  
 384 
 
 
6.0 What are the possible benefits of taking part? 
The aim of this study will hopefully tell us how best to identify people from high risk 
communities, who are infected with viral hepatitis.  
Patients who participate in the study will learn whether or not they have viral hepatitis and if 
they do have viral hepatitis then they will be able to get treatment which may be helpful.  
If you test positive for viral hepatitis, in line with standard practice, your GP will recommend 
your children to get tested for viral hepatitis. As part of the study, we would like to collect 
information about testing rates in children and so ask for your permission for access to this 
data.  
 
7.0 What happens when the research study stops?  
Nothing, you will continue to receive your clinical standard of care for your viral hepatitis. 
 
8.0 What if there is a problem? 
We believe that this study is safe and do not expect you to suffer any harm because of your 
participation. However, Queen Mary University of London has agreed that if you are harmed 
as a result of your participation in the study, you will be compensated, provided that, on 
balance of probabilities, an injury was caused as a direct result of interventions or procedures 
you received during the course of the study. These special compensation arrangements apply 
where an injury is caused to you that would have not happen if you were not participating in 
the study.  These arrangements do not affect your right to pursue a claim through legal 
action. If you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you and you can obtain advice on this, 
or any other aspect of the study from :- Patient Advice and Liaison Service (PALS) Telephone: 
is available Monday to Friday, 9.30am-4.30pm Telephone: 020 3594 2040, E-mail: 
pals@bartshealth.nhs.uk.  
 
9.0 Will my taking part be kept confidential? 
Your participation in this study will be kept confidential and your name will not be made 
known to anyone other than people working on the study. All information which is collected 
about you during the course of the research will be kept strictly confidential.   
Your patient details and details about your health will be transferred from your GP practice to 
the study team at Queen Mary University of London, in a secure and confidential manner. The 
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study team will comply with information governance policy. Data collected as part of this 
study will be kept in a secure database and will only be accessible to authorised members of 
the HepFree Team. Professor Graham Foster will be responsible for the data that is collected 
as part of this trial (data custodian). 
If you consent to take part in the research the people conducting the study will abide by the 
Data Protection Act 1998, and the patient rights you have under this Act.   
 
10.0 What will happen to any samples I give? 
All patients will need to have blood taken (about 4 teaspoons) in order to be tested for viral 
hepatitis.  The sample will be sent to a local laboratory where it will be tested to see if you 
have ever been exposed to viral hepatitis and the length of time that you have had it. After 
completion of the study, it will be kept for 2 years (to allow clinical tests to be performed in 
line with normal clinical management).  
 
11.0 Who is organising, funding and reviewing the research? 
This study is being sponsored by Queen Mary, University of London and the funder is 
Department of Health. This research study has been reviewed by an independent group of 
individuals known as a Research Ethics Committee, to protect your interests. This study has 
been reviewed and given favourable opinion by NRES Committee London - Fulham Research 
Ethics Committee. 
 
12.0 Further information and contact details  
You are encouraged to ask questions at any time in the study.  If you have a problem or 
concerns about the study or your rights as a subject, please call Prof Foster at 020 7882 7242. 
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Appendix 5: The HepFree trial consent form version 5.0 
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ Countries: 
The HepFree Study 
Consent Form Version 5.0 dated 27Mar2015 
Centre (GP practice):     Participant ID for this study: 
Please initial box to indicate agreement                                                                     INITIAL BELOW 
I confirm that I have read and understand the information sheet 
dated27Mar2015(version5.0) for the above study. I have had the opportunity to 
consider the information, ask questions and have these answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
 
I understand that relevant sections of any of my medical notes and data collected 
during the study, may be looked at by responsible individuals from the Primary Care 
Trust/ Barts Health NHS Trust/Queen Mary, University of Londonor from regulatory 
authorities, where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records.  
 
I understand that data collected as part of the study has to be stored for 20 years and 
agree to this. 
 
I understand that if I test positive for viral hepatitis, it will recommended that all 
immediate family members get tested including children (if applicable). If this is 
applicable, I give permission for these individuals to have access to data to gather 
further information about testing rates in children.  
 
I understand and agree that information held and managed by The Health and Social 
CareInformation Centre and other central NHS bodies may be used in order to 
provide information about my health status.  
 
I agree to take part in the above study.  
 
________________________ ______________                           __________ 
Name of Participant Date Signature 
_________________________ ________________                __________ 
Name of Person taking consent Date Signature 
_________________________ ________________                 ___________ 
Investigator Date  Signature 
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Appendix 6: The HepFree trial study specific sample request proforma version 2.0 
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Appendix 7: A list of countries with a prevalence of viral hepatitis of more than 2% (WHO) 
Africa 
North Africa Southern Africa 
Algeria Botswana 
Egypt Lesotho 
Libyan Arab Jamahiriya Namibia 
Morocco South Africa 
Tunisia Swaziland 
East Africa Zimbabwe 
Burundi West Africa 
Comoros Benin 
Djibouti Burkina Faso  
Eritrea Cape Verde  
Ethiopia Cote d'Ivoire  
Kenya  Gambia  
Madagascar Ghana  
Malawi Guinea 
Mauritius Guinea-Bissau  
Reunion Liberia 
Rwanda Mali 
Seychelles  Mauritania 
Somalia Niger  
Uganda Nigeria  
United R. of Tanzania Sao Tome and Principe  
Central Africa Senegal 
Angola  Sierra Leone  
Cameroon Togo 
Central African Republic  
Chad  
Congo  
D. R. of the Congo   
Equatorial Guinea  
Gabon   
Sudan   
Zambia   
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Eastern Europe and the Newly Independent States of the former Soviet Union 
Albania  Lithuania 
Armenia Poland  
Azerbaijan  Republic of Moldova  
Belarus  Romania  
Bosnia and Herzegovina  Russian Federation  
Bulgaria  Slovakia  
Croatia  Tajikistan  
Czech Republic  T.F.Y.R. Macedonia  
Estonia  Turkmenistan  
Georgia Ukraine 
Kazakhstan Uzbekistan  
Kyrgyzstan  Yugoslavia  
Latvia  
Western Europe 
Greece Portugal 
Italy Spain 
Malta  
The Americas 
Mexico and Central America Temperate South America 
Belize Argentina 
Guatemala Tropical South America 
Honduras Bolivia 
Panama Brazil 
The Caribbean Ecuador 
Antigua and Barbuda Guana 
Dominica Suriname 
Dominican Republic Venezuela 
Grenada Australia and the South Pacific Islands 
Haiti American Samoa 
Jamaica C.N.Mariana Islands 
Puerto Rico Cook Islands 
Saint Kitts and Nevis Fiji 
Saint Lucia French Polynesia 
St Vincent & Grenadines Guam 
Trinidad and Tobago Kiribati 
Turcs and Caicos Islands Marshall Islands 
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East Asia Micronesia 
China Nauru 
D. People's R. of Korea New Caledonia  
Japan  Niue 
Mongolia  Palau 
Republic of Korea  Papua New Guinea  
Middle East Samoa 
Bahrain  Solomon Islands  
Iran (Islamic Republic of)  Tonga  
Iraq Tonga  
Israel Tuvalu  
Jordan Wallis and Futuna Islands  
Kuwait Southeast Asia 
Lebanon Brunei 
Oman Cambodia 
Qatar Indonesia 
Saudi Arabia Lao People's D. R.  
Syrian Arab Republic Malaysia 
Turkey Myanmar (Burma) 
United Arab Emirates Philippines 
Yemen Singapore 
Indian Subcontinent and South Asia Thailand 
Afghanistan Vietnam 
Bangladesh   
Bhutan  
India  
Maldives  
Nepal  
Pakistan  
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Appendix 8: The HepFree trial approval letters 
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Version 4_ 19th July 2013 
Enquiries on this matter should be made to: 
The Research Management & Support Office 
Bradford Institute for Health Research (BIHR) 
Bradford Royal Infirmary 
Duckworth Lane 
BRADFORD 
BD9 6RJ 
Email: BradfordResearch.Applications@bthft.nhs.uk 
Tel: 01274 36 (6808)/(4687) 
Fax: 01274 38(2640) 
Research Support & Governance Manager 
Mrs Jane Dennison 
Email: jane.dennison@bthft.nhs.uk 
Tel: 01274 382575 (Direct) 
Director of Research/BIHR 
Professor John Wright 
Email: john.wright@bthft.nhs.uk 
Tel: 01274 364279 (Direct) 
28th March 2014 
Dr Sulleman Moreea 
Consultant Gastroenterologist 
Bradford Royal Infirmary 
Dear Dr Moreea 
NHS Permission Letter for Research at Bradford Teaching Hospitals NHS 
Foundation Trust 
 
Re: Chronic viral hepatitis in ethnic minorities. A controlled randomised cross 
sectional cluster trial to assess the impact of identifying, screening and treating 
immigrants with viral hepatitis (HepFree) 
 
Sponsor: Barts and The London NHS Trust 
REC Ref   No: 12/LO/1768 
R&D Ref   No: ReDA 1699 
CSP Reference: 115023 
 
Following submission of your Site-Specific Information form and supporting 
documentationseeking permission to conduct the above study at Bradford Teaching 
Hospitals NHS FoundationTrust (the “Foundation Trust”), I am pleased to inform you 
that your application has successfullycompleted an internal review process 
appropriate for this type of study and has satisfied ourresearch governance checks. A 
project record has been created on the Foundation Trust’sresearch database. You 
may commence research activities at the Foundation Trust in thelocations specified in 
your Site-Specific Information (SSI) form subject to the terms of this letter.The 
effective date of NHS permission for research is the date of this letter and this is the 
earliestcommencement date for research activities at the Foundation Trust. This letter 
supersedes allprevious letters you have received from us with regard to permission to 
proceed with thisresearch at Bradford Teaching Hospitals NHS Foundation Trust. 
 
NHS permission for the above research has been granted on the basis described in 
theapplication forms, protocol and supporting documentation. The documents 
reviewed were: 
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Reviewed Documents – 
Document Version Date of document 
SSI form 
 
115023/573572/6/256/204850/293629 
 
 
NHS R&D form 
 
115023/441069/14/189 
 
 
Protocol 
 
Version 3.0, dated 01 July 2013 
 
 
Patient Information Sheet: 
Screening 
Version 3.0, dated 11 July 2013 
 
 
Participant Consent Form: 
Screening 
Version 3.0, dated 11 July 2013 
 
 
Patient Information Sheet: 
Community Care 
Version 2.0, dated 05 December 2012 
 
 
Participant Consent Form: 
Community Care 
Version 2.0, dated 05 December 2012 
 
 
Participant Consent Form: 
TissueStorage 
Version 1.4, dated 07 August 2007 
 
 
Ethics Favourable Opinion 
Letter 
 24 December 2012 
 
REC Letter Substantial Amendment 1 dated14/03/2013 
 
28 March 2013 
 
REC Letter Minor Amendment 1 dated23/05/2013 
 
24 May 2013 
 
REC Letter 
 
Amendment 3.0 dated 11/07/2013 09 September 2013 
 
 
The site for which NHS permission for research is given is - 
 
Bradford Teaching Hospitals NHS Foundation Trust 
 
The terms referred to are: 
 
1. You are the Principal Investigator or Local Collaborator for this Study and you are 
responsiblefor the conduct of this Study at this site. 
 
2. NHS Indemnity applies to this Study with respect to negligent harm. However, NHS 
Indemnitydoes not provide compensation in the event of non-negligent harm. 
 
3. This Study is a non-CTIMP (ie, not a clinical trial that involves an investigational 
medicinalproduct) and you may commence recruitment on receipt of this letter if you 
are ready to start. 
 
4. Ongoing permission is subject to you adhering to the Trust’s standard conditions of 
NHSPermission for research (attached). 
 
5. You comply with the R&D Office’s Oversight Plan as detailed below. 
 
The approach taken for each Study shall be proportionate to the risks associated with 
the Studyand the level of monitoring and support being undertaken by the Sponsor. 
The R&D Office’sOversight Plan for this study is as follows – 
 
 
1 Study Tracking 
Please provide the R&D Office with – 
 
a. Completed initial project status enquiry report sent to you directly from the R&D 
Officefollowing the NHS Permission Letter. 
 
b. Completed Principal Investigator (PI) Annual Progress Report available from the 
Downloads section of the Bradford Institute for Health Research website 
atwww.bradfordresearch.nhs.uk due every year for the life of the Study on the 
anniversaryof the date of this letter. 
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c. Completed PI end of study declaration report (as defined in the protocol) (together 
withfinal recruitment figures for the Foundation Trust) available from the Downloads  
 
section ofthe Bradford Institute for Health Research website at 
www.bradfordresearch.nhs.uk 
 
d. Copy of amendment documentation and a copy of the REC and MHRA (if 
applicable)approval letters prior to implementing the changes at the Foundation Trust. 
 
2 Issue Management – 
a. Managing External Agreements. 
b. Managing Internal Agreements. 
c. Managing Study Processes. 
d. Managing Research Passports 
 
If an issue arises during the Study, please ensure you have a process in place to 
escalate thisand seek support from the R&D Office. 
 
3 Audit - 
The R&D Office performs a risk assessment prior to issuing this letter which provides 
theFoundation Trust with a risk-based approach to audit activities. The R&D Office 
undertakes toaudit at least 10% of its research projects each year. Priority will be 
given to studies with thehigher risk scores, clinical trials involving an investigational 
medicinal product(s) (CTIMPs),NIHR portfolio studies, and studies sponsored by the 
Foundation Trust. Some low risk studiesmay not be subject to scheduled audit at all. 
You will be informed by the R&D Office if ascheduled audit of this research study is 
planned in plenty of time (ie, at least six weeks’ notice). 
 
The R&D Office always has the option to conduct specific oversight activities at any 
time as theresult of any exceptional activity / events identified during the Study and 
failure to comply withthese terms may lead to suspension or termination of NHS 
Permission for research. 
 
Please inform the R&D Office immediately should you have any concerns about 
patient safety orwellbeing with regard to research at the Foundation Trust. 
 
If you have any queries during the conduct of your research, please do not hesitate to 
contactthe Research Governance Manager using the contact details provided at the 
top of this letter.May I take this opportunity to wish you well with your research Study. 
 
Please help us to improve our service by completing the feedback form emailed 
previously to you and returning it to the R&D Office as soon as possible. 
 
Yours sincerely 
 
 
PROFESSOR JOHN WRIGHT 
 
Director of Research/BIHR 
 
Encs 
 
cc CI/Sponsor/study co-ordinator 
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STANDARD CONDITIONS OF NHS PERMISSION FOR RESEARCH CONDUCTED AT BRADFORD 
TEACHING HOSPITALS NHS FOUNDATION TRUST (the “Foundation Trust”) 
 
1 Permission is granted to you, as the Principal Investigator/Local Collaborator, on 
theunderstanding that the study is conducted in accordance with the Research Governance 
Framework for Health & Social Care for England (the “Research Governance Framework”) as 
varied from time to time and compliance by you with this Framework is a requirement of this 
NHS Permission for research. The Research Governance Framework describes roles and 
responsibilities of individuals and organisations involved in research including Investigator 
and Sponsor responsibilities. You can access the Research Governance Framework at – 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuida
nc e/DH_4108962 and the annex at - 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuida
nc e/Browsable/DH_088002. 
 
2 In addition to complying with all the Foundation Trust’s Policies and Procedures generally, 
in carrying out research you must comply with the Foundation Trust’s local reporting 
requirements, systems, policies and procedures for implementing the Research Governance 
Framework (in particular, the Foundation Trust’s Policy for Research). 3 The R&D Office will 
apply their escalation procedure to ensure action is taken for noncompliance of the Principal 
Investigator including where you do not take appropriate corrective and preventative actions 
for issues found in audits or requests for action by the R&D Office. 
 
4 The Director may review the NHS Permission for research at any time in the light of any 
relevant information s/he receives. 
 
5 Failure to comply with these conditions may lead to suspension or termination of NHS 
Permission for research and the relevant Research Ethics Committee shall be informed.  
 
Your responsibilities shall include (applies to all types of research unless stated otherwise) – 
 
Before the Study commences: 
 
 Research Approvals The Principal Investigator is responsible for ensuring that the 
necessary approvals and trial registration (if applicable) are in place prior to commencing 
recruitment at the Foundation Trust. You may only use study documentation at the 
Foundation Trust that is the latest approved version by the Research Ethics Committee. 
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 Study Processes & Research Standard Operating Procedures (SOPs) The Principal 
Investigator (PI) is responsible for ensuring that Study initiation activities are satisfactorily 
completed at site so that the PI can ensure that all required study processes for the  
Foundation Trust are ready by the start of the study. The Research Management & Support 
Office (the “R&D Office”) can advise and support you in defining relevant research standard 
operating procedures (“SOPs”). Research SOPs, templates, forms and guidance are provided 
by the R&D Office and are available on the Trust’s Intranet research page. 
 
 Sufficient Time & Resources The Principal investigator is responsible for ensuring there is 
sufficient time to complete the study within the time period; there is sufficient staff who are 
adequately informed; and there are appropriate facilities and equipment available as required 
by the protocol. 
 
 Study Personnel The Principal investigator is responsible for ensuring that there is an 
adequate number of qualified staff (by education, training and experience) for the foreseen 
duration of the Study to conduct the Study properly in accordance with the regulations, Good 
Clinical Practice (GCP), Study protocol and SOPs where applicable. You should be qualified by 
education, training and experience to assume responsibility for the proper conduct of the trial 
at the Foundation Trust. All staff involved in clinical trials involving investigational medicinal 
product(s) (CTIMPs) should undertake regular Good Clinical Practice (GCP) training, ie, every 
two years or sooner if there are changes to the regulations and/or guidance. Training in 
protocol procedures and study processes should be documented. 
 
 Site File The Principal investigator is responsible for establishing and maintaining a Site 
File for the Foundation Trust which contains the study’s Essential Documents and is readily 
available at all reasonable times for inspection. The Essential Documents are those which 
enable both the conduct of the study and the quality of the data produced to be evaluated 
and show whether the study is or has been conducted in accordance with regulatory and 
good clinical practice requirements (ICH GCP Handbook Section 8). The Site File should be 
appropriately labelled and sectioned with a contents page in accordance with the Sponsor’s 
instructions. The Principal Investigator is responsible for archiving the Site File for a minimum 
of five years in a safe and secure place in accordance with the sponsor’s instructions.  
 
 Delegation of Duties The Principal investigator is responsible for maintaining a list of 
appropriately qualified persons to whom you have delegated significant study-related duties 
(the “delegation log”). 
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 Contracts/sponsor-site agreements The Principal investigator is responsible for ensuring 
that the study’s Clinical Trial Agreement (CTA)/sponsor-site agreement provided by the 
sponsor during study set-up is forwarded to the Research Management & Support Office (the 
“R&D Office”) as soon as possible for review (including subsequent amendments). Where one 
exists, you should abide by the terms of the CTA/sponsor-site agreement and inform the R&D 
Office as soon as possible should you foresee any conflicts arising which might force a 
deviation from the agreement.  
 
 
(For clinical trials that involve an investigational Medicinal Product(s)) -  
 Clinical Trials involving Investigational Medicinal Products (CTIMPs) are regulated by the 
Medicines and Healthcare Products Regulatory Agency (MHRA). The Medicines for Human 
Use (Clinical Trial) Regulations 2004 as amended (the “UK Clinical Trial Regulations”) which 
implement European Directive 2001/20/EC and European Directive 2005/28/EC (often called 
“the GCP Directive”) set out the responsibilities of investigators and sponsors. The UK Clinical 
Trial Regulations are available from the Bradford Institute for Health Research (BIHR) website 
at www.bradfordresearch.nhs.uk or at www.ct-toolkit.ac.uk. The Principal Investigator is 
required to demonstrate to the MHRA GCP Inspectorate their compliance with the UK Clinical 
Trial Regulations and adherence to the conditions and principles of good clinical practice as 
provided in the Regulations (Schedule 1). You should be thoroughly familiar with the 
appropriate use of the investigational medicinal product (IMP). The medical care given to, and 
medical decisions made on behalf of, subjects shall always be the responsibility of an 
appropriately qualified doctor, or when appropriate, of a qualified dentist.  
 
a. Prior to Commencing Recruitment The investigator is responsible for agreeing a start 
date with the Foundation Trust’s Pharmacy Department before commencing 
recruitment. This is to ensure that Pharmacy Department have all procedures in place 
before the commencement of the trial.  
 
(For research that involves a medical device(s)) - 
 Medical Devices are regulated by the Medicines and Healthcare Products Regulatory 
Agency (MHRA). The Principal Investigator is responsible for ensuring that A Notice of No 
Objection is in place before utilising any medical device(s) in a research study at the 
Foundation Trust without a CE Mark, or if it is intended to utilise the medical device after 
modification(s), or utilised following changes to the CE mark intended purpose. If a medical 
device(s) is on loan for the purposes of the research, you are responsible for ensuring that the 
Foundation Trust’s loan documentation has been successfully completed in accordance with 
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the Foundation Trust’s policy on managing medical devices and the required electrical and 
safety tests have been completed before using the medical device(s) at the Foundation Trust.  
 
(For research that involves the use of human tissue) - 
 The Human Tissue Act 2004 The Human Tissue Authority (HTA) regulates the storage, 
removal, use and disposal of human bodies, organs and tissue for a number of Scheduled 
Purposes (research being one of them) set out in the Human Tissue Act 2004. The HTA 
licenses organisations that store human tissue for research. Tissue for research can only be 
used with the person's consent. The HTA’s Codes of Practice provide practical guidance and 
lay down the standards expected of investigators. (For research that involves a person who 
lacks capacity) - 
 
 The Mental Capacity Act 2005 for England and Wales The Act sets out clear guidelines for 
research involving people who lack capacity. The research must be approved by an 
appropriate body, who will also ensure that the research is safe and relates to the person's 
condition. They must also ensure that the research would not be as effective if they use 
people who have mental capacity. The Principal Investigator is responsible for ensuring 
compliance with the Foundation Trust’s policy for assessing capacity when assessing the 
capacity of research participants. During Study conduct: 
 
 Principal Investigator Oversight The Principal Investigator is responsible for all study 
related activities at the Foundation Trust and should be fully aware of what is going on. You 
should have understanding and knowledge of the rules and regulations that govern research 
in the NHS. 
 
 Study Conduct & Good Clinical Practice (GCP) The Principal investigator is responsible for 
the conduct of this research study at the Foundation Trust in accordance with the conditions 
and principles of good clinical practice. You may only conduct research in accordance with the 
relevant protocol, current marketing authorisation for the Investigational Medicinal Product 
or, as the case may be, the Clinical Trial Authorisation and the terms and conditions of the 
approval of  the relevant Research Ethics Committee. Researchers should not deviate from 
the protocol unless for urgent safety measures and you should notify the sponsor 
immediately if this occurs.  
 
(For clinical trials that involve an investigational Medicinal Product(s)) - 
It is illegal for a person to conduct a clinical trial or perform the functions of the sponsor of a 
clinical trial (whether that person is the sponsor or is acting under arrangements made with 
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that sponsor) otherwise than in accordance with the conditions and principles of good clinical 
practice (Regulation 28 (1)). 
a. Serious Breaches You should report any serious breaches of protocol or GCP to the 
sponsor immediately in accordance with the sponsor’s instructions (usually provided in 
the protocol). For the purposes of the UK Clinical Trial Regulations, a “serious breach” is 
a breach which is likely to effect to a significant degree – 
 i. the safety or physical or mental integrity of the subjects of the trial; or 
 ii. the scientific value of the trial. 
b. Urgent Safety Measures The sponsor and the investigator may take appropriate 
urgent safety measures in order to protect the subjects of a clinical trial against any 
immediate hazard to their health or safety. You should report urgent safety measures 
immediately to the sponsor in accordance with the sponsor’s instructions. 
 Amendments The Principal Investigator is responsible for ensuring that changes to 
the study (ie, “Amendments”) are not implemented at the Foundation Trust without first 
checking that the necessary research approvals are in place. You should notify the Research 
Management & Support Office (the “R&D Office”) of all Amendments and provide the R&D 
Office with the amendment documentation including copies of the Research Ethics 
Committee (REC) approval letter(s) and Medicines and Healthcare Products Regulatory 
Agency (MHRA) authorisation letters (if applicable). 
 
 Notification of Adverse Events The Principal Investigator is responsible for ensuring 
that – 
 
a. For a clinical trial involving the use of investigational medicinal product(s) (CTIMP), the 
Foundation Trust will not accept delegation of sponsor pharmacovigilence activities 
relating to Regulation 33 of the UK Clinical Trial Regulations. Regulation 33 says it is the 
sponsor’s responsibility to notify the licensing authority (ie, the MHRA) and the relevant 
ethics committee of suspected unexpected serious adverse reactions (SUSARs) which 
occur during the course of a clinical trial. 
b. You (the investigator) are responsible for compliance with Regulation 32 of the UK 
Clinical Trial Regulations and you should follow the sponsor’s instructions for recording 
and reporting adverse events in a timely manner. You are responsible for assessing 
causality. The causality given by you (the investigator) should not be over-ruled by the 
sponsor. If there is a disagreement, both opinions should be given. 
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c. For non-CTIMPs (ie, research that is not a clinical trial involving an investigational 
medicinal product(s)), the sponsor’s instructions are complied with for recording and 
reporting adverse events to the sponsor within the specified timeframes.  
 
d. Incidents are also reported in accordance with the Foundation Trust’s Incident 
Reporting Policy and Serious Untoward Incident Policy in a timely manner using the 
Foundation Trust’s Incident Reporting Form stating clearly in the text box that the 
incident is “research-related”. 
 
 Research Monitoring & Reporting The Principal Investigator is responsible for 
monitoring the conduct of the research study at the Foundation Trust on a day-to-day basis. 
The Foundation Trust is required to oversee monitoring of research to ensure compliance 
with the Research Governance Framework and other legal and regulatory requirements. You 
should ensure that requests for reports on the progress and outcomes of the work by the 
Research Management & Support Office (the “R&D Office) or from those with a legitimate 
interest (such as the regulatory body, the sponsor, the funder(s), the Research Ethics 
Committee) are produced on time and to an acceptable standard and that all data and 
documentation associated with the study are available for audit at the request of the 
appropriate authority including the Foundation Trust.  
 Finance The Principal Investigator is responsible for ensuring compliance with the 
Foundation Trust’s Standing Orders and Standing Financial Instructions with regard to the 
management of research income and expenditure. 
 Honorary Research Contracts (HRC) and Letters of Access The Principal Investigator 
is responsible for ensuring that anyone engaged in this research study at the Foundation Trust 
who: 
 
a. is not employed by the Foundation Trust; and 
 
b. interacts with individuals in a way which has a direct bearing on their quality of care 
holds a valid honorary contract issued by the Foundation Trust that covers the required 
research activity. Thus, for example, anyone who is not an NHS employee and will be 
involved directly in the diagnosis, care or treatment of a Foundation Trust patient 
involved in research will require an honorary research contract. Anyone who is not an 
NHS employee and will not be involved directly in the diagnosis, care or treatment of a 
Foundation Trust patient will not require an honorary research contract but may require 
a Letter of Access from the Foundation Trust giving them permission to attend the 
Foundation Trust’s premises for the required purposes. 
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If you have been advised that you should complete a Research Passport application (or a 
member of your local research team), then you are responsible for ensuring that this is done 
and submitted in accordance with the Foundation Trust’s procedure and the published 
Research Passport guidance. The relevant individuals must not commence any research 
activities involving the Foundation Trust until the appropriate employment contractual 
agreements are in place for them. You are responsible for actively monitoring professional 
registration of honorary research contract holders who are working under your supervision. 
 
 Intellectual Property The Principal Investigator is responsible for informing the 
Research Management & Support Office (the “R&D Office) as soon as any intellectual 
property arises in order that it is appropriately managed in accordance with Foundation 
Trust’s policy on managing intellectual property. 
 
 Health & Safety The Principal Investigator is responsible for ensuring that the safety 
of participants and of researchers and other staff is given priority at all times, and health and 
safety regulations are being strictly observed. You should undertake or review (and 
document) a risk assessment with regard to this study and ensure that all work undertaken on 
behalf of or on Foundation Trust premises is managed in accordance with the Foundation 
Trust’s risk management policies and procedures, seeking expert advice where necessary. 
 
 Changes to the Project Status and to the Membership of the Research Team You 
should notify the Research Management & Support Office (the “R&D Office”) immediately if 
you are no longer able to continue as Principal Investigator/Local Collaborator and/or if there 
is a change to project status such as a temporary halt or early termination. 
 
 Protocol Violation Any protocol violation resulting from error, fraud or misconduct 
should be notified to the Foundation Trust using the Foundation Trust’s policies and 
procedures for reporting incidents, fraud and misconduct. Suspected fraud should be 
reported to the local Counter Fraud Specialists for the Foundation Trust. 
 
 Data Protection & NHS Patient Confidentiality The Principal investigator is 
responsible for compliance with the Data Protection Act 1998 and NHS patient confidentiality 
rules. You should make a reasonable and appropriate effort to understand any project issues 
that may arise due to the Data Protection Act 1998 and other legal provisions and guidance 
on handling information, seeking expert advice where necessary. You should ensure that the 
agreed counter measures as described in the protocol or other supporting documentation are 
kept in place for the life of the study (and for any agreed period after completion of the study) 
in order that you do not breach any of the principles outlined in the Data Protection Act 1998. 
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a. Identifying Suitable Participants and Seeking Consent - 
i. Identifying suitable participants and making the first approach must be undertaken by a 
member of the clinical team responsible for treating the patient. 
ii. The patient (or their legal guardian) should give explicit consent for the patient’s 
personal information to be used for another purpose other than patient care, ie., 
research. As regards who obtains consent, it must be a member of the clinical care 
team, because to divulge personal information to the researcher (in order for the 
researcher to obtain consent) would be to breach the NHS rules on patient 
confidentiality. If the patient declines, their personal information (for instance their 
name and contact details) must not be passed to the researcher. 
b. Transfer of Data for Research Purposes - 
i.Access, copying and subsequent use of the Clinical Records (“Data Processing”) shall be in 
accordance with the Protocol for the Study approved by the relevant Research Ethics 
Committee and in accordance with any terms and conditions specified by that 
Committee. 
ii.In the event the Foundation Trust has approved the proposal subject to terms and 
conditions, the Data Processing shall be carried out in accordance with those terms 
and conditions.  
iii.No copy of the Clinical Records or any part of them shall be removed or transferred 
from the Foundation Trust without first being anonymised. iv.Data Processing shall 
only be in accordance with the consent of the patient (or, in the case of a child, 
consent lawfully given on behalf of the child) obtained in accordance with the Protocol 
of this Study 
 
After the Study finishes: 
 
 Dissemination The Research Governance Framework says that researchers should 
open their work to critical review through the accepted scientific and professional channels. 
Once established, findings should be made available in an understandable format to those 
participating in the research (including relatives of deceased patients who have consented to 
the use of organs or tissue in the research) and to all those who could benefit from the 
research, through publication and/or other appropriate means. The Principal Investigator is 
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responsible for ensuring that feedback to their research participants is provided in 
accordance with the sponsor’s instructions. 
 
 Archiving The Principal Investigator is responsible for ensuring that there are suitable 
archiving arrangements in place at the end of the study that ensures the study’s Essential 
Documents are safe and secure and are accessible on request by the sponsor, the Foundation 
Trust or any other authority with a legitimate interest. The minimum length of time that the 
study’s Essential Documents should be kept for is 5 years. 
 
(For clinical trials that involve an investigational Medicinal Product(s)) - 
 End of Trial Notification The Principal Investigator should not accept delegation of 
sponsor responsibilities relating to Regulation 27 (end of trial notifications). 
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Appendix 9: The HepFree trial randomisation proforma version 1.0 
 
 
 
Protocol: HepFree 
GP Practice Randomisation Proforma 
Lead GP Name (please complete below) 
 
GP Practice Address (please complete below) 
 
 
GP  RegistrationPractice Code 
 
GP Practice Registration Date (Date of when Practice agreed to participate in the study) 
 
__ _/_ _ _/ _ _ _ _ 
(DD/MMM/YYYY) 
Region (please circle one listed below) 
A) East London (Newham, Tower Hamlets and WalthamForest) 
B) South London(Lambeth and Southwark) 
C) Bradford 
Number of eligible patients 
Please enter exact number below (if possible)  
_____________________ 
Please also circle the appropriate number grouping  
A) = <1600 
B) = 1600-3300 
C) = >3300 
Site Identification Number (as generated by the randomisation programme) 
Please enter below 
______________ 
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Appendix 10: The HepFree trial treatment location contract version 1.0 
Cluster Allocation Bias Training for GP Site Staff 
 
HepFree is a CLUSTER RANDOMISED TRIAL. This means that Practices are randomised to the 
study, rather than individual participants. These types of trial are common in public health 
research and effective in the analysis of interventions, ranging from changes to health 
services to attitudes/behaviours of those involved.   
 
-In HepFree, we are looking at participant uptake of Hep B/C screening and subsequent care 
and treatment for those testing positive, either in the usual local hospital setting or within 
the community. Each practice has been allocated to either usual hospital care or community 
care, and we are looking at patient engagement. 
 
IMPORTANCE OF AVOIDING  BIAS  BY INVITING ALL PATIENTS 
-When patients come to the surgery following their screening invitation letters or via another 
route, it is important not to introduce bias. Bias could be introduced if only some patients 
were invited to take part in the trial of treatment. All eligible patients should be invited to 
take part, not just those considered ‘more likely’ to give consent to take part and engage well 
with treatment 
 
-It is Important to give consistent information to potential participants (using the 
PIS/HepFreeinformed consent checklist) as well as addressing any queries. The HepFree team 
are available to assist. 
 
-Remember that selection bias can be accidently introduced by tailoring study related 
information given that will pre-dispose the patient to give written informed consent and take 
part in the study.    
 
IMPORTANCE OF AVOIDING BIAS BY GIVING EVERYONE THE SAME INFORMATION 
-It is critical for the integrity of the study that potential participants do not know whether 
they are in the STANDARD HOSPITAL REFERRAL or COMMUNITY BASED CARE arm, until they 
have agreed to participate in the screening. This is a similar process to that in drug trials when 
participants are asked to consent to a trial without knowing which drug theywill receive. 
 
-If potential participants know whether they will get STANDARD HOSPITAL REFERRAL or 
COMMUNITY BASED CARE,  this may affect their decision to be screened and we may end up 
with different sorts of patients in the two arms of the study, again introducing bias.   
-Thus, it is imperative to make sure that the participant is only made aware of the allocation 
when is required i.e. IF/WHEN PATIENT TESTS POSITIVE FOR EITHER HEP B and HEP C. Note 
that patients have the right to withdraw at this stage and may chose to be treated in hospital 
rather than the surgery 
-WHEN the patient is found to have viral hepatitis and receives their result, they are made 
aware of the allocation and additional written consent for community based care is given. 
(Patients have the right to decline to participate)  
 
-It is important that the patient is made aware that their care will be the main priority, 
irrespective of where it is received and it is ultimately their decision. 
 
I confirm that I have read and understood the above information and will make every 
effort, on behalf of the GP Practice and all staff involved in the study, to ensure that bias is 
not introduced at any stage of the study. 
 
____________________          _________________________          ____________ 
Name             Signature    Date  
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Appendix 11: The HepFree trial  research specific curriculum vitae 
CURRICULUM VITAE 
Name:  
Present appointment: (Job title, department, and organisation.) 
 
Address: (Full work address.) 
 
Telephone number: Email address: 
Qualifications:  
 
Professional registration: (Name of body, registration number and date of registration.) 
 
Previous and other appointments: (Include previous appointments in the last 5 years and 
other current appointments.) 
 
 
Research experience: (Summary of research experience, including the extent of your 
involvement.  Refer to any specific clinical or research experience relevant to the current 
application.) 
 
 
Research training: (Details of any relevant training in the design or conduct of research, for 
example in the Clinical Trials Regulations, Good Clinical Practice, consent or other training 
appropriate to non-clinical research.  Give the date of the training.) 
 
 
 
Relevant publications: (Give references to all publications in the last two years plus other 
publications relevant to the current application.) 
 
 
Signature:  Date:  
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Appendix 12: The HepFree second stage consent form version 2.0 
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ countries: 
The HepFree Study 
Consent Form Version 2.0 dated 05Dec12 
 
Centre (GP practice):    Participant ID for this study: 
 
Please initial box to indicate agreement 
I confirm that I have read and understand the community care information sheet 
dated 05 Dec 2012 (version 2.0) for the above study. I have had the opportunity to 
consider the information, ask questions and have these answered satisfactorily. 
 
 
I agree to continuing my part in the above study.  
 
 
____________________ _________________ ___________ 
Name of Participant Date Signature
  
 
 
____________________ ________________                ___________ 
Name of Person taking consent Date Signature        
(if different from investigator) 
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Appendix 13: The HepFree second stage patient information sheet version 2.0 
 
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ Countries: 
The HepFree study 
 Supplementary Patient Information Sheet for Community Care therapy 
We would like to invite you to continue to take part in our research study. Before you decide 
we would like you to understand what research is being done and what it would involve for 
you. It will tell you what will happen if you take part. One of our team will go through the 
information sheet with you and answer any questions you have.It is entirely your choice 
whether or not you take part. Talk to others about the study if you wish. 
 
1.0 Nature and purpose of the study  
You have previously read the patient information sheet for the screening component of this 
study, in which the nature and the purpose of the study have been previously highlighted. If 
you are reading this supplementary patient information sheet, it is because you have tested 
positive for viral hepatitis and have remained on study. 
2.0 Do I have to take part? 
It is up to you to decide to remain on study. We will describe the next stage of the study in 
this information sheet. If you agree to take part, we will then ask you to sign a consent form. 
You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
3.0 What will happen to me if I take part? 
In your GP practice, all patients that test positive for viral hepatitis are to be referred to a 
community care practice for treatment, where you will be under the care of your GP, a 
specialist hepatitis nurse and a hepatology consultant.  At this community based clinic, you 
will receive the same treatment as if you were referred to your local hospital specialist unit, 
like every other patient with viral hepatitis. This will not affect your treatment or subsequent 
medical care. 
 
4.0 What are the possible benefits/disadvantages of taking part? 
Patients that have viral hepatitis then they will be able to get treatment which may be 
helpful. You can receive your hepatitis treatment within a community based practice, or you 
can withdraw and continue treatment at your local hospital, as per standard of care.  
 
5.0 What happens when the research study stops?  
Nothing, you will continue to receive your clinical standard of care for your viral hepatitis. 
 
6.0 What if there is a problem? 
Provisions are the same as the screening component, regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been approached or 
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treated during the course of this study, the normal National Health Service complaints 
mechanisms should be available to you and you can obtain advice on this, or any other aspect 
of the study from :-Patient Advice and Liaison Service (PALS) Telephone: 020 7943 1335, 
Minicom: 020 7943 1350  E-mail: pals@bartsandthelondon.nhs.uk 
 
 
7.0 Will my taking part be kept confidential? 
Your continued participation, as before, will be kept confidential and your name will not be 
made known to anyone other than people working on the study.  If you consent to take part 
the study will abide by the Data Protection Act 1998, and the patient rights you have under 
this Act.   
 
8.0 Further information and contact details  
You are encouraged to ask questions at any time in the study.  If you have a problem or 
concerns about the study or your rights as a subject, please call Prof Foster at 020 7882 7242. 
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Appendix 14: The HepFree sub-study protocol version 2.0 
 
Full Title: HepFree observational  sub-study: The impact of chronic hepatitis C on healthcare 
utilisation.  
 
Short Title/Acronym   HepFree sub-study 
 
SponsorQueen Mary, University of London  
Representative of the Sponsor: 
Dr Sally Burtles 
Director of Research Services and Business Development 
Joint Research Management Office 
Queen Mary Innovation Centre   
5 Walden Street 
London 
E1 2EF  
Phone: 020 7882 7260 
Email: sponsorsrep@bartshealth.nhs.uk 
 
REC Reference010878 
 
 
Chief InvestigatorProfessor Graham Foster 
The Blizard Institute 
4 Newark St,  
London,  
E1 2AT 
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Insert as applicable list of localities 
 
Bradford Clinical Commissioning Group (CCG) 
Douglas Mill 
Bowling Old Lane 
Bradford 
West Yorkshire 
BD5 7JR 
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GLOSSARY OF TERMS AND ABBREVIATIONS 
 
 
AE   Adverse Event    
AR   Adverse Reaction 
ASR   Annual Safety Report 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
GAfREC Governance Arrangements for NHS Research Ethics Committees 
ICF   Informed Consent Form 
JRMO   Joint Research Management Office 
NHS REC   National Health Service Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
Participant  An individual who takes part in a clinical trial 
PI   Principal Investigator 
PIS   Participant Information Sheet  
QA   Quality Assurance 
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QC   Quality Control 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
TMG   Trial Management Group 
TSC   Trial Steering Committee 
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SIGNATURE PAGE 
 
 
Chief Investigator Agreement 
 
The clinical study as detailed within this research protocol (Version 2.0, dated 01/02/2016),or 
any subsequent amendments will be conducted in accordance with the Research Governance 
Framework for Health & Social Care (2005), the World Medical Association Declaration of 
Helsinki (1996) and the current applicable regulatory requirements and any subsequent 
amendments of the appropriate regulations. 
 
Chief Investigator Name: Professor Graham Foster   
Chief Investigator Site: Queen Mary University London 
Signature and Date: 01/02/2016 
 
 
 
 
 
 
Principal Investigator Agreement(if different from Chief investigator) 
 
The clinical study as detailed within this research protocol (Version XXX, dated XX XXX XX),or 
any subsequent amendments will be conducted in accordance with the Research Governance 
Framework for Health & Social Care (2005), the World Medical Association Declaration of 
Helsinki (1996) and the current applicable regulatory requirements and any subsequent 
amendments of the appropriate regulations. 
 
Principal Investigator Name: 
Principal Investigator Site: 
Signature and Date: 
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SUMMARY/SYNOPSIS 
 
Short Title HepFree sub-study 
 
Methodology Retrospective case control 
Research Sites 
 
Bradford Teaching Hospitals NHS Foundation Trust 
Participants will be recruited from all General Practices within 
Bradford City Clinical Commissioning Group which are 
participating in the HepFree trial and have been randomised to 
perform targeted screening. 
Objectives/Aims 
 
The primary aim of the HepFree sub-study is to investigate 
whether individuals with chronic hepatitis C who have been 
identified and diagnosed through the HepFree trial have made 
greater use of healthcare resources prior to diagnosis 
compared to individuals with a negative screening test.   
Number of 
Participants/Patients 
The sub-study will include all individuals who have consented 
to participate in the HepFree trial in Bradford and have had a 
positive screening test for hepatitis C between March 2014 
and February 2016.  Each case will be matched to a control; an 
individual who has consented to participate in the HepFree 
trial and tested negative for hepatitis B and C and who has 
been matched to the case using the following criteria:  
 Age 
 Sex 
 Ethnicity 
 Country of birth 
 Duration of time residing in the United Kingdom. 
The controls will be selected at random using an electronic 
randomisation function.  
Main Inclusion Criteria 
 
Inclusion Criteria  
- Participants that provide written informed consent to 
participate in the HepFree trial and have 
subsequently tested positive or negative for viral 
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hepatitis C.All participants in the sub-study will have 
given consent to participate in the main HepFree trial.   
 
For Reference: The eligibility/inclusion criteria for HepFree is 
any person registered at a general practice performing 
targeted screening who: 
 Is aged 18 or older 
 Originates from, or is born to a parent originating 
from a country with a prevalence of viral hepatitis B 
of more than 2%. 
 Is able to give consent  
 Does not have a pre-existing diagnosis of chronic 
hepatitis B or C. 
For this sub-study we will define ‘cases’ as individuals who 
have either evidence of previous chronic hepatitis C infection, 
or individuals who have evidence of on-going chronic infection 
with hepatitis C.  Controls are participants who have screened 
negative for hepatitis C and hepatitis B. 
Statistical Methodology 
and Analysis (if applicable) 
 
Pair wise comparison of  cases and controls 
Proposed Start Date Data collection will start in February 2016 and include all 
participants who have been recruited into the trial since the 
start of recruitment in Bradford in March 2014. 
Proposed End Date Data will be collected on participants who are recruited into  
the main HepFree trial up to February 2016 
Study Duration 
 
The HepFree sub-study will collect retrospective data on all 
participants with a positive hepatitis C screening test and 
controls (with a negative hepatitis B and C screening test) who 
have been  selected at  random and who have participated in 
the HepFree trial between March 2014 and February 2016. 
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INTRODUCTION 
Background  
Hepatitis C is a single stranded, positive sense RNA virus belonging to the hepacivirus genus of 
the Flaviridae family.  It is a blood borne virus with several routes of transmission.  Globally, 
the major risk of transmission is through injecting drug use and more than 90% of cases are  
 
attributable to this (Helland, Sacks & Gold, 2009). In developing countries, the transfusion of 
unscreened blood products and transmission of the virus from unsterile injection methods 
pose the largest risk of infection (Kane et al, 1999).  Spontaneous clearance of HCV happens in 
only a minority of cases, with approximately 75% progressing to chronic infection (Micallef et 
al, 2006).    
 
Worldwide there are estimated to be between 130-150 million people chronically infected 
with hepatitis C and each year between 350,000 and 500,000 people die from hepatitis C 
related liver disease (World Health Organisation, 2014).   
 
In cases of chronic infection with HCV there is slow evolution of fibrosis over many years 
culminating finally in cirrhosis (scarring of the liver resulting in chronic liver disease).  Previous 
research has suggested that although inflammation is the major factor responsible for the 
development of fibrosis, its presence has no direct effect on the well-being of the individual 
(Seeff, 2002).   There have been multiple publications assessing the impact of chronic HCV 
infection on quality of life which dispute this statement.   Individuals with chronic HCV 
frequently report symptoms of fatigue, muscle ache and depression.  Research performed on 
cohorts of cirrhotic and non-cirrhotic patients to attempt to establish the relationship 
between HCV infection, symptoms and the subsequent impact on quality of life have 
identified that fatigue is the most commonly reported extra-hepatic manifestation of chronic 
HCV (Tong et al, 1995; Barkheuizen et al, 1999; Cacoub et al, 1999; Poynard et al, 2002).  The 
presence of fatigue and musculoskeletal pain in individuals with chronic HCV was significant 
when compared to the presence of these symptoms in individuals with liver disease of other 
aetiologies.  As well as fatigue and musculoskeletal pain, a third commonly reported symptom 
in cohorts of patients with chronic HCV is depression.  In a study by Gallegos-Orozco et al 
assessing quality of life performed in patients attending a tertiary referral centre, depression 
resulting in a reduction in quality of life was reported in 59% of those interviewed (Gallegos-
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Orozco et al, 2003).  Foster et al examined the effect of chronic hepatitis C on quality of life 
experienced using the short form 36 (SF36) symptomatology questionnaire (Foster et al, 
1998).  The SF36 outcomes were compared with a cohort of patients infected with chronic 
hepatitis B and a second cohort of healthy controls (Foster et al, 1998).  In the HCV infected 
cohorts, SF36 scores related to mental and physical health domains were significantly 
reduced compared to the cohort of patients with chronic HBV in whom areas pertaining to 
mental health and general health perception only were reduced (Foster et al, 1998).  These 
findings were supported in studies conducted by Carithers, Davis and Ware et al (Davis et al, 
1994; Carithers et al, 1996; Ware et al, 1999).  As well as having evidence that chronic 
infection with HCV has an adverse impact on quality of life and how patients feel, Interferon 
therapy and sustained virological response (‘cure’) has been shown to result in marked  
 
improvements in quality of life and functioning (Bonkovsky et al, 1999; McHutchinson et al, 
2001; Bini&Mehandru, 2006; Hollander et al, 2006; Bonkovsky et al 2007, Quarantini et al, 
2008).  The major limitation of previous research in this field is that symptomatology has 
nearly always been assessed in individuals with pre-existing knowledge of their diagnosis.  In 
order to reduce reporter bias we plan to carry out an observational study using data from 
individuals who have consented to be involved in the HepFree trial.  We will use data 
collected by the HepFree study and supplement it with information contained within patients 
medical records stored in the general practice surgery to establish what reasons prompted a 
visit to the doctor and to see if individuals with hepatitis C (who were identified through the 
HepFree trial and who were unaware of their diagnosis at the time) sought medical attention 
more frequently than age and sex matched controls who originate from the same country, are 
the same ethnicity and have resided in the UK for the same length of time(uninfected 
individuals).  
 
HEPFREE SUB-STUDY TRIAL OBJECTIVES 
 
Primary objective 
The primary aim of the HepFree sub-study is to investigate whether individuals with chronic 
hepatitis C (hepatitis C antibody positive, RNA positive) who have been identified and 
diagnosed through the HepFree trial have made greater use of healthcare resources in 
primary care, prior to diagnosis, compared toindividuals with a negative viral hepatitis 
screening test. 
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Definitions 
 Chronic hepatitis C is defined as persistent infection with the virus for more than six months 
and is diagnosed by the presence of both a positive antibody and hepatitis C viral load test 
which looks for genetic material of the virus (RNA).   
If an individual is hepatitis C antibody positive but RNA negative, this indicates that they have 
previously had exposure to the virus but have not developed chronic infection indicating 
spontaneous viral eradication (viral clearance without antiviral medication).   
 
The primary aim of the sub-study will be addressed by collecting data for the following groups 
of participants 
1) ‘Cases’ – participants who have consented to the HepFree trial and have had a viral 
hepatitis screen indicating chronic infection with hepatitis C (hepatitis C antibody 
positive, RNA positive). 
2) ‘Controls’ – participants who have consented to the HepFree trial and had a viral 
hepatitis screen which is negative for hepatitis C and B.  These participants will be 
matched to ‘cases’ using the following variables: age, sex, ethnicity, country of birth 
and duration of residence in the UK. 
3) ‘Cases of previous infection’- participants who have consented to the HepFree trial 
and had a viral hepatitis screen indicating previous exposure to hepatitis C (a 
screening result of hepatitis C antibody positive RNA negative) but no evidence of 
on-going infection. 
 
The primary objective will be addressed by collecting the following data which will be used in 
conjunction with data collected by the main HepFree trial: 
 The number of attendances to GP practices for each participant from 
01/01/2005, or the point at which they enter the UK if it is after 2005. 
 
If analysis of the data supports the hypothesis that individuals with chronic hepatitis C make 
greater use of health resources in primary care compared to healthy individuals with no 
evidence of infection, further analysis will focus on the clinical outcomes of the episodes of 
care. 
Secondary objective 
To establish whether individuals with evidence of previous infection with hepatitis C (hepatitis 
C antibody positive RNAnegative) have a greater number of episodes of care in primary care 
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compared to individuals with no evidence of previous infection (controls who have tested 
negative for hepatitis B and C through the HepFree trial). 
 
METHODOLOGY 
Inclusion Criteria 
‘Cases’ are selected if they fulfil all of the following criteria below:  
 All Participants who are registered at a HepFree intervention GP surgery  
 Have provided written informed consent to take part in the HepFreetrial and  
 Have evidence of chronic hepatitis C on testing carried out between March 2014 and 
February 2016. 
 
The inclusion criteria for ‘controls’ and method of selection are listed below: 
 A ‘control’ is a participant who has provided written consent to participate in the 
HepFree trial, has tested negative for both hepatitis B and C and fulfils the criteria 
below: 
 Is born within a six month period of the ‘case’ 
 Is the same sex as the ‘case’  
 Originates from the same country as the ‘case’ 
 Is the same ethnicity as the ‘case’ 
 Has resided in the United Kingdom for the same time period (+/- six months) as the 
case. 
The inclusion criteria for ‘cases of previous infection’ 
 All Participants who are registered at a GP surgery that is performing targeted 
screening and who have provided written informed consent to take part in the 
HepFree trial and have evidence of previous exposure to hepatitis C (a screening 
result of hepatitis C antibody positive RNA negative) but no evidence of on-going 
infection carried out between March 2014 and February 2016. 
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For reference, the eligibility/inclusion criteria for HepFree are any person registered at a 
general practice performing targeted screening who: 
 Is aged 18 or older 
 Originates from, or is born to a parent originating from a country with a prevalence 
of viral hepatitis B of more than 2%. 
 Is able to give consent  
 Does not have a pre-existing diagnosis of chronic hepatitis B or C. 
 
A list of pseudoanonymised participant identifiers will be created for all controls that fulfil the 
inclusion criteria.  From this list a single control will be selected at random by a computer 
generated randomisation programme.   
Exclusion criteria 
 
Data will not be collected for participants in the following situations: 
 Individuals who have withdrawn consent to participate in the HepFree trial 
 Individuals with a positive hepatitis C screening test (cases) who are ‘lost to follow 
up’; including those who have failed to attend for study follow up events including 
diagnostic assessment in secondary care 
 Individuals with a hepatitis C screening test which has been reported by the 
laboratory as ‘indeterminate’.  
 Individuals who die following recruitment to the study. 
 Individuals who have had a screening test performed as part of HepFree despite 
having previously received hepatitis C eradication therapy in the past.  In these cases 
the antibody to hepatitis C will remain positive despite a sustained virological 
response (the virus being ‘cured’). 
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Number of subjects and subject selection 
Trial data and supplementary primary care attendance data will be collected and analysed for 
all first and second generation immigrants who have had a positive hepatitis C screening test 
as part of the HepFree study.  This group will comprise of individuals who have on-going 
evidence of chronic hepatitis C infection (hepatitis C antibody positive, RNA positive) and 
those who have evidence of previous infection with hepatitis C but without evidence of on-
going infection due to spontaneous  clearance of the virus (hepatitis C antibody positive, RNA 
negative).  ‘Cases’ will be matched to ‘controls’ using a 1:1 ratio and the method by which we 
will select controls is detailed above. 
Based on the patterns of recruitment to the trial so far, it is estimated that 7500 individuals 
will be recruited and screened for viral hepatitis in GP surgeries across Bradford between 
March 2014 and February 2016.  We estimate that as many as 1.6% will have a positive 
hepatitis C screening test based on a study performed by Uddin et al (Uddin et al, 2009).  
Using this prevalence data the sub-study may include up to 120 cases with a positive 
screening test. 
 
Study design 
 
The HepFree sub-study is a retrospective observational, case-control study which will use data 
collected from the HepFree trial, supplemented with data which is stored in medical records 
in primary care (a participant’s general practice surgery).  
 
Populations 
As part of the HepFree sub-study, ‘cases’ are defined as individuals with a positive hepatitis C 
screening test who have been screened as part of the HepFree trial.  Under this definition 
there are two types of ‘case’: 
 Individuals with evidence of on-going chronic viral hepatitis C (hepatitis C antibody 
positive, RNA positive)  
 Individuals with evidence of previous infection with chronic hepatitis C who do not 
have evidence of on-going infection which suggests spontaneous viral clearance 
(hepatitis C antibody positive, RNA negative). 
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‘Controls’ are defined as individuals who have consented for a viral hepatitis screening test as 
part of the HepFree trial who: 
 Have tested negative for hepatitis B and C 
 Who are of the same age as the ‘case’ (+/- six months). 
 Who are of  the same sex as the case 
 Who were born in the same country as the case 
 Who are the same ethnicity as the case 
 Who have resided in the United Kingdom for the same length of time as the case (+/- 
six months). 
 
Hypotheses 
The HepFree sub-study has been designed to test the following hypotheses: 
 Individuals with undiagnosed RNA-positive chronic hepatitis C are greater users of 
healthcare resources compared to individuals who do not have hepatitis C or 
hepatitis B. 
 Individuals with evidence of previous infection with hepatitis C do not use healthcare 
resources any more often than individuals who have never had hepatitis C or 
hepatitis B. 
 
Outcomes 
We aim to test these hypotheses by comparing the number of episodes of care sought by 
‘cases’ and comparing this to ‘controls’.  We intend to include all visits to the surgery from 
2005 to see any of the following healthcare professionals: 
 General practitioner (clinician)Specialist nurse practitioner 
 Practice nurse, community nurse, district nurse  
 Healthcare assistant. 
 
Data will be collected on each episode of care and the following information will be collected: 
 Date of attendance 
 Healthcare professional consulted 
 Diagnosis/outcome of the episode of care 
 READ code diagnosis if available. 
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In addition to collecting information on the number of attendances we will collect 
information on the types of symptoms reported to establish which, if any symptoms are 
experienced more frequently in individuals with chronic hepatitis C. 
 
Supplementary data from medical records on attendances to primary care is only available for 
the duration of time that the individual has been residing in the United Kingdom therefore 
this will vary from case to case.  There is currently no data to suggest how long individuals will 
start to experience symptoms following hepatitis C infection. Supplementary information 
from medical records in primary care will be collected, where available, from 01/01/2005 to 
the point of HepFree screening test been performed.  As comprehensive GP practice 
attendance began to be systematically recorded from 2005, the retrospective GP visit capture 
process will date back to 2005 where possible.   
 
Study Design / Plan – Study Visits  
Not applicable. 
As described above.   
Data collected as part of the HepFREE study will be used. This will be supplemented by 
accessing relevant medical records in GP practices to look retrospectively at attendances to 
the GP surgery.  The sub-study does not require us to contact the study participants directly.   
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Study Scheme Diagram  
 
 
 
STUDY PROCEDURES 
Informed Consent 
The consent form for the main HepFree trial (see appendix) includes signed approval for 
collection and use of data held and managed by the Health and Social Care information 
Centre and other central NHS bodies, including GP surgeries. 
 
Schedule of assessment 
Patients who have chronic hepatitis C will be monitored in secondary care using guidance 
from the HepFree study and local trust guidelines. Data collection for this study will not 
require additional patient contact. 
 
End of study definition 
 
The sub-study will include all participants with a positive hepatitis C screening test with either 
evidence of ongoing infection, or without evidence of ongoing infection and controls which 
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are matched according to the variables listed earlier in the protocol that have consented to 
participate in the HepFree trial between March 2014 and February 2016. 
 
Subject withdrawal 
Participants have the right to withdraw consent from the main HepFree trial at any time.  
Where possible the reason for revoking consent will be documented.  Data collected from 
such patients will be discarded and will not be analysed. 
 
 
Schedule of Assessment (in Diagrammatic Format) 
SeeStudy Design / Plan – Study Visits 
STATISTICAL CONSIDERATIONS 
Sample Size 
The overall prevalence of a positive hepatitis C screening test in a similar study to HepFree 
performed by Uddin et al was 1.6%.  This figure could indicate that the sample size of 
individuals with a positive hepatitis C screening test (including both RNA  positive and 
antibody positive RNA negative) would be 120 based on 7500 participants screened).  Cases 
would be matched 1:1 with controls indicating a final sample size of 240. 
 
Method of analysis 
We plan to analyse the data collected which has been described above in cohorts of patients 
with chronic hepatitis C and compare these findings with healthy controls.  The same analysis 
will be performed for thecohort with evidence of previous infection but no evidence of on-
going infection. 
Paired samplesT-test will be used to test the following hypotheses: 
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 Individuals with undiagnosed RNA-positive chronic hepatitis C are greater users 
of healthcare resources compared to individuals who do not have hepatitis C or 
hepatitis B. 
 Individuals with evidence of previous infection with hepatitis C who have now 
cleared the infection do not use healthcare resources any more frequently than 
individuals who have never had hepatitis C or hepatitis B. 
 
ETHICS 
 
Ethical Considerations 
This protocol and any subsequent amendments, along with any accompanying material will 
be submitted by the Investigator to an Independent Research Ethics Committee. Written 
Approval from the Committee will be obtained and subsequently submitted to the JRO to 
obtain Final R&D approval. 
 
SAFETY CONSIDERATIONS 
 
Not applicable – the application is purely for collection of data from pre-existing medical 
records for a research database. 
 
DATA HANDLING AND RECORD KEEPING 
 
Confidentiality 
 
Data collected on primary care attendances will be stored in a password protected Microsoft 
database on a secure, NHS computer hard drive at Bradford Royal Infirmary (Bradford 
Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, DB9 6RJ).  All data 
pertaining to participants will be stored under a unique study ID, separate from any patient 
identifiable data. The study ID is not identifiable outside of the participant’s GP surgery.  The 
study consent form is stored in the HepFreesite investigator file, in a locked room at the site 
of the consent (GP surgery).  All data will bemanaged in accordance with the data protection 
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act, NHS Caldicott Guardian, The Research Governance Framework for Health and Social Care 
and Research Ethics Committee Approval.  
Any publications relating to this research database study will be anonymous.  
 
 Study Documents   
 A sub-study protocol and any subsequent amendments 
 A patient advisory group information sheet 
 Current/Superseded Consent Forms from the main HepFree trial 
 Indemnity documentation from legal entity  
 Conditions of endorsement from R&D 
 Conditional/Final R&D Approval Ethics submissions/approvals/correspondence 
 CVs for CI and clinical fellow 
  
Record Retention and Archiving 
 
During the course of research, all records are the responsibility of the Chief Investigator and 
will be kept in secure conditions. When the research trial is complete, it is a requirement of 
the Research Governance Framework and Trust Policy that the records are kept for a 
further 20 years.   
 
Compliance 
The CI will ensure that the sub-study is conducted in compliance with the principles of the 
Declaration of Helsinki (1996), and in accordance with all applicable regulatory requirements 
including but not limited to the Research Governance Framework, Trust and Research Office 
policies and procedures and any subsequent amendments. 
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LABORATORIES (if applicable) 
 
Not applicable.  
PRODUCTS, DEVICES, TECHNIQUES AND TOOLS 
 
Not applicable. 
SAFETY REPORTING 
 
Not applicable. 
MONITORING AND AUDITING 
 
Ethical Considerations 
This protocol and any subsequent amendments, along with any accompanying material will 
be submitted by the Investigator to an Independent Research Ethics Committee. Written 
Approval from the Committee will be obtained and subsequently submitted to the JRO to 
obtain Final R&D approval. 
 
Quality Control and Quality Assurance 
Quality control of data is an integral part of all research and takes place during data 
collection, data entry and data checking.  
Data collection 
 
Data collected as part of the HepFree study is collected in accordance with the data 
management plan.  The data collected is monitored and cleaned in accordance with PCTU and 
the Sponsor’s requirements.  Data which is collected from databases at GP surgeries in 
primary care is considered source data and will not be amended or modified in any way.  The 
data which is collected from these databases in primary care by the clinical fellow who has 
authority and permission to access personal information of participants from the consent 
form.  The clinical fellow has a letter of access granted to conduct research within the 
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Bradford City CCG NHS Primary Care area and permission has been granted by GP practices 
that signed up to the main HepFree trial.  Data will be manually extracted and transferred into 
the research database.  No data exports will be made.   
Data entry 
A standardised process will be used in cases of data been transcribed and entered into a 
Microsoft database to ensure quality control. 
 
Trial committees 
 
This study will be overseen by the HepFree trial committees – specifically the HepFree trial 
steering committee and the HepFree trial monitoring committee 
 
Finance and funding 
 
The funding body for the sub-study is the National Institute for Health Research and the 
budget code is: DDCH1A9R. 
Indemnity 
 
Not required. 
Dissemination of research findings 
 
All publications using data obtained as a result of the HepFree study will be published 
with joint authorship with express consent of the study management committee. 
Anonymity of study participants will be maintained throughout.  
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Appendix 15: The Wonca Internation Classification Committee, International Classification of Primary Care 2nd Edition (ICPC) 
ICPC-2 – English 
International Classification of 
Primary Care – 2
nd
Edition 
WoncaInternational 
Classification 
Committee (WICC) 
 
Process codes 
Blood, Blood Forming 
Organs and Immune 
MechanismB 
Eye                                  F Musculoskeletal        L 
F01   Eyepain 
F02   Redeye 
L01   Necksymptom/complain 
L02   Backsymptom/complaint 
F03   Eyedischarge 
F04   Visualfloaters/spots 
F05   Visualdisturbanceother 
F13   Eye sensation abnormal 
L03   Lowbacksymptom/complaint 
L04   Chestsymptom/complaint 
L05   Flank/axillasymptom/complaint B02   Lymphgland(s)enlarged/painful 
B04   Bloodsymptom/complaint 
B25   Fear of aids/HIV 
L07   Jawsymptom/complaint 
L08   Shouldersymptom/complaint 
L09   Armsymptom/complaint 
L10   Elbowsymptom/complaint 
F14   Eyemovementsabnormal 
F15   Eyeappearanceabnormal 
F16   Eyelidsymptom/complaint 
B26   Fearcancerblood/lymph 
B27   Fearblood/lymphdiseaseother 
B28   Limitedfunction/disability 
F17   Glassessymptom/complaint 
F18   Contact lens symptom/complaint 
F27   Fearofeyedisease 
F28   Limited function/disability (f) 
L11   Wristsymptom/complaint 
L12   Hand/fingersymptom/complaint 
L13   Hipsymptom/complaint 
B29   Sympt/complt lymph/immune other 
B70   Lymphadenitisacute 
B71   Lymphadenitisnon-specific 
-30    MedicalExam/Eval-Complete 
-31    MedicalExamination/HealthEvaluation- 
Partial/Pre-opcheck 
-32    SensitivityTest 
L14   Leg/thighsymptom/complaint 
L15   
Kneesymptom/complaint 
L16    
Anklesymptom/complaint 
L17   
Foot/toesymptom/complaint 
B72   Hodgkin'sdisease/lymphoma 
F29   Eyesymptom/complaintother 
B73   Leukaemia 
B74   Malignantneoplasmbloodother 
B75   Benign/unspecified neoplasm blood 
F70   Conjunctivitisinfectious 
F71   Conjunctivitisallergic -33    Microbiological/ImmunologicalTest 
-34    BloodTest 
-35    UrineTest 
F72   Blepharitis/stye/chalazion 
F73   Eye infection/inflammation other 
L18   Musclepain 
L19   
Musclesymptom/complaintNOS 
L20   
Jointsymptom/complaintNOS 
B76   Rupturedspleentraumatic 
B77   Injuryblood/lymph/spleenother 
-36    FaecesTest 
-37    Histological/ExfoliativeCytology 
-38    OtherLaboratoryTestNEC 
-39    PhysicalFunctionTest 
F74   Neoplasmofeye/adnexa 
B78   Hereditary haemolytic anaemia 
B79   Congen.anom. blood/lymph other F75   Contusion/haemorrhageeye 
L26   Fear of cancermusculoskeletal 
L27   Fearmusculoskeletaldiseaseother 
L28   Limited function/disability (l) 
L29   Sympt/complt.Musculoskeletalother 
F76   Foreign body in eye 
F79   Injuryeyeother 
B80   Irondeficiencyanaemia 
B81   
Anaemia,VitaminB12/folatedef. 
B82   Anaemiaother/unspecified 
B83   Purpura/coagulationdefect 
-40    DiagnosticEndoscopy 
-41    DiagnosticRadiology/Imaging 
-42    ElectricalTracings 
F80   Blockedlacrimalductofinfant 
F81   Congenitalanomalyeyeother L70   Infectionsmusculoskeletalsystem 
F82   Detachedretina 
F83   Retinopathy 
F84   Maculardegeneration 
L71   Malignant neoplasmmusculoskeletal 
B84   Unexplained abnormal white cells 
B87   Splenomegaly 
B90   HIV-infection/aids 
-43    OtherDiagnosticProcedures 
-44    PreventiveImunisations/Medications 
-45    Observe/Educate/Advice/Diet 
-46    ConsultwithPrimaryCareProvider 
L72   Fracture:radius/ulna 
L73   Fracture:tibia/fibula 
F85   Cornealulcer 
F86   Trachoma 
F91   Refractiveerror 
L74   Fracture:hand/footbone 
L75   Fracture:femur 
L76   Fracture:other 
B99   Blood/lymph/spleendiseaseother 
 -47    Consultation with Specialist 
-48    Clarification/Discuss Patient’s RFE 
-49    OtherPreventiveProcedures 
 PROCESSCODES F92   Catara
ct F93   
Glauco
ma F94   
Blindn
ess F95   
Strabis
mus 
L77   Sprain/strainofankle 
L78   Sprain/strainofknee 
L79   
Sprain/strainofjointNOS 
L80   
Dislocation/subluxation 
 -50    Medicat-Script/Reqst/Renew/Inject 
-51    Incise/Drain/Flush/Aspirate 
-52    Excise/Remove/Biopsy/Destruction/ 
Debride 
-53    Instrument/Catheter/Intubate/Dilate 
-54    Repair/Fixate-Suture/Cast/Prosthetic 
-55    LocalInjection/Infiltration 
SYMPTOMS/COMPLAINT
S  F99   Eye/adnexadisease,other L81   InjurymusculoskeletalNOS INFECTIONS 
EarH L82   Congenitalanomalymusculoskeletal 
 L83   Necksyndrome 
NEOPLASMS H01    Earpain/earache L84   Back syndrome w/o radiatingpain 
L85   Acquireddeformityofspine 
L86   Backsyndrome withradiatingpain 
L87   Bursitis/tendinitis/synovitisNOS 
 H02    Hearingcomplaint 
H03    Tinnitus,ringing/buzzingear 
H04    Eardischarge 
H05    Bleedingear 
INJURIES -56    Dress/Press/Compress/Tamponade 
-57    PhysicalMedicine/Rehabilitation 
-58    TherapeuticCounselling/Listening 
-59    Other Therapeutic Procedure NEC 
 
CONGENITAL 
ANOMALIES 
L88   Rheumatoid/seropositivearthritis 
L89   Osteoarthrosis of hip 
L90   Osteoarthrosis of knee 
H13    Pluggedfeelingear 
H15    Concernwithappearanceofears 
H27    Fearofeardisease 
 
OTHER DIAGNOSES -60    ResultsTests/Procedures 
-61    ResultsExam/Test/Record 
-62    AdministrativeProcedure 
L91   Osteoarthrosisother 
L92   Shouldersyndrome 
L93   Tenniselbow 
L94   Osteochondrosis 
 
Digestive                  D 
H28    Limited function/disability ear 
H29    Earsymptom/complaintother -63    Follow-upEncounterUnspecified 
-64    Encounter Initiated by Provider 
-65    Encounter Initiated third person 
-66    Refer to Other Provider (EXCL. M.D.) 
H70    Otitisexterna 
H71    Acuteotitismedia/myringitis 
D01  Abdominalpain/crampsgeneral 
D02  Abdominalpainepigastric L95   Osteoporosis 
H72    Serousotitismedia 
H73    Eustachiansalpingitis 
H74    Chronicotitismedia 
L96   Acute internal damage knee 
D03  Heartburn 
D04  Rectal/analpain 
D05  Perianalitching 
-67    Referral to Physician/Specialist/ 
Clinic/H
ospital 
-68    OtherReferralsNEC 
L97   Neoplasmbenign/unspecmusculo. 
L98   Acquireddeformityoflimb 
L99   Musculoskeletaldisease,other H75    Neoplasmofear 
D06  Abdominal pain localized other 
D07  
Dyspepsia/indigestion 
D08  
Flatulence/gas/belchin
g D09  Nausea 
-69    OtherReasonforEncounterNEC H76    Foreign body in 
ear H77    
Perforationeardrum 
H78    
Superficialinjuryofear 
Neurological               N 
Generaland 
UnspecifiedA 
N01  Headache 
N03  Painface 
N04  Restlesslegs 
N05  Tinglingfingers/feet/toes 
H79    Ear injury other 
D10  Vomiting 
D11  Diarrhoea 
D12  Constipation 
H80    Congenitalanomalyofear 
A01    Paingeneral/multiplesites 
A02    Chills 
A03    Fever 
A04    Weakness/tirednessgeneral 
H81    Excessive ear wax 
H82    Vertiginoussyndrome 
H83    
Otosclerosis 
H84    
Presbyacusis 
H85    
Acoustictrau
ma 
N06  Sensationdisturbanceother 
N07  Convulsion/seizure 
N08  Abnormalinvoluntarymovements 
D13  Jaundice 
D14  Haematemesis/vomitingblood 
D15  Melaena 
D16  Rectalbleeding 
A05    Feelingill 
A06    Fainting/syncope 
A07    Coma 
N16  Disturbanceofsmell/taste 
N17  
Vertigo/dizziness 
N18  
Paralysis/weakne
ss N19  
Speechdisorder 
H86    Deafness 
H99    Ear/mastoiddisease,other 
D17  Incontinence of bowel 
D18  Changefaeces/bowelmovements 
D19  Teeth/gumsymptom/complaint 
A08    Swelling 
A09    Sweatingproblem 
A10    
Bleeding/haemorrhageNOS 
A11    ChestpainNOS 
Cardiovascular          K N26  Fearcancerneurologicalsystem 
N27  Fearofneurologicaldiseaseother 
N28  Limited function/disability (n) 
N29  Neurologicalsymptom/complt.other 
D20  Mouth/tongue/lipsymptom/complt. 
D21  Swallowingproblem 
D23  Hepatomegaly 
D24  AbdominalmassNOS 
K01   Heartpain 
K02   Pressure/tightness of heart 
K03   CardiovascularpainNOS 
K04   Palpitations/awareness of heart 
3    oncern/fearmedicaltreatment 
A16    Irritableinfant 
A18    Concernaboutappearance 
N70  Poliomyelitis 
N71  Meningitis/encephalitis 
N72  Tetanus 
D25  Abdominaldistension 
D26  Fearofcancerofdigestivesystem 
D27  Fearofdigestivediseaseother 
K05   Irregular heartbeat other 
K06   Prominentveins 
K07   Swollenankles/oedema 
A20    Euthanasiarequest/discussion 
A21    Risk factor for malignancy 
A23    Risk factor NOS 
A25    Fearofdeath/dying 
N73  Neurologicalinfectionother 
D28  Limited function/disability (d) 
D29  Digestive symptom/complaint other 
K22   Risk factor cardiovasculardisease 
K24   Fearofheartdisease 
K25   Fearofhypertension 
K27   Fearcardiovasculardiseaseother 
N74  Malignantneoplasmnervoussystem 
N75  Benign neoplasm nervous system 
N76  Neoplasmnervoussystemunspec. D70  Gastrointestinalinfection 
D71  Mumps 
A26    FearofcancerNOS 
A27    FearofotherdiseaseNOS 
A28    Limitedfunction/disabilityNOS 
A29    General symptom/complaint 
other 
N79  Concussion 
N80  Headinjuryother 
N81  Injury nervous system other 
D72  Viralhepatitis 
D73  Gastroenteritispresumedinfection 
K28   Limited function/disability (k) 
K29   Cardiovascularsympt./complt.other 
D74  Malignantneoplasmstomach 
A70    Tuberculosis 
A71    Measles 
A72    Chickenpox 
K70   Infectionofcirculatorysystem N85  Congenitalanomalyneurological 
D75  Malignantneoplasmcolon/rectum 
D76  Malignantneoplasmpancreas 
D77  
Malig.neoplasmdigestother/NOS 
D78  
Neoplasmdigestbenign/uncertain 
K71   Rheumatic fever/heart disease N86  Multiplesclerosis 
N87  Parkinsonism 
N88  Epilepsy 
K72   Neoplasmcardiovascular 
A73    Malaria 
A74    Rubella 
A75    Infectiousmononucleosis 
A76    Viralexanthemother 
K73   Congenitalanomalycardiovascular 
K74   Ischaemic heartdisease w.angina N89  Migraine 
N90  Clusterheadache 
N91  Facialparalysis/bell'spalsy 
9  Foreignbodydigestivesystem 
D80  Injury digestive system other 
K75   Acutemyocardialinfarction 
K76   Ischaemic heartdisease w/o angina 
K77   Heartfailure 
D81  Congen. anomaly digestive system 
A77    Viral disease other/NOS 
A78    Infectious disease other/NOS 
N92  Trigeminalneuralgia 
N93  Carpaltunnelsyndrome 
N94  Peripheralneuritis/neuropathy 
N95  Tensionheadache 
D82  Teeth/gumdisease 
D83  Mouth/tongue/lipdisease 
D84  Oesophagusdisease 
D85  Duodenalulcer 
K78   Atrialfibrillation/flutter 
K79   
Paroxysmaltachycardia 
K80   
CardiacarrhythmiaNOS 
K81   
Heart/arterialmurmurNOS 
A79    MalignancyNOS 
A80    Trauma/injuryNOS 
A81    
Multipletrauma/injuries A82    
Secondaryeffectoftrauma A84    
Poisoning by medical agent 
N99  Neurological disease, other 
D86  Peptic ulcer other 
D87  Stomachfunctiondisorder 
D88  Appendicitis 
2   Pulmonary heart 
disease K83   Heart 
valve disease NOS K84   
Heartdiseaseother 
 
A85    Adverse effect medical agent 
A86    Toxiceffectnon-medicinalsubstance 
A87    Complicationofmedicaltreatment 
D89  Inguinalhernia 
D90  Hiatushernia 
D91  Abdominal hernia other 
D92  Diverticulardisease 
K85   Elevatedbloodpressure 
K86   
Hypertensionuncomplicated 
K87   
Hypertensioncomplicated 
K88   Posturalhypotension 
A88    Adverseeffectphysicalfactor 
A89    Effectprostheticdevice 
D93  Irritablebowelsyndrome 
D94  Chronicenteritis/ulcerativecolitis 
D95  Analfissure/perianalabscess 
A90    CongenitalanomalyOS/multiple K89   Transientcerebralischaemia 
K90   Stroke/cerebrovascularaccident 
K91   Cerebrovasculardisease 
A91    AbnormalresultinvestigationNOS 
A92    Allergy/allergic reaction NOS 
A93    Prematurenewborn 
A94    Perinatalmorbidityother 
D96  Worms/otherparasites 
D97  LiverdiseaseNOS 
D98  Cholecystitis/cholelithiasis 
D99  Diseasedigestivesystem,other 
K92   Atherosclerosis/PVD 
K93   Pulmonaryembolism 
K94   Phlebitis/thrombophlebitis 
K95   Varicoseveinsofleg 
A95    Perinatalmortality 
A96    Death 
A97    Nodisease 
A98    Healthmaintenance/prevention 
 
K96   Haemorrhoids 
K99   Cardiovasculardiseaseother 
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Psychological   P Skin                    S Urological    U X75   Malignantneoplasmcervix 
X76   Malignantneoplasmbreastfemale 
X77   Malignantneoplasmgenitalother(f) P01   Feelinganxious/nervous/tense 
P02   Acutestressreaction 
S01   Pain/tendernessofskin 
S02   Pruritus 
U01   Dysuria/painfulurination 
U02   Urinaryfrequency/urgency X78   Fibromyomauterus 
X79   Benignneoplasmbreastfemale X80   
Benign neoplasm female genital X81   
Genitalneoplasmoth/unspecied(f) 
P03   Feelingdepressed 
P04   Feeling/behavingirritable/angry 
P05   Senility,feeling/behavingold 
S03   Warts U04   Incontinenceurine 
S04   Lump/swellinglocalized 
S05   Lumps/swellingsgeneralized 
U05   Urinationproblemsother 
U06   Haematuria 
P06   Sleepdisturbance 
P07   Sexualdesirereduced 
P08   Sexual fulfilment 
reduced P09   
Sexualpreferenceconcern 
S06   Rashlocalized 
S07   Rashgeneralized 
S08   Skincolourchange 
U07   Urinesymptom/complaintother 
U08   Urinaryretention 
U13   Bladder symptom/complaint other 
X82   Injurygenitalfemale 
X83   Congenitalanomalygenitalfemale 
X84  Vaginitis/vulvitisNOS 
S09   Infectedfinger/toe U14   Kidneysymptom/complaint X85   CervicaldiseaseNOS 
X86   
Abnormalcervixsmear X87   
Uterovaginalprolapse 
X88   Fibrocysticdiseasebreast 
P10   Stammering/stuttering/tic 
P11   Eatingprobleminchild 
P12   Bedwetting/enuresis 
S10   Boil/carbuncle 
S11   Skininfectionpost-traumatic 
U26   Fearofcancerofurinarysystem 
U27   Fearofurinarydiseaseother 
U28   Limitedfunction/disabilityurinary S12   Insectbite/sting 
P13   Encopresis/boweltrainingproblem 
P15   
Chronicalcoholabuse 
P16   Acute alcohol 
abuse P17   
Tobaccoabuse 
S13   Animal/humanbite 
S14   Burn/scald 
S15   Foreign body in skin 
S16   Bruise/contusion 
U29   Urinary symptom/complaint other X89   Premenstrualtensionsyndrome 
U70  Pyelonephritis/pyelitis 
U71   Cystitis/urinaryinfectionother 
U72   Urethritis 
X90   Genital herpes female 
X91   Condylomataacuminatafemale 
X92   Chlamydiainfectiongenital(f) 
P18   Medicationabuse 
P19   Drugabuse 
P20   Memorydisturbance 
S17   Abrasion/scratch/blister 
S18   Laceration/cut 
S19   Skininjuryother 
U75   Malignantneoplasmofkidney 
U76   Malignantneoplasmofbladder 
U77   Malignantneoplasm urinary other 
X99   Genital disease female, other 
MaleGenitalY 
P22   Childbehavioursymptom/complaint 
P23   
Adolescentbehav.Symptom/complt. 
P24   Specific learning problem 
P25   Phase of life problem adult 
S20   Corn/callosity 
S21   Skin texture symptom/complaint 
S22   Nailsymptom/complaint 
S23   Hairloss/baldness 
U78   Benignneoplasmurinarytract 
U79   NeoplasmurinarytractNOS 
Y01   Paininpenis 
Y02   Painintestis/scrotum 
Y03   Urethraldischarge 
Y04   Penis symptom/complaint other 
U80   Injuryurinarytract 
U85   Congenitalanomalyurinarytract 
P27   Fearofmentaldisorder 
P28   Limited function/disability (p) 
P29   Psychologicalsymptom/compltother 
S24   Hair/scalpsymptom/complaint 
S26   Fearofcancerofskin 
S27   Fearofskindiseaseother 
S28   Limited function/disability (s) 
U88   Glomerulonephritis/nephrosis 
U90   Orthostaticalbumin./proteinuria 
U95   Urinarycalculus 
U98   AbnormalurinetestNOS 
Y05   Scrotum/testissympt/complt.other 
Y06   Prostatesymptom/complaint 
Y07   ImpotenceNOS 
Y08   Sexual functionsympt./complt.(m) P70   Dementia 
P71   Organicpsychosisother 
P72   Schizophrenia 
P73   Affectivepsychosis 
S29   Skin symptom/complaint other U99   Urinary disease, other Y10   Infertility/subfertilitymale 
Y13   Sterilizationmale 
Y14   Family planning male other 
S70   Herpeszoster 
S71   Herpessimplex 
Pregnancy, 
Childbearing, Family 
Planning        W 
P74   Anxietydisorder/anxietystate 
P75   
Somatizationdisorder 
P76   
Depressivedisorder 
P77   
Suicide/suicideattemp
t 
S72   Scabies/otheracariasis 
S73   Pediculosis/skininfestationother 
S74   Dermatophytosis 
S75   Moniliasis/candidiasisskin 
Y16   Breastsymptom/complaintmale 
Y24   Fearofsexualdysfunctionmale 
Y25   Fear sexually transmitteddis.male 
Y26   Fearofgenitalcancermale 
W01 Questionofpregnancy 
W02 Fearofpregnancy 
P78   Neuraesthenia/surmenage 
P79   Phobia/compulsivedisorder 
P80   Personalitydisorder 
S76   Skininfectionother Y27   Fearofgenitaldiseasemaleother 
Y28   Limited function/disability (y) 
Y29   Genitalsympt./complt.maleother 
S77   Malignantneoplasmofskin 
S78   Lipoma 
W03 Antepartumbleeding 
W05 Pregnancyvomiting/nausea 
W10 Contraceptionpostcoital 
P81   Hyperkineticdisorder 
P82   Post-traumaticstressdisorder 
P85   Mentalretardation 
P86   Anorexianervosa/bulimia 
S79   Neoplasmskinbenign/unspecified 
S80   Solarkeratosis/sunburn 
Y70   Syphilismale 
Y71   Gonorrhoeamale 
Y72   Genital herpes male 
Y73   Prostatitis/seminalvesiculitis 
W11 Contraceptionoral 
W12 Contraceptionintrauterine 
W13 Sterilization 
W14 Contraceptionother 
S81   Haemangioma/lymphangioma 
S82   Naevus/mole 
P98   PsychosisNOS/other 
P99   Psychologicaldisorders,other 
S83   Congenital skin anomaly other Y74   Orchitis/epididymitis 
Y75   Balanitis 
Y76   Condylomataacuminatamale 
S84   Impetigo 
W15 Infertility/subfertility 
W17 Post-partumbleeding 
W18 Post-partumsymptom/complaintoth. 
RespiratoryR S85   Pilonidalcyst/fistula 
S86   Dermatitisseborrhoeic 
S87   
Dermatitis/atopiceczema 
S88   
Dermatitiscontact/allergic 
S89   Diaperrash 
Y77   Malignantneoplasmprostate 
Y78   Malignneoplasmmalegenitalother 
Y79   Benign/unspec. neoplasm gen. (m) 
R01   Painrespiratorysystem 
R02   Shortnessofbreath/dyspnoea 
R03   Wheezing 
W19 Breast/lactationsymptom/complaint 
W21 Concern 
bodyimageinpregnancy W27 
Fear complications of pregnancy 
W28 Limited function/disability 
(w) 
Y80   Injurymalegenital 
R04   Breathing problem, other 
R05   Cough 
R06   Nosebleed/epistaxis 
R07   Sneezing/nasalcongestion 
S90   Pityriasisrosea 
S91   Psoriasis 
S92   Sweatglanddisease 
Y81   Phimosis/redundantprepuce 
Y82   Hypospadias 
Y83   Undescendedtesticle 
9 Pregnancy symptom/complaint other 
W70 Puerperalinfection/sepsis 
W71 Infectioncomplicatingpregnancy 
S93   Sebaceouscyst 
S94   Ingrowingnail 
Y84   Congenitalgenl anomaly (m) other 
R08   Nosesymptom/complaintother 
R09   Sinussymptom/complaint 
R21   Throatsymptom/complaint 
Y85   Benignprostatichypertrophy 
Y86   Hydrocoele 
Y99   Genitaldiseasemale,other 
W72 Malignantneoplasm relate topreg. 
W73 Benign/unspec.neoplasm/pregnancy 
S95   Molluscumcontagiosum 
S96   Acne 
W75 Injurycomplicatingpregnancy 
R23   Voicesymptom/complaint 
R24   Haemoptysis 
R25   Sputum/phlegmabnormal 
R26   Fearofcancerrespiratorysystem 
S97   Chroniculcerskin 
S98   Urticaria 
S99   Skin disease, other 
Social Problems        Z W76 Congenital anomaly complicatepreg. 
W78 Pregnancy 
W79 Unwantedpregnancy 
W80 Ectopicpregnancy 
Z01   Poverty/financialproblem 
Z02   Food/waterproblem 
Endocrine/Metabolic 
and Nutritional         T 
R27   Fearofrespiratorydisease,other 
R28   Limited function/disability (r) 
R29   Respiratory symptom/complaintoth. 
Z03   Housing/neighbourhoodproblem 
Z04   Socialculturalproblem 
Z05   Workproblem 
W81 Toxaemiaofpregnancy 
W82 Abortionspontaneous 
W83 Abortioninduced 
W84 Pregnancyhighrisk 
R71   Whoopingcough 
R72   Strepthroat 
R73   Boil/abscessnose 
R74   Upperrespiratoryinfectionacute 
T01   Excessivethirst Z06   Unemploymentproblem 
Z07   Educationproblem 
Z08   Socialwelfareproblem 
Z09   Legalproblem 
T02   Excessiveappetite 
T03   Loss of appetite 
T04   Feedingproblemofinfant/child 
T05   Feedingproblemofadult 
W85 Gestationaldiabetes 
W90 Uncomplicate labour/delivery live 
W91 Uncomplicate labour/delivery still 
R75   Sinusitisacute/chronic 
R76   Tonsillitisacute 
R77   Laryngitis/tracheitisacute 
R78   Acutebronchitis/bronchiolitis 
Z10   Healthcaresystemproblem 
Z11   Compliance/beingillproblem 
Z12   Relationshipproblemwithpartner 
Z13   Partner'sbehaviourproblem 
T07   
Weightgai
n T08   
Weightlos
s T10   
Growthdel
ay 
W92 Complicate labour/ deliverylivebirth 
W93 Complicatelabour/deliverystillbirth 
W94 Puerperalmastitis 
W95 Breastdisorderinpregnancyother 
R79   Chronicbronchitis 
R80   Influenza 
R81   Pneumonia 
T11   
Dehydrat
ion 
T26   Fear of cancer of endocrine 
system T27   
Fearendocrine/metabolicdisother 
T28   Limited function/disability (t) 
Z14   Partner illness problem 
Z15   Loss/deathofpartnerproblem 
Z16   Relationshipproblemwithchild 
W96 Complicationsofpuerperiumother 
W99 Disorder pregnancy/delivery, other 
FemaleGenitalX R82   Pleurisy/pleuraleffusion 
R83   Respiratoryinfectionother 
Z18   Illness problem withchild 
Z19   Loss/deathofchildproblem 
Z20   Relationshipprob.parent/family 
Z21   Behaviourproblemparent/family 
T29   Endocrine/met./sympt/compltother 
X01   Genitalpainfemale 
X02   Menstrualpain 
X03   Intermenstrualpain 
X04   Painfulintercoursefemale 
R84   Malignantneoplasmbronchus/lung 
R85   Malinant neoplasm respiratory, other 
T70   Endocrineinfecti n 
71 Mal gnant eoplasmthyroid 
R86   Benign neoplasm respiratory T72   Benignneoplasmthyroid 
T73   Neoplasmendocrineoth/unspecified 
Z22   Illnessproblemparent/family 
Z23   Loss/deathparent/familymember 
Z24   Relationshipproblemfriend 
R87   Foreign body nose/larynx/bronch 
R88   Injury respiratory other 
X05   Menstruationabsent/scanty 
X06   Menstruationexcessive 
X07   Menstruationirregular/frequent 
T78   Thyroglossalduct/cyst 
T80   Congenitalanomendocrine/metab. R89   Congenitalanomalyrespiratory Z25   Assault/harmfuleventproblem 
Z27   Fearofasocialproblem 
Z28   Limited function/disability 
(z) Z29   SocialproblemNOS 
R90   Hypertrophytonsils/adenoids T81   Goitre 
T82   Obesity 
T83   Overweight 
X08   Intermenstrualbleeding 
X09   Premenstrualsymptom/complaint 
X10   Postponement of menstruation 
X11   Menopausalsymptom/complaint 
R92   Neoplasmrespiratoryunspecified 
R95   Chronic obstructive pulmonarydis 
R96   Asthma 
R97   Allergicrhinitis 
R98   Hyperventilationsyndrome 
T85   Hyperthyroidism/thyrotoxicosis 
T86   Hypothyroidism/myxoedema 
T87   Hypoglycaemia 
T89   Diabetes insulin dependent 
Abbreviations 
Anom ..........  anomaly  
behav. ......... behaviour  
bronch. ........ bronchus  
complicat....complication 
congen..........congenita  
dis.     ...... ....disease 
eval.    evaluation  
exam.examination  
gen.          genital  
malig.             malignant  
metab.            metabolic 
musculo.        musculoskeletal 
NEC                 notelsewhereclassified 
NOS        nototherwisespecified nutrit.      
nutrition 
oth                   other 
preg.          pregnancy  
prob.               problem 
RFE                  reason for ncounter 
sympt.             symptom 
unspec.       unspecified  
w                      with 
w/o                  without 
X12   Postmenopausalbleeding 
X13   Postcoitalbleeding 
X14   Vaginaldischarge 
R99   Respiratorydiseaseother 
 T90   Diabetes non-insulin dependent T91   Vitamin/nutritionaldeficiency 
T92   Gout 
PROCESSCODES X15   Vaginal symptom/complaint other 
X16   Vulvalsymptom/complaint 
X17   Pelvis symptom/complaint female 
X18   Breastpainfemale 
 
SYMPTOMS/COMPLAINT
S 
T93   Lipiddisorder 
T99   Endocrine/metab/nutrit.dis.other 
 X19   Breast lump/mass female 
X20   Nipple symptom/complaint female 
X21   Breastsymptom/complt.femaleother 
INFECTIONS  
 
NEOPLASMS X22   Concern breast appearance female 
X23   
Fearsexuallytransmitteddisease(f) 
X24   
Fearofsexualdysfunctionfemale 
X25   Fearofgenitalcancerfemale 
 
INJURIES 
 
CONGENITAL 
ANOMALIES 
X26   Fearofbreastcancerfe ale 
X27   
Feargenital/breastdiseaseother(f) 
X28   Limited function/disability 
(x) 
 
OTHER DIAGNOSES 
9   Genitalsympt m/complt femaleoth. 
  X70   Syphilisfemale X71   Gonorrhoeafemale 
X72   Genitalcandidiasisfemale 
X73   Genitaltrichomoniasisfemale 
X74   Pelvicinflammatorydisease 
 
 437 
 
 
 
